

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/75177 A2

(51) International Patent Classification⁷: C12Q 1/68

Lane, Columbia, MD 21045 (US). HOUGH, Colleen, D.
[US/US]; 169 E. Wasatch Point Lane, #30103, Draper, UT
84020 (US).

(21) International Application Number: PCT/US01/10947

(22) International Filing Date: 3 April 2001 (03.04.2001)

(74) Agents: MILLER, Mary, L. et al.; Needle & Rosenberg,
P.C., 127 Peachtree Street, N.E., Suite 1200, Atlanta, GA
30303-1811 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/194,336 3 April 2000 (03.04.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/194,336 (CIP)
Filed on 3 April 2000 (03.04.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA, as represented by THE SECRETARY,
DEPARTMENT OF HEALTH AND HUMAN SER-
VICES [US/US]; c/o National Institutes of Health, Office
of Technology Transfer, 6011 Executive Boulevard, Suite
325, Rockville, MD 20852-3804 (US).

Published:

- without international search report and to be republished
upon receipt of that report
- with sequence listing part of description published sepa-
rately in electronic form and available upon request from
the International Bureau

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MORIN, Patrice,
J. [CA/US]; 8131 Greenspring Valley Road, Owings
Mills, MD 21117 (US). SHERMAN-BAUST, Cheryl,
A. [US/US]; 8811 Baker Avenue, Baltimore, MD 21234
(US). PIZER, Ellen, S. [US/US]; 5962 Camelback

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: TUMOR MARKERS IN OVARIAN CANCER

(57) Abstract: The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

WO 01/75177 A2

TUMOR MARKERS IN OVARIAN CANCER

This invention was made with intramural support from the National Institutes of Health. The government has certain rights in the invention.

5

FIELD OF THE INVENTION

This invention relates generally to the identification of ovarian tumor markers and diagnostic, prognostic, and therapeutic methods for their use, as well as kits for use in the aforementioned methods.

10

BACKGROUND OF THE INVENTION

Ovarian cancer is one of the most common forms of neoplasia in women. Early diagnosis and treatment of any cancer ordinarily improves the likelihood of survival. However, ovarian cancer is difficult to detect in its early stages, and remains the leading cause of death among women with cancer of the female reproductive tract.

15

The low survival rate of ovarian cancer patients is in part due to the lack of good diagnostic markers for the detection of early stage neoplasms, and in part due to a deficit in the general understanding of ovarian cancer biology, which would facilitate the development of effective anti-tumor therapies. The present invention overcomes these shortcomings by providing much-needed improvements for the diagnosis, treatment, and prevention ovarian tumors, based on the identification of a series of ovarian tumor marker genes that are highly expressed in ovarian epithelial tumor cells and are minimally expressed in normal ovarian epithelial cells. Over 75% of all ovarian tumors, and about 95% of all malignant ovarian tumors, arise from the ovarian surface epithelium (OSE). Because the tumor marker genes are broadly expressed in various types of ovarian epithelial tumors, the present invention should greatly improve the diagnosis and treatment of most ovarian cancers.

20

25

SUMMARY OF THE INVENTION

30

In a first aspect, the invention features a method of detecting an ovarian tumor in a subject. The method includes the step of measuring the expression level of an

ovarian tumor marker gene in the subject, wherein an increase in the expression level of the ovarian tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in a reference subject not having an ovarian tumor, detects an ovarian tumor in the subject.

5 In a second aspect, the invention features a method of identifying a subject at increased risk for developing ovarian cancer. The method includes the step of measuring the expression level of an ovarian tumor marker gene in the subject, wherein an increase in the expression level of the ovarian tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in a reference subject
10 not at increased risk for developing ovarian cancer, identifies an individual at increased risk for developing ovarian cancer.

 In a preferred embodiment of the second aspect of the invention, the expression level of the ovarian tumor marker gene in the subject is compared to the expression level of the tumor marker gene in a reference subject that is identified as having an
15 increased risk for developing ovarian cancer.

 In a third aspect, the invention features a method of determining the effectiveness of an ovarian cancer treatment in a subject. The method includes the step of measuring the expression level of an ovarian tumor marker gene in the subject after treatment of the subject, wherein a modulation in the expression level of the ovarian
20 tumor marker gene in the subject, relative to the expression level of the ovarian tumor marker gene in the subject prior to treatment, indicates an effective ovarian cancer treatment in the subject.

 In a preferred embodiment of the first three aspects of the invention, the expression level of the ovarian tumor marker gene is determined in the subject by
25 measuring the expression level of the tumor marker gene in a sample from the subject. The sample may be, for example, a tissue biopsy, ovarian epithelial cell scrapings, peritoneal fluid, blood, urine, or serum. In another preferred embodiment of the first three aspects of the invention, the expression level of the tumor marker gene is measured *in vivo* in the subject.

30 In yet another preferred embodiment of the first three aspects of the invention, the expression level of more than one ovarian tumor marker gene is measured. For

example, the expression level of two, three, four, five, or more tumor marker genes may be measured.

In various other embodiments of the first three aspects of the invention, the expression level of the tumor marker gene may be determined by measuring the level of ovarian tumor marker mRNA. For example, the level of ovarian tumor marker mRNA may be measured using RT-PCR, Northern hybridization, dot-blotting, or *in situ* hybridization. In addition, or alternatively, the expression level of the ovarian tumor marker gene may be determined by measuring the level of ovarian tumor marker polypeptide encoded by the ovarian tumor marker gene. For example, the level of ovarian tumor marker polypeptide may be measured by ELISA, immunoblotting, or immunohistochemistry. The level of ovarian tumor marker polypeptide may also be measured *in vivo* in the subject using an antibody that specifically binds an ovarian tumor marker polypeptide, coupled to a paramagnetic label or other label used for *in vivo* imaging, and visualizing the distribution of the labeled antibody within the subject using an appropriate *in vivo* imaging method, such as magnetic resonance imaging.

In still another embodiment of the first three aspects of the invention, the expression level of the tumor marker gene may be compared to the expression level of the tumor marker gene in a reference subject diagnosed with ovarian cancer.

In a fourth aspect, the invention features a method of identifying a tumor as an ovarian tumor. The method includes the step of measuring the expression level of an ovarian tumor marker gene in a tumor cell from the tumor, wherein an increase in the expression level of the ovarian tumor marker gene in the tumor cell, relative to the expression level of the ovarian tumor marker gene in a noncancerous ovarian cell, identifies the tumor as an ovarian tumor.

In a fifth aspect, the invention features a method of treating or preventing an ovarian tumor in a subject. The method includes the step of modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in an ovarian epithelial cell in the subject.

In a sixth aspect, the invention features a method of inhibiting the growth or metastasis of an ovarian tumor cell in a subject. The method includes the step of

modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in the ovarian tumor cell in the subject.

In a seventh aspect, the invention features a method of inhibiting the growth or metastasis of an ovarian tumor in a subject. The method includes the step of contacting
5 an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide encoded by an ovarian tumor marker gene, wherein the binding of the antibody to the ovarian tumor marker polypeptide inhibits the growth or metastasis of the ovarian tumor in the subject.

In various preferred embodiments of the seventh aspect of the invention, the
10 ovarian tumor marker polypeptide may be on the surface of the ovarian tumor cell, and the antibody may be coupled to a radioisotope or to a toxic compound.

In an eighth aspect, the invention features a kit including an antibody for measuring the expression level of an ovarian tumor marker gene in a subject.

In a ninth aspect, the invention features a kit including a nucleic acid for
15 measuring the expression level of an ovarian tumor marker gene in a subject.

In a tenth aspect, the invention features a method of diagnosing ovarian cancer in a subject. The method includes the step of measuring the amount of an ovarian tumor marker polypeptide in the subject, wherein an amount of ovarian tumor marker polypeptide that is greater than the amount of ovarian tumor marker polypeptide
20 measured in a subject not having ovarian cancer diagnoses an ovarian cancer in the subject.

In various embodiments of the tenth aspect of the invention, the ovarian tumor marker polypeptide can be present at the surface of a cell (e.g., a cell-surface-localized polypeptide such as a cell adhesion molecule), or the ovarian tumor marker polypeptide
25 may be in soluble form (e.g., secreted from a cell, released from a lysed cell, or otherwise detectable in a fluid-based assay).

In a preferred embodiment of all of the above aspects of the invention, the ovarian tumor may be an epithelial ovarian tumor. The epithelial ovarian tumor may be, for example, a serous cystadenoma, a borderline serous tumor, a serous
30 cystadenocarcinoma, a mucinous cystadenoma, a borderline mucinous tumor, a mucinous cystadenocarcinoma, an endometrioid carcinoma, an undifferentiated

carcinoma, a cystadenofibroma, an adenofibroma, or a Brenner tumor. The epithelial ovarian tumor may also be a clear cell adenocarcinoma.

In preferred embodiments of all of the above aspects of the invention, the ovarian tumor marker gene can be, but is not limited to, alpha prothymosin; beta polypeptide 2-like G protein subunit 1; tumor rejection antigen-1 (gp96)1; HSP90; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67. The ovarian tumor marker gene may also be HSP60 or Lutheran blood group (B-CAM). In other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene may also be HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione peroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apolipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

The ovarian tumor marker gene may also be HOST-3 (Claudin-16) (e.g., Genbank Accession No. XM_003150; SEQ ID NOs: 141 and 142); HOST-4 (e.g., a gene that comprises SEQ ID NO: 144); or HOST-5 (sodium dependent transporter isoform NaPi-Iib) (e.g., Genbank Accession No. AF146796; SEQ ID NOs: 146 and 147).

In other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

In still other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

In yet other preferred embodiments of all aspects of the invention, the ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.

Additional advantages of the invention will be set forth in part in the description
5 which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not
10 restrictive of the invention, as claimed.

DETAILED DESCRIPTION OF THE INVENTION

The low survival rate of ovarian cancer patients is in part due to the lack of good diagnostic markers allowing early detection of the disease. Further compounding
15 this difficulty in early diagnosis is the lack of effective treatments for ovarian cancer, development of which has been impeded by a deficit in the general understanding of ovarian cancer biology. The present invention overcomes these deficits in the art by providing ovarian tumor markers that are expressed at elevated levels in ovarian epithelial tumor cells, relative to their expression in normal ovarian epithelial cells.

20 To identify marker genes that are up-regulated in ovarian tumor cells, SAGE (Serial Analysis of Gene Expression; Velculescu et al., *Science* 270:484-487, 1995) was employed to obtain global gene expression profiles of three ovarian tumors, five ovarian tumor cell lines of various histological types, a pool of ten ovarian tumor cell lines of various histological types, and normal human ovarian surface epithelium
25 (HOSE). The expression patterns were generated by acquiring thousands of short sequence tags that contain sufficient information to uniquely identify transcripts due to the unique position of each tag within the transcript. Comparing the SAGE-generated expression profiles between ovarian cancer and HOSE revealed an abundance of genes that are expressed at elevated levels in ovarian tumor cells, relative to their expression
30 in normal HOSE.

Selected SAGE results were further validated through immunohistochemical analysis of archival ovarian serous carcinoma samples. Ovarian tumor marker genes implicated in immune response pathways, regulation of cell proliferation, and protein folding were identified, many of which are membrane-localized or secreted. The ovarian tumor marker genes identified from these SAGE profiles are useful both as diagnostic and prognostic markers to detect and monitor a broad variety of ovarian cancers, and as therapeutic targets for the treatment of such ovarian cancers.

Definitions

10 In this specification and in the claims that follow, reference is made to a number of terms that shall be defined to have the following meanings.

As used in the specification and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, "a cell" can mean a single cell or more than one cell.

15 By "ovarian cell" is meant a cell that is of ovarian origin or that is a descendent of a cell of ovarian origin (e.g., a metastatic tumor cell in the liver that is derived from a tumor originating in the ovary), irrespective of whether the cell is physically within the ovary at the time at which it is subjected to a diagnostic test or an anti-tumor treatment. For example, the ovarian cell may be a normal ovarian cell or an ovarian tumor cell, 20 either within the ovary or at another location within the body. The ovarian cell may also be outside the body (for example, in a tissue biopsy). A preferred ovarian cell is an ovarian cell of epithelial origin.

By "ovarian tumor marker gene" is meant a gene of the invention, for which expression is increased (as described below) in ovarian tumor cells relative to normal ovarian cells. Preferably, an ovarian tumor marker gene has been observed to display 25 increased expression in at least two ovarian tumor SAGE libraries (relative to a HOSE library), more preferably in at least three SAGE libraries, and most preferably in at least four SAGE libraries (relative to a HOSE library). Examples of ovarian tumor marker genes are provided in Tables 2 and 4 hereinbelow.

30 By "ovarian tumor marker polypeptide" is meant a polypeptide that is encoded by an ovarian tumor marker gene and is produced at an increased level in an ovarian

tumor cell due to the increased expression of the ovarian tumor marker gene that encodes the polypeptide.

By "sample" is meant any body fluid (e.g., but not limited to, blood, serum, urine, cerebrospinal fluid, semen, sputum, saliva, tears, joint fluids, body cavity fluids
5 (e.g., peritoneal fluid), or washings), tissue, or organ obtained from a subject; a cell (either within a subject, taken directly from a subject, or a cell maintained in culture or from a cultured cell line); a lysate (or lysate fraction) or extract derived from a cell; or a molecule derived from a cell or cellular material.

By "modulate" is meant to alter, by increase or decrease.

10 By "increase in gene expression level," "expressed at an increased level," "increased expression," and similar phrases is meant a rise in the relative amount of mRNA or protein, e.g., on account of an increase in transcription, translation, mRNA stability, or protein stability, such that the overall amount of a product of the gene, i.e., an mRNA or polypeptide, is augmented. Preferably the increase is by at least about 3-
15 fold, more preferably, by at least about: 4-fold, 5-fold, 7-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold, 70-fold, or more. For example, as described herein, the expression level of the ovarian tumor marker genes of the invention is generally increased by at least 3-fold in ovarian tumor cells, relative to normal ovarian surface epithelial cells.

20 By "decrease in gene expression level" is meant a reduction in the relative amount of mRNA or protein transcription, translation, mRNA stability, or protein stability, such that the overall amount of a product of the gene, i.e., an mRNA or polypeptide, is reduced. Preferably the decrease is by at least about 20%-25%, more preferably by at least about 26%-50%, still more preferably by at least about 51%-75%,
25 even more preferably by at least about 76%-95%, and most preferably, by about 96%-100%.

By "about" is meant $\pm 10\%$ of a recited value.

By "modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene" is meant to increase or decrease gene expression level, as described
30 above, or to stimulate or inhibit the ability of an ovarian tumor marker polypeptide to perform its intrinsic biological function (examples of such functions include, but are

not limited to, enzymatic activity, e.g., kinase activity or GTPase activity; cell-signaling activity, e.g., activation of a growth factor receptor; or cell adhesion activity. The modulation may be an increase in the amount of the polypeptide produced or an increase in the activity of the polypeptide, of at least about: 2-fold, 4-fold, 6-fold, or 10-fold, or the modulation may be a decrease in the amount of the polypeptide produced or a decrease in the activity of the polypeptide, of at least about: 20%-25%, 26%-50%, 51%-75%, 76%-95%, or 96%-100%. These increases and/or decreases are compared with the amount of production and/or activity in a normal cell, sample, or subject.

By "effective amount" of a compound as provided herein is meant a nontoxic but sufficient amount of the compound to provide the desired effect, e.g., modulation of ovarian tumor marker gene expression or modulation of ovarian tumor marker polypeptide activity. As will be pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity and type of disease that is being treated, the particular compound used, its mode of administration, and the like. Thus, it is not possible to specify an exact "effective amount." However, an appropriate "effective amount" may be determined by one of ordinary skill in the art using only routine experimentation.

By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to an individual along with a molecule or compound of the invention (e.g., an antibody or nucleic acid molecule) without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.

By "having an increased risk" is meant a subject that is identified as having a higher than normal chance of developing an ovarian tumor, compared to the general population. Such subjects include, for example, women that have a hereditary disposition to develop ovarian cancer, for example, those identified as harboring one or more genetic mutations (e.g., a mutation in the BRCA-1 gene) that are known indicators of a greater than normal chance of developing ovarian cancer, or who have a familial history of ovarian cancer. In addition, a subject who has had, or who currently has, an ovarian tumor is a subject who has an increased risk for developing an ovarian

tumor, as such a subject may continue to develop new tumors. Subjects who currently have, or who have had, an ovarian tumor also have an increased risk for ovarian tumor metastases.

By "treat" is meant to administer a compound or molecule of the invention to a
5 subject in order to: eliminate an ovarian tumor or reduce the size of an ovarian tumor or the number of ovarian tumors in a subject; arrest or slow the growth of an ovarian tumor in a subject; inhibit or slow the development of a new ovarian tumor or an ovarian tumor metastasis in a subject; or decrease the frequency or severity of symptoms and/or recurrences in a subject who currently has or who previously has had
10 an ovarian tumor.

By "prevent" is meant to minimize the chance that a subject will develop an ovarian tumor or to delay the development of an ovarian tumor. For example, a woman at increased risk for an ovarian tumor, as described above, would be a candidate for therapy to prevent an ovarian tumor.

15 By "specifically binds" is meant that an antibody recognizes and physically interacts with its cognate antigen and does not significantly recognize and interact with other antigens.

By "probe," "primer," or "oligonucleotide" is meant a single-stranded DNA or RNA molecule of defined sequence that can base-pair to a second DNA or RNA
20 molecule that contains a complementary sequence (the "target"). The stability of the resulting hybrid depends upon the extent of the base-pairing that occurs. The extent of base-pairing is affected by parameters such as the degree of complementarity between the probe and target molecules, and the degree of stringency of the hybridization conditions. The degree of hybridization stringency is affected by parameters such as
25 temperature, salt concentration, and the concentration of organic molecules such as formamide, and is determined by methods known to one skilled in the art. Probes or primers specific for ovarian tumor marker nucleic acids (e.g., genes and/or mRNAs) preferably have at least 50%-55% sequence complementarity, more preferably at least 60%-75% sequence complementarity, even more preferably at least 80%-90%
30 sequence complementarity, yet more preferably at least 91%-99% sequence complementarity, and most preferably 100% sequence complementarity to the ovarian

tumor marker nucleic acid to be detected. Probes, primers, and oligonucleotides may be detectably-labeled, either radioactively, or non-radioactively, by methods well-known to those skilled in the art. Probes, primers, and oligonucleotides are used for methods involving nucleic acid hybridization, such as: nucleic acid sequencing, reverse transcription and/or nucleic acid amplification by the polymerase chain reaction, single stranded conformational polymorphism (SSCP) analysis, restriction fragment polymorphism (RFLP) analysis, Southern hybridization, Northern hybridization, *in situ* hybridization, electrophoretic mobility shift assay (EMSA).

By "specifically hybridizes" is meant that a probe, primer, or oligonucleotide recognizes and physically interacts (i.e., base-pairs) with a substantially complementary nucleic acid (e.g., an ovarian tumor marker mRNA of the invention) under high stringency conditions, and does not substantially base pair with other nucleic acids.

By "high stringency conditions" is meant conditions that allow hybridization comparable with the hybridization that occurs using a DNA probe of at least 500 nucleotides in length, in a buffer containing 0.5 M NaHPO₄, pH 7.2, 7% SDS, 1 mM EDTA, and 1 % BSA (fraction V), at a temperature of 65° C, or a buffer containing 48% formamide, 4.8X SSC, 0.2 M Tris-Cl, pH 7.6, 1X Denhardt's solution, 10% dextran sulfate, and 0.1% SDS, at a temperature of 42° C (these are typical conditions for high stringency Northern or Southern hybridizations). High stringency hybridization is relied upon for the success of numerous techniques routinely performed by molecular biologists, such as high stringency PCR, DNA sequencing, single strand conformational polymorphism analysis, and *in situ* hybridization. In contrast to Northern and Southern hybridizations, these techniques are usually performed with relatively short probes (e.g., usually 16 nucleotides or longer for PCR or sequencing, and 40 nucleotides or longer for *in situ* hybridization). The high stringency conditions used in these techniques are well known to those skilled in the art of molecular biology, and may be found, for example, in F. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, NY, 1997, herein incorporated by reference.

Examples of ovarian tumor marker genes

Examples of ovarian tumor marker genes of the invention include alpha prothymosin (e.g., Genbank Accession No. M14483; SEQ ID NOs: 1 and 2); beta polypeptide 2-like G protein subunit 1 (e.g., Genbank Accession No. M24194; SEQ ID NOs: 3 and 4); tumor rejection antigen-1 (gp96)1 (e.g., Genbank Accession No. NM_003299; SEQ ID NOs: 7 and 8); HSP90 (e.g., Genbank Accession No. AA071048; SEQ ID NOs: 9 and 10); Hepatoma-Derived Growth Factor (HGDF) (e.g., Genbank Accession No. D16431; SEQ ID NOs: 13 and 14); DKFZp5860031 (e.g., Genbank Accession No. AL117237; SEQ ID NOs: 15 and 16); CD63 antigen (melanoma 1 antigen) (e.g., Genbank Accession No. AA041408; SEQ ID NOs: 17 and 18); protein kinase C substrate 80K-H (e.g., Genbank Accession No. J03075; SEQ ID NOs: 19 and 20); Polymerase II cofactor 4 (PC4) (e.g., Genbank Accession No. X79805; SEQ ID NOs: 21 and 22); mitochondrial Tu translation elongation factor (e.g., Genbank Accession No. L38995; SEQ ID NOs: 23 and 24); hNRP H1 (e.g., Genbank Accession No. L22009; SEQ ID NOs: 25 and 26); Solute carrier family 2 (e.g., Genbank Accession No. AF070544; SEQ ID NOs: 27 and 28); KIAA0591 protein (e.g., Genbank Accession No. AB011163; SEQ ID NOs: 29 and 30); X-ray repair protein (e.g., Genbank Accession No. AF035587; SEQ ID Nos: 31 and 32); DKFZP564M2423 protein (e.g., Genbank Accession No. BC003049; SEQ ID NOs: 35 and 139); growth factor-regulated tyrosine kinase substrate (e.g., Genbank Accession No. D84064; SEQ ID NOs: 36 and 37); and/or eIF-2-associated p67 (e.g., Genbank Accession No. U29607; SEQ ID NOs: 38 and 39). The ovarian tumor marker gene may also be HSP60 (e.g., Genbank Accession No. M22382; SEQ ID NOs: 11 and 12) and Lutheran blood group protein (B-CAM) (e.g., Genbank Accession No. NM_005581; SEQ ID NOs: 5 and 6).

Other examples of ovarian tumor marker genes of the invention include HLA-DR alpha chain (e.g., Genbank Accession No. K01171; SEQ ID NOs: 40 and 41); cysteine-rich protein 1 (e.g., Genbank Accession No. NM_001311; SEQ ID NOs: 42 and 43); claudin 4 (e.g., Genbank Accession No. NM_001305; SEQ ID NOs: 44 and 45); HOST-2 (e.g., SEQ ID NO: 46); claudin 3 (e.g., Genbank Accession No. NM_001306; SEQ ID NOs: 47 and 48); ceruloplasmin (ferroxidase) (e.g., Genbank

Accession No. M13699; SEQ ID NOs: 49 and 50); glutathione peroxidase 3 (e.g., Genbank Accession No. D00632; SEQ ID NOs: 51 and 52); secretory leukocyte protease inhibitor (e.g., Genbank Accession No. AF114471; SEQ ID NOs: 53 and 54); HOST-1 (FLJ14303 fis) (e.g., Genbank Accession No. AK024365; SEQ ID NOs: 55 and 56); interferon-induced transmembrane protein 1 (e.g., Genbank Accession No. J04164; SEQ ID NOs: 57 and 58); apolipoprotein J/clusterin (e.g., Genbank Accession No. J02908; SEQ ID NOs: 59 and 60); serine protease inhibitor, Kunitz type 2 (e.g., Genbank Accession No. AF027205; SEQ ID NOs: 61 and 62); apolipoprotein E (e.g., Genbank Accession No. BC003557; SEQ ID NOs: 63 and 64); complement component 1, r subcomponent (e.g., Genbank Accession No. M14058; SEQ ID NOs: 65 and 66); G1P3/IFI-6-16 (e.g., Genbank Accession No. X02492; SEQ ID NOs: 67 and 68); Lutheran blood group (BCAM) (e.g., Genbank Accession No. X83425; SEQ ID NOs: 69 and 70); collagen type III, alpha-1 (e.g., Genbank Accession No. X14420; SEQ ID NOs: 71 and 72); Mal (T cell differentiation protein) (e.g., Genbank Accession No. M15800; SEQ ID NOs: 73 and 74); collagen type I, alpha-2 (e.g., Genbank Accession No. J03464; SEQ ID NOs: 75 and 76); HLA-DPB1 (e.g., Genbank Accession No. J03041; SEQ ID NOs: 77 and 78); bone marrow stroma antigen 2 (BST-2) (e.g., Genbank Accession No. D28137; SEQ ID NOs: 79 and 80); and HLA-Cw (e.g., Genbank Accession No. X17093; SEQ ID NOs: 81 and 82).

Still other examples of ovarian tumor marker genes of the invention include HOST-3 (Claudin-16) (e.g., Genbank Accession No. XM_003150; SEQ ID NOs: 141 and 142); HOST-4 (e.g., a gene that comprises SEQ ID NO: 144); or HOST-5 (sodium dependent transporter isoform NaPi-Iib) (e.g., Genbank Accession No. AF146796; SEQ ID NOs: 146 and 147).

Ovarian tumor marker genes of the invention may also be described by SAGE tags, as disclosed herein. For example, an ovarian tumor marker genes of the invention can include a nucleotide sequence set forth in one of SEQ ID NOs: 84-102; 103-129; or 141, 143, or 145.

Diagnostic uses of ovarian tumor marker genes and polypeptides

The ovarian tumor marker genes of the invention are overexpressed in a broad variety of ovarian epithelial tumor cells, relative to normal ovarian epithelial cells. This differential expression can be exploited in diagnostic tests for ovarian cancer, in
5 prognostic tests for assessing the relative severity of ovarian cancer, in tests for monitoring a subject in remission from ovarian cancer, and in tests for monitoring disease status in a subject being treated for ovarian cancer. Increased expression of an ovarian tumor marker gene, i.e., detection of elevated levels of ovarian tumor marker mRNA and/or protein in a subject or in a sample from a subject (i.e., levels at least
10 three-fold higher than in a normal subject or in an equivalent sample, e.g., blood, cells, or tissue from a normal subject) is diagnostic of ovarian cancer.

One of ordinary skill in the art will understand that in some instances, higher expression of a given ovarian tumor marker gene will indicate a worse prognosis for a subject having ovarian cancer. For example, relatively higher levels of ovarian tumor
15 marker gene expression may indicate a relative large primary tumor, a higher tumor burden (e.g., more metastases), or a relatively more malignant tumor phenotype.

The diagnostic and prognostic methods of the invention involve using known methods, e.g., antibody-based methods to detect ovarian tumor marker polypeptides and nucleic acid hybridization- and/or amplification-based methods to detect ovarian tumor
20 marker mRNA. One of ordinary skill in the art will understand how to choose the most appropriate method for measuring ovarian tumor marker expression, based upon the combination of the particular ovarian tumor marker to be measured, the information desired, and the particular type of diagnostic test to be used. For example, immunological tests such as enzyme-linked immunosorbent assays (ELISA),
25 radioimmunoassays (RIA), and Western blots may be used to measure the level of an ovarian tumor marker polypeptide in a body fluid sample (such as blood, serum, sputum, urine, or peritoneal fluid). Biopsies, tissue samples, and cell samples (such as ovaries, lymph nodes, ovarian surface epithelial cell scrapings, lung biopsies, liver biopsies, and any fluid sample containing cells (such as peritoneal fluid, sputum, and
30 pleural effusions) may be tested by disaggregating and/or solubilizing the tissue or cell sample and subjecting it to an immunoassay for polypeptide detection, such as ELISA,

RIA, or Western blotting. Such cell or tissue samples may also be analyzed by nucleic acid-based methods, e.g., reverse transcription-polymerase chain reaction (RT-PCR) amplification, Northern hybridization, or slot- or dot-blotting. To visualize the three-dimensional distribution of tumor cells within a tissue sample, diagnostic tests that
5 preserve the tissue structure of a sample, e.g., immunohistological staining, *in situ* RNA hybridization, or *in situ* RT-PCR may be employed to detect ovarian tumor marker polypeptide or mRNA, respectively. For *in vivo* localization of tumor masses, imaging tests such as magnetic resonance imaging (MRI) may be employed by introducing into the subject an antibody that specifically binds an ovarian tumor marker
10 polypeptide (particularly a cell surface-localized polypeptide), wherein the antibody is conjugated or otherwise coupled to a paramagnetic tracer (or other appropriate detectable moiety, depending upon the imaging method used); alternatively, localization of an unlabeled tumor marker-specific antibody may be detected using a secondary antibody coupled to a detectable moiety.

15 The skilled artisan will understand that selection of a particular ovarian tumor marker polypeptide as the target for detection in any diagnostic test and selection of the particular test to be employed will depend upon the type of sample to be tested. For example, measurement of ovarian tumor marker polypeptides that are secreted from a cell (e.g., HDGF) may be preferred for serological tests. Moreover, ovarian tumor
20 marker polypeptides that are not normally actively secreted from cells (e.g., intracellular or membrane-associated polypeptides), but that are found in blood and other fluid samples (e.g., peritoneal fluid or washings) at detectable levels in subjects having tumors (e.g., due to tumor cell lysis) are considered to be soluble ovarian tumor marker polypeptides that may be used in serological and other diagnostic assays of body
25 fluids.

A fluid sample (such as blood, peritoneal fluid, sputum, or pleural effusions) from a subject with ovarian cancer, particularly metastatic cancer, may contain one or more ovarian tumor cells or ovarian tumor cell fragments. The presence of such cells or fragments allows detection of a tumor mRNA using an RT-PCR assay, e.g., but not
30 limited to, real-time quantitative RT-PCR using the Taqman method (Heid and Stevens, *Genome Res.* 6:986-94, 1996).

In addition, since rapid tumor cell destruction often results in autoantibody generation, the ovarian tumor markers of the invention may be used in serological assays (e.g., an ELISA test of a subject's serum) to detect autoantibodies against ovarian tumor markers in a subject. Ovarian tumor marker polypeptide-specific
5 autoantibody levels that are at least about 3-fold higher (and preferably at least 5-fold or 7-fold higher, most preferably at least 10-fold or 20-fold higher) than in a control sample are indicative of ovarian cancer.

Cell-surface localized, intracellular, and secreted ovarian tumor marker polypeptides may all be employed for analysis of biopsies, e.g., tissue or cell samples
10 (including cells obtained from liquid samples such as peritoneal cavity fluid) to identify a tissue or cell biopsy as containing ovarian tumor cells. A biopsy may be analyzed as an intact tissue or as a whole-cell sample, or the tissue or cell sample may be disaggregated and/or solubilized as necessary for the particular type of diagnostic test to be used. For example, biopsies or samples may be subjected to whole-tissue or whole-
15 cell analysis of ovarian tumor marker polypeptide or mRNA levels *in situ*, e.g., using immunohistochemistry, *in situ* mRNA hybridization, or *in situ* RT-PCR. The skilled artisan will know how to process tissues or cells for analysis of polypeptide or mRNA levels using immunological methods such as ELISA, immunoblotting, or equivalent methods, or analysis of mRNA levels by nucleic acid-based analytical methods such as
20 RT-PCR, Northern hybridization, or slot- or dot-blotting.

All of the above methods are well-known in the art. For example, generation of antibodies against a given protein, ELISA, immunoblotting, selection of nucleic acid primers for PCR, RT-PCR, Northern hybridization, *in situ* hybridization, *in situ* RT-PCR, and slot- or dot-blotting are all well-described in *Current Protocols in Molecular*
25 *Biology* (Ausubel et al., eds.), John Wiley and Sons, Inc., 1996.

Kits for measuring expression levels of ovarian tumor marker genes

The present invention provides kits for detecting an increased expression level of an ovarian tumor marker gene in a subject. A kit for detecting ovarian tumor marker
30 polypeptide will contain an antibody that specifically binds a chosen ovarian tumor marker polypeptide. A kit for detecting ovarian tumor marker mRNA will contain one

or more nucleic acids (e.g., one or more oligonucleotide primers or probes, DNA probes, RNA probes, or templates for generating RNA probes) that specifically hybridize with a chosen ovarian tumor marker mRNA.

Particularly, the antibody-based kit can be used to detect the presence of, and/or
5 measure the level of, an ovarian tumor marker polypeptide that is specifically bound by the antibody or an immunoreactive fragment thereof. The kit can include an antibody reactive with the antigen and a reagent for detecting a reaction of the antibody with the antigen. Such a kit can be an ELISA kit and can contain a control (e.g., a specified amount of a particular ovarian tumor marker polypeptide), primary and secondary
10 antibodies when appropriate, and any other necessary reagents such as detectable moieties, enzyme substrates and color reagents as described above. The diagnostic kit can, alternatively, be an immunoblot kit generally comprising the components and reagents described herein.

A nucleic acid-based kit can be used to detect and/or measure the expression
15 level of an ovarian tumor marker gene by detecting and/or measuring the amount of ovarian tumor marker mRNA in a sample, such as a tissue or cell biopsy (e.g., an ovary, ovarian cell scrapings, a bone marrow biopsy, a lung biopsy or lung aspiration, etc.). For example, an RT-PCR kit for detection of elevated expression of an ovarian tumor marker gene will contain oligonucleotide primers sufficient to perform reverse
20 transcription of ovarian tumor marker mRNA to cDNA and PCR amplification of ovarian tumor marker cDNA, and will preferably also contain control PCR template molecules and primers to perform appropriate negative and positive controls, and internal controls for quantitation. One of ordinary skill in the art will understand how to select the appropriate primers to perform the reverse transcription and PCR reactions,
25 and the appropriate control reactions to be performed. Such guidance is found, for example, in F. Ausubel et al., *Current Protocols in Molecular Biology*, John Wiley & Sons, New York, NY, 1997. Numerous variations of RT-PCR are known in the art. One example of a quantitative RT-PCR assay is the real-time quantitative RT-PCR assay described by Heid and Stevens (*Genome Res.* 6:986-94, 1996), in which the
30 primers are labeled by a fluorescent tag, and the amount of amplification product may be measured in a Taqman apparatus (Perkin-Elmer; Norwal, CT).

Targeted delivery of immunotoxins to ovarian tumor cells

The tumor marker genes of the invention can be employed as therapeutic targets for the treatment or prevention of ovarian cancer. For example, an antibody molecule that specifically binds a cell surface-localized ovarian tumor marker polypeptide can be
5 conjugated to a radioisotope or other toxic compound. Antibody conjugates are administered to the subject such that the binding of the antibody to its cognate ovarian tumor marker polypeptide results in the targeted delivery of the therapeutic compound to ovarian tumor cells, thereby treating an ovarian cancer.

The therapeutic moiety can be a toxin, radioisotope, drug, chemical, or a protein
10 (see, e.g., Bera et al. "Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2" *Cancer Res.* 59:4018-4022 (1999)). For example, the antibody can be linked or conjugated to a bacterial toxin (e.g., diphtheria toxin, pseudomonas exotoxin A, cholera toxin) or plant toxin (e.g., ricin toxin) for targeted delivery of the toxin to a cell expressing the ovarian
15 tumor marker. This immunotoxin can be delivered to a cell and upon binding the cell surface-localized ovarian tumor marker polypeptide, the toxin conjugated to the ovarian tumor marker-specific antibody will be delivered to the cell.

In addition, for any ovarian tumor polypeptide for which there is a specific ligand (e.g., a ligand that binds a cell surface-localized protein), the ligand can be used
20 in place of an antibody to target a toxic compound to an ovarian tumor cell, as described above.

Antibodies that specifically bind ovarian tumor marker polypeptides

The term "antibodies" is used herein in a broad sense and includes both
25 polyclonal and monoclonal antibodies. In addition to intact immunoglobulin molecules, also included in the term "antibodies" are fragments or polymers of those immunoglobulin molecules and humanized versions of immunoglobulin molecules, so long as they exhibit any of the desired properties (e.g., specific binding of an ovarian tumor marker polypeptide, delivery of a toxin to an ovarian tumor cell expressing an
30 ovarian tumor marker gene at an increased level, and/or inhibiting the activity of an ovarian tumor marker polypeptide) described herein.

Whenever possible, the antibodies of the invention may be purchased from commercial sources. The antibodies of the invention may also be generated using well-known methods. The skilled artisan will understand that either full length ovarian tumor marker polypeptides or fragments thereof may be used to generate the antibodies of the invention. A polypeptide to be used for generating an antibody of the invention may be partially or fully purified from a natural source, or may be produced using recombinant DNA techniques. For example, a cDNA encoding an ovarian tumor marker polypeptide, or a fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect, or mammalian cells), after which the recombinant protein can be purified and used to generate a monoclonal or polyclonal antibody preparation that specifically bind the ovarian tumor marker polypeptide used to generate the antibody.

In addition, one of skill in the art will know how to choose an antigenic peptide for the generation of monoclonal or polyclonal antibodies that specifically bind ovarian tumor antigen polypeptides. Antigenic peptides for use in generating the antibodies of the invention are chosen from non-helical regions of the protein that are hydrophilic. The PredictProtein Server (http://www.embl-heidelberg.de/predictprotein/subunit_def.html) or an analogous program may be used to select antigenic peptides to generate the antibodies of the invention. In one example, a peptide of about fifteen amino acids may be chosen and a peptide-antibody package may be obtained from a commercial source such as Anaspec (San Jose, CA). One of skill in the art will know that the generation of two or more different sets of monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an antibody with the specificity and affinity required for its intended use (e.g., ELISA, immunohistochemistry, *in vivo* imaging, immunotoxin therapy). The antibodies are tested for their desired activity by known methods, in accordance with the purpose for which the antibodies are to be used (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the generation and testing of antibodies, see, e.g., Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988). For example, the antibodies may be tested in ELISA assays, Western blots, immunohistochemical staining of formalin-fixed

ovarian cancers or frozen tissue sections. After their initial *in vitro* characterization, antibodies intended for therapeutic or *in vivo* diagnostic use are tested according to known clinical testing methods.

The term "monoclonal antibody" as used herein refers to an antibody obtained
5 from a substantially homogeneous population of antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies
10 derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity (See, U.S. Pat. No. 4,816,567 and *Morrison et al.*, Proc.
15 Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

Monoclonal antibodies of the invention may be prepared using hybridoma methods, such as those described by *Kohler and Milstein*, Nature, 256:495 (1975). In a hybridoma method, a mouse or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of
20 producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional
25 procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).

In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can
30 be performed using papain. Examples of papain digestion are described in WO 94/29348 published Dec. 22, 1994 and U.S. Pat. No. 4,342,566. Papain digestion of

antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a fragment that has two antigen combining sites and is still capable of cross-linking antigen.

5 The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the nonmodified antibody or antibody fragment. These modifications can provide for some additional property, such as to
10 remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of
15 the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody fragment. (Zoller, M.J. *Curr. Opin. Biotechnol.* 3:348-354, 1992).

 The antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are
20 chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a
25 non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the
30 humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to

those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (*Jones et al.*, Nature, 321:522-525 (1986), *Reichmann et al.*, Nature, 332:323-327 (1988), and *Presta*, Curr. Op. Struct. Biol., 2:593-596 (1992)).

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers (*Jones et al.*, Nature, 321:522-525 (1986), *Riechmann et al.*, Nature, 332:323-327 (1988), *Verhoeyen et al.*, Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region (*J(H)*) gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge (see, e.g., *Jakobovits et al.*, Proc. Natl. Acad. Sci. USA, 90:2551-255 (1993); *Jakobovits et al.*, Nature, 362:255-258 (1993); *Bruggermann et al.*, Year in Immuno., 7:33 (1993)). Human antibodies can also be produced in phage display libraries (*Hoogenboom et al.*, J. Mol. Biol., 227:381 (1991); *Marks et al.*, J. Mol. Biol.,

222:581 (1991)). The techniques of Cote et al. and *Boerner et al.* are also available for the preparation of human monoclonal antibodies (*Cole et al.*, *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, p. 77 (1985) and *Boerner et al.*, *J. Immunol.*, 147(1):86-95 (1991)).

5

Administration of therapeutic and diagnostic antibodies

Antibodies of the invention are preferably administered to a subject in a pharmaceutically acceptable carrier. Suitable carriers and their formulations are described in *Remington's Pharmaceutical Sciences*, 16th ed., 1980, Mack Publishing Co., edited by Oslo et al. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

20 The antibodies can be administered to the subject, patient, or cell by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. The antibodies may also be administered by intratumoral or peritumoral routes, to exert local as well as systemic therapeutic effects. Local or intravenous injection is preferred.

25 Effective dosages and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. Guidance in selecting appropriate doses for antibodies is found in the literature on therapeutic uses of antibodies, e.g., *Handbook of Monoclonal*

30

Antibodies, Ferrone et al., eds., Noyes Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389. A typical daily dosage of the antibody used alone might range from about 1 μ g/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above.

Following administration of an antibody for treating ovarian cancer, the efficacy of the therapeutic antibody can be assessed in various ways well known to the skilled practitioner. For instance, the size, number, and/or distribution of ovarian tumors in a subject receiving treatment may be monitored using standard tumor imaging techniques. A therapeutically-administered antibody that arrests tumor growth, results in tumor shrinkage, and/or prevents the development of new tumors, compared to the disease course that would occur in the absence of antibody administration, is an efficacious antibody for treatment of ovarian cancer.

15 Antisense and gene therapy approaches for inhibiting ovarian tumor marker gene function

Because the ovarian tumor marker genes of the invention are highly expressed in ovarian tumor cells and are expressed at extremely low levels in normal ovarian cells, inhibition of ovarian tumor marker expression or polypeptide activity may be integrated into any therapeutic strategy for treating or preventing ovarian cancer.

The principle of antisense therapy is based on the hypothesis that sequence-specific suppression of gene expression (via transcription or translation) may be achieved by intracellular hybridization between genomic DNA or mRNA and a complementary antisense species. The formation of such a hybrid nucleic acid duplex interferes with transcription of the target tumor antigen-encoding genomic DNA, or processing/transport/translation and/or stability of the target tumor antigen mRNA.

Antisense nucleic acids can be delivered by a variety of approaches. For example, antisense oligonucleotides or antisense RNA can be directly administered (e.g., by intravenous injection) to a subject in a form that allows uptake into tumor cells. Alternatively, viral or plasmid vectors that encode antisense RNA (or RNA fragments) can be introduced into cells *in vivo*. Antisense effects can also be induced

by sense sequences; however, the extent of phenotypic changes are highly variable. Phenotypic changes induced by effective antisense therapy are assessed according to changes in, e.g., target mRNA levels, target protein levels, and/or target protein activity levels.

5 In a specific example, inhibition of ovarian tumor marker function by antisense gene therapy may be accomplished by direct administration of antisense ovarian tumor marker RNA to a subject. The antisense tumor marker RNA may be produced and isolated by any standard technique, but is most readily produced by *in vitro* transcription using an antisense tumor marker cDNA under the control of a high efficiency promoter (e.g., the T7 promoter). Administration of antisense tumor marker RNA to cells can be carried out by any of the methods for direct nucleic acid administration described below.

An alternative strategy for inhibiting ovarian tumor marker polypeptide function using gene therapy involves intracellular expression of an anti-ovarian tumor marker antibody or a portion of an anti-ovarian tumor marker antibody. For example, the gene (or gene fragment) encoding a monoclonal antibody that specifically binds to an ovarian tumor marker polypeptide and inhibits its biological activity is placed under the transcriptional control of a specific (e.g., tissue- or tumor-specific) gene regulatory sequence, within a nucleic acid expression vector. The vector is then administered to the subject such that it is taken up by ovarian tumor cells or other cells, which then secrete the anti-ovarian tumor marker antibody and thereby block biological activity of the ovarian tumor marker polypeptide. Preferably, the ovarian tumor marker polypeptide is present at the extracellular surface of ovarian tumor cells.

25 Nucleic Acid Delivery

In the methods described above which include the administration and uptake of exogenous DNA into the cells of a subject (i.e., gene transduction or transfection), the nucleic acids of the present invention can be in the form of naked DNA or the nucleic acids can be in a vector for delivering the nucleic acids to the cells for inhibition of ovarian tumor marker protein expression. The vector can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval,

Quebec, Canada). Delivery of the nucleic acid or vector to cells can be via a variety of mechanisms. As one example, delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMINE (GIBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and
5 TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art. In addition, the nucleic acid or vector of this invention can be delivered *in vivo* by electroporation, the technology for which is available from Genetronics, Inc. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Corp., Tucson, AZ).

10 As one example, vector delivery can be via a viral system, such as a retroviral vector system which can package a recombinant retroviral genome (see e.g., Pastan et al., *Proc. Natl. Acad. Sci. U.S.A.* 85:4486, 1988; Miller et al., *Mol. Cell. Biol.* 6:2895, 1986). The recombinant retrovirus can then be used to infect and thereby deliver to the infected cells antisense nucleic acid that inhibits expression of an ovarian tumor marker
15 gene. The exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of retroviral vectors. Other techniques are widely available for this procedure including the use of adenoviral vectors (Mitani et al., *Hum. Gene Ther.* 5:941-948, 1994), adeno-associated viral (AAV) vectors (Goodman et al., *Blood* 84:1492-1500, 1994), lentiviral vectors (Naidini et al., *Science* 272:263-267,
20 1996), pseudotyped retroviral vectors (Agrawal et al., *Exper. Hematol.* 24:738-747, 1996). Physical transduction techniques can also be used, such as liposome delivery and receptor-mediated and other endocytosis mechanisms (see, for example, Schwartzenberger et al., *Blood* 87:472-478, 1996). This invention can be used in conjunction with any of these or other commonly used gene transfer methods.

25 As one example, if the antisense nucleic acid of this invention is delivered to the cells of a subject in an adenovirus vector, the dosage for administration of adenovirus to humans can range from about 10^7 to 10^9 plaque forming units (pfu) per injection but can be as high as 10^{12} pfu per injection (Crystal, *Hum. Gene Ther.* 8:985-1001, 1997; Alvarez and Curiel, *Hum. Gene Ther.* 8:597-613, 1997). Ideally, a subject will receive
30 a single injection. If additional injections are necessary, they can be repeated at six

month intervals for an indefinite period and/or until the efficacy of the treatment has been established.

Parenteral administration of the nucleic acid or vector of the present invention, if used, is generally characterized by injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions. A more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is incorporated by reference herein. For additional discussion of suitable formulations and various routes of administration of therapeutic compounds, see, e.g., *Remington: The Science and Practice of Pharmacy* (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.

Example I: Identification of ovarian tumor marker genes using SAGE

Serial Analysis of Gene Expression is a method that enables the global analysis of gene expression from a tissue of interest (Velculescu et al., *Science* 270:484-487, 1995; Zhang et al., *Science* 276:1268-72, 1997). The advantages of SAGE over cDNA arrays, another method for the global analysis of gene expression, include: 1) the possibility of identifying novel genes, 2) determination of absolute levels of gene expression, which is difficult in hybridization-based techniques, and, 3) examination of gene expression as a whole instead of as a subset of genes.

Construction and screening of SAGE libraries

The SAGE technique has been described in detail (Velculescu et al., *Science* 270:484-487, 1995). The SAGE libraries disclosed herein were made as described by Velculescu, *supra*. First, total RNA was purified from the cells. Poly A+ RNA was then isolated and reverse transcription was performed using a biotinylated poly dT primer for first strand synthesis. The cDNA mixture was cut with *Nla*III and the biotinylated 3' fragments were collected using streptavidin beads. The beads were divided into two aliquots (A and B) and linkers containing PCR primer sites and a site for class II restriction enzyme *Bsm*FI were ligated to the DNA fragments attached to the

beads from samples A and B. The mixture was treated with the restriction enzyme *BsmFI*, which recognizes the site in the linker but cuts 14 bp downstream. The resulting fragments contained the linker and 10 bp of "cDNA sequence" that is referred to as "tag". The tags from samples A and B were ligated together to form ditags, which
5 were then amplified by PCR. Any repeated ditag (tags containing the same two individual tags) are an indication of PCR bias and were eliminated by the SAGE software (Velculescu et al., *Science* 270:484-487, 1995; Zhang et al., *Science* 276:1268-72, 1997). The tags were concatemerized and cloned into a sequencing vector. Sequencing revealed the identity and frequency of the different tags. As
10 described above, the 10 bp tag is sufficient to identify cDNA and the frequency of a particular tag represents the frequency of a particular message in the population. The SAGE software developed in the laboratories of Bert Vogelstein and Kenneth Kinzler at Johns Hopkins extracts the tags from the raw sequencing data, matches the tags to the corresponding genes (present in Genbank) and makes frequency comparisons
15 between the tags from an individual library or other libraries.

Verification of ovarian tumor marker genes identified by SAGE

The most promising candidates are selected and verified by any expression analysis method, e.g., Northern analysis or reverse transcription-polymerase chain
20 reaction (RT-PCR). For Northern analysis, radioactive probes are generated from expressed sequence tags (ESTs) corresponding to the candidate genes and are used to hybridize to membranes containing total RNA from various ovarian cancers and controls. The candidates may also be verified by real-time PCR using the Taqman method (Heid and Stevens, *Genome Res.* 6:986-94, 1996). Amplification primers and
25 fluorescent probes are synthesized according to instructions from the manufacturer (Perkin-Elmer; Norwalk, CT). Quantitative PCR is performed using a PE 5700 apparatus or an analogous instrument.

Sources of RNA for SAGE library construction

30 Eleven SAGE libraries were constructed, as shown in Table 1. The human ovarian surface epithelial cell (HOSE) library was constructed using RNA from HOSE

cells that were obtained by gently scraping the ovarian surface from a hysterectomy patient followed by short-term *in vitro* culture (three passages) of the cells. Three of the ovarian tumor libraries (designated OVT6, OVT7, and OVT8) were constructed using RNA from one of three primary high grade serous adenocarcinomas. Libraries
5 from individual ovarian tumor cell lines were generated using RNA from OV1063 (derived from an ovarian papillary adenocarcinoma; obtained from the American Type Culture Collection (ATCC; Manassas, VA; CRL-2183)); ES-2 (derived from a clear cell adenocarcinoma; from the ATCC; CRL-1978); A2780 (derived from an ovarian cancer; obtained from Dr. Vilhelm Bohr, Baltimore, MD); OVCA432 (derived from an
10 ovarian serous cystadenocarcinoma; Bast et al., *J. Clin. Invest.* 68:1331-1337, 1981); ML10 (derived from an ovarian cystadenoma; Luo et al. *Gyn. Oncol.*, 67:277-284, 1997); or IOSE29 (simian virus 40-immortalized OSE cells; Auersperg et al., *Proc. Natl. Acad. Sci. USA* 96:6249-6254, 1999).

The pooled library was generated using RNA from a pool of 10 cell lines:
15 A2780; BG-1 (poorly differentiated ovarian cancer; obtained from Dr. Carl Barrett, Durham, NC); ES-2; OVCA432; MDAH 2774 (endometrioid adenocarcinoma; obtained from the ATCC); and five cell lines obtained from Dr. Michael Birrer (Rockville, MD): AD10 (an adriamycin-resistant derivative of A2780); A222 (ovarian carcinoma); UCI101 (papillary ovarian adenocarcinoma); UCI107 (papillary ovarian
20 adenocarcinoma); and A224 (ovarian carcinoma).

TABLE 1

Library	Seq	Tags (raw)	Tags	Genes	At least 2
HOSE	2,290	49,394	47,881	16,034	4,532
OVT6	2,104	43,891	41,620	18,476	4,799
OVT7	2,089	57,725	53,898	19,523	5,669
OVT8	2,076	36,813	32,494	16,363	3,815
OV1063	2,146	41,131	37,862	15,231	4,746
ES-2	1,775	36,430	35,352	14,739	3,952
A2780**	475	9,269	8,246	5,179	1,021
OVCA432	384	3,011	2,824	1,940	310
Pool	2,201	10,952	10,554	5,956	1,627
ML10	1,935	61,083	55,700	18,727	6,637
IOSE29	*	*	*	*	*
TOTAL	17,475	349,699	326,431	75,056	25,071

* To be sequenced

**Incomplete

Results of SAGE

Eleven ovarian SAGE libraries were constructed, ten of which have been sequenced to date. The overall data are summarized in Table 1 above. For each SAGE library, Table 1 shows the number of SAGE library clones sequenced, the number of raw tags sequenced, the number of tags obtained after correction for PCR bias, the total number of genes that are represented by the corrected pool of tags, and the number of genes that were represented at least twice in the corrected pool of tags. For most libraries, 35,000-61,000 tags were obtained, yielding anywhere from 14,000-20,000 genes. In total, 75,056 genes were identified.

- 10 In order to identify genes that are up-regulated in ovarian tumors and that may serve as diagnostic markers and therapeutic targets, we compared gene expression between the normal ovarian cells (HOSE) and the cancer cells (OVT6, OVT7, OVT8, OV1063, ES2, A2780, Pool). OVCA432 was not included in this analysis because of the poor number of tags obtained from this library. We looked for genes for which expression
- 15 was absent or low (frequency smaller or equal to 2 tags per 100,000) in HOSE and at least 7- to 10-fold up-regulated in the majority of the tumor libraries, and detected a number of genes matching these criteria. Table 2 shows the libraries that were screened, the SAGE tags that were identified in the library screens, along with their corresponding genes and Genbank accession numbers, and the relative expression of
- 20 each gene in each library. Any one of these ovarian tumor marker genes may be used in the diagnostic and/or therapeutic methods of the invention.

TABLE 2

SEQ. ID NO. (Tag)	Tag	OVT8	OVT7	OVT6	A2780	OV1063	ES2	P601	HOSE	Gene Product	Genbank
83	TCAGACGCAG	52	149	91	97	49	214	82	2	Prothymosin, alpha	M14483
84	TTATGGGATC	57	80	57	140	83	126	274	2	G protein, beta polypeptide 2-like 1	M24194
85	CCCGCCCCCG	136	166	52	22	7	0	146	2	Lutheran blood group (B-CAM)	NM_005581
86	GAGGAAGAAG	14	38	57	76	53	80	100	2	Tumor rejection antigen-1 (gp96) 1	NM_003299
87	GAAGCTTTGC	27	43	43	22	27	66	73	2	HSP90	AA071048
88	TACCAGTGTA	30	16	14	140	22	30	100	2	HSP60	M22382
89	TCTTCTCCCT	8	42	32	22	27	25	46	2	Hepatoma-Derived Growth Factor (HDGF)	D16431
90	TTGGCTTTTC	14	12	71	32	10	22	18	0	DKFZp5860031	AL117237
91	GGAAGGGAGG	30	14	16	11	12	44	55	2	CD63 antigen (melanoma 1 antigen)	AA041408
92	AAGCCAGCCC	19	17	36	22	17	27	18	2	Protein kinase C substrate 80K-H	J03075
93	TTTCAGATTG	16	26	25	32	22	19	18	0	Polymerase II cofactor 4 (PC4)	X79805
94	GCATAGGCTG	11	24	25	22	12	27	9	2	Tu translation elong. factor (mitochondrial)	L38995
95	TTTGTTAATT	30	16	16	43	17	19	18	2	hnRNP H1	L22009
96	GAGACTCCTG	11	23	23	22	12	3	64	2	Solute carrier family 2	AF070544
97	CCTGTAATTC	19	10	27	32	15	8	27	2	KIAA0591 protein	AB011163
98	GTGGTGCGTG	16	10	21	11	15	19	27	2	X-ray repair protein	AF035587
99	TTGGACCTGG	11	19	9	11	27	16	18	2	ATP synthase (delta subunit)	AA524164
100	CTTAAGGATT	11	12	18	11	15	27	9	0	DKFZP564M2423 protein	BC003049
101	GTC1GTGAGA	8	17	9	22	12	22	18	0	Growth factor-regul. tyr kinase substrate	D84064
102	GAAACTGAAC	16	10	14	32	12	3	9	2	eIF-2-associated p67	U29607

Example II: Identification of additional ovarian tumor marker genes using SAGE

Serial Analysis of Gene Expression (SAGE) was used to generate global gene expression profiles from various ovarian cell lines and tissues, including primary cancers, ovarian surface epithelial (OSE) cells and cystadenoma cells. The profiles
5 were used to compare overall patterns of gene expression and identify differentially expressed genes. We have sequenced a total of 385,000 tags, yielding over 56,000 genes expressed in ten different libraries derived from ovarian tissues.

In general, ovarian cancer cell lines showed relatively high levels of similarity to libraries from other cancer cell lines, regardless of the tissue of origin (ovarian or
10 colon), indicating that these lines had lost many of their tissue specific expression patterns. In contrast, immortalized OSE (IOSE) and ovarian cystadenoma cells showed much higher similarity to primary ovarian carcinomas as compared to primary colon carcinomas. Primary tissue specimens therefore appeared to be a better model for gene expression analyses. Using the expression profiles described above and stringent
15 selection criteria, we have identified a number of genes highly differentially expressed between non-transformed ovarian epithelia and ovarian carcinomas. Some of the genes identified are already known to be overexpressed in ovarian cancer but several represent novel candidates. Many of the genes up-regulated in ovarian cancer represent surface or secreted proteins such as Claudin-3 and -4, HE4, Mucin-1, Ep-CAM and
20 Mesothelin. The genes encoding apolipoprotein E (ApoE) and apolipoprotein J (ApoJ), two proteins involved in lipid homeostasis are among the genes highly up-regulated in ovarian cancer. Selected SAGE results were further validated through immunohistochemical analysis of ApoJ, Claudin-3, Claudin-4 and Ep-CAM in archival material. These experiments provided additional evidence of the relevance of our
25 findings *in vivo*.

A) METHODS**Cell Culture and Tissue Samples**

Ovarian cancer cell lines OV1063, ES2, and MDAH 2774 were obtained from
30 the American Type Culture Collection (Manassas, VA). Cell lines A222, AD10, UCI101 and UCI107 were obtained from Dr. Michael Birrer (Rockville, MD). Cell line A2780 was obtained from Dr. Vilhelm Bohr (Baltimore, MD). The SV40-

immortalized cell lines IOSE29 (Auersperg, N., et al. *Proc. Natl Acad. Sci. USA*, 96:6249-6254, 1999) and ML10 (Luo, M. P., et al. *Gynecol. Oncol.* 67:277-284, 1997) were kindly provided by Dr. Nelly Auersperg (British Columbia, Canada) and Dr. Louis Dubeau (Los Angeles, CA), respectively. Except for IOSE29, ML-10 and HOSE-4, all cell lines were cultured in McCoy's 5A growth medium (Life Technologies, Inc, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 U/ml of Penicillin and 100 ug/ml Streptomycin). IOSE29 was cultivated in Medium 199 (Life Technologies, Inc, Gaithersburg, MD) supplemented with 5% newborn calf serum (NCS). ML10 was cultivated in MEM (Life Technologies, Inc, Gaithersburg, MD) supplemented with 10% FBS and antibiotics as above.

Three high-grade serous ovarian cancer specimens, OVT6, OVT7, and OVT8, composed of at least 80% tumor cells as determined by histopathology, were chosen for SAGE. The ovarian tumor samples were frozen immediately after surgical resection and were obtained from the Johns Hopkins gynecological tumor bank in accordance with institutional guidelines on the use of human tissue. Normal human ovarian surface epithelial (HOSE-4) cells were cultured from the right ovary of a patient undergoing hysterectomy and bilateral salpingo-oophorectomy for benign disease. The OSE cells were obtained by gently scraping the surface of the ovary with a cytobrush and grown for 2 passages in RPMI 1640 medium supplemented with 10% FBS and 10 ug/ml insulin-like growth factor (IGF).

Serial Analysis of Gene Expression (SAGE)

Total RNA was obtained from guanidinium isothiocyanate cell lysates by centrifugation on CsCl. Polyadenylated mRNA was purified from total RNA using the Messagemaker kit (Life Technologies, Gaithersburg, MD) and the cDNA generated using the cDNA Synthesis System (Life Technologies, Gaithersburg, MD). For the "Pool" library, 100 ug of total RNA from each of 10 ovarian cancer cell lines (A222, A2780, AD10, BG-1, ES-2, MDAH 2774, OVCA432, OV1063, UCI101 and UCI107) were combined and mRNA purified. SAGE was performed essentially as described (Velculescu, V. E., et al. *Science* 270:484-487, 1995) for all the libraries except HOSE. To create the HOSE library, MicroSAGE, a modified SAGE technique developed for limited sample sizes (Datson, N. A., et al. *Nucleic Acids Res.* 27:1300-1307, 1999),

was used. Approximately 1×10^6 OSE cells in short-term culture were lysed and the mRNA purified directly using Oligo (dT)₂₅ Dynabeads (Dynal, Norway). As part of the Cancer Genome Anatomy Project (CGAP) SAGE consortium, the SAGE libraries were arrayed at the Lawrence Livermore National Laboratories and sequenced at the

- 5 Washington University Human Genome Center or NISC (NIH, Bethesda, MD). The data has been posted on the CGAP website (<http://www.ncbi.nlm.nih.gov/SAGE/>) as part of the SAGEmap database (Lal, A., et al. *Cancer Res.* 59:5403-5407, 1999.).

Sequence data from each library were analyzed by the SAGE software (Velculescu, V. E., et al. *Science* 270:484-487, 1995.) to quantify tags and identify their
 10 corresponding transcripts. The data for the colon libraries NC1, NC2, Tu98, Tu102, HCT116 and SW837 were obtained from the SAGEmap database and analyzed in the same way. Because the different libraries contained various numbers of total tags, normalization (to 100,000 tags) was performed to allow meaningful comparisons. The 10,000 most highly expressed genes in each of the 16 SAGE libraries of interest were
 15 formatted in a Microsoft Excel spreadsheet and Pearson correlation coefficients were calculated for each pair-wise comparison using normalized tag values for each library. The value for the Pearson correlation coefficient (r) represents the degree of similarity (the strength of the relationship) between two libraries and is calculated using the following equation:

20

$$r = \frac{n(\sum xy) - (\sum x)(\sum y)}{\sqrt{[n\sum x^2 - (\sum x)^2][n\sum y^2 - (\sum y)^2]}}$$

where, x_i = number of tags per 100,000 for tag i in the first library and y_i = number of tags per 100,000 for tag i in the second library. For our purposes n equals 10,000 since 10,000 tags are compared. A dendrogram representing the hierarchical relationships between samples was then generated using hierarchical cluster analysis as described
 25 (Eisen, M. B., et al. *Proc. Natl Acad. Sci. USA* 95:14863-14868, 1998). In addition, the identification of differentially expressed genes was also done using this subset of the SAGE data.

Immunohistochemistry

Deparaffinized 5-um sections of formalin-fixed ovarian cancer specimens were
 30 submitted to heat-induced antigen retrieval and processed using the LSAB2 system

(DAKO, Carpinteria, CA) with 3,3'-diaminobenzidine as the chromogen and a hematoxylin counterstain. Monoclonal antibody against ApoJ/Clusterin (Clone CLI-9) was obtained from Alexis Corporation (San Diego, CA) and used at a 1:500 Dilution. Monoclonal antibody against Ep-CAM (Clone 323/A3) from NeoMarkers (Fremont, CA) was used at a 1:500 dilution. Polyclonal antibodies against Claudin-3 and -4 were a generous gift from Drs. M. Furuse and S. Tsukita (Kyoto, Japan) and were used at a dilution of 1:1000.

B) RESULTS

10 Ovarian SAGE library construction and analysis

Gene expression alterations that arise during malignant transformation can be identified a number of ways. We chose the unbiased, comprehensive method SAGE to create global gene expression profiles from ten different ovarian sources. The expression patterns are generated by sequencing thousands of short sequence tags that contain sufficient information to uniquely identify the corresponding transcripts (Velculescu, V. E., et al. *Science* 270:484-487, 1995). Ten different SAGE libraries were constructed and sequenced for this study (Table 3). Our libraries included two derived from OSE cells (IOSE29 and HOSE-4), one derived from immortalized cystadenoma cells (ML-10), three primary tumors (OVT-6, -7, -8) and four libraries derived from ovarian cancer cell lines (OV-1063, ES-2, A2780 and a pool of cell lines). Almost 20,000 sequencing reactions were performed yielding a total of 384,497 tags, of which, 82,533 were unique. Accounting for a SAGE tag error rate of 6.8% (due to sequencing errors; see Zhang, L., et al., *Science* 276:1268-1272, 1997), we estimate that we have identified a total of 56,387 genes expressed in ovarian tissues. Except for the A2780 cell line and the pooled lines (POOL) samples, a minimum of 12,000 genes were obtained from every library. Typically, for each library, 10% of the genes were expressed at levels of at least 0.01% and, collectively, these genes accounted for more than 50% of all the tags sequenced. Among the tags that appeared more than once, up to 95% matched to known sequences in the current Genbank nr database. For example, of the 6637 tags that appeared more than once in ML10, only 311 had no matches in the current database, excluding the EST databases.

Table 3 Summary of SAGE library analyses

Library ^a	Sequence	Tags ^b	Unique tags ^c	Genes ^d	≥ 2 tags ^e
HOSE	2,290	47,881	16,034	12,778	4,532
IOSE	1,912	47,549	18,004	14,771	5,681
ML10	1,935	55,700	18,727	14,939	6,637
OVT6	2,104	41,620	18,476	15,646	4,799
OVT7	2,089	53,898	19,523	15,858	5,669
OVT8	2,076	32,494	16,363	14,153	3,815
OV1063	2,146	37,862	15,231	12,656	4,746
A2780	1,332	21,587	10,717	9,249	2,761
ES2	1,775	35,352	14,739	12,335	3,952
POOL	2,201	10,554	5,956	5,238	1,627
TOTAL	19,860	384,497	82,533	56,387	28,219

^aThe libraries are: HOSE, human ovarian surface epithelium from short term culture; IOSE, SV40-immortalized ovarian surface epithelium; ML10, SV40-immortalized benign cystadenoma; OVT6, OVT7, and OVT8, primary ovarian serous adenocarcinomas; OV1063, A2780, and ES2, ovarian cancer cell lines; POOL, a pool of ten ovarian cancer cell lines.

^bTag numbers after elimination of linker-based tags and duplicate ditags.

^cThe number of unique tags identified in each library.

^dThe number of genes identified after correction for sequencing errors.

^eThe number of genes represented at least twice.

Comparisons of global gene expression between ovarian tissue samples

Although progression to malignancy requires a number of gene expression changes, the transcript levels from the vast majority of genes remain unaltered (Zhang, L., et al., *Science* 276:1268-1272, 1997; and Alon, U., et al., *Proc. Natl Acad. Sci. USA* 96:6745-6750, 1999). Similarities between the global expression profiles of two given samples can be readily visualized using scatterplots and quantitated through the calculation of Pearson correlation coefficients. Scatterplots of global gene expression analysis in IOSE (ovarian) vs. ML10 (ovarian), OVT6 (ovarian), or Tu98 (colon) cells were generated using the Spotfire Pro 4.0 software (Cambridge, MA) and the Pearson correlation coefficients for each pair-wise comparison of the 16 ovarian and colon SAGE libraries were calculated.

As expected, the immortalized IOSE29 and ovarian cystadenoma strain ML10 are much more similar to ovarian tumors than to colon tumors (average correlation coefficients of 0.70 vs. 0.51, respectively). In addition, IOSE29 and ML10 are very similar to each other, with a correlation coefficient of 0.82. The primary culture of OSE cells (HOSE-4) exhibited higher similarities to the ovarian tumors than to the colon tumors, although the similarity levels were much lower than those observed for IOSE29. Interestingly, HOSE-4 and IOSE29 appear to be much more distantly related than expected considering the fact that they were both derived from "normal" OSE cells. The differences in gene expression between these cells may be due to a number of factors. The age of the patient, the pathological state of the ovaries, the presence of non-epithelial cells in the culture and the fact that IOSE29 is SV40-immortalized may all contribute to the gene expression differences observed. However, it is unlikely that the main differences are due to SV40-immortalization since IOSE29 is much more similar to normal colon (a non SV40-immortalized epithelium) than HOSE-4. It is, of course, possible that the lower degree of similarity between HOSE-4 and the ovarian tumors compared to IOSE29 and ML-10 reflects the fact that HOSE-4 represents a better approximation of the normal *in vivo* OSE cell.

Three dendrograms were created from hierarchical cluster analysis of all colon and ovarian SAGE libraries, ovarian samples only, and non-malignant ovarian and colon epithelia as well as ovarian and colon primary tumors, using Cluster software (Eisen, M. B., et al. *Proc. Natl Acad. Sci. USA* 95:14863-14868, 1998). When all the

samples were included in the hierarchical clustering analysis, the primary colon tumors clustered with the normal colon epithelium, but colon cell lines clustered with the ovarian specimens. Clearly, the tissue clustering that was readily apparent when comparing primary tissues or immortalized lines was lost when including carcinoma cell lines. For example, A2780, a widely used ovarian cancer cell line was just as similar to colon cancer cell lines as it was to ovarian cancer cell lines. This observation supports the idea that in the process of establishment, cell lines may lose many of the gene expression characteristics of their tissue of origin, although tissue specific expression is clearly not completely lost in cancer cell lines (Ross, D. T., et al. *Nat. Genet.* 24:227-235, 2000).

It is widely believed that epithelial ovarian cancer and benign ovarian cysts, while not necessarily part of a progression sequence toward malignancy, are both derived from the ovarian surface epithelium (Scully, R. E. *J. Cell Biochem.* 23, Suppl.:208-218, 1995). OSE cells themselves are mesodermal in origin and are believed to undergo metaplasia before progressing to neoplasia (Scully, R. E. *J. Cell Biochem.* 23 Suppl.:208-218, 1995; and Maines-Bandiera, S. L. and Auersperg, N. *Int. J. Gynecol. Pathol.* 16:250-255, 1997). On the other hand, it has also been argued that ovarian cancers are not derived from OSE but rather from the secondary Mullerian system, structures lined by Mullerian epithelium but located outside the uterus, cervix and fallopian tubes (Schink, J. C. *Semin. Oncol.* 26 Suppl. 1: 2-7, 1999). This hypothesis would explain some of the shortcomings of the OSE model, such as the requirement for metaplasia and the lack of well-defined precursors in the ovary. While not wishing to be bound by theory, our results are consistent with the widely accepted dogma of the OSE origin of ovarian cancer. Indeed, IOSE29 showed high degrees of similarity to the ovarian tumors and both IOSE29 and HOSE were much more closely related to ovarian than colon primary cancers.

E-cadherin expression has been proposed to be a major determinant in the formation of metaplastic OSE (Auersperg, N., et al. *Proc. Natl Acad. Sci. USA*, 96:6249-6254, 1999; and Maines-Bandiera, S. L. and Auersperg, N. *Int. J. Gynecol. Pathol.* 16:250-255, 1997). Consistent with this hypothesis, E-cadherin was absent in IOSE29, HOSE and ML10 but was expressed in all three ovarian tumors (Table 4). Other cadherins are also shown for comparison. Interestingly, VE-cadherin is absent in

most libraries except in two of the pre-neoplastic ovarian samples, again suggesting metaplasia. As expected, LI-Cadherin was expressed exclusively in the colon-derived libraries. Interestingly, vimentin, a mesenchymal marker, was present in essentially all the ovarian libraries but very low in the colon specimens. Although the specificity of
5 vimentin as a mesenchymal marker has been questioned, this suggests that OSE may retain some of their mesenchymal characteristics, even after turning on the expression of E-cadherin.

The cytokeratins (CKs) and carcinoembryonic antigen (CEA) have been used to differentiate between colon cancer and ovarian cancer (Lagendijk, J. H., et al. *Hum.*
10 *Pathol.* 29:491-497, 1998; and Berezowski, K., et al. *Mod. Pathol.* 9:426-429, 1996). Typically, colon cancer expresses CK20 and CEA while ovarian cancer expresses CK7. The expression patterns in our libraries were consistent with previously reported observations: CK20 and CEA were found in normal colon and colon tumors but absent from all of our ovarian samples (Table 4). Conversely, CK7 was expressed in all three
15 primary ovarian tumors and, while not absent, was much lower in the colon samples. Examination of the differential expression patterns of a variety of established ovarian cancer markers thus provided validation of the SAGE database and cluster analysis.

Differential gene expression

20 The ultimate goal of comparing SAGE libraries is to identify differentially expressed genes. Criteria for differential expression can be determined for each comparison and transcripts within the determined range selected for study. We found a large number of genes that were up-regulated in only one or two of the three tumors on which SAGE was performed. For example, a total of 444 genes were up-regulated
25 more than 10-fold in at least one of the three ovarian primary cancers compared to IOSE29. However, only 45 genes were overexpressed more than 10-fold in all three ovarian tumors analyzed compared to IOSE29.

Our analysis of three different primary ovarian cancers allowed us to reduce the number of candidates by looking for consistency between samples. In order to identify
30 genes that are very likely to be frequently up-regulated during ovarian tumorigenesis we set the following conservative criteria for our analysis. First, the fold induction was calculated by adding the number of normalized tags from the three primary tumors and

dividing this number by the total normalized tags in the three non-malignant specimens. Cell lines were not included here for reasons described above. In addition, although HOSE-4 appeared more distantly related to the other non-transformed specimens, we believe that the inclusion of HOSE-4, while possibly eliminating real candidates makes our analysis more conservative and more likely to identify truly overexpressed genes in ovarian cancer. Second, all three primary tumors were required to consistently show elevated levels (>12 tags/100,000) of the gene in question. This eliminated genes that may be very highly overexpressed in one tumor but not in others. Finally, the candidate genes were required to be expressed in at least one ovarian cell line at a level greater than 3 tags/100,000. This last criterion was used to reduce the possibility of identifying genes because of their high level of expression in inflammatory cells or in the stroma of the primary tumors. Using these criteria, the genes that exhibited more than 10-fold overexpression were identified and are shown in Table 4.

Two members of the Claudin family of tight junction proteins, Claudin-3 and -4 were found among the top six differentially expressed genes and likely represent transmembrane receptors. In addition, Apolipoprotein J (ApoJ) and Apolipoprotein E (ApoE) were both overexpressed in ovarian cancer.

Of the 27 overexpressed genes shown in Table 4, ten were relatively specific for the ovary (HLA-DR, two different ESTs, GA733-1, ceruloplasmin, glutathione peroxidase-3, the secretory leukocyte protease inhibitor, ApoJ, ApoE and mesothelin) while the others were also expressed in colon tissues. In any event, it is significant that MUC1, HE4, Ep-CAM and mesothelin, four genes already known to be up-regulated in epithelial ovarian cancer, were identified in this study. This fact validates our approach as well as our set of criteria used to determine the genes differentially expressed.

Similarly, stringent criteria were used to identify genes down-regulated in ovarian tumors compared to IOSE29, HOSE-4 and ML10. Again, the fold difference was calculated by adding tag frequency for all three "normal" specimens and dividing by the total number of tags in the three ovarian tumors. A candidate was required to be expressed at a level of 12 tags/100,000 or greater in all three normal samples. The genes found elevated more than ten-fold in normal tissue compared to tumors are shown in Table 4.

Table 4. A subset of genes differentially expressed in ovarian tumors compared to non-malignant ovarian samples

SEQ ID NO. (TAG)	TAG	GENE	EXPRESSION ^a					FUNCTION
			Fold	OSE ML10	Ovarian Tumors	Colon Epithelium	Colon Tumors	
		up-regulated ^a						
103	GGGCACTCT	HLA-DR α chain	289	-	++	-	-	Major histocompatibility complex, class II/ antigen presentation
104	TTTGGCCCTA	Cysteine-rich protein 1	123	-	++	+	+	LIM/double zinc finger
105	ATCGTGGCGG	Claudin 4	109	-	+	++	+	Tight junction barrier function
106	TATTATGGTA	ESTs (HOST-2)	101	-	+	-	-	Unknown
107	GCCTACCCGA	Surface marker 1/ GA733-1/ TROP2	93	-	+	-	-	Tumor Ag/ Ca ²⁺ signal transducer
108	CTGGCGCTGG	Claudin 3	83	-	+	++	+	Tight junction barrier function
109	TTGCTTGCCA	Ceruloplasmin (ferroxidase)	79	-	+	-	-	Secreted metalloprotein/ antioxidant
110	AGGGAGGGC	HE4	72	-	++	+	-	Secreted protease inhibitor
111	TGTGGAAAT	Glutathione peroxidase 3 (plasma)	69	-	+	-	-	Secreted selenoprotein/ peroxidase
112	CCTGATCTGC	Secretory leukocyte protease inhibitor	60	-	++	-	-	Secreted serine protease inhibitor
113	AGTTTGTAG	ESTs (HOST-1)	56	-	+	-	-	Unknown
114	CAACTAATTC	Interferon-induced transmembrane protein 1	49	-	++	-	+	Receptor for interferon signaling
115	GCCTGACATC	Ep-CAM/ EGP2/ TROP1/ GA733-2	48	-	+	++	+	Tumor Ag/ Ca ²⁺ -independent CAM/ proliferation
116	CGACCCACGC	Mucin 1	43	-	++	+	+	Tumor Ag/ Type-I membrane glycoprotein
117	TTCTGTGCTG	Apolipoprotein 1/ clusterin	39	-	++	-	-	Secreted chaperone/ cytoprotection
118	CGCCGCCCGG	Serine protease inhibitor, Kunitz type, 2	34	-	++	++	+	Transmembrane/ protease inhibitor
119	GATCAGGCCA	Apolipoprotein E	34	-	++	-	-	Lipoprotein particle binding, internalization and catabolism
120	GTGGAAGACG	Complement component 1, r subcomponent	24	-	+	-	-	Serine protease of complement system/ autoimmune diseases
121	GIP3/ IFI-6-16		24	-	++	+	+	Interferon primary response/ α IFN-inducible
122	CCCGCTGCAG	Lutheran blood group protein/ BCAM	17	-	++	-	-	Possible cell surface receptor/ immunoglobulin superfamily
123	TTCCCTCTCT	Collagen Type III, alpha-1	16	-	++	-	+	Unknown
124	TGCTGCCTGT	Mal (T cell differentiation protein)	16	-	+	-	+	Trans-Golgi membrane protein (epithelial cells)/ T-cell differentiation
124	TGCAGCACGA	ESTs (Collagen Type I, alpha-2)	13	+	++	-	+	Unknown
126		HLA-DPB1	13	-	+	-	-	Major histocompatibility complex, class II/ antigen presentation
127		Mesothelin	12	-	++	-	-	GPI-anchored/ mesothelioma and ovarian cancer antigen/ cell adhesion
128		Bone marrow stroma antigen 2/ BST-2	12	-	++	-	+	Type II transmembrane protein/ pre-B-cell growth
129		HLA-Cw	10	-	++	++	+	Major histocompatibility complex, class I/ antigen presentation
		down-regulated ^b						
130	GGTATATTTG	Unknown	99	+	-	-	-	Unknown
131	TGTCAATACA	Lysyl oxidase-like 2	73	+	-	-	-	Secreted/ collagen and elastin crosslinker
132	AAAAATAACA	Chloride intracellular channel 4 like	29	+	-	-	-	Ion transport
133	TAAAAATGTT	Plasminogen activator inhibitor, type 1	26	++	-	-	-	Serine protease inhibitor family/ tPA inhibitor
134	GAGCTTTTGA	EST	14	+	-	-	-	Unknown
135	GGCTGATGTG	Glycine t-RNA synthetase	13	+	-	-	-	Protein synthesis
136	CGACGAGGAG	Epithelial membrane protein-3	13	+	-	-	-	Proliferation, differentiation, and apoptosis
137	GCCCCCAATA	Galectin-1	10	++	+	-	-	β -galactoside binding lectin/ ECM interaction and proliferation
138	GCAACTTGGA	Vinexin 6	10	+	-	-	-	Cell-adhesion and cytoarchitecture

^a Candidates up-regulated at least 30-fold in tumors^b Candidates down-regulated at least 10-fold in tumors^c Expression is defined as: -, 0-9 tags/100,000; +, 10-49 tags/100,000; ++, > 49 tags/100,000

In order to validate the candidates identified by SAGE, we performed immunohistochemical analysis of thirteen cases of serous cancer of the ovary using antibodies against four of the genes identified as up-regulated in ovarian cancer (Table 5). This was particularly important since the SAGE analysis was initially performed from primary ovarian cancers, which contain a mixture of cell types. Ep-CAM exhibited diffuse, strong staining of tumor cell membranes in all thirteen tumors, without blood cell or stromal staining. Importantly, only one of six samples of the ovarian surface epithelium present in the cases showed weak focal staining, and the rest were negative. The strong immunoreactivity of all thirteen ovarian tumors confirms the validity of our approach to identify genes highly and consistently up-regulated in ovarian cancer. Similarly, ApoJ was found to be expressed in ovarian cancer cells and absent from the surface epithelium. While some expression was detected in non-tumor stroma and inflammatory cells, most of the immuno-reactivity was in tumor cells, and a majority (nine out of thirteen) of the cases showed staining. This observation represents the first report of ApoJ expression in ovarian cancer and provides a novel target for diagnosis or therapy. Claudin-3 and -4 also exhibited staining limited to the tumor component of the specimens. Most tumor cells showed strong membrane staining with weak cytoplasmic reactivity. Some tumors specimens showed decreased membrane staining with strong cytoplasmic reactivity. The normal surface epithelial component (or mesothelial cells) examined did not stain or only stained weakly with the Claudin-4 antibody, while the determination of Claudin-3 levels in normal epithelium was complicated by a low background reactivity with this antibody.

Incorporation by Reference

Throughout this application, various publications, patents, and/or patent applications are referenced in order to more fully describe the state of the art to which this invention pertains. The disclosures of these publications, patents, and/or patent applications are herein incorporated by reference in their entireties to the same extent as if each independent publication, patent, and/or patent application was specifically and individually indicated to be incorporated by reference.

Other Embodiments

It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the scope or spirit of the invention. Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

What is claimed is:

1. A method of detecting an ovarian tumor in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not having an ovarian tumor, detects an ovarian tumor in said subject.

2. A method of identifying a subject at increased risk for developing ovarian cancer, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject, wherein an increase in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in a reference subject not at increased risk for developing ovarian cancer, identifies an individual at increased risk for developing ovarian cancer.

3. A method of determining the effectiveness of an ovarian cancer treatment in a subject, said method comprising measuring the expression level of an ovarian tumor marker gene in said subject after treatment of said subject, wherein a modulation in said expression level of said ovarian tumor marker gene in said subject, relative to the expression level of said ovarian tumor marker gene in said subject prior to said treatment, indicates an effective ovarian cancer treatment in said subject.

4. The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined in said subject by measuring the expression level of said tumor marker gene in a sample from said subject.

5. The method of claim 4, wherein said sample from said subject is selected from the group consisting of a tissue biopsy, ovarian epithelial cell scrapings, peritoneal fluid, blood, urine, and serum.
6. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is measured *in vivo* in said subject.
7. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is determined by measuring the level of ovarian tumor marker mRNA.
8. The method of claim 7, wherein said level of ovarian tumor marker mRNA is measured using RT-PCR, Northern hybridization, dot-blotting, or *in situ* hybridization.
9. The method of claim 1, 2, or 3, wherein said expression level of said ovarian tumor marker gene is determined by measuring the level of ovarian tumor marker polypeptide encoded by said ovarian tumor marker gene.
10. The method of claim 9, wherein said level of ovarian tumor marker polypeptide is measured by ELISA, immunoblotting, or immunohistochemistry.
11. The method of claim 1, 2, or 3, wherein said expression level of said tumor marker gene is compared to the expression level of said tumor marker gene in a reference subject diagnosed with ovarian cancer.
12. The method of claim 2, wherein said expression level of said ovarian tumor marker gene in said subject is compared to the expression level of said tumor marker gene in a reference subject that is identified as having an increased risk for developing ovarian cancer.

13. A method of identifying a tumor as an ovarian tumor, said method comprising measuring the expression level of an ovarian tumor marker gene in a tumor cell from said tumor, wherein an increase in said expression level of said ovarian tumor marker gene in said tumor cell, relative to the expression level of said ovarian tumor marker gene in a noncancerous ovarian cell, identifies the tumor as an ovarian tumor.

14. A method of treating or preventing an ovarian tumor in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in an ovarian epithelial cell in said subject.

15. A method of inhibiting the growth or metastasis of an ovarian tumor cell in a subject, said method comprising modulating production or activity of a polypeptide encoded by an ovarian tumor marker gene in said ovarian tumor cell in said subject.

16. A method of inhibiting the growth or metastasis of an ovarian tumor in a subject, said method comprising contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide encoded by an ovarian tumor marker gene, wherein the binding of said antibody to said ovarian tumor marker polypeptide inhibits the growth or metastasis of said ovarian tumor in said subject.

17. The method of claim 16, wherein said ovarian tumor marker polypeptide is on the surface of said ovarian tumor cell.

18. The method of claim 16, wherein said antibody is coupled to a radioisotope or a toxic compound.

19. A method of diagnosing ovarian cancer in a subject, said method comprising measuring the amount of an ovarian tumor marker polypeptide in said subject, wherein an

amount of ovarian tumor marker polypeptide that is greater than the amount of ovarian tumor marker polypeptide measured in a subject not having ovarian cancer diagnoses an ovarian cancer in the subject.

20. The method of claim 19, wherein said ovarian tumor marker polypeptide is present at the surface of a cell.

21. The method of claim 19, wherein said ovarian tumor marker polypeptide is in soluble form.

22. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96); HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.

23. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione peroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apolipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

24. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-IIb).

25. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

26. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

27. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.

28. The method of claim 1, 2, 3, 13, 14, 15, 16, or 19, wherein said ovarian tumor is an epithelial ovarian tumor.

29. The method of claim 28, wherein said epithelial ovarian tumor is selected from the group consisting of a serous cystadenoma, a borderline serous tumor, a serous cystadenocarcinoma, a mucinous cystadenoma, a borderline mucinous tumor, a mucinous cystadenocarcinoma, an endometrioid carcinoma, an undifferentiated carcinoma, a clear cell adenocarcinoma, a cystadenofibroma, an adenofibroma, and a Brenner tumor.

30. A kit comprising an antibody for measuring the expression level of an ovarian tumor marker gene in a subject.

31. A kit comprising a nucleic acid for measuring the expression level of an ovarian tumor marker gene in a subject.

32. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of alpha prothymosin; beta polypeptide 2-like G protein subunit 1; Lutheran blood group (B-CAM); tumor rejection antigen-1 (gp96)1; HSP90; HSP60; Hepatoma-Derived Growth Factor (HGDF); DKFZp5860031; CD63 antigen (melanoma 1 antigen); protein kinase C substrate 80K-H; Polymerase II cofactor 4 (PC4); mitochondrial Tu translation elongation factor; hNRP H1; Solute carrier family 2; KIAA0591 protein; X-ray repair protein; DKFZP564M2423 protein; growth factor-regulated tyrosine kinase substrate; and eIF-2-associated p67.

33. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HLA-DR alpha chain; cysteine-rich protein 1; claudin 4; claudin 3; ceruloplasmin (ferroxidase); glutathione peroxidase 3; secretory leukocyte protease inhibitor; HOST-1 (FLJ14303 fis); interferon-induced transmembrane protein 1; apolipoprotein J/clusterin; serine protease inhibitor, Kunitz type 2; apolipoprotein E; complement component 1, r subcomponent; G1P3/IFI-6-16; Lutheran blood group (BCAM); collagen type III, alpha-1; Mal (T cell differentiation protein); collagen type I, alpha-2; HLA-DPB1; bone marrow stroma antigen 2 (BST-2); or HLA-Cw.

34. The kit of claim 30 or 31, wherein said ovarian tumor marker gene is selected from the group consisting of HOST-3 (Claudin-16); HOST-4; or HOST-5 (sodium dependent transporter isoform NaPi-Iib).

35. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 84-102.

36. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 103-129.

37. The kit of claim 30 or 31, wherein said ovarian tumor marker gene comprises a nucleotide sequence set forth in one of SEQ ID NOs: 141, 143, or 145.

SEQUENCE LISTING

<110> The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services

Morin, Patrice J.
 Sherman-Baust, Cheryl A.
 Pizer, Ellen S.
 Hough, Colleen D.

<120> TUMOR MARKERS IN OVARIAN CANCER

<130> 14014.0369P1

<150> 60/194,336

<151> 2000-04-03

<160> 147

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 490

<212> DNA

<213> Homo sapiens

<400> 1

tccttgccccg	ccgcagtcgc	ctccgcgcgcg	cgctctctcc	gccgcgcgcg	actccggcag	60
ctttatcgcc	agagtccttg	aactctcgct	ttctttttaa	tcccctgcat	cggatcaccg	120
gcgtgcccc	ccatgtcaga	cgcagccgta	gacaccagct	ccgaaatcac	caccaaggac	180
ttaaaggaga	agaaggaagt	tgtggaagag	gcagaaaatg	gaagagacgc	ccctgctaac	240
gggaatgcta	atgaggaaaa	cggggagcag	gaggctgaca	atgaggtaga	cgaagaagag	300
gaagaagggtg	gggaggaaga	ggaggaggaa	gaagaagggtg	atggtgagga	agaggatgga	360
gatgaagatg	aggaagctga	gtcagctacg	ggcaagcggg	cagctgaaga	tgatgaggat	420
gacgatgtcg	ataccaagaa	gcagaagacc	gacgaggatg	actagacagc	aaaaaaggaa	480
aagttaaact						490

<210> 2

<211> 110

<212> PRT

<213> Homo sapiens

<400> 2

Met	Ser	Asp	Ala	Ala	Val	Asp	Thr	Ser	Ser	Glu	Ile	Thr	Thr	Lys	Asp
1			5					10						15	
Leu	Lys	Glu	Lys	Lys	Glu	Val	Val	Glu	Glu	Ala	Glu	Asn	Gly	Arg	Asp
		20						25				30			
Ala	Pro	Ala	Asn	Gly	Asn	Ala	Asn	Glu	Glu	Asn	Gly	Glu	Gln	Glu	Ala
		35				40				45					
Asp	Asn	Glu	Val	Asp	Glu	Glu	Glu	Glu	Glu	Gly	Gly	Glu	Glu	Glu	Glu
	50				55					60					
Glu	Glu	Glu	Glu	Gly	Asp	Gly	Glu	Glu	Glu	Asp	Gly	Asp	Glu	Asp	Glu
65				70				75					80		
Glu	Ala	Glu	Ser	Ala	Thr	Gly	Lys	Arg	Ala	Ala	Glu	Asp	Asp	Glu	Asp
			85					90					95		
Asp	Asp	Val	Asp	Thr	Lys	Lys	Gln	Lys	Thr	Asp	Glu	Asp	Asp		
		100					105						110		

<210> 3
 <211> 1093
 <212> DNA
 <213> Homo sapiens

<400> 3
 ctgcaaggcg gcgccaggag aggttgtggt gctagtttct ctaagccatc cagtgccatc 60
 ctgctcgctg cagcgacacc gctctcgccg ccgccatgac tgagcagatg acccttcgtg 120
 gcaccctcaa gggccacaac ggctgggtaa ccagatcgc tactaccccg cagttcccgg 180
 acatgatcct ctccgcctct cgagataaga ccatcatcat gtggaaactg accagggatg 240
 agaccaacta tgggaattcca cagcgtgctc tgccgggtca ctcccacttt gttagtgatg 300
 tggttatctc ctcatatggc cagtttgccc tctcaggctc ctgggatgga accctgcgcc 360
 tctgggatct cacaacgggc accaccacga ggcgatttgt gggccatacc aaggatgtgc 420
 tgagtgtggc cttctcctct gacaaccggc agattgtctc tggatctcga gataaaacca 480
 tcaagctatg gaataccctg ggtgtgtgca aatacactgt ccaggatgag agccactcag 540
 agtgggtgtc ttgtgtccgc ttctcgccca acagcagcaa ccctatcatc gtctcctgtg 600
 gctgggacaa gctgggtcaag gtatggaacc tggctaactg caagctgaag accaaccaca 660
 ttggccacac aggcctatctg aacacgggtga ctgtctctcc agatggatcc ctctgtgctt 720
 ctggaggcaa ggtatggccag gccatgttat gggatctcaa cgaaggcaaa caccctttaca 780
 cgctagatgg tggggacatc atcaacgccc tgtgcttcag ccctaaccgc tactggctgt 840
 gtgctgccac agggcccagc atcaagatct gggatttaga gggaaagatc attgtagatg 900
 aactgaagca agaagttatc agtaccagca gcaaggcaga accaccccag tgcacttccc 960
 tggcctgggc tgctgatggc cagactctgt ttgctggcta cacggacaac ctggtgcgag 1020
 tgtggcaggt gaccattggc acacgctaga agtttatggc agagctttac aaataaaaaa 1080
 aaaatggctt ttc 1093

<210> 4
 <211> 317
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Thr Glu Gln Met Thr Leu Arg Gly Thr Leu Lys Gly His Asn Gly
 1 5 10 15
 Trp Val Thr Gln Ile Ala Thr Thr Pro Gln Phe Pro Asp Met Ile Leu
 20 25 30
 Ser Ala Ser Arg Asp Lys Thr Ile Met Trp Lys Leu Thr Arg Asp
 35 40 45
 Glu Thr Asn Tyr Gly Ile Pro Gln Arg Ala Leu Arg Gly His Ser His
 50 55 60
 Phe Val Ser Asp Val Val Ile Ser Ser Asp Gly Gln Phe Ala Leu Ser
 65 70 75 80
 Gly Ser Trp Asp Gly Thr Leu Arg Leu Trp Asp Leu Thr Thr Gly Thr
 85 90 95
 Thr Thr Arg Arg Phe Val Gly His Thr Lys Asp Val Leu Ser Val Ala
 100 105 110
 Phe Ser Ser Asp Asn Arg Gln Ile Val Ser Gly Ser Arg Asp Lys Thr
 115 120 125
 Ile Lys Leu Trp Asn Thr Leu Gly Val Cys Lys Tyr Thr Val Gln Asp
 130 135 140
 Glu Ser His Ser Glu Trp Val Ser Cys Val Arg Phe Ser Pro Asn Ser
 145 150 155 160
 Ser Asn Pro Ile Ile Val Ser Cys Gly Trp Asp Lys Leu Val Lys Val
 165 170 175
 Trp Asn Leu Ala Asn Cys Lys Leu Lys Thr Asn His Ile Gly His Thr
 180 185 190
 Gly Tyr Leu Asn Thr Val Thr Val Ser Pro Asp Gly Ser Leu Cys Ala
 195 200 205
 Ser Gly Gly Lys Asp Gly Gln Ala Met Leu Trp Asp Leu Asn Glu Gly
 210 215 220

Lys His Leu Tyr Thr Leu Asp Gly Gly Asp Ile Ile Asn Ala Leu Cys
 225 230 235 240
 Phe Ser Pro Asn Arg Tyr Trp Leu Cys Ala Ala Thr Gly Pro Ser Ile
 245 250 255
 Lys Ile Trp Asp Leu Glu Gly Lys Ile Ile Val Asp Glu Leu Lys Gln
 260 265 270
 Glu Val Ile Ser Thr Ser Ser Lys Ala Glu Pro Pro Gln Cys Thr Ser
 275 280 285
 Leu Ala Trp Ser Ala Asp Gly Gln Thr Leu Phe Ala Gly Tyr Thr Asp
 290 295 300
 Asn Leu Val Arg Val Trp Gln Val Thr Ile Gly Thr Arg
 305 310 315

<210> 5

<211> 2402

<212> DNA

<213> Homo sapiens

<400> 5

agtctccgcc	gccgccgtga	acatggagcc	cccggacgca	ccggcccagg	cgcgcggggc	60
cccgcggctg	ctgttgetcg	cagtcctgct	ggcggcgcac	ccagatgccc	aggcggaggt	120
gcgcttgtct	gtacccccgc	tggtggaggt	gatgcgagga	aagtctgtca	ttctggactg	180
caccctacg	ggaaccacg	accattatat	gctggaatgg	ttccttaccg	accgctcggg	240
agctcgcccc	cgctagcct	cggtcgagat	gcagggtctt	gagctccagg	tcacaatgca	300
cgacaccggg	ggcgcagtc	ccccatacca	gctggactcc	caggggcgcc	tggtgctggc	360
tgaggcccg	gtgggcgacg	agcgagacta	cgtgtgcgtg	gtgagggcag	ggcgggcagg	420
cactgctgag	gccactgcgc	ggctcaacgt	gtttgcaaag	ccagaggcca	ctgaggtctc	480
ccccaacaaa	gggacactgt	ctgtgatgga	ggactctgcc	caggagatcg	ccacctgcaa	540
cagccggaac	gggaaccggg	cccccaagat	cacgtggtat	cgcaacgggc	agcgcttgga	600
ggtgcccgta	gagatgaacc	cagaggggcta	catgaccagc	cgcacgggtc	gggaggcctc	660
gggcctgctc	tccctcacca	gcacctctta	cctgcgggtc	cgcaaggatg	accgagacgc	720
cagcttccac	tgcgcgcgcc	actacagcct	gccccagggc	cgccacggcc	gcctggacag	780
ccccaccttc	cacctacccc	tgcactatcc	cacggagcac	gtgcagttct	gggtgggcag	840
cccgctccacc	ccagcaggct	gggtacgcga	gggtgacct	gtccagctgc	tctgccgggg	900
ggacggcagc	cccagccggg	agtatacget	tttcgcctt	caggatgagc	aggaggaagt	960
gctgaatgtg	aatctcgagg	ggaacttgac	cctggaggga	gtgacccggg	gccagagcgg	1020
gacctatggc	tgcagagtgg	aggattacga	cgcggcagat	gacgtgcagc	tctccaagac	1080
gctggagctg	cgcggtggcct	atctggaccc	cctggagctc	agcgagggga	aggtgctttc	1140
cttacctcta	aacagcagtg	cagtcgtgaa	ctgctccgtg	cacggcctgc	ccaccctgc	1200
cctacgctgg	accaaggact	ccactcccct	gggcgatggc	cccatgctgt	cgctcagttc	1260
tatcaccttc	gattccaatg	gcacctacgt	atgtgaggcc	tccctgcccc	cagtcccggg	1320
cctcagccgc	accagaact	tcacgtgct	ggtccaaggc	tgcgcagagc	taaagacagc	1380
ggaaatagag	cccaaggcag	atggcagctg	gaggggaagg	gacgaagtca	cactcatctg	1440
ctctgcccgc	ggccatccag	accccaaact	cagctggagc	caattggggg	gcagccccgc	1500
agagccaatc	cccggacggc	agggttgggt	gagcagctct	ctgacctga	aagtgaccag	1560
cgccctgagc	cgcgatggca	tctcctgtga	agcctccaac	ccccacggga	acaagcgcca	1620
tgtcttccac	ttcggcgcgc	tgagccccca	gacctcccag	gctggagtgg	ccgtcatggc	1680
cgtggccgct	agcgtgggce	tctgtctcct	cgctcgttgc	gtcttctact	gcgtgagacg	1740
caaagggggc	ccctgctgcc	gccagcggcg	ggagaagggg	gtcccgccgc	caggggagcc	1800
agggctgagc	cactcggggg	cggagcaacc	agagcagacc	ggccttctca	tgggaggtgc	1860
ctccggagga	gccaggggtg	gcagcggggg	cttcggagac	gagtgtgtag	ccaagaacct	1920
cctagaggct	gtccctggac	ctggagetgc	aggcatcaga	gaaccagccc	tgtctacgcc	1980
atgcccgccc	ccgccttccc	tcttccctct	tccctctccc	tgcccagccc	tcccttccct	2040
cctctgcccg	caaggcaggg	acccacagtg	gctgcctgcc	tccgggaggg	aaggagaggg	2100
aggggtgggtg	ggtgggaggg	ggccttccct	cagggaatgt	gactctccca	ggccccagaa	2160
tagctcctgg	acccaagccc	aaggcccagc	ctgggacaag	gctccgaggg	tgggctggcc	2220
ggagctatct	ttacctcccc	cctccccctg	tggtcccccc	acctgacgtc	ttgtgcagaa	2280
gtctgacact	ggattcccc	ccctcacccc	gcccctgggc	ccactcctgc	ccccgcctta	2340
cctccgcccc	accccatcat	ctgtggacac	tggagtctgg	aataaatgct	gtttgtcaca	2400
tc						2402

<210> 6
 <211> 628
 <212> PRT
 <213> Homo sapiens

<400> 6
 Met Glu Pro Pro Asp Ala Pro Ala Gln Ala Arg Gly Ala Pro Arg Leu
 1 5 10 15
 Leu Leu Leu Ala Val Leu Leu Ala Ala His Pro Asp Ala Gln Ala Glu
 20 25 30
 Val Arg Leu Ser Val Pro Pro Leu Val Glu Val Met Arg Gly Lys Ser
 35 40 45
 Val Ile Leu Asp Cys Thr Pro Thr Gly Thr His Asp His Tyr Met Leu
 50 55 60
 Glu Trp Phe Leu Thr Asp Arg Ser Gly Ala Arg Pro Arg Leu Ala Ser
 65 70 75 80
 Ala Glu Met Gln Gly Ser Glu Leu Gln Val Thr Met His Asp Thr Arg
 85 90 95
 Gly Arg Ser Pro Pro Tyr Gln Leu Asp Ser Gln Gly Arg Leu Val Leu
 100 105 110
 Ala Glu Ala Gln Val Gly Asp Glu Arg Asp Tyr Val Cys Val Val Arg
 115 120 125
 Ala Gly Ala Ala Gly Thr Ala Glu Ala Thr Ala Arg Leu Asn Val Phe
 130 135 140
 Ala Lys Pro Glu Ala Thr Glu Val Ser Pro Asn Lys Gly Thr Leu Ser
 145 150 155 160
 Val Met Glu Asp Ser Ala Gln Glu Ile Ala Thr Cys Asn Ser Arg Asn
 165 170 175
 Gly Asn Pro Ala Pro Lys Ile Thr Trp Tyr Arg Asn Gly Gln Arg Leu
 180 185 190
 Glu Val Pro Val Glu Met Asn Pro Glu Gly Tyr Met Thr Ser Arg Thr
 195 200 205
 Val Arg Glu Ala Ser Gly Leu Leu Ser Leu Thr Ser Thr Leu Tyr Leu
 210 215 220
 Arg Leu Arg Lys Asp Asp Arg Asp Ala Ser Phe His Cys Ala Ala His
 225 230 235 240
 Tyr Ser Leu Pro Glu Gly Arg His Gly Arg Leu Asp Ser Pro Thr Phe
 245 250 255
 His Leu Thr Leu His Tyr Pro Thr Glu His Val Gln Phe Trp Val Gly
 260 265 270
 Ser Pro Ser Thr Pro Ala Gly Trp Val Arg Glu Gly Asp Thr Val Gln
 275 280 285
 Leu Leu Cys Arg Gly Asp Gly Ser Pro Ser Pro Glu Tyr Thr Leu Phe
 290 295 300
 Arg Leu Gln Asp Glu Gln Glu Val Leu Asn Val Asn Leu Glu Gly
 305 310 315 320
 Asn Leu Thr Leu Glu Gly Val Thr Arg Gly Gln Ser Gly Thr Tyr Gly
 325 330 335
 Cys Arg Val Glu Asp Tyr Asp Ala Ala Asp Asp Val Gln Leu Ser Lys
 340 345 350
 Thr Leu Glu Leu Arg Val Ala Tyr Leu Asp Pro Leu Glu Leu Ser Glu
 355 360 365
 Gly Lys Val Leu Ser Leu Pro Leu Asn Ser Ser Ala Val Val Asn Cys
 370 375 380
 Ser Val His Gly Leu Pro Thr Pro Ala Leu Arg Trp Thr Lys Asp Ser
 385 390 395 400
 Thr Pro Leu Gly Asp Gly Pro Met Leu Ser Leu Ser Ser Ile Thr Phe
 405 410 415
 Asp Ser Asn Gly Thr Tyr Val Cys Glu Ala Ser Leu Pro Thr Val Pro
 420 425 430

Val Leu Ser Arg Thr Gln Asn Phe Thr Leu Leu Val Gln Gly Ser Pro
 435 440 445
 Glu Leu Lys Thr Ala Glu Ile Glu Pro Lys Ala Asp Gly Ser Trp Arg
 450 455 460
 Glu Gly Asp Glu Val Thr Leu Ile Cys Ser Ala Arg Gly His Pro Asp
 465 470 475 480
 Pro Lys Leu Ser Trp Ser Gln Leu Gly Gly Ser Pro Ala Glu Pro Ile
 485 490 495
 Pro Gly Arg Gln Gly Trp Val Ser Ser Ser Leu Thr Leu Lys Val Thr
 500 505 510
 Ser Ala Leu Ser Arg Asp Gly Ile Ser Cys Glu Ala Ser Asn Pro His
 515 520 525
 Gly Asn Lys Arg His Val Phe His Phe Gly Ala Val Ser Pro Gln Thr
 530 535 540
 Ser Gln Ala Gly Val Ala Val Met Ala Val Ala Val Ser Val Gly Leu
 545 550 555 560
 Leu Leu Leu Val Val Ala Val Phe Tyr Cys Val Arg Arg Lys Gly Gly
 565 570 575
 Pro Cys Cys Arg Gln Arg Arg Glu Lys Gly Ala Pro Pro Pro Gly Glu
 580 585 590
 Pro Gly Leu Ser His Ser Gly Ser Glu Gln Pro Glu Gln Thr Gly Leu
 595 600 605
 Leu Met Gly Gly Ala Ser Gly Gly Ala Arg Gly Gly Ser Gly Gly Phe
 610 615 620
 Gly Asp Glu Cys
 625

<210> 7

<211> 2780

<212> DNA

<213> Homo sapiens

<400> 7

gtgggcggac	cgcgcggtg	gaggtgtgag	gatccgaacc	caggggtggg	gggtggaggg	60
ggctcctgcg	atcgaagggg	acttgagact	caccggccgc	acgccatgag	ggccctgtgg	120
gtgctggggc	tctgctgctg	cctgctgacc	ttcgggtcgg	tcagagctga	cgatgaagtt	180
gatgtgagtg	gtacagtaga	agaggatctg	ggtaaaagta	gagaaggatc	aaggacggat	240
gatgaagtag	tacagagaga	ggaagaagct	attcagttgg	atggattaaa	tgcatcacaa	300
ataagagAAC	ttagagagaa	gtcggaaaag	tttgcccttc	aagccgaagt	taacagaatg	360
atgaaactta	tcatacaattc	attgtataaa	aataaagaga	ttttcctgag	agaactgatt	420
tcaaattgctt	ctgatgcttt	agataagata	aggctaatat	cactgactga	tgaaaatgct	480
ctttctggaa	atgaggaact	aacagtcaaa	attaagtgtg	ataaggagaa	gaacctgctg	540
catgtcacag	acaccggtgt	aggaatgacc	agagaagagt	tggttaaaaa	ccttggtacc	600
atagccaaat	ctgggacaag	cgagttttta	aacaaaatga	ctgaagcaca	ggaagatggc	660
cagtcaactt	ctgaattgat	tggccagttt	ggtgtcgggt	tctattccgc	cttccttgta	720
gcagataaag	ttattgtcac	ttcaaaacac	aacaacgata	cccagcacat	ctgggagtct	780
gactccaattg	aattgtctgt	aattgtctgac	ccaagaggaa	acactctagg	acggggaacg	840
acaattacc	ttgtcttaaa	agaagaagca	tctgattacc	ttgaattgga	tacaattaaa	900
aatctcgtca	aaaaatattc	acagttcata	aactttccta	tttatgtatg	gagcagcaag	960
actgaaactg	ttgaggagcc	catggaggaa	gaagaagcag	ccaaagaaga	gaaagaagaa	1020
tctgatgatg	aagctgcagt	agaggaagaa	gaagaagaaa	agaaaccaa	gactaaaaaa	1080
gttgaaaaaa	ctgtctggga	ctgggaactt	atgaatgata	tcaaaccaat	atggcagaga	1140
ccatcaaaag	aagtagaaga	agatgaatac	aaagctttct	acaaatcatt	ttcaaaggaa	1200
agtgatgacc	ccatggctta	tattcacttt	actgctgaag	gggaagttac	cttcaaataca	1260
atthttattg	taccacatc	tgctccacgt	ggtctgtttg	acgaatatgg	atctaaaaag	1320
agcgattaca	taaagctcta	tgtgcgcctg	gtattcatca	cagacgactt	ccatgatatg	1380
atgcctaaat	acctcaattt	tgtcaagggg	gtggtggact	cagatgatct	ccccttgaat	1440
gtttcccgcg	agactcttca	gcaacataaa	ctgcttaagg	tgattaggaa	gaagcttggg	1500
cgtaaaacgc	tggacatgat	caagaagatt	gctgatgata	aatacaatga	tactttttgg	1560
aaagaatttg	gtaccaacat	caagcttggt	gtgattgaag	accactcgaa	tcgaacacgt	1620

cttgctaaac	ttcttaggtt	ccagtcttct	catcatccaa	ctgacattac	tagcctagac	1680
cagtatgtgg	aaagaatgaa	ggaaaaacaa	gacaaaatct	acttcatggc	tggttccagc	1740
agaaaagagg	ctgaatcttc	tccatttggt	gagcgacttc	tgaaaaaggg	ctatgaagtt	1800
atttacctca	cagaacctgt	ggatgaatac	tgtattcagg	cccttcccga	atttgatggg	1860
aagaggttcc	agaatggtgc	caaggaagga	gtgaagttcg	atgaaagtga	gaaaactaag	1920
gagagtcgtg	aagcagttga	gaaagaattt	gagcctctgc	tgaattggat	gaaagataaa	1980
gcccttaagg	acaagattga	aaaggctgtg	gtgtctcagc	gcctgacaga	atctccgtgt	2040
gctttggtgg	ccagccagta	cggatggtct	ggcaacatgg	agagaatcat	gaaagcacia	2100
gcgtaccaa	cgggcaagga	catctctaca	aattactatg	cgagtcagaa	gaaaacattt	2160
gaaattaatc	ccagacaccc	gctgatcaga	gacatgcttc	gacgaattaa	ggaagtga	2220
gatgataaaa	cagtttttga	tcttgctgtg	gttttggttg	aaacagcaac	gcttcggtca	2280
gggtatcttt	taccagacac	taaagcatat	ggagatagaa	tagaaagaat	gcttcgcctc	2340
agtttgaaca	ttgacctga	tgcaaaggtg	gaagaagagc	ccgaagaaga	acctgaagag	2400
acagcagaag	acacaacaga	agacacagag	caagacgaag	atgaagaaat	ggatgtggga	2460
acagatgaag	aagaagaaac	agcaaaggaa	tctacagctg	aaaaagatga	attgtaaatt	2520
atactctcac	catttggatc	ctgtgtggag	agggaaatgtg	aaattttacat	catttctttt	2580
tgggagagac	ttgttttga	tgccccctaa	tccccctctc	ccctgcactg	taaaatgtgg	2640
gattatgggt	cacaggaaaa	agtgggtttt	ttagttgaat	tttttttaac	attcctcatg	2700
aatgtaaatt	tgtactattt	aactgactat	tcttgatgta	aatcttgtc	atgtgtataa	2760
aaataaaaaa	gatcccaa					2780

<210> 8

<211> 838

<212> PRT

<213> Homo sapiens

<400> 8

Val	Gly	Gly	Pro	Arg	Gly	Trp	Arg	Cys	Glu	Asp	Pro	Asn	Pro	Gly	Val
1				5					10					15	
Gly	Gly	Gly	Gly	Gly	Ser	Cys	Asp	Arg	Arg	Gly	Leu	Glu	Thr	His	Arg
			20					25					30		
Pro	His	Ala	Met	Arg	Ala	Leu	Trp	Val	Leu	Gly	Leu	Cys	Cys	Val	Leu
		35					40					45			
Leu	Thr	Phe	Gly	Ser	Val	Arg	Ala	Asp	Asp	Glu	Val	Asp	Val	Asp	Gly
	50					55					60				
Thr	Val	Glu	Glu	Asp	Leu	Gly	Lys	Ser	Arg	Glu	Gly	Ser	Arg	Thr	Asp
65				70					75					80	
Asp	Glu	Val	Val	Gln	Arg	Glu	Glu	Glu	Ala	Ile	Gln	Leu	Asp	Gly	Leu
				85					90					95	
Asn	Ala	Ser	Gln	Ile	Arg	Glu	Leu	Arg	Glu	Lys	Ser	Glu	Lys	Phe	Ala
			100					105					110		
Phe	Gln	Ala	Glu	Val	Asn	Arg	Met	Met	Lys	Leu	Ile	Ile	Asn	Ser	Leu
		115					120					125			
Tyr	Lys	Asn	Lys	Glu	Ile	Phe	Leu	Arg	Glu	Leu	Ile	Ser	Asn	Ala	Ser
	130					135					140				
Asp	Ala	Leu	Asp	Lys	Ile	Arg	Leu	Ile	Ser	Leu	Thr	Asp	Glu	Asn	Ala
145				150					155					160	
Leu	Ser	Gly	Asn	Glu	Glu	Leu	Thr	Val	Lys	Ile	Lys	Cys	Asp	Lys	Glu
				165					170					175	
Lys	Asn	Leu	Leu	His	Val	Thr	Asp	Thr	Gly	Val	Gly	Met	Thr	Arg	Glu
			180					185					190		
Glu	Leu	Val	Lys	Asn	Leu	Gly	Thr	Ile	Ala	Lys	Ser	Gly	Thr	Ser	Glu
		195					200					205			
Phe	Leu	Asn	Lys	Met	Thr	Glu	Ala	Gln	Glu	Asp	Gly	Gln	Ser	Thr	Ser
	210					215					220				
Glu	Leu	Ile	Gly	Gln	Phe	Gly	Val	Gly	Phe	Tyr	Ser	Ala	Phe	Leu	Val
225				230					235					240	
Ala	Asp	Lys	Val	Ile	Val	Thr	Ser	Lys	His	Asn	Asn	Asp	Thr	Gln	His
				245					250					255	

Ile	Trp	Glu	Ser 260	Asp	Ser	Asn	Glu	Phe 265	Ser	Val	Ile	Ala	Asp 270	Pro	Arg
Gly	Asn	Thr	Leu	Gly	Arg	Gly	Thr	Thr	Ile	Thr	Leu	Val	Leu	Lys	Glu
		275					280					285			
Glu	Ala	Ser	Asp	Tyr	Leu	Glu	Leu	Asp	Thr	Ile	Lys	Asn	Leu	Val	Lys
	290					295					300				
Lys	Tyr	Ser	Gln	Phe	Ile	Asn	Phe	Pro	Ile	Tyr	Val	Trp	Ser	Ser	Lys
305					310					315					320
Thr	Glu	Thr	Val	Glu	Glu	Pro	Met	Glu	Glu	Glu	Glu	Ala	Ala	Lys	Glu
				325					330					335	
Glu	Lys	Glu	Glu	Ser	Asp	Asp	Glu	Ala	Ala	Val	Glu	Glu	Glu	Glu	Glu
			340					345					350		
Glu	Lys	Lys	Pro	Lys	Thr	Lys	Lys	Val	Glu	Lys	Thr	Val	Trp	Asp	Trp
		355					360					365			
Glu	Leu	Met	Asn	Asp	Ile	Lys	Pro	Ile	Trp	Gln	Arg	Pro	Ser	Lys	Glu
	370					375					380				
Val	Glu	Glu	Asp	Glu	Tyr	Lys	Ala	Phe	Tyr	Lys	Ser	Phe	Ser	Lys	Glu
385					390					395					400
Ser	Asp	Asp	Pro	Met	Ala	Tyr	Ile	His	Phe	Thr	Ala	Glu	Gly	Glu	Val
				405					410					415	
Thr	Phe	Lys	Ser	Ile	Leu	Phe	Val	Pro	Thr	Ser	Ala	Pro	Arg	Gly	Leu
			420					425					430		
Phe	Asp	Glu	Tyr	Gly	Ser	Lys	Lys	Ser	Asp	Tyr	Ile	Lys	Leu	Tyr	Val
		435					440					445			
Arg	Arg	Val	Phe	Ile	Thr	Asp	Asp	Phe	His	Asp	Met	Met	Pro	Lys	Tyr
	450					455					460				
Leu	Asn	Phe	Val	Lys	Gly	Val	Val	Asp	Ser	Asp	Asp	Leu	Pro	Leu	Asn
465					470					475					480
Val	Ser	Arg	Glu	Thr	Leu	Gln	Gln	His	Lys	Leu	Leu	Lys	Val	Ile	Arg
				485					490					495	
Lys	Lys	Leu	Val	Arg	Lys	Thr	Leu	Asp	Met	Ile	Lys	Lys	Ile	Ala	Asp
			500					505					510		
Asp	Lys	Tyr	Asn	Asp	Thr	Phe	Trp	Lys	Glu	Phe	Gly	Thr	Asn	Ile	Lys
		515					520					525			
Leu	Gly	Val	Ile	Glu	Asp	His	Ser	Asn	Arg	Thr	Arg	Leu	Ala	Lys	Leu
		530				535					540				
Leu	Arg	Phe	Gln	Ser	Ser	His	His	Pro	Thr	Asp	Ile	Thr	Ser	Leu	Asp
545					550					555					560
Gln	Tyr	Val	Glu	Arg	Met	Lys	Glu	Lys	Gln	Asp	Lys	Ile	Tyr	Phe	Met
				565					570					575	
Ala	Gly	Ser	Ser	Arg	Lys	Glu	Ala	Glu	Ser	Ser	Pro	Phe	Val	Glu	Arg
			580					585					590		
Leu	Leu	Lys	Lys	Gly	Tyr	Glu	Val	Ile	Tyr	Leu	Thr	Glu	Pro	Val	Asp
		595					600					605			
Glu	Tyr	Cys	Ile	Gln	Ala	Leu	Pro	Glu	Phe	Asp	Gly	Lys	Arg	Phe	Gln</

Lys Glu Asp Glu Asp Asp Lys Thr Val Leu Asp Leu Ala Val Val Leu
 740 745 750
 Phe Glu Thr Ala Thr Leu Arg Ser Gly Tyr Leu Leu Pro Asp Thr Lys
 755 760 765
 Ala Tyr Gly Asp Arg Ile Glu Arg Met Leu Arg Leu Ser Leu Asn Ile
 770 775 780
 Asp Pro Asp Ala Lys Val Glu Glu Glu Pro Glu Glu Glu Pro Glu Glu
 785 790 795 800
 Thr Ala Glu Asp Thr Thr Glu Asp Thr Glu Gln Asp Glu Asp Glu Glu
 805 810 815
 Met Asp Val Gly Thr Asp Glu Glu Glu Glu Thr Ala Lys Glu Ser Thr
 820 825 830
 Ala Glu Lys Asp Glu Leu
 835

<210> 9

<211> 2912

<212> DNA

<213> Homo sapiens

<400> 9

cagttgcttc	agcgtcccgg	tgtggctgtg	ccgttggtcc	tgtgcggtca	cttagccaag	60
atgcctgagg	aaacccagac	ccaagaccaa	ccgatggagg	aggaggaggt	tgagacgttc	120
gcctttcagg	cagaaattgc	ccagttgatg	tcattgatca	tcaatacttt	ctactcgaac	180
aaagagatct	ttctgagaga	gctcatttca	aattcatcag	atgcattgga	caaaatccgg	240
tatgaaactt	tgacagatcc	cagtaaatta	gactctggga	aagagctgca	tattaacctt	300
ataccgaaca	aacaagatcg	aactctcact	attgtggata	ctggaattgg	aatgaccaag	360
gctgacttga	tcaataacct	tggtactatc	gccaaagtctg	ggaccaaagc	gttcatggaa	420
gctttgcagg	ctggtgcaga	tatctctatg	attggccagt	tcggtgttgg	tttttattct	480
gcttatattg	ttgctgagaa	agtaactgtg	atcaccaaac	ataacgatga	tgagcagtac	540
gcttgggagt	cctcagcagg	gggatcattc	acagtgagga	cagacacagg	tgaacctatg	600
ggtcgtggaa	caaaagttat	cctacacctg	aaagaagacc	aaactgagta	cttggaggaa	660
cgaagaataa	aggagattgt	gaagaaacat	tctcagttta	ttggatatcc	cattactctt	720
tttgtggaga	aggaacgtga	taaagaagta	agcgatgatg	aggctgaaga	aaaggaagac	780
aaagaagaag	aaaaagaaaa	agaagagaaa	gagtcggaag	acaaacctga	aattgaagat	840
gttggttctg	atgaggaaga	agaaaagaag	gatggtgaca	agaagaagaa	gaagaagatt	900
aaggaaaagt	acatcgatca	agaagagctc	aacaaaacaa	agcccatctg	gaccagaaat	960
cccgcagata	ttactaatga	ggagtacgga	gaattctata	agagcttgac	caatgactgg	1020
gaagatcact	tggcagtga	gcatttttca	gttgaaggac	agttggaatt	cagagccctt	1080
ctatttgtcc	cacgacgtgc	tccttttgat	ctgtttgaaa	acagaaagaa	aaagaacaat	1140
atcaaattgt	atgtacgcag	agttttcatc	atggataact	gtgaggagct	aatccctgaa	1200
tatctgaact	tcattagagg	ggtggtagac	tcggaggatc	tccctctaaa	catatcccgt	1260
gagatgttgc	aacaaagcaa	aattttgaaa	gttatcagga	agaatttggt	caaaaaatgc	1320
ttagaactct	ttactgaact	ggcggaagat	aaagagaact	acaagaaatt	ctatgagcag	1380
ttctctaaaa	acataaagct	tggaatacac	gaagactctc	aaaatcgga	gaagctttca	1440
gagctgttaa	ggtactacac	atctgcctct	ggtgatgaga	tggtttctct	caaggactac	1500
tgaccagaa	tgaaggagaa	ccagaaacat	atctattata	tcacagggtga	gaccaaggac	1560
caggtagcta	actcagcctt	tgtggaacgt	cttcggaaac	atggccttaga	agtgatctat	1620
atgattgagc	ccattgatga	gtactgtgtc	caacagctga	aggaatttga	ggggaagact	1680
ttagtgtcag	tcaccaaaga	aggcctggaa	cttccagagg	atgaagaaga	gaaaaagaag	1740
caggaagaga	aaaaaacaaa	gtttgagaac	ctctgcaaaa	tcattgaaaga	catattggag	1800
aaaaaagttg	aaaaggtggt	tgtgtcaaac	cgattggtga	catctccatg	ctgtattgtc	1860
acaagcacat	atggctggac	agcaaacatg	gagagaatca	tgaaagctca	agccctaaga	1920
gacaactcaa	caatgggtta	catggcagca	aagaaacacc	tggagataaa	ccctgaccat	1980
tccattattg	agaccttaag	gcaaaaggca	gaggctgata	agaacgacaa	gtctgtgaag	2040
gactgtgtca	tcttgcctta	tgaaactgcy	ctcctgtctt	ctggcttcag	tctggaagat	2100
ccccagacac	atgctaacag	gatctacag	atgatcaaac	ttggtctggg	tattcttgaa	2160
gatgacccta	ctgctgatga	taccagtgtc	gctgtaactg	aagaaatgcc	accccttgaa	2220
ggagatgacg	acacatcacg	catggaagaa	gtagactaat	ctctggctga	gggatgactt	2280
acctgttcag	tactctacaa	ttcctctgat	aatatatattt	caaggatgtt	tttctttatt	2340

tttgtaata	ttaaaaagtc	tgtatggcat	gacaactact	ttaaggggaa	gataagattt	2400
ctgtctacta	agtgatgctg	tgatacctta	ggcactaaag	cagagctagt	aatgcttttt	2460
gagtttcatg	ttggttcttt	cacagatggg	gtaacgtgca	ctgtaagacg	tatgtaacat	2520
gatgttaact	ttgtgtggtc	taaagtgttt	agctgtcaag	ccggatgcct	aagtagacca	2580
aatcttggtta	ttgaagtgtt	ctgagctgta	tcttgatggt	tagaaaagta	ttcgttacat	2640
cttgtaggat	ctactttttg	aacttttcat	tccctgtagt	tgacaattct	gcatgtacta	2700
gtcctctaga	aataggttaa	actgaagcaa	cttgatggaa	ggatctctcc	acagggcttg	2760
ttttccaaag	aaaagtattg	tttggaggag	caaagttaaa	agcctaccta	agcatatcgt	2820
aaagctgttc	aaatactcga	gccagtcctt	gtggatggaa	atgtagtgct	cgagtcacat	2880
tctgcttaaa	gttgtaacaa	atacagatga	gt			2912

<210> 10

<211> 732

<212> PRT

<213> Homo sapiens

<400> 10

Met	Pro	Glu	Glu	Thr	Gln	Thr	Gln	Asp	Gln	Pro	Met	Glu	Glu	Glu	Glu
1				5					10					15	
Val	Glu	Thr	Phe	Ala	Phe	Gln	Ala	Glu	Ile	Ala	Gln	Leu	Met	Ser	Leu
			20					25				30			
Ile	Ile	Asn	Thr	Phe	Tyr	Ser	Asn	Lys	Glu	Ile	Phe	Leu	Arg	Glu	Leu
		35					40					45			
Ile	Ser	Asn	Ser	Ser	Asp	Ala	Leu	Asp	Lys	Ile	Arg	Tyr	Glu	Thr	Leu
	50				55						60				
Thr	Asp	Pro	Ser	Lys	Leu	Asp	Ser	Gly	Lys	Glu	Leu	His	Ile	Asn	Leu
65					70					75					80
Ile	Pro	Asn	Lys	Gln	Asp	Arg	Thr	Leu	Thr	Ile	Val	Asp	Thr	Gly	Ile
				85					90					95	
Gly	Met	Thr	Lys	Ala	Asp	Leu	Ile	Asn	Asn	Leu	Gly	Thr	Ile	Ala	Lys
			100					105					110		
Ser	Gly	Thr	Lys	Ala	Phe	Met	Glu	Ala	Leu	Gln	Ala	Gly	Ala	Asp	Ile
			115				120					125			
Ser	Met	Ile	Gly	Gln	Phe	Gly	Val	Gly	Phe	Tyr	Ser	Ala	Tyr	Leu	Val
	130					135					140				
Ala	Glu	Lys	Val	Thr	Val	Ile	Thr	Lys	His	Asn	Asp	Asp	Glu	Gln	Tyr
145					150					155					160
Ala	Trp	Glu	Ser	Ser	Ala	Gly	Gly	Ser	Phe	Thr	Val	Arg	Thr	Asp	Thr
				165					170					175	
Gly	Glu	Pro	Met	Gly	Arg	Gly	Thr	Lys	Val	Ile	Leu	His	Leu	Lys	Glu
			180					185					190		
Asp	Gln	Thr	Glu	Tyr	Leu	Glu	Glu	Arg	Arg	Ile	Lys	Glu	Ile	Val	Lys
			195					200				205			
Lys	His	Ser	Gln	Phe	Ile	Gly	Tyr	Pro	Ile	Thr	Leu	Phe	Val	Glu	Lys
	210					215					220				
Glu	Arg	Asp	Lys	Glu	Val	Ser	Asp	Asp	Glu	Ala	Glu	Glu	Lys	Glu	Asp
225					230					235					240
Lys	Glu	Glu	Glu	Lys	Glu	Lys	Glu	Glu	Lys	Glu	Ser	Glu	Asp	Lys	Pro
				245					250					255	
Glu	Ile	Glu	Asp	Val	Gly	Ser	Asp	Glu	Glu	Glu	Glu	Lys	Lys	Asp	Gly
			260					265					270		
Asp	Lys	Lys	Lys	Lys	Lys	Lys	Lys	Ile	Lys	Glu	Lys	Tyr	Ile	Asp	Gln
			275					280					285		
Glu	Leu	Asn	Lys	Thr	Lys	Pro	Ile	Trp	Thr	Arg	Asn	Pro	Asp	Asp	Ile
	290					295					300				
Thr	Asn	Glu	Glu	Tyr	Gly	Glu	Phe	Tyr	Lys	Ser	Leu	Thr	Asn	Asp	Trp
305					310					315					320
Glu	Asp	His	Leu	Ala	Val	Lys	His	Phe	Ser	Val	Glu	Gly	Gln	Leu	Glu
				325						330					335

Phe Arg Ala Leu Leu Phe Val Pro Arg Arg Ala Pro Phe Asp Leu Phe
 340 345 350
 Glu Asn Arg Lys Lys Lys Asn Asn Ile Lys Leu Tyr Val Arg Arg Val
 355 360 365
 Phe Ile Met Asp Asn Cys Glu Leu Ile Pro Glu Tyr Leu Asn Phe
 370 375 380
 Ile Arg Gly Val Val Asp Ser Glu Asp Leu Pro Leu Asn Ile Ser Arg
 385 390 395 400
 Glu Met Leu Gln Gln Ser Lys Ile Leu Lys Val Ile Arg Lys Asn Leu
 405 410 415
 Val Lys Lys Cys Leu Glu Leu Phe Thr Glu Leu Ala Glu Asp Lys Glu
 420 425 430
 Asn Tyr Lys Lys Phe Tyr Glu Gln Phe Ser Lys Asn Ile Lys Leu Gly
 435 440 445
 Ile His Glu Asp Ser Gln Asn Arg Lys Lys Leu Ser Glu Leu Leu Arg
 450 455 460
 Tyr Tyr Thr Ser Ala Ser Gly Asp Glu Met Val Ser Leu Lys Asp Tyr
 465 470 475 480
 Cys Thr Arg Met Lys Glu Asn Gln Lys His Ile Tyr Tyr Ile Thr Gly
 485 490 495
 Glu Thr Lys Asp Gln Val Ala Asn Ser Ala Phe Val Glu Arg Leu Arg
 500 505 510
 Lys His Gly Leu Glu Val Ile Tyr Met Ile Glu Pro Ile Asp Glu Tyr
 515 520 525
 Cys Val Gln Gln Leu Lys Glu Phe Glu Gly Lys Thr Leu Val Ser Val
 530 535 540
 Thr Lys Glu Gly Leu Glu Leu Pro Glu Asp Glu Glu Lys Lys Lys
 545 550 555 560
 Gln Glu Glu Lys Lys Thr Lys Phe Glu Asn Leu Cys Lys Ile Met Lys
 565 570 575
 Asp Ile Leu Glu Lys Lys Val Glu Lys Val Val Val Ser Asn Arg Leu
 580 585 590
 Val Thr Ser Pro Cys Cys Ile Val Thr Ser Thr Tyr Gly Trp Thr Ala
 595 600 605
 Asn Met Glu Arg Ile Met Lys Ala Gln Ala Leu Arg Asp Asn Ser Thr
 610 615 620
 Met Gly Tyr Met Ala Ala Lys Lys His Leu Glu Ile Asn Pro Asp His
 625 630 635 640
 Ser Ile Ile Glu Thr Leu Arg Gln Lys Ala Glu Ala Asp Lys Asn Asp
 645 650 655
 Lys Ser Val Lys Asp Leu Val Ile Leu Leu Tyr Glu Thr Ala Leu Leu
 660 665 670
 Ser Ser Gly Phe Ser Leu Glu Asp Pro Gln Thr His Ala Asn Arg Ile
 675 680 685
 Tyr Arg Met Ile Lys Leu Gly Leu Gly Ile Asp Glu Asp Asp Pro Thr
 690 695 700
 Ala Asp Asp Thr Ser Ala Ala Val Thr Glu Glu Met Pro Pro Leu Glu
 705 710 715 720
 Gly Asp Asp Asp Thr Ser Arg Met Glu Glu Val Asp
 725 730

<210> 11

<211> 2227

<212> DNA

<213> Homo sapiens

<400> 11

gacgacctgt	ctcgccgagc	gcacgcttgc	cgccgccccg	cagaaatgct	tcggttaccc	60
acagtctttc	gccagatgag	accggtgtcc	agggtactgg	ctcctcatct	cactcgggct	120
tatgccaaag	atgtaaaatt	tggtgcagat	gcccagacct	taatgcttca	agggttagac	180

```

cttttagccg atgctgtggc cgttacaatg gggccaaagg gaagaacagt gattattgag 240
cagagttggg gaagtcccaa agtaacaaaa gatggtgtga ctggtgcaaa gtcaattgac 300
ttaaaagata aatacaagaa cattggagct aaacttggtc aagatggtgc caataacaca 360
aatgaagaag ctgggggatgg cactaccact gctactgtac tggcacgctc tatagccaag 420
gaaggcttcg agaagattag caaaggtgct aatccagtgg aaatcaggag aggtgtgatg 480
ttagctgttg atgctgtaat tgctgaactt aaaaagcagt ctaaacctgt gaccaccctt 540
gaagaaattg cacaggttgc tacgatttct gcaaacggag acaaagaaat tggcaatatc 600
atctctgatg caatgaaaaa agttggaaga aaggggtgtc tcacagtaaa ggatggaaaa 660
acactgaatg atgaattaga aattattgaa ggcatagaag ttgatcgagg ctatatctct 720
ccatacttta ttaatacatc aaaaggtcag aaatgtgaat tccaggatgc ctatgttctg 780
ttgagtgaag agaaaatttc tagtatccag tccattgtac ctgctcttga aattgccaat 840
gctcaccgta agccttttgg cataatcgct gaagatgttg atggagaagc tctaagtaca 900
ctcgtcttga ataggctaaa ggttgggtctt caggttgttg cagtcaaggc tccagggttt 960
ggtgacaata gaaagaacca gcttaagat atggctattg ctactgggtg tgcagtgttt 1020
ggagaagagg gattgaccct gaatcttgaa gacgttcagc ctcatgactt aggaaaagtt 1080
ggagaggtca ttgtgaccaa agacgatgcc atgctcttaa aaggaaaagg tgacaaggct 1140
caaattgaaa aacgtattca agaaatcatt gagcagttag atgtcacaac tagtgaatat 1200
gaaaaggaaa aactgaatga acggcttgca aaactttcag atggagtggc tgtgctgaag 1260
ggtggtggga caagtgatgt tgaagtgaat gaaaagaaag acagagttac agatgccctt 1320
aatgctacaa gagctgctgt tgaagaaggc attgttttgg gagggggttg tgccctcctt 1380
cgatgcattc cagccttgga ctcatgact ccagctaag aagatcaaaa aattggtata 1440
gaaattatta aaagaacact caaaattcca gcaatgacca ttgctaagaa tgcaggtgtt 1500
gaaggatctt tgatagttga gaaaattatg caaagttcct cagaagttgg ttatgatgct 1560
atggctggag attttgtgaa tatggtggaa aaaggaatca ttgacccaac aaaggttgtg 1620
agaactgctt tattggatgc tgctggtgtg gcctctctgt taactacagc agaagttgta 1680
gtcacagaaa ttcctaaaga agagaaggac cctggaatgg gtgcaatggg tggaaatggga 1740
ggtggtatgg gaggtggcat gttctaactc ctagactagt gctttacctt tattaatgaa 1800
ctgtgacagg aagcccaagg cagtggtcct caccaataac ttcagagaag tcatgtggag 1860
aaaatgaaga aaaaggctgg ctgaaaatca ctataaccat cagttactgg tttcagttga 1920
caaaatatat aatggtttac tgctgtcatt gtccatgcct acagataatt tattttgtat 1980
ttttgaataa aaaacatttg tacattcctg atactgggta caagagccat gtaccagtgt 2040
actgctttca acttaaatca ctgaggcatt tttactacta ttctgttaaa atcaggattt 2100
tagtgcttgc caccaccaga tgagaagtta agcagccttt ctgtggagag tgagaataat 2160
tgtgtacaaa gtagagaagt atccaattat gtgacaacct ttgtgtaata aaaatttgtt 2220
taaagtt 2227

```

<210> 12

<211> 573

<212> PRT

<213> Homo sapiens

<400> 12

```

Met Leu Arg Leu Pro Thr Val Phe Arg Gln Met Arg Pro Val Ser Arg
1          5          10          15
Val Leu Ala Pro His Leu Thr Arg Ala Tyr Ala Lys Asp Val Lys Phe
20          25          30
Gly Ala Asp Ala Arg Ala Leu Met Leu Gln Gly Val Asp Leu Leu Ala
35          40          45
Asp Ala Val Ala Val Thr Met Gly Pro Lys Gly Arg Thr Val Ile Ile
50          55          60
Glu Gln Ser Trp Gly Ser Pro Lys Val Thr Lys Asp Gly Val Thr Val
65          70          75          80
Ala Lys Ser Ile Asp Leu Lys Asp Lys Tyr Lys Asn Ile Gly Ala Lys
85          90          95
Leu Val Gln Asp Val Ala Asn Asn Thr Asn Glu Glu Ala Gly Asp Gly
100         105         110
Thr Thr Thr Ala Thr Val Leu Ala Arg Ser Ile Ala Lys Glu Gly Phe
115         120         125
Glu Lys Ile Ser Lys Gly Ala Asn Pro Val Glu Ile Arg Arg Gly Val
130         135         140

```

Met Leu Ala Val Asp Ala Val Ile Ala Glu Leu Lys Lys Gln Ser Lys
 145 150 155 160
 Pro Val Thr Thr Pro Glu Glu Ile Ala Gln Val Ala Thr Ile Ser Ala
 165 170 175
 Asn Gly Asp Lys Glu Ile Gly Asn Ile Ile Ser Asp Ala Met Lys Lys
 180 185 190
 Val Gly Arg Lys Gly Val Ile Thr Val Lys Asp Gly Lys Thr Leu Asn
 195 200 205
 Asp Glu Leu Glu Ile Ile Glu Gly Met Lys Phe Asp Arg Gly Tyr Ile
 210 215 220
 Ser Pro Tyr Phe Ile Asn Thr Ser Lys Gly Gln Lys Cys Glu Phe Gln
 225 230 235 240
 Asp Ala Tyr Val Leu Leu Ser Glu Lys Lys Ile Ser Ser Ile Gln Ser
 245 250 255
 Ile Val Pro Ala Leu Glu Ile Ala Asn Ala His Arg Lys Pro Leu Val
 260 265 270
 Ile Ile Ala Glu Asp Val Asp Gly Glu Ala Leu Ser Thr Leu Val Leu
 275 280 285
 Asn Arg Leu Lys Val Gly Leu Gln Val Val Ala Val Lys Ala Pro Gly
 290 295 300
 Phe Gly Asp Asn Arg Lys Asn Gln Leu Lys Asp Met Ala Ile Ala Thr
 305 310 315 320
 Gly Gly Ala Val Phe Gly Glu Glu Gly Leu Thr Leu Asn Leu Glu Asp
 325 330 335
 Val Gln Pro His Asp Leu Gly Lys Val Gly Glu Val Ile Val Thr Lys
 340 345 350
 Asp Asp Ala Met Leu Leu Lys Gly Lys Gly Asp Lys Ala Gln Ile Glu
 355 360 365
 Lys Arg Ile Gln Glu Ile Ile Glu Gln Leu Asp Val Thr Thr Ser Glu
 370 375 380
 Tyr Glu Lys Glu Lys Leu Asn Glu Arg Leu Ala Lys Leu Ser Asp Gly
 385 390 395 400
 Val Ala Val Leu Lys Val Gly Gly Thr Ser Asp Val Glu Val Asn Glu
 405 410 415
 Lys Lys Asp Arg Val Thr Asp Ala Leu Asn Ala Thr Arg Ala Ala Val
 420 425 430
 Glu Glu Gly Ile Val Leu Gly Gly Gly Cys Ala Leu Leu Arg Cys Ile
 435 440 445
 Pro Ala Leu Asp Ser Leu Thr Pro Ala Asn Glu Asp Gln Lys Ile Gly
 450 455 460
 Ile Glu Ile Ile Lys Arg Thr Leu Lys Ile Pro Ala Met Thr Ile Ala
 465 470 475 480
 Lys Asn Ala Gly Val Glu Gly Ser Leu Ile Val Glu Lys Ile Met Gln
 485 490 495
 Ser Ser Ser Glu Val Gly Tyr Asp Ala Met Ala Gly Asp Phe Val Asn
 500 505 510
 Met Val Glu Lys Gly Ile Ile Asp Pro Thr Lys Val Val Arg Thr Ala
 515 520 525
 Leu Leu Asp Ala Ala Gly Val Ala Ser Leu Leu Thr Thr Ala Glu Val
 530 535 540
 Val Val Thr Glu Ile Pro Lys Glu Glu Lys Asp Pro Gly Met Gly Ala
 545 550 555 560
 Met Gly Gly Met Gly Gly Gly Met Gly Gly Met Phe
 565 570

<210> 13

<211> 2376

<212> DNA

<213> Homo sapiens

<400> 13

gaggaggagt	ggggaccggg	cggggggttg	aggaagaggc	ctcgcgcaga	ggagggagca	60
attgaatttc	aaacacaaac	aactcgacga	gcgcgcaccc	accgcgccgg	agccttgccc	120
cgatccgcgc	ccgccccgtc	cgtgcggcgc	gcggggcgag	acgccgtggc	cgcgccggag	180
ctcggggccg	ggggccaccat	cgaggcgggg	gccgcgcgag	ggccggagcg	gagcggcgcc	240
gccaccgccc	cacgcgcaaa	cttgggctcg	cgcttcccgg	cccggcgccg	agcccggggc	300
gcccggagcc	ccgccatgtc	gcgatccaac	cggcagaagg	agtacaaatg	cggggacctg	360
gtgttcgcca	agatgaaggg	ctaccacac	tggccggccc	ggattgacga	gatgcctgag	420
gctgccgtga	aatcaacagc	caacaaatac	caagtctttt	ttttcggggac	ccacgagacg	480
gcattcctgg	gccccaaaga	cctcttccct	tacgaggaat	ccaaggagaa	gtttggcaag	540
cccaacaaga	ggaaagggtt	cagcgagggg	ctgtgggaga	tcgagaacaa	ccctactgtc	600
aaggcttccg	gctatcagtc	ctcccagaaa	aagagctgtg	tggaagagcc	tgaaccagag	660
cccgaagctg	cagaggggtga	cggtgataag	aaggggaatg	cagagggcag	cagcgacgag	720
gaaggggaagc	tggtcattga	tgagccagcc	aaggagaaga	acgagaaagg	agcgttgaag	780
aggagagcag	gggacttgct	ggaggactct	cctaaacgtc	ccaaggaggc	agaaaaccct	840
gaaggagagg	agaaggaggc	agccaccttg	gaggttgaga	ggccccttcc	tatggaggtg	900
gaaaagaata	gcaccccctc	tgagcccgcc	tctggccggg	ggcctcccca	agaggaagaa	960
gaagagaggag	atgaagagga	agaggctacc	aaggaagatg	ctgaggcccc	aggcatcaga	1020
gatcatgaga	gcctgtagcc	accaatgttt	caagaggagc	ccccaccctg	ttcctgctgc	1080
tgtctgggtg	ctactgggga	aactggccat	ggcctgcaaa	ctgggaaccc	ctttcccacc	1140
ccaacctgct	ctcctcttct	actcactttt	cccactccaa	gcccagccca	tggagattga	1200
cctggatggg	gcaggccacc	tggctctcac	ctctaggtcc	ccatactcct	atgatctgag	1260
tcagagccat	gtcttctccc	tggaatgagt	tgaggccact	gtgttccctc	cgcttggagc	1320
tattttccag	gcttctgctg	gggcctggga	caactgctcc	cacctcctga	cacccttctc	1380
ccactctcct	aggcattctg	gacctctggg	ttgggatcag	gggtaggaat	ggaaggatgg	1440
agcatcaaca	gcagggtggg	cttgtggggc	ctgggagggg	caatcctcaa	atgcgggggtg	1500
ggggcagcac	aggaggcgcc	cctccttctg	agctcctgtc	ccctgctaca	cctattatcc	1560
cagctgccta	gattcagggg	aagtgggaca	gcttgtaggg	gaggggctcc	tttccataaa	1620
tccttgatga	ttgacaacac	ccatttttcc	ttttgccgac	cccaagagtt	ttgggagttg	1680
tagttaatca	tcaagagaat	ttggggcttc	caagttgttc	gggccaagga	cctgagacct	1740
gaagggttga	ctttacccat	ttgggtggga	gtgttgagca	tctgtccccc	tttagatctc	1800
tgaagccaca	aataggatgc	ttgggaagac	tcctagctgt	cctttttcct	ctccacacag	1860
tgtcaaggc	cagcttatag	tcatatata	caccagaca	taaaggaaaa	gacacatttt	1920
ttaggaaatg	tttttaataa	aagaaaatta	caaaaaaaaa	ttttaagac	ccctaaccct	1980
ttgtgtgctc	tccattctgc	tccttcccca	tcgttgcccc	catttctgag	gtgcactggg	2040
aggctcccct	tctatttggg	gcttgatgac	tttctttttg	tagctggggc	tttgaatgtc	2100
cttccagtgt	catttctcat	ccacataccc	tgacctggcc	ccctcagtgt	tgtcaccaga	2160
tctgatttgt	aaccactga	gaggacagag	agaaataagt	gccctctccc	accctcttcc	2220
tactggtctc	tctatgcctc	tctacagtct	cgtctctttt	accctggccc	ctctcccttg	2280
ggctctgatg	aaaaattgct	gactgtagct	ttggaagttt	agctctgaga	accgtagatg	2340
atttcagttc	taggaaaata	aaaccctgtg	attact			2376

<210> 14

<211> 240

<212> PRT

<213> Homo sapiens

<400> 14

Met	Ser	Arg	Ser	Asn	Arg	Gln	Lys	Glu	Tyr	Lys	Cys	Gly	Asp	Leu	Val
1				5					10					15	
Phe	Ala	Lys	Met	Lys	Gly	Tyr	Pro	His	Trp	Pro	Ala	Arg	Ile	Asp	Glu
			20					25					30		
Met	Pro	Glu	Ala	Ala	Val	Lys	Ser	Thr	Ala	Asn	Lys	Tyr	Gln	Val	Phe
		35				40					45				
Phe	Phe	Gly	Thr	His	Glu	Thr	Ala	Phe	Leu	Gly	Pro	Lys	Asp	Leu	Phe
	50				55					60					
Pro	Tyr	Glu	Glu	Ser	Lys	Glu	Lys	Phe	Gly	Lys	Pro	Asn	Lys	Arg	Lys
65					70				75					80	
Gly	Phe	Ser	Glu	Gly	Leu	Trp	Glu	Ile	Glu	Asn	Asn	Pro	Thr	Val	Lys
				85					90					95	

Ala	Ser	Gly	Tyr	Gln	Ser	Ser	Gln	Lys	Lys	Ser	Cys	Val	Glu	Glu	Pro
			100					105					110		
Glu	Pro	Glu	Pro	Glu	Ala	Ala	Glu	Gly	Asp	Gly	Asp	Lys	Lys	Gly	Asn
		115					120					125			
Ala	Glu	Gly	Ser	Ser	Asp	Glu	Glu	Gly	Lys	Leu	Val	Ile	Asp	Glu	Pro
		130				135					140				
Ala	Lys	Glu	Lys	Asn	Glu	Lys	Gly	Ala	Leu	Lys	Arg	Arg	Ala	Gly	Asp
145				150						155					160
Leu	Leu	Glu	Asp	Ser	Pro	Lys	Arg	Pro	Lys	Glu	Ala	Glu	Asn	Pro	Glu
			165					170						175	
Gly	Glu	Glu	Lys	Glu	Ala	Ala	Thr	Leu	Glu	Val	Glu	Arg	Pro	Leu	Pro
			180					185					190		
Met	Glu	Val	Glu	Lys	Asn	Ser	Thr	Pro	Ser	Glu	Pro	Gly	Ser	Gly	Arg
		195					200					205			
Gly	Pro	Pro	Gln	Glu	Glu	Glu	Glu	Glu	Glu	Asp	Glu	Glu	Glu	Glu	Ala
		210				215					220				
Thr	Lys	Glu	Asp	Ala	Glu	Ala	Pro	Gly	Ile	Arg	Asp	His	Glu	Ser	Leu
225					230					235					240

<210> 15

<211> 3689

<212> DNA

<213> Homo sapiens

<400> 15

aagatctcat	aaaatctatg	ctgaggaatg	agcgacagtt	caaggaggag	aagcttgacg	60
agcagctcaa	gcaagctgag	gagctcaggc	aatataaaagt	cctgggttcac	gctcaggaac	120
gagagctgac	ccagtttaagg	gagaagttgc	gggaaggggag	agatgcctcc	cgctcattga	180
atgagcatct	ccaggccctc	ctcactccgg	atgagccgga	caagtcccag	gggcaggacc	240
tccaagaaca	gctggctgag	gggtgtagac	tggcacagca	ccttgtccaa	aagctcagcc	300
cagaaaatga	caacgatgac	gatgaagatg	ttcaagttga	ggtggctgag	aaagtgcaga	360
aatcgtctgc	ccccagggag	atgcagaagg	ctgaagaaaa	ggaagtcctt	gaggactcac	420
tggaggaatg	tgccatcact	tgttcaaata	gccatggccc	ttatgactcc	aaccagccac	480
ataggaaaac	caaaatcaca	tttgaggaag	acaaagtcga	ctcaactctc	attggctcat	540
cctctcatgt	tgaatgggag	gatgctgtac	acattattcc	agaaaatgaa	agtgatgatg	600
aggaagagga	agaaaaagga	ccagtgtctc	ccaggaatct	gcaggagtct	gaagaggagg	660
aagtccccca	ggagtccctg	gatgaagggt	attcgactct	ctcaattcct	cctgaaatgt	720
tggcctcgta	caagtcttac	agcagcacat	ttcactcatt	agaggaacag	caagtctgca	780
tggctgttga	cataggcaga	catcggtggg	atcaagtga	aaaggaggac	cacgaggcaa	840
caggtcccag	gctcagcaga	gagctgctgg	atgagaaagg	gcctgaagtc	ttgcaggact	900
cactggatag	atgttattca	actccttcag	gttgtcttga	actgactgac	tcatgccagc	960
cctacagaag	tgcccttttac	gtattggagc	aacagcgtgt	tggtttggct	gttaacatgg	1020
atgaaattga	aaagtaccaa	gaagtggaag	aagaccaaga	cccatcatgc	cccaggctca	1080
gcagggaagt	gctggatgag	aaagagcctg	aagtcttgca	ggactcactg	ggtagatggt	1140
attcgactcc	ttcaggttat	cttgaactgc	ctgacttagg	ccagccctac	agcagtgtctg	1200
tttactcatt	ggaggaacag	taccttggct	tggctcttga	cgtggacaga	attaaaaagg	1260
accaagaaga	ggaagaagac	caaggccac	catgccccag	gctcagcagg	gagctgctgg	1320
aggtagtaga	gcctgaagtc	ttgcaggact	cactggatag	atgttattca	actccttcca	1380
gttgtcttga	acagcctgac	tctgccagc	cctatggaag	ttccttttat	gcattggagg	1440
aaaagcatgt	tggcttttct	cttgacgtgg	gagaaattga	aaagaagggg	aagggaaga	1500
aaagaagggg	aagaagatca	agaaggaaa	gaagaagggg	aagaaaagaa	ggggaagaag	1560
atcaaaaccc	accatgcccc	aggctcagca	gggagctgct	ggatgagaaa	gggcctgaag	1620
tcttgacaga	ctcactggat	agatgttatt	caactccttc	aggttgtctt	gaactgactg	1680
actcatgcc	gcctacaga	agtgcctttt	acatattgga	gcaacagcgt	gttggtctgg	1740
ctgttgacat	ggatgaaatt	gaaaagtacc	agaagtgga	agaagaccaa	gacctcat	1800
gccccaggct	cagcggggag	ctgttggatg	agaaagagcc	tgaagtcttg	caggagtcac	1860
tggatagatg	ctattcaact	ccttcagggt	gtcttgaact	gactgactca	tgccagccct	1920
acagaagtgc	cttttacata	ttggagcaac	agcgtgttgg	cttggctgtt	gacatggatg	1980
aaattgaaaa	gtaccaagaa	gtggaagaag	accaagaccc	atcatgcccc	aggctcagca	2040
gggagctgct	ggatgagaaa	gagcctgaag	tcttgcagga	ctcactgggt	agatgttatt	2100

cgactccttc	aggttatctt	gaactgcctg	acttaggccca	gccctacagc	agtgtctgtt	2160
actcattgga	ggaacagtac	cttggcttgg	ctcttgacgt	ggacagaatt	aaaaaggacc	2220
aagaagagga	agaagaccaa	ggcccaccat	gccccaggct	cagcagggag	ctgctggagg	2280
tagtagagcc	tgaagtcttg	caggactcac	tggatagatg	ttattcaact	ccttccagtt	2340
gtcttgaaca	gcctgactcc	tgccagccct	atggaagttc	cttttatgca	ttggaggaaa	2400
aacatgttgg	cttttctctt	gacgtgggag	aaattgaaaa	gaaggggaag	gggaagaaaa	2460
gaaggggaag	aagatcaaag	aaggaaagaa	gaaggggaag	aaaagaaggg	gaagaagatc	2520
aaaaccaccc	atgccccagg	ctcaacagca	tgctgatgga	agtggaagag	cctgaagtct	2580
tgcaggactc	actggatata	tgttattcga	ctccgtcaat	gtactttgaa	ctacctgact	2640
cattccagca	ctacagaagt	gtgttttact	catttgagga	agagcatatc	agcttcgccc	2700
tttacgtgga	caatagggtt	tttactttga	cggtgacaag	tctccacctg	gtgttccaga	2760
tgggagtcac	attcccacaa	taagcagccc	ttactaagcc	gagaggtgtc	attcctgcag	2820
gcaggaccta	taggcacgtg	aagatttgaa	tgaagtagca	gttccatttg	gaagcccaga	2880
cataggatgg	gtcagtgggc	atggctctat	tcctattctc	aaaccatgcc	agtggcaacc	2940
tgtgtcagtc	ctgaagacaa	tggacccacg	ttaggtgtga	cacgttcaca	taactgtgca	3000
gcacatgccg	ggagtgatca	gtcagacatt	ttaatttgaa	ccacgtatct	ctgggtagct	3060
acaaaattcc	tcagggatgt	cattttgcag	gcattgtctc	gagcttctat	acctgtctca	3120
ggtcattgtc	atcttttgtt	ttagctcatc	caaagggtgt	accctgggtt	caatgaacct	3180
aacctcattc	tttgtgtctt	cagtgttggc	ttgttttagc	tgatccatct	gtaacacagg	3240
agggatcctt	ggctgaggat	tgtatttcag	aaccaccaac	tgctcttgac	aattgttaac	3300
ccgctaggct	cctttgggta	gagaagccac	agtccttcag	cctccaattg	gtgtcagtac	3360
ttaggaagac	cacagctaga	tggacaaaca	gcattgggag	gccttagccc	tgctcctctc	3420
aattccatcc	tgtagagaac	aggagtcagg	agccgctggc	aggagacagc	atgtcaccca	3480
ggactctgcc	ggtgcagaat	atgagcaatg	ccatgttctt	gcagaaaacg	cttaacctga	3540
gtttcatagg	aggtaatcac	cagacaactg	cagaatgtag	aacactgagc	aggacaactg	3600
acctgtctcc	ttcacatagt	ccatatcacc	acaaatcaca	caacaaaaag	gagaagagat	3660
atthtcggtt	gaaaaaaagt	aaaaagata				3689

<210> 16

<211> 921

<212> PRT

<213> Homo sapiens

<400> 16

Met	Leu	Arg	Asn	Glu	Arg	Gln	Phe	Lys	Glu	Glu	Lys	Leu	Ala	Glu	Gln
1			5					10						15	
Leu	Lys	Gln	Ala	Glu	Glu	Leu	Arg	Gln	Tyr	Lys	Val	Leu	Val	His	Ala
		20					25						30		
Gln	Glu	Arg	Glu	Leu	Thr	Gln	Leu	Arg	Glu	Lys	Leu	Arg	Glu	Gly	Arg
		35				40						45			
Asp	Ala	Ser	Arg	Ser	Leu	Asn	Glu	His	Leu	Gln	Ala	Leu	Leu	Thr	Pro
	50					55					60				
Asp	Glu	Pro	Asp	Lys	Ser	Gln	Gly	Gln	Asp	Leu	Gln	Glu	Gln	Leu	Ala
65				70					75					80	
Glu	Gly	Cys	Arg	Leu	Ala	Gln	His	Leu	Val	Gln	Lys	Leu	Ser	Pro	Glu
			85					90					95		
Asn	Asp	Asn	Asp	Asp	Asp	Glu	Asp	Val	Gln	Val	Glu	Val	Ala	Glu	Lys
		100					105						110		
Val	Gln	Lys	Ser	Ser	Ala	Pro	Arg	Glu	Met	Gln	Lys	Ala	Glu	Glu	Lys
		115				120						125			
Glu	Val	Pro	Glu	Asp	Ser	Leu	Glu	Glu	Cys	Ala	Ile	Thr	Cys	Ser	Asn
		130				135					140				
Ser	His	Gly	Pro	Tyr	Asp	Ser	Asn	Gln	Pro	His	Arg	Lys	Thr	Lys	Ile
145				150					155					160	
Thr	Phe	Glu	Glu	Asp	Lys	Val	Asp	Ser	Thr	Leu	Ile	Gly	Ser	Ser	Ser
			165				170						175		
His	Val	Glu	Trp	Glu	Asp	Ala	Val	His	Ile	Ile	Pro	Glu	Asn	Glu	Ser
		180					185					190			
Asp	Asp	Glu	Glu	Glu	Glu	Glu	Lys	Gly	Pro	Val	Ser	Pro	Arg	Asn	Leu
		195				200					205				

Ser Leu Gly Arg Cys Tyr Ser Thr Pro Ser Gly Tyr Leu Glu Leu Pro
 690 695 700
 Asp Leu Gly Gln Pro Tyr Ser Ser Ala Val Tyr Ser Leu Glu Glu Gln
 705 710 715 720
 Tyr Leu Gly Leu Ala Leu Asp Val Asp Arg Ile Lys Lys Asp Gln Glu
 725 730 735
 Glu Glu Glu Asp Gln Gly Pro Pro Cys Pro Arg Leu Ser Arg Glu Leu
 740 745 750
 Leu Glu Val Val Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Arg Cys
 755 760 765
 Tyr Ser Thr Pro Ser Ser Cys Leu Glu Gln Pro Asp Ser Cys Gln Pro
 770 775 780
 Tyr Gly Ser Ser Phe Tyr Ala Leu Glu Glu Lys His Val Gly Phe Ser
 785 790 795 800
 Leu Asp Val Gly Glu Ile Glu Lys Lys Gly Lys Gly Lys Lys Arg Arg
 805 810 815
 Gly Arg Arg Ser Lys Lys Glu Arg Arg Gly Arg Lys Glu Gly Glu
 820 825 830
 Glu Asp Gln Asn Pro Pro Cys Pro Arg Leu Asn Ser Met Leu Met Glu
 835 840 845
 Val Glu Glu Pro Glu Val Leu Gln Asp Ser Leu Asp Ile Cys Tyr Ser
 850 855 860
 Thr Pro Ser Met Tyr Phe Glu Leu Pro Asp Ser Phe Gln His Tyr Arg
 865 870 875 880
 Ser Val Phe Tyr Ser Phe Glu Glu Glu His Ile Ser Phe Ala Leu Tyr
 885 890 895
 Val Asp Asn Arg Phe Phe Thr Leu Thr Val Thr Ser Leu His Leu Val
 900 905 910
 Phe Gln Met Gly Val Ile Phe Pro Gln
 915 920

<210> 17

<211> 664

<212> DNA

<213> Homo sapiens

<400> 17

aacccaatga tctctgcagca gcccttgcag cgaggccccc agggagggggc ccagcgcctc 60
 ccgcggggccg ccttgggggt gacttggggc ctggacgcca gctcccctct ccgaggagct 120
 gtgcccata gaaccaagcg gcgcctggag gaggagcagg agcctctgcg caagcagttt 180
 ctgtctgagg agaacatggc caccacttc tctcaactca gcctgcacaa tgaccacccc 240
 tactgcagcc ccccatgac cttctcccca gccctgcccc cactcaggag cccttgctct 300
 gagctgcttc tctggcgcta tcttggcagc ctcacccctg aggccctccg tctgctgagg 360
 ctgggggaca cccccagtcc cccctaccct gcaaccccag ctgggggacat aatggagctc 420
 tgagtgcctgg tggacagtgc cccctccacc ttccttcttc ccacacacag aagagaccag 480
 cgactcccgc aaagggacaa gggtccctccc tctcctgcag agtaggcatac tgggcaccaa 540
 gaccttccct caacagagga cactgagccc aacggagttc tgggatggga ggggtgggag 600
 catgggaagg gaggcataccc accccaaga agaactgaat aaagattgct gagcaaagga 660
 aggc 664

<210> 18

<211> 138

<212> PRT

<213> Homo sapiens

<400> 18

Met Ile Leu Gln Gln Pro Leu Gln Arg Gly Pro Gln Gly Gly Ala Gln
 1 5 10 15
 Arg Leu Pro Arg Ala Ala Leu Gly Val Thr Trp Gly Leu Asp Ala Ser
 20 25 30

Ser Pro Leu Arg Gly Ala Val Pro Met Ser Thr Lys Arg Arg Leu Glu
 35 40 45
 Glu Glu Gln Glu Pro Leu Arg Lys Gln Phe Leu Ser Glu Glu Asn Met
 50 55 60
 Ala Thr His Phe Ser Gln Leu Ser Leu His Asn Asp His Pro Tyr Cys
 65 70 75 80
 Ser Pro Pro Met Thr Phe Ser Pro Ala Leu Pro Pro Leu Arg Ser Pro
 85 90 95
 Cys Ser Glu Leu Leu Leu Trp Arg Tyr Pro Gly Ser Leu Ile Pro Glu
 100 105 110
 Ala Leu Arg Leu Leu Arg Leu Gly Asp Thr Pro Ser Pro Pro Tyr Pro
 115 120 125
 Ala Thr Pro Ala Gly Asp Ile Met Glu Leu
 130 135

<210> 19

<211> 2056

<212> DNA

<213> Homo sapiens

<400> 19

ggaaccgcgg	ctgctggaca	agaggggtgc	ggtggatact	gacctttgct	ccggcctcgt	60
cgtgaagaca	cagcgcattct	ccccgctgta	ggcttctccc	acagaaccgc	tttcgggcct	120
cagagcgtct	ggtgagatgc	tggttgcgct	gctgctgctg	ctacccatgt	gctgggcctg	180
ggaggtcaag	aggccccggg	gcgtctccct	caccaatcat	cacttctacg	atgagtccaa	240
gcctttcacc	tgcctggacg	gttcggccac	catcccattt	gatcaggtea	acgatgacta	300
ttgcgactgc	aaagatggct	ctgacgagcc	aggcacggct	gcctgtccta	atggcagctt	360
ccactgcacc	aacactggct	ataagcccct	gtatatcccc	tccaaccggg	tcaacgatgg	420
tgttttgtgac	tgctgcgatg	gaacagacga	gtacaacagc	ggcgtcatct	gtgagaacac	480
ctgcaaagag	aagggccgta	aggagagaga	gtccctgcag	cagatggccg	aggtcacccg	540
cgaaggggttc	cgtctgaaga	agatccctat	tgaggactgg	aagaaggcac	gggaggagaa	600
gcagaaaaag	ctcattgagc	tacaggctgg	gaagaagtct	ctggaagacc	aggtggagat	660
gctgcgggaca	gtgaaggagg	aagctgagaa	gccagagaga	gaggccaaag	agcagcacca	720
gaagctgtgg	gaagagcagc	tggctgctgc	caaggcccaa	caggagcagg	agctggcggc	780
tgatgccttc	aaggagctgg	atgatgacat	ggacgggacg	gtctcggtga	ctgagctgca	840
gactcacccg	gagctggaca	cagatgggga	tggggcggtg	tcagaagcgg	aagctcaggc	900
cctcctcagt	ggggacacac	agacagacgc	cacctctttc	tacgaccgcg	cttgggcgcg	960
catcaggggac	aagtaccggt	ccgaggcact	gccaccgcac	cttccagcac	cttctgcccc	1020
tgacttgacg	gagcccaagg	aggagcagcc	gccagtgcgc	tcgtcgccca	cagaggagga	1080
ggaggaggag	gaggaggagg	aagaagaggc	tgaagaagag	gaggaggagg	aggattccga	1140
ggaggcccca	ccgccactgt	cacccccgca	gccggccagc	cctgctgagg	aagacaaaat	1200
gccgccctac	gacgagcaga	cgcaggcctt	catcgatgct	gccaggagg	cccgcaacaa	1260
gttcgaggag	gccgagcggg	cgctgaagga	catggaggag	tccatcagga	acctggagca	1320
agagattttct	tttgactttg	gccccaacgg	ggagtttgct	tacctgtaca	gccagtgcct	1380
cgagctcacc	accaacgaat	acgtctaccg	cctctgcccc	ttcaagcttg	tctcgagaa	1440
accaaactc	gggggtcttc	ccaccagcct	tggcacctgg	ggctcatgga	ttggccccga	1500
ccacgacaag	ttcagtgcga	tgaagtatga	gcaaggcacg	ggctgctggc	agggccccaa	1560
ccgctccacc	atcgtgcgcc	tcctgtgcgg	gaaagagacc	atgggtgacca	gcaccacaga	1620
gccagctcgc	tgcgagtacc	tcatggagct	gatgacgcca	gccgcctgcc	gggagccacc	1680
gcctgaagca	cccaccgaag	acgacctatga	cgagctctag	ctggatgggc	gcagagaacc	1740
tcaagaaggc	atgaagccag	cccctgcagt	gccgtccacc	cgcccctctg	ggcctgcctg	1800
tggtctctgtt	gccctcctct	gtggcggcag	gacctttgtg	gggcttcgtg	ccctgctctg	1860
gggcccaggc	ggggctggtc	cacattccca	ggcccaaca	gcctccaaag	atgggtaaag	1920
gagcttgccc	tccctggggc	ccccaccttg	gtgactcgcc	ccaccacccc	cagccctgtc	1980
cctgccaccc	ctcctagtgg	ggactagtga	atgacttgac	ctgtgacctc	aatacaataa	2040
atgtgatccc	ccacc					2056

<210> 20

<211> 527

<212> PRT

<213> Homo sapiens.

<400> 20

Met	Leu	Leu	Pro	Leu	Leu	Leu	Leu	Leu	Pro	Met	Cys	Trp	Ala	Val	Glu	1	5	10	15
Val	Lys	Arg	Pro	Arg	Gly	Val	Ser	Leu	Thr	Asn	His	His	Phe	Tyr	Asp	20	25	30	
Glu	Ser	Lys	Pro	Phe	Thr	Cys	Leu	Asp	Gly	Ser	Ala	Thr	Ile	Pro	Phe	35	40	45	
Asp	Gln	Val	Asn	Asp	Asp	Tyr	Cys	Asp	Cys	Lys	Asp	Gly	Ser	Asp	Glu	50	55	60	
Pro	Gly	Thr	Ala	Ala	Cys	Pro	Asn	Gly	Ser	Phe	His	Cys	Thr	Asn	Thr	65	70	75	80
Gly	Tyr	Lys	Pro	Leu	Tyr	Ile	Pro	Ser	Asn	Arg	Val	Asn	Asp	Gly	Val	85	90	95	
Cys	Asp	Cys	Cys	Asp	Gly	Thr	Asp	Glu	Tyr	Asn	Ser	Gly	Val	Ile	Cys	100	105	110	
Glu	Asn	Thr	Cys	Lys	Glu	Lys	Gly	Arg	Lys	Glu	Arg	Glu	Ser	Leu	Gln	115	120	125	
Gln	Met	Ala	Glu	Val	Thr	Arg	Glu	Gly	Phe	Arg	Leu	Lys	Lys	Ile	Leu	130	135	140	
Ile	Glu	Asp	Trp	Lys	Lys	Ala	Arg	Glu	Glu	Lys	Gln	Lys	Lys	Leu	Ile	145	150	155	160
Glu	Leu	Gln	Ala	Gly	Lys	Lys	Ser	Leu	Glu	Asp	Gln	Val	Glu	Met	Leu	165	170	175	
Arg	Thr	Val	Lys	Glu	Glu	Ala	Glu	Lys	Pro	Glu	Arg	Glu	Ala	Lys	Glu	180	185	190	
Gln	His	Gln	Lys	Leu	Trp	Glu	Glu	Gln	Leu	Ala	Ala	Ala	Lys	Ala	Gln	195	200	205	
Gln	Glu	Gln	Glu	Leu	Ala	Ala	Asp	Ala	Phe	Lys	Glu	Leu	Asp	Asp	Asp	210	215	220	
Met	Asp	Gly	Thr	Val	Ser	Val	Thr	Glu	Leu	Gln	Thr	His	Pro	Glu	Leu	225	230	235	240
Asp	Thr	Asp	Gly	Asp	Gly	Ala	Leu	Ser	Glu	Ala	Glu	Ala	Gln	Ala	Leu	245	250	255	
Leu	Ser	Gly	Asp	Thr	Gln	Thr	Asp	Ala	Thr	Ser	Phe	Tyr	Asp	Arg	Val	260	265	270	
Trp	Ala	Ala	Ile	Arg	Asp	Lys	Tyr	Arg	Ser	Glu	Ala	Leu	Pro	Thr	Asp	275	280	285	
Leu	Pro	Ala	Pro	Ser	Ala	Pro	Asp	Leu	Thr	Glu	Pro	Lys	Glu	Glu	Gln	290	295	300	
Pro	Pro	Val	Pro	Ser	Ser	Pro	Thr	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Glu	305	310	315	320
Glu	Glu	Glu	Glu	Ala	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Asp	Ser	Glu	Glu	325	330	335	
Ala	Pro	Pro	Pro	Leu	Ser	Pro	Pro	Gln	Pro	Ala	Ser	Pro	Ala	Glu	Glu	340	345	350	
Asp	Lys	Met	Pro	Pro	Tyr	Asp	Glu	Gln	Thr	Gln	Ala	Phe	Ile	Asp	Ala	355	360	365	
Ala	Gln	Glu	Ala	Arg	Asn	Lys	Phe	Glu	Glu	Ala	Glu	Arg	Ser	Leu	Lys	370	375	380	
Asp	Met	Glu	Glu	Ser	Ile	Arg	Asn	Leu	Glu	Gln	Glu	Ile	Ser	Phe	Asp	385	390	395	400
Phe	Gly	Pro	Asn	Gly	Glu	Phe	Ala	Tyr	Leu	Tyr	Ser	Gln	Cys	Tyr	Glu	405	410	415	
Leu	Thr	Thr	Asn	Glu	Tyr	Val	Tyr	Arg	Leu	Cys	Pro	Phe	Lys	Leu	Val	420	425	430	
Ser	Gln	Lys	Pro	Lys	Leu	Gly	Gly	Ser	Pro	Thr	Ser	Leu	Gly	Thr	Trp	435	440	445	
Gly	Ser	Trp	Ile	Gly	Pro	Asp	His	Asp	Lys	Phe	Ser	Ala	Met	Lys	Tyr				

20

450		455		460
Glu Gln Gly Thr Gly Cys Trp Gln Gly Pro Asn Arg Ser Thr Thr Val				
465		470		475
Arg Leu Leu Cys Gly Lys Glu Thr Met Val Thr Ser Thr Thr Glu Pro				480
	485		490	495
Ser Arg Cys Glu Tyr Leu Met Glu Leu Met Thr Pro Ala Ala Cys Pro				
	500		505	510
Glu Pro Pro Pro Glu Ala Pro Thr Glu Asp Asp His Asp Glu Leu				
	515		520	525

<210> 21
 <211> 384
 <212> DNA
 <213> Homo sapiens

<400> 21
 atgcctaaat caaaggaact tgttttcttca agctcttctg gcagtgattc tgacagtgag 60
 gttgacaaaa agttaagag gaaaaagcaa gttgctccag aaaaacctgt aaagaaacaa 120
 aagacagggt agacttcgag agccctgtca tcttctaaac agagcagcag cagcagagat 180
 gataacatgt ttcagattgg gaaaatgagg tacgttagtg ttcgcgattt taaaggcaaa 240
 gtgctaattg atattagaga atattggatg gatcctgaag gtgaaatgaa accaggaaga 300
 aaaggtattt ctttaaattcc agaacaatgg agccagctga aggaacagat ctctgatata 360
 gatgacgcag taagaaagct gtga 384

<210> 22
 <211> 127
 <212> PRT
 <213> Homo sapiens

<400> 22
 Met Pro Lys Ser Lys Glu Leu Val Ser Ser Ser Ser Ser Gly Ser Asp
 1 5 10 15
 Ser Asp Ser Glu Val Asp Lys Lys Leu Lys Arg Lys Lys Gln Val Ala
 20 25 30
 Pro Glu Lys Pro Val Lys Lys Gln Lys Thr Gly Glu Thr Ser Arg Ala
 35 40 45
 Leu Ser Ser Ser Lys Gln Ser Ser Ser Arg Asp Asp Asn Met Phe
 50 55 60
 Gln Ile Gly Lys Met Arg Tyr Val Ser Val Arg Asp Phe Lys Gly Lys
 65 70 75 80
 Val Leu Ile Asp Ile Arg Glu Tyr Trp Met Asp Pro Glu Gly Glu Met
 85 90 95
 Lys Pro Gly Arg Lys Gly Ile Ser Leu Asn Pro Glu Gln Trp Ser Gln
 100 105 110
 Leu Lys Glu Gln Ile Ser Asp Ile Asp Asp Ala Val Arg Lys Leu
 115 120 125

<210> 23
 <211> 1554
 <212> DNA
 <213> Homo sapiens

<400> 23
 gaccacaatg gggccgcca ccctgctgcg cgcgacgccc cacttcagcg gtctcgccgc 60
 cggccggacc ttctgctgc agggctctgtt gggctgctg aaagccccgg cattgcctct 120
 ctgtgcccgc ggccctggccg tggaggccaa gaagacttac gtgcgcgaca agccacatgt 180
 gaatgtgggt accatcgcc atgtggacca cggaagacc acgctgactg cagccatcac 240
 gaagattcta gctgaggag gtggggctaa gttcaagaag tacgaggaga ttgacaatgc 300
 cccggaggag cgagctcggg gtatcaccat caatgcgggt catgtggagt atagcactgc 360
 cgcccggcac tacgcccaca cagactgccc gggctcatgca gattatgtta agaatatgat 420

cacaggcact	gcacccctcg	acggctgcat	cctgggtgta	gcagccaatg	acggcccat	480
gccccagacc	cgagagcact	tattactggc	cagacagatt	ggggtggagc	atgtggtggt	540
gtatgtgaac	aaggctgacg	ctgtccagga	ctctgagatg	gtggaactgg	tggaactgga	600
gatccgggag	ctgctcaccg	agtttggtta	taaaggggag	gagacccag	tcacgtagg	660
ctctgctctc	tgtgcccttg	agggtcgga	ccctgagtta	ggcctgaagt	ctgtgcagaa	720
gctactggat	gctgtggaca	cttacatccc	agtgcgcc	cgggacctgg	agaagccttt	780
cctgctgcct	gtggaggcgg	tgtactccgt	ccctggcctg	ggcaccgtgg	tgacaggtag	840
actagagcgt	ggcattttta	agaagggaga	cgagtgtgag	ctcctaggac	atagcaagaa	900
catccgcact	gtggtgacag	gcattgagat	gttcacaag	agcctggaga	gggcccaggc	960
cggagataac	ctcggggccc	tgggtccgagg	cttgaagcgg	gaggacttgc	ggcggggcct	1020
ggtcatggtc	aagccagggt	ccatcaagcc	ccaccagaag	gtggaggccc	aggtttacat	1080
cctcagcaag	gaggaagggt	gccgccacaa	gccctttgtg	tcccacttca	tgccgtgcat	1140
gttctccctg	acttggaaaca	tggcctgtcg	gattatcctg	ccccagaga	aggagcttgc	1200
catgcccggg	gaggacctga	agttcaacct	aatcttgccg	cagccaatga	tcttagagaa	1260
aggccagcgt	ttcaccctgc	gagatggcaa	ccggactatt	ggcaccggtc	tagtcaccaa	1320
cacgtgggcc	atgactgagg	aggagaagaa	tatcaaattg	ggttgagtgt	gcagatctct	1380
gctcagcttc	ccttgcgttt	aaggcctgcc	ctagccaggg	ctccctctcg	cttcaggtac	1440
cctctcatgg	cataggctgc	aaccagcag	agggcagcta	gatggacatt	tcccctgctc	1500
ggaagggttg	gcctgcctgg	ctggggagggt	cagtaaactt	tgaatagtaa	gcca	1554

<210> 24

<211> 452

<212> PRT

<213> Homo sapiens

<400> 24

Met	Ala	Ala	Ala	Thr	Leu	Leu	Arg	Ala	Thr	Pro	His	Phe	Ser	Gly	Leu
1				5					10					15	
Ala	Ala	Gly	Arg	Thr	Phe	Leu	Leu	Gln	Gly	Leu	Leu	Arg	Leu	Leu	Lys
			20					25					30		
Ala	Pro	Ala	Leu	Pro	Leu	Leu	Cys	Arg	Gly	Leu	Ala	Val	Glu	Ala	Lys
		35					40					45			
Lys	Thr	Tyr	Val	Arg	Asp	Lys	Pro	His	Val	Asn	Val	Gly	Thr	Ile	Gly
	50					55				60					
His	Val	Asp	His	Gly	Lys	Thr	Thr	Leu	Thr	Ala	Ala	Ile	Thr	Lys	Ile
65					70					75				80	
Leu	Ala	Glu	Gly	Gly	Gly	Ala	Lys	Phe	Lys	Lys	Tyr	Glu	Glu	Ile	Asp
			85						90					95	
Asn	Ala	Pro	Glu	Glu	Arg	Ala	Arg	Gly	Ile	Thr	Ile	Asn	Ala	Ala	His
			100					105					110		
Val	Glu	Tyr	Ser	Thr	Ala	Ala	Arg	His	Tyr	Ala	His	Thr	Asp	Cys	Pro
		115					120					125			
Gly	His	Ala	Asp	Tyr	Val	Lys	Asn	Met	Ile	Thr	Gly	Thr	Ala	Pro	Leu
	130					135					140				
Asp	Gly	Cys	Ile	Leu	Val	Val	Ala	Ala	Asn	Asp	Gly	Pro	Met	Pro	Gln
145					150					155					160
Thr	Arg	Glu	His	Leu	Leu	Leu	Ala	Arg	Gln	Ile	Gly	Val	Glu	His	Val
				165					170					175	
Val	Val	Tyr	Val	Asn	Lys	Ala	Asp	Ala	Val	Gln	Asp	Ser	Glu	Met	Val
			180					185					190		
Glu	Leu	Val	Glu	Leu	Glu	Ile	Arg	Glu	Leu	Leu	Thr	Glu	Phe	Gly	Tyr
		195					200					205			
Lys	Gly	Glu	Glu	Thr	Pro	Val	Ile	Val	Gly	Ser	Ala	Leu	Cys	Ala	Leu
	210					215					220				
Glu	Gly	Arg	Asp	Pro	Glu	Leu	Gly	Leu	Lys	Ser	Val	Gln	Lys	Leu	Leu
225					230					235					240
Asp	Ala	Val	Asp	Thr	Tyr	Ile	Pro	Val	Pro	Ala	Arg	Asp	Leu	Glu	Lys
				245					250					255	
Pro	Phe	Leu	Leu	Pro	Val	Glu	Ala	Val	Tyr	Ser	Val	Pro	Gly	Arg	Gly
			260					265						270	

Thr Val Val Thr Gly Thr Leu Glu Arg Gly Ile Leu Lys Lys Gly Asp
 275 280 285
 Glu Cys Glu Leu Leu Gly His Ser Lys Asn Ile Arg Thr Val Val Thr
 290 295 300
 Gly Ile Glu Met Phe His Lys Ser Leu Glu Arg Ala Glu Ala Gly Asp
 305 310 315 320
 Asn Leu Gly Ala Leu Val Arg Gly Leu Lys Arg Glu Asp Leu Arg Arg
 325 330 335
 Gly Leu Val Met Val Lys Pro Gly Ser Ile Lys Pro His Gln Lys Val
 340 345 350
 Glu Ala Gln Val Tyr Ile Leu Ser Lys Glu Glu Gly Gly Arg His Lys
 355 360 365
 Pro Phe Val Ser His Phe Met Pro Val Met Phe Ser Leu Thr Trp Asn
 370 375 380
 Met Ala Cys Arg Ile Ile Leu Pro Pro Glu Lys Glu Leu Ala Met Pro
 385 390 395 400
 Gly Glu Asp Leu Lys Phe Asn Leu Ile Leu Arg Gln Pro Met Ile Leu
 405 410 415
 Glu Lys Gly Gln Arg Phe Thr Leu Arg Asp Gly Asn Arg Thr Ile Gly
 420 425 430
 Thr Gly Leu Val Thr Asn Thr Leu Ala Met Thr Glu Glu Glu Lys Asn
 435 440 445
 Ile Lys Trp Gly
 450

<210> 25

<211> 2201

<212> DNA

<213> Homo sapiens

<400> 25

tttttttttt	cgtcttagcc	acgcagaagt	cgcgtgtcta	gtttgtttcg	acgccggacc	60
gcgtaagaga	cgatgatgtt	gggcacggaa	ggtggagagg	gattcgtggt	gaaggtccgg	120
ggcttgccct	ggtcttgctc	ggccgatgaa	gtgcagaggt	ttttttctga	ctgcaaaatt	180
caaaatgggg	ctcaaggtat	tcgtttcatc	tacaccagag	aaggcagacc	aagtggcgag	240
gcttttggtg	aacttgaatc	agaagatgaa	gtcaaattgg	ccctgaaaaa	agacagagaa	300
actatgggac	acagatatgt	tgaagtattc	aagtcaaaca	acgttgaaat	ggattgggtg	360
ttgaagcata	ctgggtccaaa	tagtcctgac	acggccaatg	atggcctttgt	acggcttaga	420
ggacttcctt	ttggatgtag	caaggaagaa	attgttcagt	tcttctcagg	gttggaatc	480
gtgccaaatg	ggataacatt	gccggtggac	ttccagggga	ggagtacggg	ggaggccttc	540
gtgcagtttg	cttcacagga	aatagctgaa	aaggctctaa	agaaacacaa	ggaaagaata	600
gggcacaggt	atattgaaat	ctttaagagc	agtagagctg	aagttagaac	tcattatgat	660
ccaccacgaa	agcttatggc	catgcagcgg	ccaggtcctt	atgacagacc	tggggctggt	720
agaggggtata	acagcattgg	cagaggagct	ggctttgaga	ggatgaggcg	tgggtgcttat	780
ggtggaggct	atggaggcta	tgatgattac	aatggctata	atgatggcta	tggatttggg	840
tcagatagat	ttggaagaga	cctcaattac	tgtttttcag	gaatgtctga	tcacagatac	900
ggggatgggtg	gctctacttt	ccagagcaca	acaggacact	gtgtacacat	gcgggggatta	960
ccttacagag	ctactgagaa	tgacatttat	aatttttttt	caccgctcaa	ccctgtgaga	1020
gtacacattg	aaatttggcc	tgatggcaga	gtaactgggtg	aagcagatgt	cgagttcgca	1080
actcatgaag	atgctgtggc	agctatgtca	aaagacaaag	caaatatgca	acacagatat	1140
gtagaactct	tcttgaattc	tacagcagga	gcaagcgggtg	gtgcttacga	acacagatat	1200
gtagaactct	tcttgaattc	tacagcagga	gcaagcgggtg	gtgcttatgg	tagccaaatg	1260
atgggaggca	tgggcttgtc	aaaccagtcc	agctacgggg	gcccagccag	ccagcagctg	1320
agtggggggtt	acggaggcgg	ctacgggtggc	cagagcagca	tgagtggata	cgaccaagtt	1380
ttacaggaaa	actccagtga	ttttcaatca	aacattgcat	aggtaaccaa	ggagcagtga	1440
acagcagcta	ctacagtagt	ggaagccgtg	catctatggg	cgtgaacgga	atgggagggt	1500
tgtctagcat	gtccagtatg	agtgggtggat	ggggaatgta	attgatcgat	cctgatcact	1560
gactcttgggt	caacccttttt	tttttttttt	ttttctttaa	gaaaacttca	gtttaacagt	1620
ttctgcaata	caagcttgtg	atttatgctt	actctaagtg	gaaatcagga	ttgttatgaa	1680
gacttaaggc	ccagtatttt	tgaatacaat	actcatctag	gatgtaacag	tgaagctgag	1740

taaactataa	ctgttaaact	taagttccag	cttttctcaa	gttagttata	ggatgtactt	1800
aagcagtaag	cgtatttagg	taaaagcagt	tgaattatgt	taaatgttgc	cctttgccac	1860
gttaaattga	acactgtttt	ggatgcatgt	tgaagacat	gcttttattt	tttttgtaaa	1920
acaatatagg	agctgtgtct	actattaata	gtgaaacatt	ttggcatgtt	tgttaattct	1980
agtttcattt	aataacctgt	aaggcacgta	agtttaagct	tttttttttt	ttaagttaat	2040
gggaaaaatt	tgagacgcaa	taccaatact	taggattttg	gtcttggtgt	ttgtatgaaa	2100
ttctgaggcc	ttgatttaaa	tctttcattg	tattgtgatt	tccttttagg	tatattgcgc	2160
taagtgaaac	ttgtcaaata	aatcctcctt	ttaaaaactg	c		2201

<210> 26

<211> 449

<212> PRT

<213> Homo sapiens

<400> 26

Met	Met	Leu	Gly	Thr	Glu	Gly	Gly	Glu	Gly	Phe	Val	Val	Lys	Val	Arg	
1				5					10					15		
Gly	Leu	Pro	Trp	Ser	Cys	Ser	Ala	Asp	Glu	Val	Gln	Arg	Phe	Phe	Ser	
			20					25					30			
Asp	Cys	Lys	Ile	Gln	Asn	Gly	Ala	Gln	Gly	Ile	Arg	Phe	Ile	Tyr	Thr	
		35					40					45				
Arg	Glu	Gly	Arg	Pro	Ser	Gly	Glu	Ala	Phe	Val	Glu	Leu	Glu	Ser	Glu	
		50				55					60					
Asp	Glu	Val	Lys	Leu	Ala	Leu	Lys	Lys	Asp	Arg	Glu	Thr	Met	Gly	His	
65					70					75					80	
Arg	Tyr	Val	Glu	Val	Phe	Lys	Ser	Asn	Asn	Val	Glu	Met	Asp	Trp	Val	
				85					90					95		
Leu	Lys	His	Thr	Gly	Pro	Asn	Ser	Pro	Asp	Thr	Ala	Asn	Asp	Gly	Phe	
			100					105					110			
Val	Arg	Leu	Arg	Gly	Leu	Pro	Phe	Gly	Cys	Ser	Lys	Glu	Glu	Ile	Val	
		115					120					125				
Gln	Phe	Phe	Ser	Gly	Leu	Glu	Ile	Val	Pro	Asn	Gly	Ile	Thr	Leu	Pro	
						135					140					
Val	Asp	Phe	Gln	Gly	Arg	Ser	Thr	Gly	Glu	Ala	Phe	Val	Gln	Phe	Ala	
145					150					155					160	
Ser	Gln	Glu	Ile	Ala	Glu	Lys	Ala	Leu	Lys	Lys	His	Lys	Glu	Arg	Ile	
				165					170					175		
Gly	His	Arg	Tyr	Ile	Glu	Ile	Phe	Lys	Ser	Ser	Arg	Ala	Glu	Val	Arg	
			180					185					190			
Thr	His	Tyr	Asp	Pro	Pro	Arg	Lys	Leu	Met	Ala	Met	Gln	Arg	Pro	Gly	
		195					200					205				
Pro	Tyr	Asp	Arg	Pro	Gly	Ala	Gly	Arg	Gly	Tyr	Asn	Ser	Ile	Gly	Arg	
		210				215					220					
Gly	Ala	Gly	Phe	Glu	Arg	Met	Arg	Arg	Gly	Ala	Tyr	Gly	Gly	Gly	Tyr	
225					230					235					240	
Gly	Gly	Tyr	Asp	Asp	Tyr	Asn	Gly	Tyr	Asn	Asp	Gly	Tyr	Gly	Phe	Gly	
				245					250					255		
Ser	Asp	Arg	Phe	Gly	Arg	Asp	Leu	Asn	Tyr	Cys	Phe	Ser	Gly	Met	Ser	
			260					265					270			
Asp	His	Arg	Tyr	Gly	Asp	Gly	Gly	Ser	Thr	Phe	Gln	Ser	Thr	Thr	Gly	
		275					280					285				
His	Cys	Val	His	Met	Arg	Gly	Leu	Pro	Tyr	Arg	Ala	Thr	Glu	Asn	Asp	
		290				295					300					
Ile	Tyr	Asn	Phe	Phe	Ser	Pro	Leu	Asn	Pro	Val	Arg	Val	His	Ile	Glu	
305					310					315					320	
Ile	Gly	Pro	Asp	Gly	Arg	Val	Thr	Gly	Glu	Ala	Asp	Val	Glu	Phe	Ala	
				325					330					335		
Thr	His	Glu	Asp	Ala	Val	Ala	Ala	Met	Ser	Lys	Asp	Lys	Ala	Asn	Met	
			340					345					350			

Gln His Arg Tyr Val Glu Leu Phe Leu Asn Ser Thr Ala Gly Ala Ser
 355 360 365
 Gly Gly Ala Tyr Glu His Arg Tyr Val Glu Leu Phe Leu Asn Ser Thr
 370 375 380
 Ala Gly Ala Ser Gly Gly Ala Tyr Gly Ser Gln Met Met Gly Gly Met
 385 390 395 400
 Gly Leu Ser Asn Gln Ser Ser Tyr Gly Gly Pro Ala Ser Gln Gln Leu
 405 410 415
 Ser Gly Gly Tyr Gly Gly Gly Tyr Gly Gly Gln Ser Ser Met Ser Gly
 420 425 430
 Tyr Asp Gln Val Leu Gln Glu Asn Ser Ser Asp Phe Gln Ser Asn Ile
 435 440 445
 Ala

<210> 27

<211> 1852

<212> DNA

<213> Homo sapiens

<400> 27

```

acagcccttc gtggggccct gggcaccctg caccagctgg gcatcgtcgt cggcatcctc      60
atcgcccagg tgttcggcct ggactccatc atgggcaaca aggacctgtg gcccctgctg      120
ctgagcatca tcttcatccc ggccctgctg cagtgcacgt tgctgccctt ctgccccgag      180
agtccccgct tcctgctcat caaccgcaac gaggagaacc gggccaagag tgtgctaaag      240
aagctgcgcg ggacagctga cgtgacccat gacctgcagg agatgaagga agagagtcgg      300
cagatgatgc gggagaagaa ggtcaccatc ctggagctgt tccgctcccc cgcctaccgc      360
cagcccatcc tcatcgctgt ggtgctgcag ctgtcccagc agctgtctgg catcaacgct      420
gtcttctatt actccaagag catcttcgag aaggcggggg tgcagcagcc tgtgtatgcc      480
accattggct cgggtatcgt caacacggcc ttactgtcgt tgtcgtctgt tgtgggtggag      540
cgagcaggcc ggcggaccct gcacctcata ggctcgtctg gcatggcggg ttgtgccata      600
ctcatgacca tcgcgctagc actgctggag cagctaccct ggatgtccta tctgagcatc      660
gtggccatct ttggctttgt ggccttcttt gaagtgggtc ctggcccccatt cccatggttc      720
atcgtggctg aactcttcag ccagggtcca cgtccagctg ccattgccgt tgcaggcttc      780
tccaactgga cctcaaattt cattgtgggc atgtgcttcc agtatgtgga gcaactgtgt      840
ggtcctctacg tcttcatcat cttcactgtg ctcttggttc tgttcttcat cttcacctac      900
ttcaaagtcc ctgagactaa aggcgggacc ttcgatgaga tcgcttccgg cttccggcag      960
gggggagcca gccaaagtga caagacaccc gaggagctgt tccatcccct gggggctgat      1020
tccaagtgtg gagtgcgccc agatcaccag cccggcctgc tcccagcagc cctaaggatc      1080
tctcaggagc acaggcagct ggatgagact tccaaacctg acagatgtca gccgagccgg      1140
gcctggggct cttttctcca gccagcaatg atgtccagaa gaatattcag gacttaacgg      1200
ctccaggatt ttaacaaaag caagactgtt gctcaaactc attcagacaa gcaacagggt      1260
ttataatttt tttattactg attttgttat ttttatatca gcctgagttc cctgtgcccc      1320
catcccaggc ttcaccctga atggttccat gcctgagggt ggagactaag ccctgtcgag      1380
acacttgctt tcttcaccca gctaactctg agggctggac ctatgtccta aggacacact      1440
aatcgaacta tgaactacaa agcttctatc ccaggagggt gctatggcca cccgttctgc      1500
tggcctggat ctcccactc taggggtcag gctccattag gatttgcccc ttcccatctc      1560
ttcctaccca accactcaaa ttaatctttc tttacctgag accagttggg agcactggag      1620
tgcagggagg agaggggaag ggccagtctg ggctgccggg ttctagtctc ctttgactgc      1680
agggccacac tattaccatg agaagagggc ctgtgggagc ctgcaaactc actgctcaag      1740
aagacatgga gactcctgcc ctgttgtgta tagatgcaag atatttatat atatttttgg      1800
ttgtcaatat taaatacaga cactaagtta tagtaaaaaa aaaaaaaaaa aa      1852

```

<210> 28

<211> 343

<212> PRT

<213> Homo sapiens

<400> 28

Thr Ala Leu Arg Gly Ala Leu Gly Thr Leu His Gln Leu Gly Ile Val
 1 5 10 15
 Val Gly Ile Leu Ile Ala Gln Val Phe Gly Leu Asp Ser Ile Met Gly
 20 25 30
 Asn Lys Asp Leu Trp Pro Leu Leu Ser Ile Ile Phe Ile Pro Ala
 35 40 45
 Leu Leu Gln Cys Ile Val Leu Pro Phe Cys Pro Glu Ser Pro Arg Phe
 50 55 60
 Leu Leu Ile Asn Arg Asn Glu Glu Asn Arg Ala Lys Ser Val Leu Lys
 65 70 75 80
 Lys Leu Arg Gly Thr Ala Asp Val Thr His Asp Leu Gln Glu Met Lys
 85 90 95
 Glu Glu Ser Arg Gln Met Met Arg Glu Lys Lys Val Thr Ile Leu Glu
 100 105 110
 Leu Phe Arg Ser Pro Ala Tyr Arg Gln Pro Ile Leu Ile Ala Val Val
 115 120 125
 Leu Gln Leu Ser Gln Gln Leu Ser Gly Ile Asn Ala Val Phe Tyr Tyr
 130 135 140
 Ser Thr Ser Ile Phe Glu Lys Ala Gly Val Gln Gln Pro Val Tyr Ala
 145 150 155 160
 Thr Ile Gly Ser Gly Ile Val Asn Thr Ala Phe Thr Val Val Ser Leu
 165 170 175
 Phe Val Val Glu Arg Ala Gly Arg Arg Thr Leu His Leu Ile Gly Leu
 180 185 190
 Ala Gly Met Ala Gly Cys Ala Ile Leu Met Thr Ile Ala Leu Ala Leu
 195 200 205
 Leu Glu Gln Leu Pro Trp Met Ser Tyr Leu Ser Ile Val Ala Ile Phe
 210 215 220
 Gly Phe Val Ala Phe Phe Glu Val Gly Pro Gly Pro Ile Pro Trp Phe
 225 230 235 240
 Ile Val Ala Glu Leu Phe Ser Gln Gly Pro Arg Pro Ala Ala Ile Ala
 245 250 255
 Val Ala Gly Phe Ser Asn Trp Thr Ser Asn Phe Ile Val Gly Met Cys
 260 265 270
 Phe Gln Tyr Val Glu Gln Leu Cys Gly Pro Tyr Val Phe Ile Ile Phe
 275 280 285
 Thr Val Leu Leu Val Leu Phe Ile Phe Thr Tyr Phe Lys Val Pro
 290 295 300
 Glu Thr Lys Gly Arg Thr Phe Asp Glu Ile Ala Ser Gly Phe Arg Gln
 305 310 315 320
 Gly Gly Ala Ser Gln Ser Asp Lys Thr Pro Glu Glu Leu Phe His Pro
 325 330 335
 Leu Gly Ala Asp Ser Gln Val
 340

<210> 29

<211> 5368

<212> DNA

<213> Homo sapiens

<400> 29

ggaatcagag	aagatcattg	ctgagttgaa	tgaaacttgg	gaagagaagc	ttcgtaaaac	60
agaggccatc	agaatggaga	gagaggcttt	gttggctgag	atgggagttg	ccattcggga	120
agatggagga	accctagggg	ttttctcacc	taaaaagacc	ccacatcttg	ttaacctcaa	180
tgaagacca	ctaattgtctg	agtgcctact	ttattacatc	aaagatggaa	ttacaagggt	240
tggccaagca	gatgctgagc	ggcgccagga	catagtgtctg	agcggggctc	acattaaaga	300
agagcattgt	atcttccgga	gtgagagaag	caacagcggg	gaagttatcg	tgaccttaga	360
gccctgtgag	cgctcagaaa	cctacgtaaa	tggcaagagg	gtgtcccagc	ctgttcagct	420
gcgctcagga	aaccgtatca	tcatgggtaa	aaaccatgtt	ttccgcttta	accaccggga	480
acaagcacga	gctgagcgag	agaagactcc	ttctgctgag	acccctctg	agcctgtgga	540

ctggacattt	gcccagaggg	agcttctgga	aaaacaagga	attgatatga	aacaagagat	600
ggagaaaagg	ctacaggaaa	tggagatctt	atacaaaaag	gagaaggaag	aagcagatct	660
tcttttggag	cagcagagac	tggactatga	gagtaaattg	caggccttgc	agaagcaggt	720
tgaaacccga	tctctggctg	cagaaacaac	tgaagaggag	gaagaagagg	aagaagttcc	780
ttggacacag	catgaatttg	agttggccca	atgggccttc	cggaaatgga	agtctcatca	840
gtttacttca	ttacgggact	tactctgggg	caatgccgtg	tacctaaagg	aggccaatgc	900
catcagtgtg	gaactgaaaa	agaagggtgca	gtttcagttt	gttctgctga	ctgacacact	960
gtactcccct	ttgcctcctg	aattacttcc	cactgagatg	gaaaaaactc	atgaggacag	1020
gcctttccct	cgcacagtgg	tagcagtaga	agtccaggat	ttgaagaatg	gagcaacaca	1080
ctattggtct	ttggagaaac	tcaagcagag	gctggatttg	atgcgagaga	tgtatgatag	1140
ggcaggggag	atggcctcca	gtgcccaaga	cgaagcgaa	accactgtga	ctggcagcga	1200
tcccttctat	gatcggttcc	actggttcaa	acttgtgggg	agctccccca	ttttccacgg	1260
ctgtgtgaac	gagcgccttg	ccgaccgcac	accctccccc	actttttcca	cggccgattc	1320
cgacatcact	gagctggctg	acgagcagca	agatgagatg	gaggattttg	atgatgaggc	1380
attcgtggat	gacgcgggct	ctgacgcagg	gacggaggag	ggatcagatc	tcttcagtga	1440
cgggcatgac	cegttttacg	accgatcccc	ttggttcatt	ttagtgggaa	gggcatttgt	1500
ttacctgagc	aatctgctgt	atcccgtgcc	cctgatccac	aggggtggcca	tcgtcagtga	1560
gaaaggtgaa	gtgcggggat	ttctgcgtgt	ggctgtacag	gccatcgag	cggatgaaga	1620
agctcctgat	tatggctctg	gaattcgaca	gtcaggaaca	gctaaaatat	cttttgataa	1680
tgaatacttt	aatcagagtg	acttttcgtc	tgttgcaatg	actcgttctg	gtctgtcctt	1740
ggaggagtgt	aggattgtgg	aaggacaggg	tcagagttct	gaggatcatca	ctcctccaga	1800
agaaatcagt	cgaattaatg	acttggattt	gaagtcaagc	actttgctgg	atggtaagat	1860
ggtaatggaa	gggttttctg	aagagatttg	caaccacctg	aaactgggca	gtgccttcac	1920
tttccgagta	acagtgttgc	aggccagtgg	aatcctccca	gagtatgcag	atatcttctg	1980
tcagttcaac	tttttgcatc	gccatgatga	agcattctcc	acggagcccc	tcaaaaacaa	2040
tggcagagga	agtcccctgg	ccttttatca	tgtgcagaat	attgcagtgg	agatcactga	2100
atcatttgtg	gattacatca	aaaccaagcc	tattgtattt	gaagtctttg	ggcattatca	2160
gcagcaccca	cttcactctg	aaggacagga	gcttaacagt	ccgcctcagc	cgtgccgcgg	2220
attcttccct	ccaccatgac	cactgtccaa	ccaggttcca	gccaccaagt	taaacacgat	2280
gagcaaaacc	agccttggcc	agagcatgag	caagtatgac	ctcctgggtt	ggtttgagat	2340
cagtgaactg	gagcctacag	gagagtatat	cccagctgtg	gttgaccaca	cagcaggcctt	2400
gccttgccag	gggacatttt	tgcctcatca	gggcatccag	cgaaggatca	cagtgaccat	2460
tatccatgag	aaggggagcg	agctccattg	gaaagatgtt	cgtgaactgg	tggtaggtcg	2520
tattcggaat	aagcctgagg	tggatgaagc	tgcagttgat	gccatcctct	ccctaaatat	2580
tattttctgcc	aagtacctga	agtcttccca	caactctagc	aggaccttct	accgctttga	2640
ggctgtgtgg	gatagctctc	tgcataactc	ccttcttctg	aaccgagtga	caccctatgg	2700
agaaaagatc	tacatgacct	tgtcggccta	cctagagctg	gatcattgca	tccagccggc	2760
tgtcatcacc	aaggatgtgt	gcattggtct	ctactcccga	gatgccaaga	ctccaccacc	2820
acgtctctctg	cgtagcctct	ttggcagcgg	ctactcaaag	tcaccagatt	cgaattcgagt	2880
cactggcatt	tacgaactca	gcttatgcaa	aatgtcagac	acaggtagtc	caggtagtga	2940
gagaaggaga	agaaaaatct	tagatacgtc	agtggcatat	gtgcggggag	aagagaactt	3000
agcaggctgg	cggccccgtg	gagacagcct	cactccttag	caccagtggg	agctggagaa	3060
gctggagctc	ctacatgagg	tggaaaaaac	cogccacttt	ttgctgctgc	gtgagagact	3120
tggtgacagc	atccccaaat	ccctgagcga	ctcgttatcc	cccagcctca	gcagtgggac	3180
cctcagcacc	tccaccagta	tctcctctca	gatctcaacc	actacctttg	aaagcgccat	3240
cacacctagc	gagagcagtg	gctatgatte	aggagacatc	gaaagcctgg	tggaccgaga	3300
gaaagagctg	gctaccaagt	gcctgcaact	tctcaccac	actttcaaca	gagaattcag	3360
ccagggtcac	ggcagcgtca	gtgactgtaa	gttctctgat	atctctccaa	ttggcaggga	3420
tccctctgag	tccagtttca	gcagtgccac	cctcactccc	tcctccacct	gtccctctct	3480
ggtagactct	aggagcaact	ctctggatca	gaagacccca	gaagccaatt	cccgggcctc	3540
tagtccctgc	ccagaatttg	aacagtttca	gattgtccca	gctgtggaaa	caccatattt	3600
ggcccagaca	ggaaaaaacg	aattttctca	tcttgtttcca	gatattgaag	aaattagacc	3660
aagctcagtg	gtctctaaga	aaggatacct	tcattttcaag	gagcctcttt	acagtaactg	3720
ggctaaacat	tttgttgtcg	tccgtcggcc	ttatgtcttc	atctataaca	gtgacaaaga	3780
ccctgtggag	cgtggaatca	ttaacctgtc	cacagcacag	gtggagtaca	gtgaggacca	3840
gcaggccatg	gtgaagacac	caaacacctt	tgtgtctctg	acaaagcacc	gtggggtcct	3900
tttgagggcc	ctcaatgaca	aagacatgaa	cgactgggtg	tatgccttca	accacttctt	3960
agctggcaca	atacgggtcaa	agctttcccg	cagatgcccg	agccagtcga	aataactaagt	4020
gactctgccg	agtgccttca	ctcgccttcg	agagataaag	aaagcggtac	ctctcatttc	4080
tcttttgtgat	tcttgacggg	gactcttgta	tgtaatcctg	tggcttaact	acttctccct	4140

ccttggtccag	cacttttcta	gctctcccgt	tccccatctc	cattgctctg	tactcttttc	4200
ttttttcttg	tgctgagaat	ctcgttagta	gcatgtggcc	taacaaaagg	aaaaaatggt	4260
tttaaacaca	cacacacaca	cacacacaca	cacacacata	cacagacaaa	aacacaaaaa	4320
ctctgagggg	atctggtgaa	tctccaaatt	attgtgggtg	tactttggct	tccttttgta	4380
tgataggtcc	ccatcatgac	cacctctgat	gtctgtgctg	ctgtcaccag	gcacctttgt	4440
ttttcaagac	aacatacttt	ttttttcttt	tctctgtttg	tgatatcact	ttaatttttc	4500
ttgggtggct	tagagactaa	gggaggagac	atctggcctt	tttagaacct	gagaggaaaa	4560
aaagagtctt	tttttcccct	ctgtctcttt	ttgccatggc	taatccctgc	atttccattc	4620
agggaaaagg	tggtagttag	catagaactg	caacagttat	attctgagtc	aaagttgggg	4680
ctttttacgg	cataattatg	gaatttttat	ttactggtag	agaggagacg	agaggccttt	4740
tcagtggggc	tgggacagtg	gctgctcttg	actttgtgtg	aagggaaatg	ccaaggatgc	4800
ttctggtgga	cttcagggga	ccccagggtt	tggccgtggg	ccgtgatggc	agcaggcggg	4860
gggatgcttg	tagctcctca	cagcaggatt	ctgcccact	gttttttctc	tggtgggagg	4920
gaagctcttt	tctaggagtg	tctcagttct	gcttttggca	ttagttagtg	tggtggtaca	4980
ggttgaatta	gtgccatgtc	atacacaaat	gttcacaaag	gcgggagtgt	ttcactttct	5040
ggtgataaac	ttgatggtca	ttgttatgat	taagataatg	ccgggcaggg	cgggcacagt	5100
ggctcacgcc	tgtaatccaa	gcacttgggg	aggccgaggg	gggcagatca	cgagatcagg	5160
agttcaagac	cagcctggcc	aatgtgatga	aaccccgctc	ctactaaaaa	tacaaaatta	5220
gtcgggtatg	gtggcacatg	cctgtaattc	cagctgcttg	ggagcctgag	gcaggagaac	5280
tgcttgaacc	caggaggcag	aggttgtagt	gagccaagat	cgcgctattg	cactccagcc	5340
tgggtgacag	agcaagactc	tgccctcag				5368

<210> 30

<211> 1338

<212> PRT

<213> Homo sapiens

<400> 30

Glu	Ser	Glu	Lys	Ile	Ile	Ala	Glu	Leu	Asn	Glu	Thr	Trp	Glu	Glu	Lys
1				5				10					15		
Leu	Arg	Lys	Thr	Glu	Ala	Ile	Arg	Met	Glu	Arg	Glu	Ala	Leu	Leu	Ala
			20					25					30		
Glu	Met	Gly	Val	Ala	Ile	Arg	Glu	Asp	Gly	Gly	Thr	Leu	Gly	Val	Phe
		35					40					45			
Ser	Pro	Lys	Lys	Thr	Pro	His	Leu	Val	Asn	Leu	Asn	Glu	Asp	Pro	Leu
	50					55					60				
Met	Ser	Glu	Cys	Leu	Leu	Tyr	Tyr	Ile	Lys	Asp	Gly	Ile	Thr	Arg	Val
65				70						75				80	
Gly	Gln	Ala	Asp	Ala	Glu	Arg	Arg	Gln	Asp	Ile	Val	Leu	Ser	Gly	Ala
			85					90						95	
His	Ile	Lys	Glu	Glu	His	Cys	Ile	Phe	Arg	Ser	Glu	Arg	Ser	Asn	Ser
			100					105					110		
Gly	Glu	Val	Ile	Val	Thr	Leu	Glu	Pro	Cys	Glu	Arg	Ser	Glu	Thr	Tyr
		115				120					125				
Val	Asn	Gly	Lys	Arg	Val	Ser	Gln	Pro	Val	Gln	Leu	Arg	Ser	Gly	Asn
	130					135					140				
Arg	Ile	Ile	Met	Gly	Lys	Asn	His	Val	Phe	Arg	Phe	Asn	His	Pro	Glu
145				150						155				160	
Gln	Ala	Arg	Ala	Glu	Arg	Glu	Lys	Thr	Pro	Ser	Ala	Glu	Thr	Pro	Ser
			165					170						175	
Glu	Pro	Val	Asp	Trp	Thr	Phe	Ala	Gln	Arg	Glu	Leu	Leu	Glu	Lys	Gln
		180					185						190		
Gly	Ile	Asp	Met	Lys	Gln	Glu	Met	Glu	Lys	Arg	Leu	Gln	Glu	Met	Glu
		195				200					205				
Ile	Leu	Tyr	Lys	Lys	Glu	Lys	Glu	Glu	Ala	Asp	Leu	Leu	Leu	Glu	Gln
	210					215					220				
Gln	Arg	Leu	Asp	Tyr	Glu	Ser	Lys	Leu	Gln	Ala	Leu	Gln	Lys	Gln	Val
225				230						235					240

Glu	Thr	Arg	Ser	Leu	Ala	Ala	Glu	Thr	Thr	Glu	Glu	Glu	Glu	Glu	Glu	
				245					250					255		
Glu	Glu	Val	Pro	Trp	Thr	Gln	His	Glu	Phe	Glu	Leu	Ala	Gln	Trp	Ala	
			260					265					270			
Phe	Arg	Lys	Trp	Lys	Ser	His	Gln	Phe	Thr	Ser	Leu	Arg	Asp	Leu	Leu	
		275					280					285				
Trp	Gly	Asn	Ala	Val	Tyr	Leu	Lys	Glu	Ala	Asn	Ala	Ile	Ser	Val	Glu	
	290					295					300					
Leu	Lys	Lys	Lys	Val	Gln	Phe	Gln	Phe	Val	Leu	Leu	Thr	Asp	Thr	Leu	
305					310					315					320	
Tyr	Ser	Pro	Leu	Pro	Pro	Glu	Leu	Leu	Pro	Thr	Glu	Met	Glu	Lys	Thr	
				325					330					335		
His	Glu	Asp	Arg	Pro	Phe	Pro	Arg	Thr	Val	Val	Ala	Val	Glu	Val	Gln	
			340					345					350			
Asp	Leu	Lys	Asn	Gly	Ala	Thr	His	Tyr	Trp	Ser	Leu	Glu	Lys	Leu	Lys	
	355						360					365				
Gln	Arg	Leu	Asp	Leu	Met	Arg	Glu	Met	Tyr	Asp	Arg	Ala	Gly	Glu	Met	
	370					375					380					
Ala	Ser	Ser	Ala	Gln	Asp	Glu	Ser	Glu	Thr	Thr	Val	Thr	Gly	Ser	Asp	
385					390					395					400	
Pro	Phe	Tyr	Asp	Arg	Phe	His	Trp	Phe	Lys	Leu	Val	Gly	Ser	Ser	Pro	
				405					410					415		
Ile	Phe	His	Gly	Cys	Val	Asn	Glu	Arg	Leu	Ala	Asp	Arg	Thr	Pro	Ser	
			420					425					430			
Pro	Thr	Phe	Ser	Thr	Ala	Asp	Ser	Asp	Ile	Thr	Glu	Leu	Ala	Asp	Glu	
		435					440					445				
Gln	Gln	Asp	Glu	Met	Glu	Asp	Phe	Asp	Asp	Glu	Ala	Phe	Val	Asp	Asp	
	450					455					460					
Ala	Gly	Ser	Asp	Ala	Gly	Thr	Glu	Glu	Gly	Ser	Asp	Leu	Phe	Ser	Asp	
465					470					475					480	
Gly	His	Asp	Pro	Phe	Tyr	Asp	Arg	Ser	Pro	Trp	Phe	Ile	Leu	Val	Gly	
				485					490					495		
Arg	Ala	Phe	Val	Tyr	Leu	Ser	Asn	Leu	Leu	Tyr	Pro	Val	Pro	Leu	Ile	
			500					505					510			
His	Arg	Val	Ala	Ile	Val	Ser	Glu	Lys	Gly	Glu	Val	Arg	Gly	Phe	Leu	
		515					520					525				
Arg	Val	Ala	Val	Gln	Ala	Ile	Ala	Ala	Asp	Glu	Glu	Ala	Pro	Asp	Tyr	
		530				535					540					
Gly	Ser	Gly	Ile	Arg	Gln	Ser	Gly	Thr	Ala	Lys	Ile	Ser	Phe	Asp	Asn	
545					550					555					560	
Glu	Tyr	Phe	Asn	Gln	Ser	Asp	Phe	Ser	Ser	Val	Ala	Met	Thr	Arg	Ser	
				565					570					575		
Gly	Leu	Ser	Leu	Glu	Glu	Leu	Arg	Ile	Val	Glu	Gly	Gln	Gly	Gln	Ser	
			580					585					590			
Ser	Glu	Val	Ile	Thr	Pro	Pro	Glu	Glu	Ile	Ser	Arg	Ile	Asn	Asp	Leu	
		595					600					605				
Asp	Leu	Lys	Ser	Ser	Thr	Leu	Leu	Asp	Gly	Lys	Met	Val	Met	Glu	Gly	
	610					615					620					
Phe	Ser	Glu	Glu	Ile	Gly	Asn	His	Leu	Lys	Leu	Gly	Ser	Ala	Phe	Thr	
625					630					635					640	
Phe	Arg	Val	Thr	Val	Leu	Gln	Ala	Ser	Gly	Ile	Leu	Pro	Glu	Tyr	Ala	
				645					650					655		
Asp	Ile	Phe	Cys	Gln	Phe	Asn	Phe	Leu	His	Arg	His	Asp	Glu	Ala	Phe	
			660					665					670			
Ser	Thr	Glu	Pro	Leu	Lys	Asn	Asn	Gly	Arg	Gly	Ser	Pro	Leu	Ala	Phe	
		675					680					685				
Tyr	His	Val	Gln	Asn	Ile	Ala	Val	Glu	Ile	Thr	Glu	Ser	Phe	Val	Asp	
	690					695					700					
Tyr	Ile	Lys	Thr	Lys	Pro	Ile	Val	Phe	Glu	Val	Phe	Gly	His	Tyr	Gln	
705					710					715					720	

Gln His Pro Leu His Leu Gln Gly Gln Glu Leu Asn Ser Pro Pro Gln
 725 730 735
 Pro Cys Arg Arg Phe Phe Pro Pro Pro Met Pro Leu Ser Lys Pro Val
 740 745 750
 Pro Ala Thr Lys Leu Asn Thr Met Ser Lys Thr Ser Leu Gly Gln Ser
 755 760 765
 Met Ser Lys Tyr Asp Leu Leu Val Trp Phe Glu Ile Ser Glu Leu Glu
 770 775 780
 Pro Thr Gly Glu Tyr Ile Pro Ala Val Val Asp His Thr Ala Gly Leu
 785 790 795 800
 Pro Cys Gln Gly Thr Phe Leu Leu His Gln Gly Ile Gln Arg Arg Ile
 805 810 815
 Thr Val Thr Ile Ile His Glu Lys Gly Ser Glu Leu His Trp Lys Asp
 820 825 830
 Val Arg Glu Leu Val Val Gly Arg Ile Arg Asn Lys Pro Glu Val Asp
 835 840 845
 Glu Ala Ala Val Asp Ala Ile Leu Ser Leu Asn Ile Ile Ser Ala Lys
 850 855 860
 Tyr Leu Lys Ser Ser His Asn Ser Ser Arg Thr Phe Tyr Arg Phe Glu
 865 870 875 880
 Ala Val Trp Asp Ser Ser Leu His Asn Ser Leu Leu Leu Asn Arg Val
 885 890 895
 Thr Pro Tyr Gly Glu Lys Ile Tyr Met Thr Leu Ser Ala Tyr Leu Glu
 900 905 910
 Leu Asp His Cys Ile Gln Pro Ala Val Ile Thr Lys Asp Val Cys Met
 915 920 925
 Val Phe Tyr Ser Arg Asp Ala Lys Ile Ser Pro Pro Arg Ser Leu Arg
 930 935 940
 Ser Leu Phe Gly Ser Gly Tyr Ser Lys Ser Pro Asp Ser Asn Arg Val
 945 950 955 960
 Thr Gly Ile Tyr Glu Leu Ser Leu Cys Lys Met Ser Asp Thr Gly Ser
 965 970 975
 Pro Gly Met Gln Arg Arg Arg Arg Lys Ile Leu Asp Thr Ser Val Ala
 980 985 990
 Tyr Val Arg Gly Glu Glu Asn Leu Ala Gly Trp Arg Pro Arg Gly Asp
 995 1000 1005
 Ser Leu Ile Leu Glu His Gln Trp Glu Leu Glu Lys Leu Glu Leu Leu
 1010 1015 1020
 His Glu Val Glu Lys Thr Arg His Phe Leu Leu Leu Arg Glu Arg Leu
 1025 1030 1035 1040
 Gly Asp Ser Ile Pro Lys Ser Leu Ser Asp Ser Leu Ser Pro Ser Leu
 1045 1050 1055
 Ser Ser Gly Thr Leu Ser Thr Ser Thr Ser Ile Ser Ser Gln Ile Ser
 1060 1065 1070
 Thr Thr Thr Phe Glu Ser Ala Ile Thr Pro Ser Glu Ser Ser Gly Tyr
 1075 1080 1085
 Asp Ser Gly Asp Ile Glu Ser Leu Val Asp Arg Glu Lys Glu Leu Ala
 1090 1095 1100
 Thr Lys Cys Leu Gln Leu Leu Thr His Thr Phe Asn Arg Glu Phe Ser
 1105 1110 1115 1120
 Gln Val His Gly Ser Val Ser Asp Cys Lys Leu Ser Asp Ile Ser Pro
 1125 1130 1135
 Ile Gly Arg Asp Pro Ser Glu Ser Ser Phe Ser Ser Ala Thr Leu Thr
 1140 1145 1150
 Pro Ser Ser Thr Cys Pro Ser Leu Val Asp Ser Arg Ser Asn Ser Leu
 1155 1160 1165
 Asp Gln Lys Thr Pro Glu Ala Asn Ser Arg Ala Ser Ser Pro Cys Pro
 1170 1175 1180
 Glu Phe Glu Gln Phe Gln Ile Val Pro Ala Val Glu Thr Pro Tyr Leu
 1185 1190 1195 1200

Ala Arg Ala Gly Lys Asn Glu Phe Leu Asn Leu Val Pro Asp Ile Glu
 1205 1210 1215
 Glu Ile Arg Pro Ser Ser Val Val Ser Lys Lys Gly Tyr Leu His Phe
 1220 1225 1230
 Lys Glu Pro Leu Tyr Ser Asn Trp Ala Lys His Phe Val Val Val Arg
 1235 1240 1245
 Arg Pro Tyr Val Phe Ile Tyr Asn Ser Asp Lys Asp Pro Val Glu Arg
 1250 1255 1260
 Gly Ile Ile Asn Leu Ser Thr Ala Gln Val Glu Tyr Ser Glu Asp Gln
 1265 1270 1275 1280
 Gln Ala Met Val Lys Thr Pro Asn Thr Phe Ala Val Cys Thr Lys His
 1285 1290 1295
 Arg Gly Val Leu Leu Gln Ala Leu Asn Asp Lys Asp Met Asn Asp Trp
 1300 1305 1310
 Leu Tyr Ala Phe Asn Pro Leu Leu Ala Gly Thr Ile Arg Ser Lys Leu
 1315 1320 1325
 Ser Arg Arg Cys Pro Ser Gln Ser Lys Tyr
 1330 1335

<210> 31

<211> 3094

<212> DNA

<213> Homo sapiens

<400> 31

tttgactggc	cgtagagtct	gcgcagttgg	tgaatggcgt	tggtggcggg	aaagttgagt	60
ctctcctgcg	ccgagccttc	ggggcgatgt	gtagtgcctt	ccatagggct	gagtctggga	120
ccgagctcct	tgcccgactt	gaaggtagaa	gttccttgaa	agaaatagaa	ccaaatctgt	180
ttgctgatga	agattcacct	gtgcatgggt	atattcttga	atttcatggc	ccagaaggaa	240
caggaaaaac	agaaatgctt	tatcacctaa	cagcacgatg	tatacttccc	aaatcagaag	300
gtggcctgga	agtagaagtc	ttattttattg	atacagatta	ccactttgat	atgctccggc	360
tagttacaat	tcttgagcac	agactatccc	aaagctctga	agaaataatc	aaatactgcc	420
tgggaagatt	ttttttgggtg	tactgcagta	gtagcaccca	cttacttctt	acactttact	480
cactagaaag	tatgttttgt	agtcacccat	ctctctgcct	tttgattttg	gatagcctgt	540
cagcttttta	ctggatagac	cgcgtcaatg	gaggagaaag	tgtgaactta	caggagtcta	600
ctctgaggaa	atgttctcag	tgcttagaga	agcttgtaaa	tgactatcgc	ctggttcttt	660
ttgcaacgac	acaaactata	atgcagaaag	cctcgagctc	atcagaagaa	ccttctcatg	720
cctctcgacg	actgtgtgat	gtggacatag	actacagacc	ttatctctgt	aaggcatggc	780
agcaactggt	gaagcacagg	atgtttttct	ccaaacaaga	tgattctcaa	agcagcaacc	840
aatttttcatt	agtttcacgt	tgtttaaaaa	gtaacagttt	aaaaaaacat	ttttttatta	900
ttggagaaag	tgggggttgaa	ttttgttgat	atacatcata	aaatagtctt	ttgcagggta	960
ctacgcaagc	cttaaaatth	ttcttaagac	agagtcttgc	tctgtctccc	aggctggagt	1020
gcagtggcac	aatcatggct	cactgcagcc	ttgaactcct	ggcctcaagg	gatcctccta	1080
tgtgtgcctc	ctagagtgca	gggattacag	gcgtgagcca	ctgctcgtgg	ccaaaagttt	1140
tctttttttt	tttttttctt	tttgaaacag	tcttactctg	tctcccaggc	tgctggagtg	1200
cagtggcaca	atctcgccc	gctgcagcct	ctgcctcttg	ggttcaagtg	attcttccac	1260
ctcagcctcc	caggtagctg	ggattacagg	caccaccac	cacgcctggc	taatttttgt	1320
atttttaata	gagacggggt	ttcaccatgt	tggccaggct	ggtctcgaa	tcctgacctc	1380
aagtgatcca	cccacctcgg	cctcccaaag	tgctaggatt	acaggcccgt	gcccagccct	1440
aaagttttta	actctagggg	aattaacagt	atctctttac	agaatggatt	tgttaaacta	1500
gcacagtaaa	agtaaagact	attctgtttc	taggctgttg	aatcaaagtg	attttagcaa	1560
ttaaactttg	tattaattta	ccaccaatat	ttcttcacaa	aggaactttt	aaaagattat	1620
ctcagaaagt	aaatctgaga	ggtaagaagt	aataatgagt	aaatggtaag	tacttgagta	1680
aatctaaaga	aatattgata	gtaaggcaat	cctaagcaaa	agaacaaag	ctggaggcat	1740
cacgctaccc	agcttcaaac	tatactacaa	ggctacagta	acaaaaacag	catagtactg	1800
gcacaaaaac	acacgtagac	tgatggaaca	gaatagagaa	tttagaaatg	agaccacaca	1860
cctataattt	ttttgatctt	cgatgaacct	gacaaaaaca	agcaatgggc	aatggattct	1920
ctattcaata	aatcgtgctg	ggataactgg	ccagccatat	ggaaaagatt	gaaaatggac	1980
gccttcctta	tgccatatac	aaaaattaac	tcaagatgga	ttaaagactt	aatgtaaaac	2040
ccaaaacagt	aaaaatcctg	gaagacaacc	caggcagtac	cattcaggac	ataggcacag	2100

gcaagattt	catgacgaag	acgccaaaaa	caattgcaac	agaagcaaaa	attcacaaat	2160
gggatcta	taactaaag	agctgcacag	caaaagaaac	tatcaagaga	gtaaacagac	2220
agcttacaga	atgggagaaa	attgttgcaa	actatgcac	tgagaaaggt	ctgaaatcca	2280
gcattctata	gtaattttaa	caaattttaga	agaaaaaacc	accccattaa	aaagtgggca	2340
aaggacatga	acagacactt	ttcaaaagaa	gacatctgtg	gccaacaatc	ctatggaaaa	2400
aagcccagca	tactgatca	ttagagaaat	gcaaatcgaa	acaacaacga	gataccatct	2460
cacaccagtc	caaattggcta	ttataaaaaat	gtcagaaaat	aacagatgct	ggtgaggttg	2520
tggagaaaaa	gatattgctta	tacactgttg	gtggaaatgt	aaattaaatt	agttcagcca	2580
ttgtggaaga	cagtgtgggg	ataaagacag	agataccatt	caaccagca	atctcattac	2640
tgggtatata	cccaaaggaa	tagaaatcat	tgttataaag	acacatgcac	gcgtatgttc	2700
gttgccagc	tgcccatcag	tgacagactg	gattaaaaaa	atgtggtaca	tacacaccag	2760
ggaatactat	acagccataa	aaaggaacaa	gactgactgg	gcgtgggtgg	tcatgcctgt	2820
gatccctagca	ctttgcgag	ccgaggtggg	tggattgccc	gcgctcagga	ggtcaagacc	2880
agcctgggca	acacgggtgaa	accccatctc	tattaaaata	caaaaaatta	gctgggcatg	2940
gtggtgcgtg	ctctgtagtgc	cagctactca	ggaggccgag	gcaggagaat	tgctggaacc	3000
caggaggtgg	aggttgagct	gagctgagat	gcgcgcattg	cactcccgcc	tgggcgactc	3060
catctctaaa	aaaaaaaaaa	aaaaaaaaaa	aaaa			3094

<210> 32

<211> 280

<212> PRT

<213> Homo sapiens

<400> 32

Met 1	Cys	Ser	Ala	Phe 5	His	Arg	Ala	Glu	Ser 10	Gly	Thr	Glu	Leu	Leu 15	Ala
Arg	Leu	Glu	Gly 20	Arg	Ser	Ser	Leu	Lys 25	Glu	Ile	Glu	Pro	Asn 30	Leu	Phe
Ala	Asp	Glu 35	Asp	Ser	Pro	Val	His 40	Gly	Asp	Ile	Leu	Glu 45	Phe	His	Gly
Pro	Glu 50	Gly	Thr	Gly	Lys	Thr 55	Glu	Met	Leu	Tyr	His 60	Leu	Thr	Ala	Arg
Cys 65	Ile	Leu	Pro	Lys	Ser 70	Glu	Gly	Gly	Leu	Glu 75	Val	Glu	Val	Leu 80	Phe
Ile	Asp	Thr	Asp	Tyr 85	His	Phe	Asp	Met	Leu 90	Arg	Leu	Val	Thr	Ile 95	Leu
Glu	His	Arg	Leu 100	Ser	Gln	Ser	Ser 105	Glu	Glu	Ile	Ile	Lys 110	Tyr	Cys	Leu
Gly	Arg	Phe 115	Phe	Leu	Val	Tyr	Cys 120	Ser	Ser	Ser	Thr	His 125	Leu	Leu	Leu
Thr	Leu 130	Tyr	Ser	Leu	Glu	Ser 135	Met	Phe	Cys	Ser	His 140	Pro	Ser	Leu	Cys
Leu 145	Leu	Ile	Leu	Asp 150	Ser	Leu	Ser	Ala	Phe 155	Tyr	Trp	Ile	Asp	Arg	Val
Asn	Gly	Gly	Glu	Ser 165	Val	Asn	Leu	Gln	Glu 170	Ser	Thr	Leu	Arg	Lys 175	Cys
Ser	Gln	Cys	Leu 180	Glu	Lys	Leu	Val	Asn 185	Asp	Tyr	Arg	Leu	Val 190	Leu	Phe
Ala	Thr	Thr 195	Gln	Thr	Ile	Met	Gln 200	Lys	Ala	Ser	Ser	Ser 205	Ser	Glu	Glu
Pro	Ser 210	His	Ala	Ser	Arg	Arg 215	Leu	Cys	Asp	Val	Asp 220	Ile	Asp	Tyr	Arg
Pro 225	Tyr	Leu	Cys	Lys	Ala 230	Trp	Gln	Gln	Leu	Val 235	Lys	His	Arg	Met	Phe
Phe	Ser	Lys	Gln	Asp 245	Asp	Ser	Gln	Ser	Ser 250	Asn	Gln	Phe	Ser	Leu 255	Val
Ser	Arg	Cys	Leu 260	Lys	Ser	Asn	Ser	Leu 265	Lys	Lys	His	Phe	Phe 270	Ile	Ile
Gly	Glu	Ser 275	Gly	Val	Glu	Phe	Cys 280								

<210> 33
 <211> 691
 <212> DNA
 <213> Homo sapiens

<400> 33
 gtcctcctcg ccctccaggc cgcccgcgcc gcgcccggagt ccgctgtccg ccagctaccc 60
 gcttcctgcc gcccgcgcgt gccatgctgc ccgcccgcgt gctccgccgc ccgggacttg 120
 gccgcctcgt ccgccacgcc cgtgcctatg ccgaggccgc cgccgccccg gctgccgcct 180
 ctggccccaa ccagatgtcc ttcaccttcg cctctccac gcaggtgttc ttcaacgggtg 240
 ccaacgtccg gcaggtggac gtgcccacgc tgaccggagc cttcggcatc ctggcggccc 300
 acgtgccac gctgcaggtc ctgcccgcgg ggctggctgt ggtgcatgca gaggacggca 360
 ccacctcaa atactttgtg agcagcgggt ccacgcagc gaacgccgac tcttcgggtgc 420
 agttgttggt cgaagaggcc gtgacgctgg acatgttgga cctgggggca gccaaaggcaa 480
 acttgagaaa ggcccaggcg gagctgggtg ggacagctga cgaggccacg cgggcagaga 540
 tccagatccg aatcgaggcc aacgaggccc tgggtgaaggc cctggagtag gcgagccagc 600
 cgccaagggt gacctcagct tcggagccac ctctggatga actgccccca gccccgcgcc 660
 cattaagac ccggaagcct gaaaaaaaaa a 691

<210> 34
 <211> 168
 <212> PRT
 <213> Homo sapiens

<400> 34
 Met Leu Pro Ala Ala Leu Leu Arg Arg Pro Gly Leu Gly Arg Leu Val
 1 5 10 15
 Arg His Ala Arg Ala Tyr Ala Glu Ala Ala Ala Pro Ala Ala Ala
 20 25 30
 Ser Gly Pro Asn Gln Met Ser Phe Thr Phe Ala Ser Pro Thr Gln Val
 35 40 45
 Phe Phe Asn Gly Ala Asn Val Arg Gln Val Asp Val Pro Thr Leu Thr
 50 55 60
 Gly Ala Phe Gly Ile Leu Ala Ala His Val Pro Thr Leu Gln Val Leu
 65 70 75 80
 Arg Pro Gly Leu Val Val Val His Ala Glu Asp Gly Thr Thr Ser Lys
 85 90 95
 Tyr Phe Val Ser Ser Gly Ser Ile Ala Val Asn Ala Asp Ser Ser Val
 100 105 110
 Gln Leu Leu Ala Glu Glu Ala Val Thr Leu Asp Met Leu Asp Leu Gly
 115 120 125
 Ala Ala Lys Ala Asn Leu Glu Lys Ala Gln Ala Glu Leu Val Gly Thr
 130 135 140
 Ala Asp Glu Ala Thr Arg Ala Glu Ile Gln Ile Arg Ile Glu Ala Asn
 145 150 155 160
 Glu Ala Leu Val Lys Ala Leu Glu
 165

<210> 35
 <211> 1378
 <212> DNA
 <213> Homo sapiens

<400> 35
 gcgcggcccc ctgcaatccg tggaggaacg cgccgccgag ccaccatcat gcctggggcac 60
 ttacaggaag gcttcgggtg cgtggtcacc aaccgattcg accagttatt tgacgacgaa 120
 tcggaccctc tcgaggtgct gaaggcagca gagaacaaga aaaaagaagc cggcgggggc 180
 ggcgttgggg gccctggggc caagagcgca gctcaggccg cggcccagac caactccaac 240
 gcggcaggca aacagctgcg caaggagtcc cagaaagacc gcaagaaccc gctgcccccc 300
 agcgttggcg tggttgacaa gaaagaggag acgcagccgc ccgtggcgct taagaaagaa 360

ggaataagac	gagttggaag	aagacctgat	caacaacttc	agggtgaagg	gaaaataatt	420
gatagaagac	cagaaaggcg	accacctcgt	gaacgaagat	tcgaaaagcc	acttgaagaa	480
aagggtgaag	gaggcgaatt	ttcagttgat	agaccgatta	ttgaccgacc	tattcgaggt	540
cgtggtggtc	ttggaagagg	tcgagggggc	cgtggacgtg	gaatgggccc	aggagatgga	600
tttgattctc	gtggcaaacg	tgaatttgat	aggcatagtg	gaagtgatag	atcttctttt	660
tcacattaca	gtggcctgaa	gcacgaggac	aaacgtggag	gtagcggatc	tcacaactgg	720
ggaactgtca	aagacgaatt	aacagagtcc	cccaaataca	ttcagaaaca	aatatcttat	780
aattacagtg	acttgatca	atcaaagtgt	actgaggaaa	cacctgaagg	tgaagaacat	840
catccagtg	cagacactga	aaataaggag	aatgaagttg	aagaggtaaa	agaggagggt	900
ccaaaagaga	tgactttgga	tgagtgggaag	gctattcaaa	ataaggaccg	ggcaaaagta	960
gaatttaata	tccgaaaacc	aaatgaaggt	gctgatgggc	agtggagaa	gggatttgtt	1020
cttcataaat	caaagagtga	agaggctcat	gctgaagatt	cggttatgga	ccatcatttc	1080
cggaagccag	caaatgatat	aacgtctcag	ctggagatca	atthttggaga	ccttggccgc	1140
ccaggacgtg	gcggcagggg	aggacgaggt	ggacgtgggc	gtggtgggcg	cccaaaccgt	1200
ggcagcagga	ccgacaagtc	aagtgtctct	gctcctgatg	tggatgaccc	agaggcattc	1260
ccagctctgg	cttaactgga	tgccataaga	caaccctggg	tcctttgtga	acccttctgt	1320
tcaaagcttt	tgcattgctta	aggattccaa	acgactaaga	aaaaaaaaaa	aaaaaaaaaa	1378

<210> 36

<211> 2896

<212> DNA

<213> Homo sapiens

<400> 36

gggagcgcca	gctcgtagca	ggggagcgcc	cgcggcgtcg	ggtttgggct	ggaggtcgcc	60
atggggcgag	gcagcggcac	cttcgagcgt	ctcctagaca	aggcgaccag	ccagctcctg	120
ttggagacag	attgggagtc	cattttgcag	atctgcgacc	tgatccgcca	aggggacaca	180
caagcaaaat	atgctgtgaa	ttccatcaag	aagaaagtca	acgacaagaa	cccacacgtc	240
gccttgtatg	ccctggaggt	catggaatct	gtggtaaaga	actgtggcca	gacagttcat	300
gatgaggtgg	ccaacaagca	gaccatggag	gagctgaagg	acctgctgaa	gagacaagtg	360
gaggtaaacg	tccgtaacaa	gatcctgtac	ctgatccagg	cctgggcgca	tgccttccgg	420
aacgagccca	agtacaaggt	ggtccaggac	acctaccaga	tcatgaaggt	ggaggggcac	480
gtctttccag	aattcaaaga	gagcgtatgc	atgtttgctg	ccgagagagc	cccagactgg	540
gtggacgctg	aggaatgcca	ccgctgcagg	gtgcagttcg	gggtgatgac	ccgtaagcac	600
cactgcccgg	cgtgtgggca	gatattctgt	ggaaagtgtt	cttccaagta	ctccaccatc	660
cccaagtttg	gcatcgagaa	ggaggtgcgc	gtgtgtgagc	cctgctacga	gcagctgaac	720
aggaagaagg	agggaaaggc	cacttccacc	actgagctgc	cccccgagta	cctgaccagc	780
ccctgtcttc	agcagtccca	gctgcccccc	aagaggagcg	agacggccct	gcagaggagag	840
gaggagctgc	agctggccct	gctgctgtca	cagtcaagag	cggaggagaa	ggagaggctg	900
agacagaagt	ccacgtacac	ttcgtacccc	aaggcggagc	ccatgccctc	ggcctctca	960
gogccccccg	ccagcagcct	gtactcttca	cctgtgaact	cgtcggcgcc	tctggctgag	1020
gacatcgacc	ctgagctcgc	acggtatctc	aaccggaact	actgggagaa	gaagcaggag	1080
gaggctcgca	agagccccac	gccatctgcg	cccgtgcccc	tgacggagcc	ggctgcacag	1140
cctgggggaag	ggcacgcagc	ccccaccaac	gtggtggaga	acccctcccc	ggagacagac	1200
tctcagccca	ttcctccctc	tgggtggcccc	tttagtgagc	cacagttcca	caatggcgag	1260
tctgaggaga	gccacgagca	gttcctgaag	gcgctgcaga	acgcgctcac	caccttctgt	1320
aaccgcatga	agagtaacca	catgcggggc	cgcagcatca	ccaatgactc	ggccgtgtct	1380
tcactcttcc	agtcctatcaa	cggcatgcac	ccgcagctgc	tggagctgct	caaccagctg	1440
gacgagcgca	ggctgtacta	tgaggggctg	caggacaagc	tggcacagat	ccgcgatgcc	1500
cggggggcgc	tgagtgcctt	gcgcgaagag	caccggggaga	agcttcgccc	ggcagccgag	1560
gaggcagagc	gccagcgcca	gatccagctg	gcccagaagc	tggagataat	gcggcagaag	1620
aagcaggagt	acctggaggt	gcagaggcag	ctggccatcc	agcgcctgca	ggagcaggag	1680
aaggagcggc	agatgcggct	ggagcagcag	aagcagacgg	tccagatgcg	cgcgcatatg	1740
cccgcccttc	ccctgcccta	cgcccagctc	caggccatgc	ccgcagccgg	aggtgtgctc	1800
taccagccct	cgggaccagc	cagcttcccc	agcaccttca	gccctgcccg	ctcggtggag	1860
ggctccccaa	tgcacggcgt	gtacatgagc	cagccggccc	ctgccgctgg	cccctacccc	1920
agcatgcccc	gcactgcggc	tgatcccagc	atgggtgagt	cctacatgta	cccagcaggg	1980
gccactgggg	cgcaggcggc	ccccaggcc	caggccggac	ccaccgcccag	ccccgcttac	2040
tcactctacc	agcctactcc	cacagcgggc	taccagaacg	tggcctccca	ggccccacag	2100
agcctcccg	ccatctctca	gcctccgcag	tccagcacca	tgggctacat	ggggagccag	2160

tcagtctcca	tgggctacca	gccttacaac	atgcagaatc	tcattgaccac	cctcccaagc	2220
caggatgcgt	ctctgccacc	ccagcagccc	tacatcgcg	ggcagcagcc	catgtaccag	2280
cagatggcac	cctctggcgg	tcccccccag	cagcagcccc	ccgtggccca	gcaaccgcag	2340
gcacaggggc	cgccggcaca	gggcagcgag	gcccagctca	tttcattcga	ctgaccaggg	2400
ccatgctcac	gtccggagta	acactacata	cagttcacct	gaaacgcctc	gtctctaact	2460
gccgtcgccc	tgcctccctg	tcctctactg	ccggtagtg	cccttctctg	cgagtggagg	2520
ggggccttca	ccccaaagcc	acctcccttg	tcctcagcct	actgcagtcc	ctgagttagt	2580
ctctgctttc	tttccccagg	gctggggccat	ggggaggga	ggactttctc	ccaggggaag	2640
ccccagccc	tgtgggtcat	ggtctgtgag	aggtggcagg	aatggggacc	ctcaccctcc	2700
aagcagcctg	tgccctctgg	ccgcactgtg	agctggctgt	ggtgtctggg	tgtggcctgg	2760
ggctccctct	gcaggggcct	ctctcggcag	ccacagccaa	gggtggaggc	ttcaggtctc	2820
cagcttctct	gcttctcagc	tgccatctcc	agtgccccag	aatggtacag	cgataataaa	2880
atgtatttca	gaaagg					2896

<210> 37

<211> 777

<212> PRT

<213> Homo sapiens

<400> 37

Met	Gly	Arg	Gly	Ser	Gly	Thr	Phe	Glu	Arg	Leu	Leu	Asp	Lys	Ala	Thr
1				5				10						15	
Ser	Gln	Leu	Leu	Leu	Glu	Thr	Asp	Trp	Glu	Ser	Ile	Leu	Gln	Ile	Cys
		20						25					30		
Asp	Leu	Ile	Arg	Gln	Gly	Asp	Thr	Gln	Ala	Lys	Tyr	Ala	Val	Asn	Ser
		35					40					45			
Ile	Lys	Lys	Lys	Val	Asn	Asp	Lys	Asn	Pro	His	Val	Ala	Leu	Tyr	Ala
	50					55					60				
Leu	Glu	Val	Met	Glu	Ser	Val	Val	Lys	Asn	Cys	Gly	Gln	Thr	Val	His
	65				70				75					80	
Asp	Glu	Val	Ala	Asn	Lys	Gln	Thr	Met	Glu	Glu	Leu	Lys	Asp	Leu	Leu
			85					90						95	
Lys	Arg	Gln	Val	Glu	Val	Asn	Val	Arg	Asn	Lys	Ile	Leu	Tyr	Leu	Ile
		100						105					110		
Gln	Ala	Trp	Ala	His	Ala	Phe	Arg	Asn	Glu	Pro	Lys	Tyr	Lys	Val	Val
	115						120					125			
Gln	Asp	Thr	Tyr	Gln	Ile	Met	Lys	Val	Glu	Gly	His	Val	Phe	Pro	Glu
	130					135				140					
Phe	Lys	Glu	Ser	Asp	Ala	Met	Phe	Ala	Ala	Glu	Arg	Ala	Pro	Asp	Trp
	145				150				155					160	
Val	Asp	Ala	Glu	Glu	Cys	His	Arg	Cys	Arg	Val	Gln	Phe	Gly	Val	Met
			165					170					175		
Thr	Arg	Lys	His	His	Cys	Arg	Ala	Cys	Gly	Gln	Ile	Phe	Cys	Gly	Lys
		180				185						190			
Cys	Ser	Ser	Lys	Tyr	Ser	Thr	Ile	Pro	Lys	Phe	Gly	Ile	Glu	Lys	Glu
	195					200					205				
Val	Arg	Val	Cys	Glu	Pro	Cys	Tyr	Glu	Gln	Leu	Asn	Arg	Lys	Ala	Glu
	210				215					220					
Gly	Lys	Ala	Thr	Ser	Thr	Thr	Glu	Leu	Pro	Pro	Glu	Tyr	Leu	Thr	Ser
	225				230				235					240	
Pro	Leu	Ser	Gln	Gln	Ser	Gln	Leu	Pro	Pro	Lys	Arg	Asp	Glu	Thr	Ala
			245					250						255	
Leu	Gln	Glu	Glu	Glu	Glu	Leu	Gln	Leu	Ala	Leu	Ala	Leu	Ser	Gln	Ser
		260				265							270		
Glu	Ala	Glu	Glu	Lys	Glu	Arg	Leu	Arg	Gln	Lys	Ser	Thr	Tyr	Thr	Ser
	275					280						285			
Tyr	Pro	Lys	Ala	Glu	Pro	Met	Pro	Ser	Ala	Ser	Ser	Ala	Pro	Pro	Ala
	290					295					300				
Ser	Ser	Leu	Tyr	Ser	Ser	Pro	Val	Asn	Ser	Ser	Ala	Pro	Leu	Ala	Glu
	305				310				315						320

Asp Ile Asp Pro Glu Leu Ala Arg Tyr Leu Asn Arg Asn Tyr Trp Glu
 325 330 335
 Lys Lys Gln Glu Glu Ala Arg Lys Ser Pro Thr Pro Ser Ala Pro Val
 340 345 350
 Pro Leu Thr Glu Pro Ala Ala Gln Pro Gly Glu Gly His Ala Ala Pro
 355 360 365
 Thr Asn Val Val Glu Asn Pro Leu Pro Glu Thr Asp Ser Gln Pro Ile
 370 375 380
 Pro Pro Ser Gly Gly Pro Phe Ser Glu Pro Gln Phe His Asn Gly Glu
 385 390 395 400
 Ser Glu Glu Ser His Glu Gln Phe Leu Lys Ala Leu Gln Asn Ala Val
 405 410 415
 Thr Thr Phe Val Asn Arg Met Lys Ser Asn His Met Arg Gly Arg Ser
 420 425 430
 Ile Thr Asn Asp Ser Ala Val Leu Ser Leu Phe Gln Ser Ile Asn Gly
 435 440 445
 Met His Pro Gln Leu Leu Glu Leu Leu Asn Gln Leu Asp Glu Arg Arg
 450 455 460
 Leu Tyr Tyr Glu Gly Leu Gln Asp Lys Leu Ala Gln Ile Arg Asp Ala
 465 470 475 480
 Arg Gly Ala Leu Ser Ala Leu Arg Glu Glu His Arg Glu Lys Leu Arg
 485 490 495
 Arg Ala Ala Glu Glu Ala Glu Arg Gln Arg Gln Ile Gln Leu Ala Gln
 500 505 510
 Lys Leu Glu Ile Met Arg Gln Lys Lys Gln Glu Tyr Leu Glu Val Gln
 515 520 525
 Arg Gln Leu Ala Ile Gln Arg Leu Gln Glu Gln Glu Lys Glu Arg Gln
 530 535 540
 Met Arg Leu Glu Gln Gln Lys Gln Thr Val Gln Met Arg Ala Gln Met
 545 550 555 560
 Pro Ala Phe Pro Leu Pro Tyr Ala Gln Leu Gln Ala Met Pro Ala Ala
 565 570 575
 Gly Gly Val Leu Tyr Gln Pro Ser Gly Pro Ala Ser Phe Pro Ser Thr
 580 585 590
 Phe Ser Pro Ala Gly Ser Val Glu Gly Ser Pro Met His Gly Val Tyr
 595 600 605
 Met Ser Gln Pro Ala Pro Ala Ala Gly Pro Tyr Pro Ser Met Pro Ser
 610 615 620
 Thr Ala Ala Asp Pro Ser Met Val Ser Ala Tyr Met Tyr Pro Ala Gly
 625 630 635 640
 Ala Thr Gly Ala Gln Ala Ala Pro Gln Ala Gln Ala Gly Pro Thr Ala
 645 650 655
 Ser Pro Ala Tyr Ser Ser Tyr Gln Pro Thr Pro Thr Ala Gly Tyr Gln
 660 665 670
 Asn Val Ala Ser Gln Ala Pro Gln Ser Leu Pro Ala Ile Ser Gln Pro
 675 680 685
 Pro Gln Ser Ser Thr Met Gly Tyr Met Gly Ser Gln Ser Val Ser Met
 690 695 700
 Gly Tyr Gln Pro Tyr Asn Met Gln Asn Leu Met Thr Thr Leu Pro Ser
 705 710 715 720
 Gln Asp Ala Ser Leu Pro Pro Gln Gln Pro Tyr Ile Ala Gly Gln Gln
 725 730 735
 Pro Met Tyr Gln Gln Met Ala Pro Ser Gly Gly Pro Pro Gln Gln Gln
 740 745 750
 Pro Pro Val Ala Gln Gln Pro Gln Ala Gln Gly Pro Pro Ala Gln Gly
 755 760 765
 Ser Glu Ala Gln Leu Ile Ser Phe Asp
 770 775

<211> 2569
 <212> DNA
 <213> Homo sapiens

<400> 38

tccctcgtct	ctctcgggca	acatggcggg	cgtggaggag	gtagcggcct	ccgggagcca	60
cctgaatggc	gacctggatc	cagacgacag	ggaagaagga	gctgcctcta	cggtcgagga	120
agcagccaag	aaaaaaagac	gaaagaagaa	gaagagcaaa	gggccttctg	cagcagggga	180
acaggaacct	gataaagaat	caggagcctc	agtggatgaa	gtagcaagac	agttggaaag	240
atcagcattg	gaagataaag	aaagagatga	agatgatgaa	gatggagatg	gcgatggaga	300
tggagcaact	ggaaagaaga	agaaaaagaa	gaagaagaag	agaggaccaa	aagttcaaac	360
agaccctccc	tcagttccaa	tatgtgacct	gtatcctaata	ggtgtatttc	ccaaaggaca	420
agaatgcgaa	taccacacca	cacaagatgg	gcgaacagct	gcttggagaa	ctacaagtga	480
agaaaagaaa	gcattagatc	aggcaagtga	agagatttgg	aatgattttc	gagaagctgc	540
agaagcacat	cgacaagtta	gaaaatacgt	aatgagctgg	atcaagcctg	ggatgacaat	600
gatagaaatc	tgtgaaaagt	tggaaagactg	ttcacgcaag	ttaataaaaag	agaatggatt	660
aaatgcaggc	ctggcatttc	ctactggatg	ttctctcaat	aattgtgctg	cccattatac	720
tcccaatgcc	ggtgacacaa	cagtattaca	gtatgatgac	atctgtaaaa	tagactttgg	780
aacacatata	agtggtagga	ttattgactg	tgcttttact	gtcactttta	atcccaaata	840
tgatacgtta	ttaaaagctg	taaaagatgc	tactaacact	ggaataaagt	gtgctggaat	900
tgatgttcgt	ctgtgtgatg	ttggtgaggc	catccaagaa	ggtatggagt	cctatggaat	960
tgaatatagat	gggaagacat	atcaagtga	accaatccgt	aatctaaatg	gacattcaat	1020
tgggcaatat	agaatacatg	ctggaaaaaac	agtgccgatt	gtgaaaggag	gggaggcaac	1080
aagaatggag	gaaggagaag	tatatgcaat	tgaaaccttt	ggtagtacag	gaaaagggtg	1140
tgttcatgat	gatatggaat	gttcacatta	catgaaaaat	tttgatgttg	gacatgtgcc	1200
aataaggctt	ccaagaacaa	aacacttggt	aaatgtcatc	aatgaaaaact	ttggaaccct	1260
tgctttctgc	cgcagatggc	tggatcgctt	gggagaaaagt	aaatacttga	tggctctgaa	1320
gaatctgtgt	gacttgggca	ttgtagatcc	atatccacca	ttatgtgaca	ttaaagggat	1380
atatacagcg	caatttgaaac	ataccatcct	gttgcgtcca	acatgtaaag	aagtgtgcag	1440
cagaggagat	gactattaaa	cttagtccaa	agccacctca	acacctttat	tttctgagct	1500
ttgttgga	acatgatacc	agaattaatt	tgccacatgt	tgtctgtttt	aacagtggac	1560
ccatgtaata	cttttatcca	tgtttaaaaa	agaaggaatt	tggacaaagg	caaaccgtct	1620
aatgtaatta	accaacgaaa	aagctttccg	gactttttaa	tgctaactgt	ttttcccctt	1680
cctgtctagg	aaaatgctat	aaagctcaaa	ttagttagga	atgacttata	cgttttgttt	1740
tgaataccta	agagatactt	tttggatatt	tatatggcca	tattcttact	tgaatgcttt	1800
gaatgactac	atccagttct	gcacctatac	cctctgggtg	tgttttttaa	ccttcctgga	1860
atccattttc	taaaaaataa	agacacattc	ttctcagcac	cacacaacac	ctattccaaa	1920
atcgaccaca	tatttgggaag	taaagctctc	ctcagcaaat	gtaaaagaac	agaaattata	1980
acaaactgtc	tctcagacca	cagtataacc	aaactagaac	tcaggattaa	gaaactcact	2040
caaaaccaca	caactacatg	gaaactgaac	aacctgctcc	tgaatgacta	ctggatacat	2100
aacaaaatga	aggcagaaat	aaagatgttc	tttaaaacca	atgagaacaa	agacacaaca	2160
taccagaatc	tctgggacac	attcaaagca	gtgtgtagag	ggaaatttat	agcactaaat	2220
gccacaaga	gaaagcagga	aatatctaaa	attgacaccc	taacatcaca	attaaaagaa	2280
ctagagaagc	aagagcaaac	acattgaaaa	gctaagagaa	ggcaagaaat	aactaagatc	2340
agagcagaac	tgaaggaaat	agagacacaa	aaaactcttc	aaaaaatcaa	tgaatccagg	2400
agctggtttt	ttgaaacgat	caacaaaatt	gatagacact	agcaagacta	ataaagaaga	2460
aaggagagaa	gaatcaaata	gaagcaataa	aaaatgataa	aggggatatc	accaccaatc	2520
ccacagaaat	aaaccaccat	cagagaatac	tacaaacacc	tctaagcaa		2569

<210> 39
 <211> 478
 <212> PRT
 <213> Homo sapiens

<400> 39

Met	Ala	Gly	Val	Glu	Val	Ala	Ala	Ser	Gly	Ser	His	Leu	Asn	Gly
1			5				10					15		
Asp	Leu	Asp	Pro	Asp	Asp	Arg	Glu	Glu	Gly	Ala	Ala	Ser	Thr	Ala
			20				25					30		

Glu Ala Ala Lys Lys Lys Arg Arg Lys Lys Lys Lys Ser Lys Gly Pro
 35 40 45
 Ser Ala Ala Gly Glu Gln Glu Pro Asp Lys Glu Ser Gly Ala Ser Val
 50 55 60
 Asp Glu Val Ala Arg Gln Leu Glu Arg Ser Ala Leu Glu Asp Lys Glu
 65 70 75 80
 Arg Asp Glu Asp Asp Glu Asp Gly Asp Gly Asp Gly Asp Gly Ala Thr
 85 90 95
 Gly Lys Lys Lys Lys Lys Lys Lys Lys Arg Gly Pro Lys Val Gln
 100 105 110
 Thr Asp Pro Pro Ser Val Pro Ile Cys Asp Leu Tyr Pro Asn Gly Val
 115 120 125
 Phe Pro Lys Gly Gln Glu Cys Glu Tyr Pro Pro Thr Gln Asp Gly Arg
 130 135 140
 Thr Ala Ala Trp Arg Thr Thr Ser Glu Glu Lys Lys Ala Leu Asp Gln
 145 150 155 160
 Ala Ser Glu Glu Ile Trp Asn Asp Phe Arg Glu Ala Ala Glu Ala His
 165 170 175
 Arg Gln Val Arg Lys Tyr Val Met Ser Trp Ile Lys Pro Gly Met Thr
 180 185 190
 Met Ile Glu Ile Cys Glu Lys Leu Glu Asp Cys Ser Arg Lys Leu Ile
 195 200 205
 Lys Glu Asn Gly Leu Asn Ala Gly Leu Ala Phe Pro Thr Gly Cys Ser
 210 215 220
 Leu Asn Asn Cys Ala Ala His Tyr Thr Pro Asn Ala Gly Asp Thr Thr
 225 230 235 240
 Val Leu Gln Tyr Asp Asp Ile Cys Lys Ile Asp Phe Gly Thr His Ile
 245 250 255
 Ser Gly Arg Ile Ile Asp Cys Ala Phe Thr Val Thr Phe Asn Pro Lys
 260 265 270
 Tyr Asp Thr Leu Leu Lys Ala Val Lys Asp Ala Thr Asn Thr Gly Ile
 275 280 285
 Lys Cys Ala Gly Ile Asp Val Arg Leu Cys Asp Val Gly Glu Ala Ile
 290 295 300
 Gln Glu Val Met Glu Ser Tyr Glu Val Glu Ile Asp Gly Lys Thr Tyr
 305 310 315 320
 Gln Val Lys Pro Ile Arg Asn Leu Asn Gly His Ser Ile Gly Gln Tyr
 325 330 335
 Arg Ile His Ala Gly Lys Thr Val Pro Ile Val Lys Gly Gly Glu Ala
 340 345 350
 Thr Arg Met Glu Glu Gly Glu Val Tyr Ala Ile Glu Thr Phe Gly Ser
 355 360 365
 Thr Gly Lys Gly Val Val His Asp Asp Met Glu Cys Ser His Tyr Met
 370 375 380
 Lys Asn Phe Asp Val Gly His Val Pro Ile Arg Leu Pro Arg Thr Lys
 385 390 395 400
 His Leu Leu Asn Val Ile Asn Glu Asn Phe Gly Thr Leu Ala Phe Cys
 405 410 415
 Arg Arg Trp Leu Asp Arg Leu Gly Glu Ser Lys Tyr Leu Met Ala Leu
 420 425 430
 Lys Asn Leu Cys Asp Leu Gly Ile Val Asp Pro Tyr Pro Pro Leu Cys
 435 440 445
 Asp Ile Lys Gly Ser Tyr Thr Ala Gln Phe Glu His Thr Ile Leu Leu
 450 455 460
 Arg Pro Thr Cys Lys Glu Val Val Ser Arg Gly Asp Asp Tyr
 465 470 475

<210> 40

<211> 1183

<212> DNA

<213> Homo sapiens.

<220>

<221> misc_feature

<222> (0)...(0)

<223> n = a, t, c or g

<400> 40

cgcccaagaa	gaaaatggcc	ataagtggag	tccctgtgct	aggatttttc	atcatagctg	60
tgctgatgag	cgctcaggaa	tcatgggcta	tcaaagaaga	acatgtgatc	atccaggccg	120
agttctatct	gaatcctgac	caatcaggcg	agtttatgtt	tgactttgat	ggtgatgaga	180
ttttccatgt	ggatatggca	aagaaggaga	cggctctggcg	gcttgaagaa	tttggacgat	240
ttgccagctt	tgaggctcaa	ggtgcattgg	ccaacatagc	tgtggacaaa	gccaaacttg	300
aaatcatgac	aaagcgctcc	aactatactc	cgatcaccaa	tgtacctcca	gaggtaactg	360
tgctcacgaa	cagccctgtg	gaactgagag	agcccaacgt	cctcatctgt	ttcatcgaca	420
agttcacccc	accagtggtc	aatgtcacgt	ggcttcgaaa	tggaaaacct	gtcaccacag	480
gagtgtcaga	gacagtcttc	ctgcccaggg	aagaccacct	tttccgcaag	ttccactatc	540
tccccttctt	gcctcaact	gaggacgttt	acgactgca	ggtggagcac	tggggcttgg	600
atgagcctct	tctcaagcac	tgggagtttg	atgctccaag	ccctctccca	gagactacag	660
agaacgtggg	gtgtgccctg	ggcctgactg	tgggtctggg	gggcatcatt	attgggacca	720
tcttcatcat	caagggagtg	cgcaaaagca	atgcagcaga	acgcaggggg	cctctgtaag	780
gcacatggag	gtgatgatgt	ttcttagaga	gaagatcact	gaagaaactt	ctgctttaat	840
gactttacaa	agctggcaat	attacaatcc	ttgacctcag	tgaagcagt	catcttcagc	900
gttttccagc	cctatagcca	ccccaaagtg	ggttatgcct	cctcgattgc	tccgtactct	960
aacatctagc	tggcttccct	gtctattgcc	ttttcctgta	tctattttcc	tctatttcct	1020
atcattttat	tatcaccatg	caatgcctct	ggaataaaac	atacaggagt	ctgtctctgc	1080
tatggaatgc	cccatggggc	atctctttgt	tacttattgt	ttaaggtttc	ctcaaaactgn	1140
gattcttctg	aacacaataa	actattttga	tgatcttggg	tgg		1183

<210> 41

<211> 254

<212> PRT

<213> Homo sapiens

<400> 41

Met	Ala	Ile	Ser	Gly	Val	Pro	Val	Leu	Gly	Phe	Phe	Ile	Ile	Ala	Val
1				5					10					15	
Leu	Met	Ser	Ala	Gln	Glu	Ser	Trp	Ala	Ile	Lys	Glu	Glu	His	Val	Ile
			20					25					30		
Ile	Gln	Ala	Glu	Phe	Tyr	Leu	Asn	Pro	Asp	Gln	Ser	Gly	Glu	Phe	Met
		35				40					45				
Phe	Asp	Phe	Asp	Gly	Asp	Glu	Ile	Phe	His	Val	Asp	Met	Ala	Lys	Lys
	50				55						60				
Glu	Thr	Val	Trp	Arg	Leu	Glu	Glu	Phe	Gly	Arg	Phe	Ala	Ser	Phe	Glu
65					70				75					80	
Ala	Gln	Gly	Ala	Leu	Ala	Asn	Ile	Ala	Val	Asp	Lys	Ala	Asn	Leu	Glu
			85					90						95	
Ile	Met	Thr	Lys	Arg	Ser	Asn	Tyr	Thr	Pro	Ile	Thr	Asn	Val	Pro	Pro
		100						105					110		
Glu	Val	Thr	Val	Leu	Thr	Asn	Ser	Pro	Val	Glu	Leu	Arg	Glu	Pro	Asn
		115				120						125			
Val	Leu	Ile	Cys	Phe	Ile	Asp	Lys	Phe	Thr	Pro	Pro	Val	Val	Asn	Val
	130					135					140				
Thr	Trp	Leu	Arg	Asn	Gly	Lys	Pro	Val	Thr	Thr	Gly	Val	Ser	Glu	Thr
145					150					155				160	
Val	Phe	Leu	Pro	Arg	Glu	Asp	His	Leu	Phe	Arg	Lys	Phe	His	Tyr	Leu
			165					170						175	
Pro	Phe	Leu	Pro	Ser	Thr	Glu	Asp	Val	Tyr	Asp	Cys	Arg	Val	Glu	His
		180						185						190	

Trp Gly Leu Asp Glu Pro Leu Leu Lys His Trp Glu Phe Asp Ala Pro
 195 200 205
 Ser Pro Leu Pro Glu Thr Thr Glu Asn Val Val Cys Ala Leu Gly Leu
 210 215 220
 Thr Val Gly Leu Val Gly Ile Ile Ile Gly Thr Ile Phe Ile Ile Lys
 225 230 235 240
 Gly Val Arg Lys Ser Asn Ala Ala Glu Arg Arg Gly Pro Leu
 245 250

<210> 42
 <211> 266
 <212> DNA
 <213> Homo sapiens

<400> 42
 atgcccaagt gtcccaagt caacaaggag gtgtacttcg ccgagagggt gacctctctg 60
 ggcaaggact ggcatcggcc ctgcctgaag tgcgagaaat gtgggaagac gctgacctct 120
 gggggccacg ctgagcacga aggcaaacc tactgcaacc acccctgcta cgcagccatg 180
 tttgggccta aaggctttgg gcggggcgga gccgagagcc acactttcaa gtaaaccagg 240
 tgggtggagac ccataccttg ctgctt 266

<210> 43
 <211> 77
 <212> PRT
 <213> Homo sapiens

<400> 43
 Met Pro Lys Cys Pro Lys Cys Asn Lys Glu Val Tyr Phe Ala Glu Arg
 1 5 10 15
 Val Thr Ser Leu Gly Lys Asp Trp His Arg Pro Cys Leu Lys Cys Glu
 20 25 30
 Lys Cys Gly Lys Thr Leu Thr Ser Gly Gly His Ala Glu His Glu Gly
 35 40 45
 Lys Pro Tyr Cys Asn His Pro Cys Tyr Ala Ala Met Phe Gly Pro Lys
 50 55 60
 Gly Phe Gly Arg Gly Gly Ala Glu Ser His Thr Phe Lys
 65 70 75

<210> 44
 <211> 1665
 <212> DNA
 <213> Homo sapiens

<400> 44
 gaaggaactg gttctgctca cacttgctgg cttgcgcatac aggactggct ttatctcctg 60
 actcacgggtg caaagggtgca ctctgcgaac gttaagtccg tccccagcgc ttggaatcct 120
 acggccccca cagccggatc ccctcagcct tccaggctcct caactcccgt ggacgctgaa 180
 caatggcctc catggggcta caggtaatgg gcatcgcgct ggccgtcctg ggctggctgg 240
 ccgtcatgct gtgctgcgag ctgcccattg ggcgcgtgac ggccttcata ggcagcaaca 300
 ttgtcacctc gcagaccatc tgggagggcc tatggatgaa ctgcgtggtg cagagcaccg 360
 gccagatgca gtgcaagggtg tacgactcgc tgctggcact gccgcaggac ctgcaggcgg 420
 cccgcgccct cgtcatcatc agcatcatcg tggtgctct gggcgtgctg ctgtccgtgg 480
 tggggggcaa gtgtaccaac tgctggagg atgaaagcgc caaggccaag accatgatcg 540
 tggcgggcgt ggtgttctg ttggccggcc ttatggtgat agtgccgggtg tcctggacgg 600
 cccacaacat catccaagac ttctacaatc cgttggtggc ctccgggcag aagcggggaga 660
 tgggtgcctc gctctacgtc ggttggggcg cctccggcct gctgctcctt ggcggggggc 720
 tgctttgctg caactgtcca cccgcacag acaagcctta ctccgccaag tattctgctg 780
 cccgctctgc tgctgccagc aactacgtgt aagggtgccac ggctccactc tgttctctc 840
 tgctttgttc ttccctggac tgagctcagc gcaggctgtg accccaggag ggccctgcc 900
 cggggccactg gctgctgggg actggggact gggcagagac tgagccaggc aggaaggcag 960


```

cagccttcag cctctctggc ccactcggac aacttcccaa ggccgcctcc tgctagcaag 1020
aacagagtc accctcctct ggatattggg gagggacgga agtgacaggg tgtgggtggtg 1080
gagtggggag ctggcttctg ctggccagga tagcttaacc ctgactttgg gatctgcctg 1140
catcggcggt ggccactgtc cccatttaca ttttccccac tctgtctgcc tgcattctct 1200
ctgttccggg taggccttga tatcacctct gggactgtgc cttgctcacc gaaacccgcg 1260
cccaggagta tggctgaggc ctgtcccacc cacctgcctg ggaagtgcag agtggatgga 1320
cgggttttaga ggggaggggc gaagggtgctg taaacaggtt tgggcagtgg tgggggaggg 1380
ggccagagag gcggtcagg ttgccagct ctgtggcctc aggactctct gcctcaccgc 1440
cttcagccca gggcccctgg agactgatcc cctctgagtc ctctgcccct tccaaggaca 1500
ctaagagcc tgggaggggtg gcagggagga ggggacagct tcacccttgg aagtctgtgg 1560
gtttttcctc ttcttcttt gtggtttctg ttttgtaatt taagaagagc tattcatcac 1620
tgtaattatt attattttct acaataaatg ggacctgtgc acagg 1665

```

<210> 45

<211> 209

<212> PRT

<213> Homo sapiens

<400> 45

```

Met Ala Ser Met Gly Leu Gln Val Met Gly Ile Ala Leu Ala Val Leu
 1          5          10          15
Gly Trp Leu Ala Val Met Leu Cys Cys Ala Leu Pro Met Trp Arg Val
 20          25          30
Thr Ala Phe Ile Gly Ser Asn Ile Val Thr Ser Gln Thr Ile Trp Glu
 35          40          45
Gly Leu Trp Met Asn Cys Val Val Gln Ser Thr Gly Gln Met Gln Cys
 50          55          60
Lys Val Tyr Asp Ser Leu Leu Ala Leu Pro Gln Asp Leu Gln Ala Ala
 65          70          75          80
Arg Ala Leu Val Ile Ile Ser Ile Ile Val Ala Ala Leu Gly Val Leu
 85          90          95
Leu Ser Val Val Gly Gly Lys Cys Thr Asn Cys Leu Glu Asp Glu Ser
100          105          110
Ala Lys Ala Lys Thr Met Ile Val Ala Gly Val Val Phe Leu Leu Ala
115          120          125
Gly Leu Met Val Ile Val Pro Val Ser Trp Thr Ala His Asn Ile Ile
130          135          140
Gln Asp Phe Tyr Asn Pro Leu Val Ala Ser Gly Gln Lys Arg Glu Met
145          150          155          160
Gly Ala Ser Leu Tyr Val Gly Trp Ala Ala Ser Gly Leu Leu Leu Leu
165          170          175
Gly Gly Gly Leu Leu Cys Cys Asn Cys Pro Pro Arg Thr Asp Lys Pro
180          185          190
Tyr Ser Ala Lys Tyr Ser Ala Ala Arg Ser Ala Ala Ala Ser Asn Tyr
195          200          205
Val

```

<210> 46

<211> 1009

<212> DNA

<213> Homo sapiens

<400> 46

```

ggcagtagct tgctgatgct ccagctgaa taaagccctt ccttctacaa tttggtgtct 60
gaggggtttt gtctgaggct cgtcctgcta catttcttgg ttccctgacc aggaacagag 120
gtaactgatg gacagccgag gcagcccctt aggcggctta ggccctccct gtggagcatc 180
cctgaggcgg actccggcca gcccgagtga tgcgatccaa agagcactcc cgggtaggaa 240
attgccccgg tggaatgcct caccagagca gcgtgtagca gttccctgtg gaggattaac 300
acagtggctg aacaccggga aggaactggc acttggagtc cggacatctg aaacttggtgta 360

```

agactagtct	ttggaacttg	ccccactcca	tctagggtgga	agtgtggcct	gatcacccac	420
gacatgcctg	cattggcact	tctgttcttg	ttttgacttg	acttagattg	tgtgatactt	480
tggttttggt	tttggtttga	cctggccttg	attctagata	ctctgatttg	gttttgattt	540
tggtttggtg	taaactgcaa	gagtgtgtat	gcccttttta	cctgtttttt	tgtttgtggc	600
atgtgtgtgg	tgtgggtgtg	gtgttttgtc	tcgaagaagc	atgggtcagg	tacaaataag	660
cccacccac	taggaactat	gttaaaaaaa	aattcaagaa	agaatttaag	ggagattaca	720
gtgttactgt	gacaccagga	aaacttagaa	ctttgtgtga	aatagactgg	ccagcattag	780
aggtgggttg	gccatcagaa	ggaagcctgg	acaggtccct	tgtttcaaag	gtatgacaca	840
aggtaacacc	aattctaagt	taatttgaag	tttgcttaaa	gttaacagtg	taacatgtat	900
tatggtaact	tctaactctg	tggccttaga	cagtctagtc	caaaggcata	aagaaagtgt	960
gctttaaaaa	aaaaaaaaag	gaatggttat	cttcaaaaaa	aaaaaaaaaa		1009

<210> 47

<211> 1250

<212> DNA

<213> Homo sapiens

<400> 47

aattcggcac	gagggcaggt	gcaggcgcac	gcggcgagag	cgtatggagc	cgagccgta	60
gcgcgcgccg	tcggtgagtc	agtccgtccg	tccgtccgtc	cgtcggggcg	ccgcagctcc	120
cgccaggccc	agcgcccccg	gcccctcgtc	tccccgcacc	cggagccacc	cgggtggagcg	180
ggccttgccg	cggcagccat	gtccatgggc	ctggagatca	cgggcaccgc	gctggccgtg	240
ctgggctggc	tgggcacccat	cgtgtgctgc	gcgttgccca	tgtggcgctg	gtcggccttc	300
atcggcagca	acatcatcac	gtcgcagAAC	atctgggagg	gcctgtggat	gaactgcgtg	360
gtgcagagca	ccggccagat	gcagtgcAag	gtgtacgact	cgctgctggc	actgccacag	420
gaccttcagg	cggcccgcgc	cctcatcgctg	gtggccatcc	tgttgccgcg	cttcgggctg	480
ctagtggcgc	tgggtgggcgc	ccagtgcacc	aactgcgtgc	aggacgacac	ggccaaggcc	540
aagatcacca	tcgtggcagg	cgtgctgttc	cttctcgccg	ccctgctcac	cctcgtgccg	600
gtgtcctggt	cgccaacac	cattatccgg	gacttctaca	accccggtgt	gcccagggcg	660
cagaagcgcg	agatgggcgc	gggcctgtac	gtgggtctggg	cggccgcggc	gctgcagctg	720
ctggggggcg	cgctgctctg	ctgctcgtgt	ccccacgcg	agaagaagta	cacggccacc	780
aaggtcgtct	actccgcgcc	gcgtccacc	ggcccgggag	ccagcctggg	cacaggctac	840
gaccgcaagg	actacgtcta	agggacagac	gcagggagac	cccaccacca	ccaccaccac	900
caacaccacc	accaccaccg	cgagctggag	cgcgaccacg	gccatccagc	gtgcagcctt	960
gcctcggagg	ccagcccacc	cccagaagcc	aggaagcccc	cgcgctggac	tggggcagct	1020
tccccagcag	ccacggcctt	gcgggcgggg	cagtcgactt	cggggcccgag	ggaccaacct	1080
gcatggactg	tgaaacctca	cccttctgga	gcacggggcc	tgggtgaccg	ccaatacttg	1140
accaccccg	cgagccccat	cgggcgcgtg	cccccatgtc	gcgctgggca	gggaccggca	1200
gcctggaag	gggcacttga	tatttttcaa	taaaagcctc	tcgttttagc		1250

<210> 48

<211> 220

<212> PRT

<213> Homo sapiens

<400> 48

Met	Ser	Met	Gly	Leu	Glu	Ile	Thr	Gly	Thr	Ala	Leu	Ala	Val	Leu	Gly
1				5					10					15	
Trp	Leu	Gly	Thr	Ile	Val	Cys	Cys	Ala	Leu	Pro	Met	Trp	Arg	Val	Ser
			20					25					30		
Ala	Phe	Ile	Gly	Ser	Asn	Ile	Ile	Thr	Ser	Gln	Asn	Ile	Trp	Glu	Gly
			35				40					45			
Leu	Trp	Met	Asn	Cys	Val	Val	Gln	Ser	Thr	Gly	Gln	Met	Gln	Cys	Lys
			50			55				60					
Val	Tyr	Asp	Ser	Leu	Leu	Ala	Leu	Pro	Gln	Asp	Leu	Gln	Ala	Ala	Arg
65				70				75					80		
Ala	Leu	Ile	Val	Val	Ala	Ile	Leu	Leu	Ala	Ala	Phe	Gly	Leu	Leu	Val
			85					90					95		
Ala	Leu	Val	Gly	Ala	Gln	Cys	Thr	Asn	Cys	Val	Gln	Asp	Asp	Thr	Ala
			100					105					110		

Lys Ala Lys Ile Thr Ile Val Ala Gly Val Leu Phe Leu Leu Ala Ala
 115 120 125
 Leu Leu Thr Leu Val Pro Val Ser Trp Ser Ala Asn Thr Ile Ile Arg
 130 135 140
 Asp Phe Tyr Asn Pro Val Val Pro Glu Ala Gln Lys Arg Glu Met Gly
 145 150 155 160
 Ala Gly Leu Tyr Val Gly Trp Ala Ala Ala Leu Gln Leu Leu Gly
 165 170 175
 Gly Ala Leu Leu Cys Cys Ser Cys Pro Pro Arg Glu Lys Lys Tyr Thr
 180 185 190
 Ala Thr Lys Val Val Tyr Ser Ala Pro Arg Ser Thr Gly Pro Gly Ala
 195 200 205
 Ser Leu Gly Thr Gly Tyr Asp Arg Lys Asp Tyr Val
 210 215 220

<210> 49

<211> 3321

<212> DNA

<213> Homo sapiens

<400> 49

atgaagattt	tgataacttg	tatttttctg	tttttatgta	gtaccccgagc	ctgggcgaaa	60
gaaaagcatt	attacattgg	aattattgaa	acgacttggg	attatgcctc	tgaccatggg	120
gaaaagaaac	ttattttctgt	tgacacggaa	cattccaata	tctatcttca	aaatggccca	180
gatagaattg	ggagactata	taagaaggcc	ctttatcttc	agtacacaga	tgaaaccttt	240
aggacaacta	tagaaaaacc	ggtctggctt	gggtttttag	gccctattat	caaagctgaa	300
actggagata	aagtttatgt	acacttaaaa	aaccttgcc	ctaggcccta	cacctttcat	360
tcacatggaa	taacttacta	taaggaacat	gagggggcca	tctaccctga	taacaccaca	420
gattttcaaa	gagcagatga	caaagtatat	ccaggagagc	agtatacata	catgttgctt	480
gccactgaag	aacaaagtcc	tggggaagga	gatggcaatt	gtgtgactag	gatttaccat	540
tcccacattg	atgctccaaa	agatattgcc	tcaggactca	tcggaccttt	aataatctgt	600
aaaaaagatt	ctctagataa	agaaaaagaa	aaacatattg	accgagaatt	tgtggtgatg	660
ttttctgtgg	tggatgaaaa	tttcagctgg	tacctagaag	acaacattaa	aacctactgc	720
tcagaaccag	agaaaagttga	caaagacaac	gaagacttcc	aggagagtaa	cagaatgtat	780
tctgtgaatg	gatacacttt	tgggaagtctc	ccaggactct	ccatgtgtgc	tgaagacaga	840
gtaaaatgg	accttttttg	tatgggtaat	gaagttgatg	tgcacgcagc	tttctttcac	900
gggcaagcac	tgactaacaa	gaactaccgt	attgacacaa	tcaacctctt	tccgtctacc	960
ctgtttgatg	cttatatgg	ggcccagaac	cctggagaat	ggatgctcag	ctgtcagaat	1020
ctaaaccatc	tgaaagccgg	tttgcaagcc	tttttccagg	tccaggagt	taacaagtct	1080
tcatacaagg	ataatatccg	tgggaagcat	gtagacact	actacattgc	cgctgaggaa	1140
atcatctgga	actatgctcc	ctctggtata	gacatcttca	ctaaagaaaa	cttaacagca	1200
cctggaagt	actcagcgg	gttttttgaa	caaggtacca	caagaattgg	aggctcttat	1260
aaaaagctgg	tttatcgtga	gtacacagat	gcctccttca	caaatcgaaa	ggagagaggc	1320
cctgaagaag	agcatcttgg	catcctgggt	cctgtcattt	gggcagagg	gggagacacc	1380
atcagagtaa	ccttccataa	caaaggagca	tatccctcca	gtattgagcc	gattgggggtg	1440
agattcaata	agaacaacga	gggcacatac	tattccccaa	attacaaccc	ccagagcaga	1500
agtgtgcctc	cttcagcctc	ccatgtggca	cccacagaaa	cattcaccta	tgaatggact	1560
gtccccaag	aagtaggacc	cactaatgca	gatcctgtgt	gtctagctaa	gatgtattat	1620
tctgtctgtg	atcccactaa	agatatattc	actgggctta	ttgggccaat	gaaaatatgc	1680
aagaaaggaa	gtttacatgc	aaatgggaga	cagaaagatg	tagacaagga	attctatttg	1740
tttctacag	tatttgatga	gaatgagagt	ttactcctgg	aagataatat	tagaatgttt	1800
acaactgcac	ctgatcaggt	ggataaggaa	gatgaagact	ttcaggaatc	taataaaatg	1860
cactccatga	atggattcat	gtatgggaat	cagccgggtc	tcactatgtg	caaaggagat	1920
tcggtcgtgt	ggtacttatt	cagcgccgga	aatgaggccg	atgtacatgg	aatatacttt	1980
tcaggaaaca	catatctgtg	gagaggagaa	cggagagaca	cagcaaacct	cttccctcaa	2040
acaagtctta	cgctccacat	gtggcctgac	acagagggga	cttttaatgt	tgaatgcctt	2100
acaactgatc	attacacagg	cggcatgaa	caaaaatata	ctgtgaacca	atgcaggcgg	2160
cagtctgagg	attccacctt	ctacctggga	gagaggacat	actatatcgc	agcagtgag	2220
gtggaatggg	attattcccc	acaaagggag	tgggaaaagg	agctgcatca	tttacaagag	2280
cagaatgttt	caaatgcatt	tttagataag	ggagagtttt	acataggctc	aaagtacaag	2340

```

aaagttgtgt atcggcagta tactgatagc acattccgtg ttccagtgga gagaaaagct 2400
gaagaagaac atctgggaat tctaggtcca caacttcatg cagatgttgg agacaaagtc 2460
aaaattatct ttaaaaacat ggccacaagg ccctactcaa tacatgcca tggggtacaa 2520
acagagagtt ctacagttac tccaacatta ccaggtgaaa ctctcactta cgtatggaaa 2580
atcccagaaa gatctggagc tgggaacagag gattctgctt gtattccatg ggcttattat 2640
tcaactgtgg atcaagttaa ggacctctac agtggattaa ttggccccct gattgtttgt 2700
cgaagacctt acttgaaagt attcaatccc agaaggaagc tgggaatttgc ccttctgttt 2760
ctagtttttg atgagaatga atcttggtac ttagatgaca acatcaaaac atactctgat 2820
caccctcgaga aagtaaacia agatgatgag gaattcatag aaagcaataa aatgcatgct 2880
attaatggaa gaatgtttgg aaacctacaa ggcctcacaa tgcacgtggg agatgaagtc 2940
aactgggtatc tgatgggaat gggcaatgaa atagacttac acactgtaca ttttcacggc 3000
catagcttcc aatacaagca caggggagtt tatagttctg atgtctttga cattttccct 3060
ggaacatacc aaacctaga aatgtttcca agaacacctg gaatttggtt actccactgc 3120
catgtgaccg accacattca tgctggaatg gaaaccactt acaccgttct acaaaatgaa 3180
gacaccaaat ctggctgaat gaaataaatt ggtgataagt ggaaaaaaga gaaaaaccaa 3240
tgattcataa caatgtatgt gaaagtgtaa aatagaatgt tactttggaa tgactataaa 3300
cattaaaaga gactggagca t 3321

```

<210> 50

<211> 1065

<212> PRT

<213> Homo sapiens

<400> 50

```

Met Lys Ile Leu Ile Leu Gly Ile Phe Leu Phe Leu Cys Ser Thr Pro
1      5      10      15
Ala Trp Ala Lys Glu Lys His Tyr Tyr Ile Gly Ile Ile Glu Thr Thr
20     25     30
Trp Asp Tyr Ala Ser Asp His Gly Glu Lys Lys Leu Ile Ser Val Asp
35     40     45
Thr Glu His Ser Asn Ile Tyr Leu Gln Asn Gly Pro Asp Arg Ile Gly
50     55     60
Arg Leu Tyr Lys Lys Ala Leu Tyr Leu Gln Tyr Thr Asp Glu Thr Phe
65     70     75     80
Arg Thr Thr Ile Glu Lys Pro Val Trp Leu Gly Phe Leu Gly Pro Ile
85     90     95
Ile Lys Ala Glu Thr Gly Asp Lys Val Tyr Val His Leu Lys Asn Leu
100    105    110
Ala Ser Arg Pro Tyr Thr Phe His Ser His Gly Ile Thr Tyr Tyr Lys
115    120    125
Glu His Glu Gly Ala Ile Tyr Pro Asp Asn Thr Thr Asp Phe Gln Arg
130    135    140
Ala Asp Asp Lys Val Tyr Pro Gly Glu Gln Tyr Thr Tyr Met Leu Leu
145    150    155    160
Ala Thr Glu Glu Gln Ser Pro Gly Glu Gly Asp Gly Asn Cys Val Thr
165    170    175
Arg Ile Tyr His Ser His Ile Asp Ala Pro Lys Asp Ile Ala Ser Gly
180    185    190
Leu Ile Gly Pro Leu Ile Ile Cys Lys Lys Asp Ser Leu Asp Lys Glu
195    200    205
Lys Glu Lys His Ile Asp Arg Glu Phe Val Val Met Phe Ser Val Val
210    215    220
Asp Glu Asn Phe Ser Trp Tyr Leu Glu Asp Asn Ile Lys Thr Tyr Cys
225    230    235    240
Ser Glu Pro Glu Lys Val Asp Lys Asp Asn Glu Asp Phe Gln Glu Ser
245    250    255
Asn Arg Met Tyr Ser Val Asn Gly Tyr Thr Phe Gly Ser Leu Pro Gly
260    265    270
Leu Ser Met Cys Ala Glu Asp Arg Val Lys Trp Tyr Leu Phe Gly Met
275    280    285

```

Gly Asn Glu Val Asp Val His Ala Ala Phe Phe His Gly Gln Ala Leu
 290 295 300
 Thr Asn Lys Asn Tyr Arg Ile Asp Thr Ile Asn Leu Phe Pro Ala Thr
 305 310 315 320
 Leu Phe Asp Ala Tyr Met Val Ala Gln Asn Pro Gly Glu Trp Met Leu
 325 330 335
 Ser Cys Gln Asn Leu Asn His Leu Lys Ala Gly Leu Gln Ala Phe Phe
 340 345 350
 Gln Val Gln Glu Cys Asn Lys Ser Ser Ser Lys Asp Asn Ile Arg Gly
 355 360 365
 Lys His Val Arg His Tyr Tyr Ile Ala Ala Glu Glu Ile Ile Trp Asn
 370 375 380
 Tyr Ala Pro Ser Gly Ile Asp Ile Phe Thr Lys Glu Asn Leu Thr Ala
 385 390 395 400
 Pro Gly Ser Asp Ser Ala Val Phe Phe Glu Gln Gly Thr Thr Arg Ile
 405 410 415
 Gly Gly Ser Tyr Lys Lys Leu Val Tyr Arg Glu Tyr Thr Asp Ala Ser
 420 425 430
 Phe Thr Asn Arg Lys Glu Arg Gly Pro Glu Glu Glu His Leu Gly Ile
 435 440 445
 Leu Gly Pro Val Ile Trp Ala Glu Val Gly Asp Thr Ile Arg Val Thr
 450 455 460
 Phe His Asn Lys Gly Ala Tyr Pro Leu Ser Ile Glu Pro Ile Gly Val
 465 470 475 480
 Arg Phe Asn Lys Asn Asn Glu Gly Thr Tyr Tyr Ser Pro Asn Tyr Asn
 485 490 495
 Pro Gln Ser Arg Ser Val Pro Pro Ser Ala Ser His Val Ala Pro Thr
 500 505 510
 Glu Thr Phe Thr Tyr Glu Trp Thr Val Pro Lys Glu Val Gly Pro Thr
 515 520 525
 Asn Ala Asp Pro Val Cys Leu Ala Lys Met Tyr Tyr Ser Ala Val Asp
 530 535 540
 Pro Thr Lys Asp Ile Phe Thr Gly Leu Ile Gly Pro Met Lys Ile Cys
 545 550 555 560
 Lys Lys Gly Ser Leu His Ala Asn Gly Arg Gln Lys Asp Val Asp Lys
 565 570 575
 Glu Phe Tyr Leu Phe Pro Thr Val Phe Asp Glu Asn Glu Ser Leu Leu
 580 585 590
 Leu Glu Asp Asn Ile Arg Met Phe Thr Thr Ala Pro Asp Gln Val Asp
 595 600 605
 Lys Glu Asp Glu Asp Phe Gln Glu Ser Asn Lys Met His Ser Met Asn
 610 615 620
 Gly Phe Met Tyr Gly Asn Gln Pro Gly Leu Thr Met Cys Lys Gly Asp
 625 630 635 640
 Ser Val Val Trp Tyr Leu Phe Ser Ala Gly Asn Glu Ala Asp Val His
 645 650 655
 Gly Ile Tyr Phe Ser Gly Asn Thr Tyr Leu Trp Arg Gly Glu Arg Arg
 660 665 670
 Asp Thr Ala Asn Leu Phe Pro Gln Thr Ser Leu Thr Leu His Met Trp
 675 680 685
 Pro Asp Thr Glu Gly Thr Phe Asn Val Glu Cys Leu Thr Thr Asp His
 690 695 700
 Tyr Thr Gly Gly Met Lys Gln Lys Tyr Thr Val Asn Gln Cys Arg Arg
 705 710 715 720
 Gln Ser Glu Asp Ser Thr Phe Tyr Leu Gly Glu Arg Thr Tyr Tyr Ile
 725 730 735
 Ala Ala Val Glu Val Glu Trp Asp Tyr Ser Pro Gln Arg Glu Trp Glu
 740 745 750
 Lys Glu Leu His His Leu Gln Glu Gln Asn Val Ser Asn Ala Phe Leu
 755 760 765

Asp Lys Gly Glu Phe Tyr Ile Gly Ser Lys Tyr Lys Lys Val Val Tyr
 770 775 780
 Arg Gln Tyr Thr Asp Ser Thr Phe Arg Val Pro Val Glu Arg Lys Ala
 785 790 795 800
 Glu Glu Glu His Leu Gly Ile Leu Gly Pro Gln Leu His Ala Asp Val
 805 810 815
 Gly Asp Lys Val Lys Ile Ile Phe Lys Asn Met Ala Thr Arg Pro Tyr
 820 825 830
 Ser Ile His Ala His Gly Val Gln Thr Glu Ser Ser Thr Val Thr Pro
 835 840 845
 Thr Leu Pro Gly Glu Thr Leu Thr Tyr Val Trp Lys Ile Pro Glu Arg
 850 855 860
 Ser Gly Ala Gly Thr Glu Asp Ser Ala Cys Ile Pro Trp Ala Tyr Tyr
 865 870 875 880
 Ser Thr Val Asp Gln Val Lys Asp Leu Tyr Ser Gly Leu Ile Gly Pro
 885 890 895
 Leu Ile Val Cys Arg Arg Pro Tyr Leu Lys Val Phe Asn Pro Arg Arg
 900 905 910
 Lys Leu Glu Phe Ala Leu Leu Phe Leu Val Phe Asp Glu Asn Glu Ser
 915 920 925
 Trp Tyr Leu Asp Asp Asn Ile Lys Thr Tyr Ser Asp His Pro Glu Lys
 930 935 940
 Val Asn Lys Asp Asp Glu Glu Phe Ile Glu Ser Asn Lys Met His Ala
 945 950 955 960
 Ile Asn Gly Arg Met Phe Gly Asn Leu Gln Gly Leu Thr Met His Val
 965 970 975
 Gly Asp Glu Val Asn Trp Tyr Leu Met Gly Met Gly Asn Glu Ile Asp
 980 985 990
 Leu His Thr Val His Phe His Gly His Ser Phe Gln Tyr Lys His Arg
 995 1000 1005
 Gly Val Tyr Ser Ser Asp Val Phe Asp Ile Phe Pro Gly Thr Tyr Gln
 1010 1015 1020
 Thr Leu Glu Met Phe Pro Arg Thr Pro Gly Ile Trp Leu Leu His Cys
 1025 1030 1035 1040
 His Val Thr Asp His Ile His Ala Gly Met Glu Thr Thr Tyr Thr Val
 1045 1050 1055
 Leu Gln Asn Glu Asp Thr Lys Ser Gly
 1060 1065

<210> 51

<211> 1603

<212> DNA

<213> Homo sapiens

<400> 51

ggccagggat	caggcagcgg	ctcaggcgac	cctgagtgtg	ccccaccacc	gcatatggccc	60
ggctgctgca	ggcgctctgc	ctgctttccc	tgctcctggc	cggcttcgct	tcgcagagcc	120
ggggacaaga	gaagtcgaag	atggactgcc	atgggtggcat	aagtggcacc	atttacgagt	180
acggagccct	caccattgat	ggggaggagt	acatcccctt	caagcagtat	gctggcaaat	240
acgtcctctt	tgtcaacgtg	gccagctact	gaggcctgac	gggccagtac	attgaactga	300
atgcactaca	ggaagagctt	gcaccattcg	gtctgggtcat	tctgggcttt	ccctgcaacc	360
aatttgga	acaggaacca	ggagagaact	cagagatcct	tcctaccctc	aagtatgtcc	420
gaccaggtgg	aggctttgtc	cctaatttcc	agctctttga	gaaaggggat	gtcaatggag	480
agaaagagca	gaaattctac	actttcctaa	agaactcctg	tcctcccacc	tcggagctcc	540
tgggtacatc	tgaccgcctc	ttctgggaac	ccatgaaggt	tcacgacatc	cgctggaact	600
ttgagaagtt	cctgggtggg	ccagatggta	tacccatcat	gcgctggcac	caccggacca	660
cggtcagcaa	cgtcaagatg	gacatcctgt	cctacatgag	gcggcaggca	gccctggggg	720
tcaagaggaa	gtaactgaag	gccgtctcat	ccatgttcca	ccatgtaggg	gagggacttt	780
gttcaggaag	aaatccgtgt	ctccaaccac	actatctacc	catcacagac	ccctttccta	840
tcactcaagg	ccccagcctg	gcacaaatgg	atgcatacag	ttctgtgtac	tgccaggcat	900

```

gtgggtgtgg gtgcatgtgg gtgtttacac acatgcctac aggtatgcgt gattgtgtgt      960
gtgtgcatgg gtgtacagcc acgtgtccta cctatgtgtc tttctgggaa tgtgtaccat      1020
ctgtgtgcct gcagctgtgt agtgctggac agtgacaacc ctttctctcc agttctccac      1080
tccaatgata atagttcact tacacctaaa cccaaaggaa aaaccagctc taggtccaat      1140
tgttctgctc taactgatac ctcaaccttg gggccagcat ctcccactgc ctccaaatat      1200
tagtaactat gactgacgtc cccagaagtt tctgggtcta ccacactccc caacccccca      1260
ctcctacttc ctgaagggcc ctcccaaggc tacatcccca cccacagtt ctccctgaga      1320
gagatcaacc tccctagatc aaccaaggca gatgtgacaa gcaagggcca cggaccccat      1380
aggcaggggt ggcgtcttca tgagggaggg gcccaaagcc cttgtgggcg gacctccct      1440
gagcctgtct gaggggccag cccttagtgc attcaggcta aggcccctgg gcagggatgc      1500
caccctgctc cttcggagga cgtgccctca cccctcactg gtccactggc ttgagactca      1560
ccccgtctgc ccagtaaaag cctttctgca gcaaaaaacc ccc                        1603

```

<210> 52

<211> 226

<212> PRT

<213> Homo sapiens

<220>

<221> VARIANT

<222> 0-00

<223> Xaa = any amino acid

<400> 52

```

Met Ala Arg Leu Leu Gln Ala Ser Cys Leu Leu Ser Leu Leu Leu Ala
 1           5           10          15
Gly Phe Val Ser Gln Ser Arg Gly Gln Glu Lys Ser Lys Met Asp Cys
 20          25          30
His Gly Gly Ile Ser Gly Thr Ile Tyr Glu Tyr Gly Ala Leu Thr Ile
 35          40          45
Asp Gly Glu Glu Tyr Ile Pro Phe Lys Gln Tyr Ala Gly Lys Tyr Val
 50          55          60
Leu Phe Val Asn Val Ala Ser Tyr Xaa Gly Leu Thr Gly Gln Tyr Ile
 65          70          75          80
Glu Leu Asn Ala Leu Gln Glu Glu Leu Ala Pro Phe Gly Leu Val Ile
 85          90          95
Leu Gly Phe Pro Cys Asn Gln Phe Gly Lys Gln Glu Pro Gly Glu Asn
100         105         110
Ser Glu Ile Leu Pro Thr Leu Lys Tyr Val Arg Pro Gly Gly Gly Phe
115         120         125
Val Pro Asn Phe Gln Leu Phe Glu Lys Gly Asp Val Asn Gly Glu Lys
130         135         140
Glu Gln Lys Phe Tyr Thr Phe Leu Lys Asn Ser Cys Pro Pro Thr Ser
145         150         155         160
Glu Leu Leu Gly Thr Ser Asp Arg Leu Phe Trp Glu Pro Met Lys Val
165         170         175
His Asp Ile Arg Trp Asn Phe Glu Lys Phe Leu Val Gly Pro Asp Gly
180         185         190
Ile Pro Ile Met Arg Trp His His Arg Thr Thr Val Ser Asn Val Lys
195         200         205
Met Asp Ile Leu Ser Tyr Met Arg Arg Gln Ala Ala Leu Gly Val Lys
210         215         220
Arg Lys
225

```

<210> 53

<211> 399

<212> DNA

<213> Homo sapiens

<400> 53

atgaagtcca	gcggcctctt	ccccttctctg	gtgctgcttg	ccctgggaac	tctggcacct	60
tgggctgtgg	aaggctctgg	aaagtccttc	aaagctggag	tctgtcctcc	taagaaatct	120
gcccagtgcc	ttagatacaa	gaaacctgag	tgccagagtg	actggcagtg	tccagggag	180
aagagatgtt	gtcctgacac	ttgtggcatc	aaatgcctgg	atcctgttga	caccccaaac	240
ccaacaagga	ggaagcctgg	gaagtgccca	gtgacttatg	gccaatgttt	gatgcttaac	300
ccccccaatt	tctgtgagat	ggatggccag	tgcaagcgtg	acttgaagtg	ttgcatgggc	360
atgtgtggga	aatcctgcgt	ttccctgtg	aaagcttga			399

<210> 54

<211> 132

<212> PRT

<213> Homo sapiens

<400> 54

Met	Lys	Ser	Ser	Gly	Leu	Phe	Pro	Phe	Leu	Val	Leu	Leu	Ala	Leu	Gly
1				5					10					15	
Thr	Leu	Ala	Pro	Trp	Ala	Val	Glu	Gly	Ser	Gly	Lys	Ser	Phe	Lys	Ala
			20					25					30		
Gly	Val	Cys	Pro	Pro	Lys	Lys	Ser	Ala	Gln	Cys	Leu	Arg	Tyr	Lys	Lys
		35					40					45			
Pro	Glu	Cys	Gln	Ser	Asp	Trp	Gln	Cys	Pro	Gly	Lys	Lys	Arg	Cys	Cys
	50					55					60				
Pro	Asp	Thr	Cys	Gly	Ile	Lys	Cys	Leu	Asp	Pro	Val	Asp	Thr	Pro	Asn
65					70				75						80
Pro	Thr	Arg	Arg	Lys	Pro	Gly	Lys	Cys	Pro	Val	Thr	Tyr	Gly	Gln	Cys
				85					90					95	
Leu	Met	Leu	Asn	Pro	Pro	Asn	Phe	Cys	Glu	Met	Asp	Gly	Gln	Cys	Lys
			100					105					110		
Arg	Asp	Leu	Lys	Cys	Cys	Met	Gly	Met	Cys	Gly	Lys	Ser	Cys	Val	Ser
		115					120						125		
Pro	Val	Lys	Ala												
															130

<210> 55

<211> 3557

<212> DNA

<213> Homo sapiens

<400> 55

gagaggggtcc	ttcaggggtct	gcttatgccc	ttgttcaaga	acaccagtgt	cagctctctg	60
tactctggtt	gcagactgac	cttgctcagg	cctgagaagg	atggggcagc	caccagagtg	120
gatgctgtct	gcacccatcg	tcctgacccc	aaaagccctg	gactggacag	agagcggctg	180
tactggaagc	tgagccagct	gacccacggc	atcactgagc	tgggccccta	caccctggac	240
aggcacagtc	tctatgtcaa	tggtttcacc	catcagagct	ctatgacgac	caccagaact	300
cctgatacct	ccacaatgca	cctggcaacc	tcgagaactc	cagcctccct	gtctggacct	360
acgaccgcca	gccctctcct	ggtgctattc	acaattaact	tcaccatcac	taacctgegg	420
tatgaggaga	acatgcatca	ccctggctct	agaaagttta	acaccacgga	gagagtcctt	480
caggggtctgc	tcaggcctgt	gttcaagaac	accagtgttg	gccctctgta	ctctggctgc	540
agactgacct	tgctcaggcc	caagaaggat	ggggcagcca	ccaaagtgga	tgccatctgc	600
acctaccgcc	ctgatcccaa	aagccctgga	ctggacagag	agcagctata	ctgggagctg	660
agccagctaa	cccacagcat	cactgagctg	ggcccctaca	ccctggacag	ggacagtctc	720
tatgtcaatg	gtttcacaca	gcggagctct	gtgcccacca	ctagcattcc	tgggaccccc	780
acagtggacc	tgggaaacatc	tgggactcca	gtttctaaac	ctggctccctc	ggctgccagc	840
cctctcctgg	tgctattcac	tctcaacttc	accatcacca	acctgcggta	tgaggagaaac	900
atgcagcacc	ctggctccag	gaagttcaac	accacggaga	gggtccttca	gggcctgctc	960
aggtccctgt	tcaagagcac	cagtgttggc	cctctgtact	ctggctgcag	actgactttg	1020
ctcagggcctg	aaaaggatgg	gacagccact	ggagtggatg	ccatctgcac	ccaccaccct	1080
gacccccaaa	gccctaggct	ggacagagag	cagctgtatt	gggagctgag	ccagctgacc	1140
cacaatatca	ctgagctggg	ccactatgcc	ctggacaacg	acagcctctt	tgtcaatggt	1200


```

ttcactcatc ggagctctgt gtcaccacc agcactcctg ggacccccac agtgtatctg 1260
ggagcatcta agactccagc ctcgatatatt ggcccttcag ctgccagcca tctcctgata 1320
ctattcaccc tcaacttcac catcactaac ctgcggtatg aggagaacat gtggcctggc 1380
tccaggaagt tcaacactac agagaggggtc cttcagggcc tgctaaggcc cttgttcaag 1440
aacaccagtg ttggccctct gtactctggc tccaggctga ccttgcctcag gccagagaaa 1500
gatggggaag ccaccggagt ggatgccatc tgcaccacc gccctgacct cacaggccct 1560
gggctggaca gagagcagct gtatttggag ctgagccagc tgaccacacg catcactgag 1620
ctgggcccct acacactgga cagggacagt ctctatgtca atggtttcac ccatcgagc 1680
tctgtaccca ccaccagcac cggggtgggtc agcgaggagc cattcacact gaacttcacc 1740
atcaacaacc tgcgtacat ggcgagacatg ggccaacccg gctccctcaa gttcaacatc 1800
acagacaacg tcatgaagca cctgctcagt cctttgttcc agaggagcag cctgggtgca 1860
cggtacacag gctgcagggt catgcacta aggtctgtga agaacggtgc tgagacacgg 1920
gtggacctcc tctgcacctc cctgcagccc ctgagcggcc caggtctgcc tatcaagcag 1980
gtgttccatg agctgagcca gcagacctat ggcatcaccg ggctgggccc ctactctctg 2040
gacaaagaca gcctctacct taacggttac aatgaacctg gtctagatga gcctcctaca 2100
actcccaagc cagccaccac attcctgcct cctctgtcag aagccacaac agccatgggg 2160
taccacctga agaccctcac actcaacttc accactccta atctccagta ttcaccagat 2220
atgggcaagg gctcagctac attcaactcc accgaggggg tccttcagca cctgctcaga 2280
cccttgttcc agaagagcag catgggcccc ttctacttgg gttgccaaact gatctccctc 2340
aggcctgaga aggatggggc agccactggt gtggacacca cctgcacctc ccacctgac 2400
cctgtgggccc cggggtgga catacagcag ctttactggg agctgagtca gctgacctat 2460
gggtgtcacc aactgggctt ctatgtctctg gacagggata gcctcttcat caatggctat 2520
gcaccccaga atttatcaat ccggggcgag taccagataa atttccacat tgtcaactgg 2580
aacctcagta atccagacct cacatcctca gagtacatca ccctgctgag ggacatccag 2640
gacaaggta ccacactcta caaaggcagt caactacatg acacattccg cttctgcctg 2700
gtcaccaact tgacgatgga ctccgtgttg gtcactgtca aggcattgtt ctcctccaat 2760
ttggacccca gcctgggtgga gcaagtcttt ctagataaga cctgaatgc ctcattccat 2820
tggctgggct ccacctacca gttggtggag atccatgtga cagaaatgga gtcacagtt 2880
tatcaaccaa caagcagctc cagcaccag cacttctacc cgaatttcac catcaccaac 2940
ctaccatatt cccaggacaa agcccagcca ggcaccacca attaccagag gaacaaaagg 3000
aatattgagg atgcgtcaa ccaactcttc cgaaacagca gcatcaagag ttatttttct 3060
gactgtcaag tttcaacatt caggtctgtc cccaacaggc accacaccgg ggtggactcc 3120
ctgtgtaact tctcgccact ggctcggaga gtagacagag ttgccatcta tgaggaatth 3180
ctgcggatga cccggaatgg taccagctg cagaacttca ccctggacag gagcagtgtc 3240
cttgtggatg ggtattctcc caacagaaat gagcccttaa ctgggaattc tgaccttccc 3300
ttctgggtct tcatcttcat cggcttggca ggaactcctg gactcatcac atgctgtatc 3360
tgcggtgtcc tgggtgaccac ccgcggcgga agaaggaag gagaatacaa cgtccagcaa 3420
cagtgccag gctactacca gtcacacct gacctggagg atctgcaatg actgggaactt 3480
gccggtgcct ggggtgcctt tccccagcc aggttccaaa gaagcttggc tggggcagaa 3540
ataaaccata ttggtcg 3557

```

<210> 56

<211> 1148

<212> PRT

<213> Homo sapiens

<400> 56

```

Met Pro Leu Phe Lys Asn Thr Ser Val Ser Ser Leu Tyr Ser Gly Cys
 1           5           10          15
Arg Leu Thr Leu Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Arg Val
 20          25          30
Asp Ala Val Cys Thr His Arg Pro Asp Pro Lys Ser Pro Gly Leu Asp
 35          40          45
Arg Glu Arg Leu Tyr Trp Lys Leu Ser Gln Leu Thr His Gly Ile Thr
 50          55          60
Glu Leu Gly Pro Tyr Thr Leu Asp Arg His Ser Leu Tyr Val Asn Gly
 65          70          75          80
Phe Thr His Gln Ser Ser Met Thr Thr Thr Arg Thr Pro Asp Thr Ser
 85          90          95

```


Arg Tyr Met Ala Asp Met Gly Gln Pro Gly Ser Leu Lys Phe Asn Ile
 580 585 590
 Thr Asp Asn Val Met Lys His Leu Leu Ser Pro Leu Phe Gln Arg Ser
 595 600 605
 Ser Leu Gly Ala Arg Tyr Thr Gly Cys Arg Val Ile Ala Leu Arg Ser
 610 615 620
 Val Lys Asn Gly Ala Glu Thr Arg Val Asp Leu Leu Cys Thr Tyr Leu
 625 630 635 640
 Gln Pro Leu Ser Gly Pro Gly Leu Pro Ile Lys Gln Val Phe His Glu
 645 650 655
 Leu Ser Gln Gln Thr His Gly Ile Thr Arg Leu Gly Pro Tyr Ser Leu
 660 665 670
 Asp Lys Asp Ser Leu Tyr Leu Asn Gly Tyr Asn Glu Pro Gly Leu Asp
 675 680 685
 Glu Pro Pro Thr Thr Pro Lys Pro Ala Thr Thr Phe Leu Pro Pro Leu
 690 695 700
 Ser Glu Ala Thr Thr Ala Met Gly Tyr His Leu Lys Thr Leu Thr Leu
 705 710 715 720
 Asn Phe Thr Ile Ser Asn Leu Gln Tyr Ser Pro Asp Met Gly Lys Gly
 725 730 735
 Ser Ala Thr Phe Asn Ser Thr Glu Gly Val Leu Gln His Leu Leu Arg
 740 745 750
 Pro Leu Phe Gln Lys Ser Ser Met Gly Pro Phe Tyr Leu Gly Cys Gln
 755 760 765
 Leu Ile Ser Leu Arg Pro Glu Lys Asp Gly Ala Ala Thr Gly Val Asp
 770 775 780
 Thr Thr Cys Thr Tyr His Pro Asp Pro Val Gly Pro Gly Leu Asp Ile
 785 790 795 800
 Gln Gln Leu Tyr Trp Glu Leu Ser Gln Leu Thr His Gly Val Thr Gln
 805 810 815
 Leu Gly Phe Tyr Val Leu Asp Arg Asp Ser Leu Phe Ile Asn Gly Tyr
 820 825 830
 Ala Pro Gln Asn Leu Ser Ile Arg Gly Glu Tyr Gln Ile Asn Phe His
 835 840 845
 Ile Val Asn Trp Asn Leu Ser Asn Pro Asp Pro Thr Ser Ser Glu Tyr
 850 855 860
 Ile Thr Leu Leu Arg Asp Ile Gln Asp Lys Val Thr Thr Leu Tyr Lys
 865 870 875 880
 Gly Ser Gln Leu His Asp Thr Phe Arg Phe Cys Leu Val Thr Asn Leu
 885 890 895
 Thr Met Asp Ser Val Leu Val Thr Val Lys Ala Leu Phe Ser Ser Asn
 900 905 910
 Leu Asp Pro Ser Leu Val Glu Gln Val Phe Leu Asp Lys Thr Leu Asn
 915 920 925
 Ala Ser Phe His Trp Leu Gly Ser Thr Tyr Gln Leu Val Asp Ile His
 930 935 940
 Val Thr Glu Met Glu Ser Ser Val Tyr Gln Pro Thr Ser Ser Ser Ser
 945 950 955 960
 Thr Gln His Phe Tyr Pro Asn Phe Thr Ile Thr Asn Leu Pro Tyr Ser
 965 970 975
 Gln Asp Lys Ala Gln Pro Gly Thr Thr Asn Tyr Gln Arg Asn Lys Arg
 980 985 990
 Asn Ile Glu Asp Ala Leu Asn Gln Leu Phe Arg Asn Ser Ser Ile Lys
 995 1000 1005
 Ser Tyr Phe Ser Asp Cys Gln Val Ser Thr Phe Arg Ser Val Pro Asn
 1010 1015 1020
 Arg His His Thr Gly Val Asp Ser Leu Cys Asn Phe Ser Pro Leu Ala
 1025 1030 1035 1040
 Arg Arg Val Asp Arg Val Ala Ile Tyr Glu Glu Phe Leu Arg Met Thr
 1045 1050 1055

Arg Asn Gly Thr Gln Leu Gln Asn Phe Thr Leu Asp Arg Ser Ser Val
 1060 1065 1070
 Leu Val Asp Gly Tyr Ser Pro Asn Arg Asn Glu Pro Leu Thr Gly Asn
 1075 1080 1085
 Ser Asp Leu Pro Phe Trp Ala Val Ile Phe Ile Gly Leu Ala Gly Leu
 1090 1095 1100
 Leu Gly Leu Ile Thr Cys Leu Ile Cys Gly Val Leu Val Thr Thr Arg
 1105 1110 1115 1120
 Arg Arg Lys Lys Glu Gly Glu Tyr Asn Val Gln Gln Gln Cys Pro Gly
 1125 1130 1135
 Tyr Tyr Gln Ser His Leu Asp Leu Glu Asp Leu Gln
 1140 1145

<210> 57
 <211> 853
 <212> DNA
 <213> Homo sapiens

<400> 57
 ctagtccctga cttcacttct gatgaggaag cctctctcct tagccttcag cctttcctcc 60
 caccctgcca taagtaattt gatcctcaag aagttaaacc acacctcatt ggtccctggc 120
 taattcacca atttacaac agcaggaaat agaaacttaa gagaaatata cacttctgag 180
 aaactgaaac gacaggggaa aggaggtctc actgagcacc gtcccagcat ccggacacca 240
 cagcggccct tcgctccacg cagaaaacca cacttctcaa accttcactc aacacttctc 300
 tccccaaagc cagaagatgc acaaggagga acatgaggtg gctgtgctgg gggcaccccc 360
 cagcaccatc cttccaaggt ccaccgtgat caacatccac agcgagacct ccgtgcccga 420
 ccatgtcgtc tgggtccctgt tcaacaccct cttcttgaac tgggtgctgtc tgggcttcat 480
 agcattcgcc tactccgtga agtctagga caggaagatg gttggcgacg tgaccggggc 540
 ccaggcctat gcctccaccg ccaagtgcct gaacatctgg gccctgattc tgggcattct 600
 catgaccatt ggattcatcc tgtcactggt attcggctct gtgacagtct accatattat 660
 gttacagata atacaggaaa aacgggggta ctagtaccg cccatagcct gcaacctttg 720
 cactccactg tgcaatgctg gccctgcacg ctggggctgt tggccctgcc ccttggtcc 780
 tgccctaga tacagcagtt tatacccaca cacctgtcta cagtgtcatt caataaagtg 840
 cacgtgcttg tga 853

<210> 58
 <211> 125
 <212> PRT
 <213> Homo sapiens

<400> 58
 Met His Lys Glu Glu His Glu Val Ala Val Leu Gly Ala Pro Pro Ser
 1 5 10 15
 Thr Ile Leu Pro Arg Ser Thr Val Ile Asn Ile His Ser Glu Thr Ser
 20 25 30
 Val Pro Asp His Val Val Trp Ser Leu Phe Asn Thr Leu Phe Leu Asn
 35 40 45
 Trp Cys Cys Leu Gly Phe Ile Ala Phe Ala Tyr Ser Val Lys Ser Arg
 50 55 60
 Asp Arg Lys Met Val Gly Asp Val Thr Gly Ala Gln Ala Tyr Ala Ser
 65 70 75 80
 Thr Ala Lys Cys Leu Asn Ile Trp Ala Leu Ile Leu Gly Ile Leu Met
 85 90 95
 Thr Ile Gly Phe Ile Leu Ser Leu Val Phe Gly Ser Val Thr Val Tyr
 100 105 110
 His Ile Met Leu Gln Ile Ile Gln Glu Lys Arg Gly Tyr
 115 120 125

<210> 59
 <211> 1512

<212> DNA

<213> Homo sapiens

<400> 59

ttccggtccc	ccaggacatg	tccaatcagg	gaagtaagta	cgtcaataag	gaaattcaaa	60
atgctgtcaa	cggggtgaaa	cagataaaga	ctctcataga	aaaaacaaac	gaagagcgca	120
agacactgct	cagcaaccta	gaagaagcca	agaagaagaa	agaggatgcc	ctaaatgaga	180
ccagggaatc	agagacaaaag	ctgaaggagc	tcccaggagt	gtgcaatgag	accatgatgg	240
ccctctggga	agagtgtaaag	ccctgcctga	aacagacctg	catgaagttc	tacgcacgcg	300
tctgcagaag	tggctcaggc	ctgggtggcc	gccagcttga	ggagttcctg	aaccagagct	360
cgcccttcta	cttctgggatg	aatggtgacc	gcacgcactc	cctgctggag	aacgaccggc	420
agcagacgca	catgctggat	gtcatgcagg	accacttcag	ccgcgcgtcc	agcatcatag	480
acgagctctt	ccaggacagg	ttcttcaccc	gggagcccca	ggatacctac	cactacctgc	540
ccttcagcct	gccccaccgg	agggcctcact	tcttctttcc	caagtcccgc	atcgtccgca	600
gcttgatgcc	cttctctccg	tacgagcccc	tgaacttcca	cgccatgttc	cagcccttcc	660
ttgagatgat	acacgaggct	cagcaggcca	tggacatcca	cttcacagc	ccggccttcc	720
agcaccgcgc	aacagaattc	atacgagaag	gcgacgatga	ccggactgtg	tgccggggaga	780
tccgccacaa	ctccacgggc	tgcctgcgga	tgaaggacca	gtgtgacaag	tgccggggaga	840
tcttgctgtg	ggactgttcc	accaacaacc	cctcccaggc	taagctgcgg	cgggagctcg	900
acgaatccct	ccaggctcgt	gagagggtga	ccaggaaata	caacgagctg	ctaaagtctc	960
accagtggaa	gatgctcaac	acctctctct	tgctggagca	gctgaacgag	cagtttaact	1020
gggtgtcccg	gctggcaaac	ctcacgcaag	gcgaagacca	gtactatctg	cgggtcacca	1080
cggtggcttc	ccacacttct	gactcggacg	ttccttccgg	tgtcactgag	gtggctcgta	1140
agctctttga	ctctgatccc	atcactgtga	cggtccctgt	agaagtctcc	aggaagaacc	1200
ctaaatttat	ggagaccgtg	gcggagaaaag	cgctgcagga	ataccgcaaa	aagcaccggg	1260
aggagtgaga	tgtggatgtt	gcttttgcac	ctacgggggc	atctgagtcc	agctcccccc	1320
aagatgagct	gcagcccccc	agagagagct	ctgcacgtca	ccaagtaacc	aggccccagc	1380
ctccaggccc	ccaactccgc	ccagcctctc	cccgctctgg	atcctgcact	ctaactctcg	1440
actctgctgc	tcatgggaag	aacagaattg	ctcctgcatg	caactaattc	aataaaaactg	1500
tcttgtgagc	tg					1512

<210> 60

<211> 416

<212> PRT

<213> Homo sapiens

<400> 60

Met	Ser	Asn	Gln	Gly	Ser	Lys	Tyr	Val	Asn	Lys	Glu	Ile	Gln	Asn	Ala
1				5					10					15	
Val	Asn	Gly	Val	Lys	Gln	Ile	Lys	Thr	Leu	Ile	Glu	Lys	Thr	Asn	Glu
			20					25					30		
Glu	Arg	Lys	Thr	Leu	Leu	Ser	Asn	Leu	Glu	Glu	Ala	Lys	Lys	Lys	Lys
			35				40					45			
Glu	Asp	Ala	Leu	Asn	Glu	Thr	Arg	Glu	Ser	Glu	Thr	Lys	Leu	Lys	Glu
	50					55					60				
Leu	Pro	Gly	Val	Cys	Asn	Glu	Thr	Met	Met	Ala	Leu	Trp	Glu	Glu	Cys
65					70					75					80
Lys	Pro	Cys	Leu	Lys	Gln	Thr	Cys	Met	Lys	Phe	Tyr	Ala	Arg	Val	Cys
				85					90					95	
Arg	Ser	Gly	Ser	Gly	Leu	Val	Gly	Arg	Gln	Leu	Glu	Glu	Phe	Leu	Asn
			100					105					110		
Gln	Ser	Ser	Pro	Phe	Tyr	Phe	Trp	Met	Asn	Gly	Asp	Arg	Ile	Asp	Ser
		115					120					125			
Leu	Leu	Glu	Asn	Asp	Arg	Gln	Gln	Thr	His	Met	Leu	Asp	Val	Met	Gln
	130					135					140				
Asp	His	Phe	Ser	Arg	Ala	Ser	Ser	Ile	Ile	Asp	Glu	Leu	Phe	Gln	Asp
145					150					155					160
Arg	Phe	Phe	Thr	Arg	Glu	Pro	Gln	Asp	Thr	Tyr	His	Tyr	Leu	Pro	Phe
				165					170					175	

Ser Leu Pro His Arg Arg Pro His Phe Phe Phe Pro Lys Ser Arg Ile
 180 185 190
 Val Arg Ser Leu Met Pro Phe Ser Pro Tyr Glu Pro Leu Asn Phe His
 195 200 205
 Ala Met Phe Gln Pro Phe Leu Glu Met Ile His Glu Ala Gln Gln Ala
 210 215 220
 Met Asp Ile His Phe His Ser Pro Ala Phe Gln His Pro Pro Thr Glu
 225 230 235 240
 Phe Ile Arg Glu Gly Asp Asp Asp Arg Thr Val Cys Arg Glu Ile Arg
 245 250 255
 His Asn Ser Thr Gly Cys Leu Arg Met Lys Asp Gln Cys Asp Lys Cys
 260 265 270
 Arg Glu Ile Leu Ser Val Asp Cys Ser Thr Asn Asn Pro Ser Gln Ala
 275 280 285
 Lys Leu Arg Arg Glu Leu Asp Glu Ser Leu Gln Val Ala Glu Arg Leu
 290 295 300
 Thr Arg Lys Tyr Asn Glu Leu Leu Lys Ser Tyr Gln Trp Lys Met Leu
 305 310 315 320
 Asn Thr Ser Ser Leu Leu Glu Gln Leu Asn Glu Gln Phe Asn Trp Val
 325 330 335
 Ser Arg Leu Ala Asn Leu Thr Gln Gly Glu Asp Gln Tyr Tyr Leu Arg
 340 345 350
 Val Thr Thr Val Ala Ser His Thr Ser Asp Ser Asp Val Pro Ser Gly
 355 360 365
 Val Thr Glu Val Val Val Lys Leu Phe Asp Ser Asp Pro Ile Thr Val
 370 375 380
 Thr Val Pro Val Glu Val Ser Arg Lys Asn Pro Lys Phe Met Glu Thr
 385 390 395 400
 Val Ala Glu Lys Ala Leu Gln Glu Tyr Arg Lys Lys His Arg Glu Glu
 405 410 415

<210> 61

<211> 1564

<212> DNA

<213> Homo sapiens

<400> 61

cggacgcgtg ggcggacgcg tgggcgaggg cgcgagtgcg gagcagaccc aggcacgcgc 60
 cgccgagaag gccggagcgt cggcacctga acgcgagggc ctccattgcg cgtgcgcgctt 120
 gaggggcttc ccgcacctga tcgcgagacc ccaacggctg gtggcgctcg ctgcgcgggc 180
 gtccccacac tgccggtccg gaaaggcgac ttccgggggc tttggcacct ggcggacgct 240
 cdcggagcgt cggcacctga acgcgagggc ctccattgcg cgtgcgcgctt gaggggcttc 300
 ccgcacctga tcgcgagacc ccaacggctg gtggcgctcg ctgcgcgctt cggctgagct 360
 ggccatggcg cacctgtgcg ggctgagggc gagccggggc tttctcgccc tgctgggac 420
 gctgctctc tctgggggtcc tggcggccga ccgagaacgc agcatccacg acttctgcct 480
 ggtgtcgaag gtggtgggca gatgccgggc ctccatgcct aagtgggtgtt acaatgtcac 540
 tgacggatcc tgccagctgt ttgtgtatgg gggctgtgac ggaaacagca ataattacct 600
 gaccaaggag gagtgcctca agaaatgtgc cactgtcaca gagaatgcca cgggtgacct 660
 ggccaccagc aggaatgcag cggattcctc tgtcccaagt gctccagaa ggcaggattc 720
 tgaagaccac tccagcgata tgttcaacta tgaagaatac tgcaccgcca acgcagtcac 780
 tgggccttgc cgtgcacact tcccacgctg gtactttgac gtggagagga actcctgcaa 840
 taacttcac tatggaggct gccggggcaa taagaacagc taccgctctg aggaggcctg 900
 catgctccgc tgcttccgcc agcaggagaa tcctccccctg ccccttgggt caaagggtgt 960
 ggttctggcg gggctgttcg tgatggtgtt gatcctcttc ctgggagcct ccatggtcta 1020
 cctgatccgg gtggcacgga ggaaccagga gcgtgcccct cgcaccgtct ggagctccgg 1080
 acatgacaag gaggcagctgg tgaagaacac atatgtcctg tgaccgccct gtcgccaaga 1140
 ggactgggga agggagggga gactatgtgt gagctttttt taaatagcgg gattgactcg 1200
 gatttgagt atcattaggg ctgaggtgtg tttctctggg aggtaggacg gctgcttctc 1260
 ggtctggcag ggatgggttt gctttggaaa tcctctagga ggctcctcct cgcagtgcc 1320
 gcagtctggc agcagccccg agttgtttcc tcgctgatcg atttctttcc tccaggtaga 1380

gttttctttg cttatgttga attccattgc ctcttttctc atcacagaag tgatgttggg 1440
 atcgtttctt ttgtttgtct gatttatggg ttttttaagt ataaacaaaa gttttttatt 1500
 aacatctgaa agaaggaaag taaaatgtac aagttaata aaaaggggcc ttccccttta 1560
 gaat 1564

<210> 62

<211> 252

<212> PRT

<213> Homo sapiens

<400> 62

Met Ala His Leu Cys Gly Leu Arg Arg Ser Arg Ala Phe Leu Ala Leu
 1 5 10 15
 Leu Gly Ser Leu Leu Leu Ser Gly Val Leu Ala Ala Asp Arg Glu Arg
 20 25 30
 Ser Ile His Asp Phe Cys Leu Val Ser Lys Val Val Gly Arg Cys Arg
 35 40 45
 Ala Ser Met Pro Lys Trp Trp Tyr Asn Val Thr Asp Gly Ser Cys Gln
 50 55 60
 Leu Phe Val Tyr Gly Gly Cys Asp Gly Asn Ser Asn Asn Tyr Leu Thr
 65 70 75 80
 Lys Glu Glu Cys Leu Lys Lys Cys Ala Thr Val Thr Glu Asn Ala Thr
 85 90 95
 Gly Asp Leu Ala Thr Ser Arg Asn Ala Ala Asp Ser Ser Val Pro Ser
 100 105 110
 Ala Pro Arg Arg Gln Asp Ser Glu Asp His Ser Ser Asp Met Phe Asn
 115 120 125
 Tyr Glu Glu Tyr Cys Thr Ala Asn Ala Val Thr Gly Pro Cys Arg Ala
 130 135 140
 Ser Phe Pro Arg Trp Tyr Phe Asp Val Glu Arg Asn Ser Cys Asn Asn
 145 150 155 160
 Phe Ile Tyr Gly Gly Cys Arg Gly Asn Lys Asn Ser Tyr Arg Ser Glu
 165 170 175
 Glu Ala Cys Met Leu Arg Cys Phe Arg Gln Gln Glu Asn Pro Pro Leu
 180 185 190
 Pro Leu Gly Ser Lys Val Val Val Leu Ala Gly Leu Phe Val Met Val
 195 200 205
 Leu Ile Leu Phe Leu Gly Ala Ser Met Val Tyr Leu Ile Arg Val Ala
 210 215 220
 Arg Arg Asn Gln Glu Arg Ala Leu Arg Thr Val Trp Ser Ser Gly His
 225 230 235 240
 Asp Lys Glu Gln Leu Val Lys Asn Thr Tyr Val Leu
 245 250

<210> 63

<211> 1147

<212> DNA

<213> Homo sapiens

<400> 63

ggacgtcctt ccccaggagc cgactggcca atcacaggca ggaagatgaa ggttctgtgg 60
 gctgcgttgc tggtcacatt cctggcagga tgccaggcca aggtggagca agcgggtggag 120
 acagagccgg agcccagact gcgccagcag accgagtggc agagcggcca gcgctgggaa 180
 ctggcactgg gtcgcttttg ggattacctg cgctgggtgc agacactgtc tgagcaggtg 240
 caggaggagc tgctcagctc ccaggtcacc caggaaactga gggcgctgat ggacgagacc 300
 atgaaggagt tgaaggccta caaatcggaa ctggaggaaac aactgacccc ggtggcggag 360
 gagacgcggg caccgctgtc caaggagctg caggcggcgc aggcccggtc gggcgcgagc 420
 atggaggacg tgtgcggccg cctggtgcag taccgcggcg aggtgcaggc catgctcggc 480
 cagagcaccg aggagctgcg ggtgcgctc gcctccacc tcgcgaagct gcgtaagcgg 540
 ctctccgcg atgccgatga cctgcagaag cgctggcag tgtaccaggc cggggccccg 600

```

gagggcgccg agcgcgccct cagcgccatc cgcgagcgcc tggggcccct ggtggaacag      660
ggccgcgtgc gggccgccac tgtgggctcc ctggccggcc agccgctaca ggagcgggcc      720
caggcctggg gcgagcggct gcgcgcgcgg atggaggaga tgggcagccg gaccgcgcac      780
cgcttggaag aggtgaagga gcaggtggcg gaggtgcgcg ccaagctgga ggagcaggcc      840
cagcagatac gcctgcaggc cgaggccttc caggcccgcc tcaagagctg gttcgagccc      900
ctggtggaag acatgcagcg ccagtgggccc gggctgggtg agaaggtgca ggctgccgtg      960
ggcaccagcg ccgcccctgt gccacgcgac aatcactgaa cgccgaagcc tgcagccatg     1020
cgacccacag ccaccccgtg cctcctgcct ccgcgcagcc tgcagcggga gaccctgtcc     1080
ccgcccacgc cgtcctcctg ggttggaacc tagtttaata aagattcacc aagtttcacg     1140
caaaaaa

```

<210> 64

<211> 317

<212> PRT

<213> Homo sapiens

<400> 64

```

Met Lys Val Leu Trp Ala Ala Leu Leu Val Thr Phe Leu Ala Gly Cys
 1          5          10          15
Gln Ala Lys Val Glu Gln Ala Val Glu Thr Glu Pro Glu Pro Glu Leu
 20          25          30
Arg Gln Gln Thr Glu Trp Gln Ser Gly Gln Arg Trp Glu Leu Ala Leu
 35          40          45
Gly Arg Phe Trp Asp Tyr Leu Arg Trp Val Gln Thr Leu Ser Glu Gln
 50          55          60
Val Gln Glu Glu Leu Leu Ser Ser Gln Val Thr Gln Glu Leu Arg Ala
 65          70          75          80
Leu Met Asp Glu Thr Met Lys Glu Leu Lys Ala Tyr Lys Ser Glu Leu
 85          90          95
Glu Glu Gln Leu Thr Pro Val Ala Glu Glu Thr Arg Ala Arg Leu Ser
100          105          110
Lys Glu Leu Gln Ala Ala Gln Ala Arg Leu Gly Ala Asp Met Glu Asp
115          120          125
Val Cys Gly Arg Leu Val Gln Tyr Arg Gly Glu Val Gln Ala Met Leu
130          135          140
Gly Gln Ser Thr Glu Glu Leu Arg Val Arg Leu Ala Ser His Leu Arg
145          150          155          160
Lys Leu Arg Lys Arg Leu Leu Arg Asp Ala Asp Asp Leu Gln Lys Arg
165          170          175
Leu Ala Val Tyr Gln Ala Gly Ala Arg Glu Gly Ala Glu Arg Gly Leu
180          185          190
Ser Ala Ile Arg Glu Arg Leu Gly Pro Leu Val Glu Gln Gly Arg Val
195          200          205
Arg Ala Ala Thr Val Gly Ser Leu Ala Gly Gln Pro Leu Gln Glu Arg
210          215          220
Ala Gln Ala Trp Gly Glu Arg Leu Arg Ala Arg Met Glu Glu Met Gly
225          230          235          240
Ser Arg Thr Arg Asp Arg Leu Asp Glu Val Lys Glu Gln Val Ala Glu
245          250          255
Val Arg Ala Lys Leu Glu Glu Gln Ala Gln Gln Ile Arg Leu Gln Ala
260          265          270
Glu Ala Phe Gln Ala Arg Leu Lys Ser Trp Phe Glu Pro Leu Val Glu
275          280          285
Asp Met Gln Arg Gln Trp Ala Gly Leu Val Glu Lys Val Gln Ala Ala
290          295          300
Val Gly Thr Ser Ala Ala Pro Val Pro Ser Asp Asn His
305          310          315

```

<210> 65

<211> 2493

<212> DNA

<213> Homo sapiens

<400> 65

```

ggatcgattt gagtaagagc atagctgtcg ggagagccca ggattcaaca cgggccttga      60
gaaatgtggc tcttgtacct cctgggtgccg gccctgttct gcagggcagg aggtccatt      120
cccatccctc agaagttatt tggggagggtg acttcccctc tgttcccaa gccttaccce      180
aacaactttg aaacaaccac tgtgatcaca gtccccacgg gatacagggt gaagctcgtc      240
ttccagcagt ttgacctgga gccttctgaa ggctgttct atgattatgt caagatctct      300
gctgataaga aaagcctggg gaggttctgt gggcaactgg gttctccact gggcaacccc      360
ccgggaaaga aggaatttat gtcccaaggg aacaagatgc tgctgacctt ccacacagac      420
ttctccaacg aggagaatgg gaccatcatg ttctacaagg gcttcctggc ctactacca      480
gctgtggacc ttgatgaatg tgcttcccg agcaaatacagg gggaggagga tccccagccc      540
cagtgccagc acctgtgtca caactacgtt ggaggctact tctgttcctg ccgtccaggc      600
tatgagcttc aggaagacag gcattcctgc caggctgagt gcagcagcga gctgtacacg      660
gaggcatcag gctacatctc cagcctggag taccctcggt cctaccccc tgacctgcgc      720
tgcaactaca gcatccgggt ggagcggggc ctaccctgc acctcaagtt cctggagcct      780
tttgatattg atgaccacca gcaagtacac tgccccatg accagctaca gatctatgcc      840
aacgggaaga acattggcga gttctgtggg aagcaaaggc cccccgacct cgacaccagc      900
agcaatgctg tggatctgct gttcttcaca gatgagtcgg gggacagccg gggctggaag      960
ctgcgctaca ccaccgagat catcaagtgc cccagccca agaccctaga cgagttcacc     1020
atcatccaga acctgcagcc tcagtaccag ttccgtgact acttcattgc tacctgcaag     1080
caaggctacc agctcataga ggggaaccag gtgctgcatt ccttcacagc tgtctgccag     1140
gatgatggca cgtggcatcg tgccatgcc agatgcaaga tcaaggactg tgggcagccc     1200
cgaaacctgc ctaatggtga cttccgttac accaccacaa tgggagtga cacctacaag     1260
gcccgtatcc agtactactg ccatgagcca tattacaaga tgcagaccag agctggcagc     1320
agggagtctg agcaagggtg gtacacctgc acagcacagg gcatttggaa gaatgaacag     1380
aaggagagaga agattcctcg gtgcttgcca gtgtgtggga agcccgtgaa ccccgaggaa     1440
cagaggcagc gcataatcgg agggcaaaaa gccaagatgg gcaacttccc ctggcaggtg     1500
ttaccaaca tccacgggcg cgggggaggg gccctgctgg gcgacgctg gatcctcaca     1560
gctgccca cctgtatcc caaggaacac gaagcgcaa gcaacgcctc tttggatgtg     1620
ttcctgggccc acacaaatgt ggaagagctc atgaagctag gaaatcacc catccgcagg     1680
gtcagcgctc acccgacta ccgtcaggat gagtcctaca attttgaggg ggacatcgcc     1740
ctgctggagc tggaaaatag tgtcacctc ggtcccaacc tctcccat ctgcctccct     1800
gacaacgata ctttctacga cctgggcttg atgggctatg tcagtggctt cggggctcatg     1860
gaggagaaga ttgctcatga cctcaggttt gtccgtctgc ccgtagctaa tccacaggcc     1920
tgtgagaact ggctccgggg aaagaatagg atggatgtgt tctctcaaaa catgttctgt     1980
gctggacacc catctctaaa gcaggacgcc tgccaggggg atagtggggg cgtttttgca     2040
gtaagggacc cgaacactga tcgctgggtg gccacgggca tcgtgtcctg gggcatcggg     2100
tgcagcaggg gctatggctt ctacaccaa gtgctcaact acgtggactg gatcaagaaa     2160
gagatggagg agggaggact agcccagaat tcactagggt cgaatccaga gagcagtgtg     2220
gaaaaaaaaa aaacaaaaaa caactgacca gttgttgata accactaaga gtctctatta     2280
aaattactga tgcagaaaga ccgtgtgtga aattctctt cctgtagtcc cattgatgta     2340
ctttacctga aacaaccaa agggcccttt ctttctcttg aggattgcag aggatatagt     2400
tatcaatctc tagttgtcac tttcctcttc cactttgata ccattgggtc attgaatata     2460
actttttcca aataaagttt tatgagaaat gcc                                     2493

```

<210> 66

<211> 705

<212> PRT

<213> Homo sapiens

<400> 66

```

Met Trp Leu Leu Tyr Leu Leu Val Pro Ala Leu Phe Cys Arg Ala Gly
 1              5              10              15
Gly Ser Ile Pro Ile Pro Gln Lys Leu Phe Gly Glu Val Thr Ser Pro
      20              25              30
Leu Phe Pro Lys Pro Tyr Pro Asn Asn Phe Glu Thr Thr Thr Val Ile
      35              40              45

```

Thr	Val	Pro	Thr	Gly	Tyr	Arg	Val	Lys	Leu	Val	Phe	Gln	Gln	Phe	Asp
50						55					60				
Leu	Glu	Pro	Ser	Glu	Gly	Cys	Phe	Tyr	Asp	Tyr	Val	Lys	Ile	Ser	Ala
65					70					75					80
Asp	Lys	Lys	Ser	Leu	Gly	Arg	Phe	Cys	Gly	Gln	Leu	Gly	Ser	Pro	Leu
				85					90					95	
Gly	Asn	Pro	Pro	Gly	Lys	Lys	Glu	Phe	Met	Ser	Gln	Gly	Asn	Lys	Met
			100					105					110		
Leu	Leu	Thr	Phe	His	Thr	Asp	Phe	Ser	Asn	Glu	Glu	Asn	Gly	Thr	Ile
		115					120					125			
Met	Phe	Tyr	Lys	Gly	Phe	Leu	Ala	Tyr	Tyr	Gln	Ala	Val	Asp	Leu	Asp
	130					135					140				
Glu	Cys	Ala	Ser	Arg	Ser	Lys	Ser	Gly	Glu	Glu	Asp	Pro	Gln	Pro	Gln
145					150					155					160
Cys	Gln	His	Leu	Cys	His	Asn	Tyr	Val	Gly	Gly	Tyr	Phe	Cys	Ser	Cys
				165					170					175	
Arg	Pro	Gly	Tyr	Glu	Leu	Gln	Glu	Asp	Arg	His	Ser	Cys	Gln	Ala	Glu
			180					185					190		
Cys	Ser	Ser	Glu	Leu	Tyr	Thr	Glu	Ala	Ser	Gly	Tyr	Ile	Ser	Ser	Leu
		195					200					205			
Glu	Tyr	Pro	Arg	Ser	Tyr	Pro	Pro	Asp	Leu	Arg	Cys	Asn	Tyr	Ser	Ile
	210					215					220				
Arg	Val	Glu	Arg	Gly	Leu	Thr	Leu	His	Leu	Lys	Phe	Leu	Glu	Pro	Phe
225					230					235					240
Asp	Ile	Asp	Asp	His	Gln	Gln	Val	His	Cys	Pro	Tyr	Asp	Gln	Leu	Gln
				245					250					255	
Ile	Tyr	Ala	Asn	Gly	Lys	Asn	Ile	Gly	Glu	Phe	Cys	Gly	Lys	Gln	Arg
			260					265					270		
Pro	Pro	Asp	Leu	Asp	Thr	Ser	Ser	Asn	Ala	Val	Asp	Leu	Leu	Phe	Phe
		275					280					285			
Thr	Asp	Glu	Ser	Gly	Asp	Ser	Arg	Gly	Trp	Lys	Leu	Arg	Tyr	Thr	Thr
	290					295					300				
Glu	Ile	Ile	Lys	Cys	Pro	Gln	Pro	Lys	Thr	Leu	Asp	Glu	Phe	Thr	Ile
305					310					315					320
Ile	Gln	Asn	Leu	Gln	Pro	Gln	Tyr	Gln	Phe	Arg	Asp	Tyr	Phe	Ile	Ala
				325					330					335	
Thr	Cys	Lys	Gln	Gly	Tyr	Gln	Leu	Ile	Glu	Gly	Asn	Gln	Val	Leu	His
			340					345					350		
Ser	Phe	Thr	Ala	Val	Cys	Gln	Asp	Asp	Gly	Thr	Trp	His	Arg	Ala	Met
	355						360					365			
Pro	Arg	Cys	Lys	Ile	Lys	Asp	Cys	Gly	Gln	Pro	Arg	Asn	Leu	Pro	Asn
	370					375					380				
Gly	Asp	Phe	Arg	Tyr	Thr	Thr	Thr	Met	Gly	Val	Asn	Thr	Tyr	Lys	Ala
385					390					395					400
Arg	Ile	Gln	Tyr	Tyr	Cys	His	Glu	Pro	Tyr	Tyr	Lys	Met	Gln	Thr	Arg
				405					410					415	
Ala	Gly	Ser	Arg	Glu	Ser	Glu	Gln	Gly	Val	Tyr	Thr	Cys	Thr	Ala	Gln
			420					425					430		
Gly	Ile	Trp	Lys	Asn	Glu	Gln	Lys	Gly	Glu	Lys	Ile	Pro	Arg	Cys	Leu
	435						440					445			
Pro	Val	Cys	Gly	Lys	Pro	Val	Asn	Pro	Val	Glu	Gln	Arg	Gln	Arg	Ile
	450					455					460				
Ile	Gly	Gly	Gln	Lys	Ala	Lys	Met	Gly	Asn	Phe	Pro	Trp	Gln	Val	Phe
465					470					475					480
Thr	Asn	Ile	His	Gly	Arg	Gly	Gly	Gly	Ala	Leu	Leu	Gly	Asp	Arg	Trp
				485					490					495	
Ile	Leu	Thr	Ala	Ala	His	Thr	Leu	Tyr	Pro	Lys	Glu	His	Glu	Ala	Gln
			500					505					510		
Ser	Asn	Ala	Ser	Leu	Asp	Val	Phe	Leu	Gly	His	Thr	Asn	Val	Glu	Glu
		515					520						525		

Leu Met Lys Leu Gly Asn His Pro Ile Arg Arg Val Ser Val His Pro
 530 535 540
 Asp Tyr Arg Gln Asp Glu Ser Tyr Asn Phe Glu Gly Asp Ile Ala Leu
 545 550 555 560
 Leu Glu Leu Glu Asn Ser Val Thr Leu Gly Pro Asn Leu Leu Pro Ile
 565 570 575
 Cys Leu Pro Asp Asn Asp Thr Phe Tyr Asp Leu Gly Leu Met Gly Tyr
 580 585 590
 Val Ser Gly Phe Gly Val Met Glu Glu Lys Ile Ala His Asp Leu Arg
 595 600 605
 Phe Val Arg Leu Pro Val Ala Asn Pro Gln Ala Cys Glu Asn Trp Leu
 610 615 620
 Arg Gly Lys Asn Arg Met Asp Val Phe Ser Gln Asn Met Phe Cys Ala
 625 630 635 640
 Gly His Pro Ser Leu Lys Gln Asp Ala Cys Gln Gly Asp Ser Gly Gly
 645 650 655
 Val Phe Ala Val Arg Asp Pro Asn Thr Asp Arg Trp Val Ala Thr Gly
 660 665 670
 Ile Val Ser Trp Gly Ile Gly Cys Ser Arg Gly Tyr Gly Phe Tyr Thr
 675 680 685
 Lys Val Leu Asn Tyr Val Asp Trp Ile Lys Lys Glu Met Glu Glu Glu
 690 695 700
 Asp
 705

<210> 67
 <211> 777
 <212> DNA
 <213> Homo sapiens

<400> 67
 gctccgggct gaagattgct tctcttctct cctccaaggt ctagtgacgg agcccgcgcg 60
 cgcgccacca tgcggcagaa ggcggtatcc gttttcttgt gctacctgct gctcttcact 120
 tgcagtgggg tggaggcagg taagaaaaag tgctcggaga gctcggacag cggctccggg 180
 ttctggaagg ccctgacctt catggccgctc ggaggaggac tgcagtcgc cgggtgccc 240
 gcgctgggct tcaccggcgc cggcatcgcg gccaaactcgg tggctgcctc gctgatgagc 300
 tggctctgca tcttgaatgg gggcggcgctg cccgccgggg ggctagtggc cacgtgcag 360
 agcctcgggg ctggtggcag cagcgtcgctc ataggtaata ttggtgccct gatcggtac 420
 gccaccaca agtatctcga tagtgaggag gatgaggagt agccagcagc tcccagaacc 480
 tcttcttctt tcttggccta actcttccag ttaggatcta gaactttgcc tttttttttt 540
 tttttttttt tttgagatgg gttctcacta tattgtccag gctagagtgc agtggctatt 600
 cacagatgcg aacatagtag actgcagcct ccaactccta gcctcaagtg atcctcctgt 660
 ctcaacctcc caagtaggat tacaagcatg cgccgacgat gcccagaatc cagaactttg 720
 tctatcactc tcccacaaca cctagatgtg aaaacagaat aaacttcacc cagaaaa 777

<210> 68
 <211> 130
 <212> PRT
 <213> Homo sapiens

<400> 68
 Met Arg Gln Lys Ala Val Ser Val Phe Leu Cys Tyr Leu Leu Leu Phe
 1 5 10 15
 Thr Cys Ser Gly Val Glu Ala Gly Lys Lys Lys Cys Ser Glu Ser Ser
 20 25 30
 Asp Ser Gly Ser Gly Phe Trp Lys Ala Leu Thr Phe Met Ala Val Gly
 35 40 45
 Gly Gly Leu Ala Val Ala Gly Leu Pro Ala Leu Gly Phe Thr Gly Ala
 50 55 60

Gly Ile Ala Ala Asn Ser Val Ala Ala Ser Leu Met Ser Trp Ser Ala
 65 70 75 80
 Ile Leu Asn Gly Gly Gly Val Pro Ala Gly Gly Leu Val Ala Thr Leu
 85 90 95
 Gln Ser Leu Gly Ala Gly Gly Ser Ser Val Val Ile Gly Asn Ile Gly
 100 105 110
 Ala Leu Met Arg Tyr Ala Thr His Lys Tyr Leu Asp Ser Glu Glu Asp
 115 120 125
 Glu Glu
 130

<210> 69

<211> 2402

<212> DNA

<213> Homo sapiens

<400> 69

```

agtctccgcc gccgccgtga acatggagcc cccggacgca cgggccagg cgcgcggggc      60
cccgcggtct ctgttgctcg cagtcctgct ggcggcgcac ccagatgcc aggcggagg      120
gcgcttgctt gtacccccgc tgggtggagg gatgcgagga aagtctgtca ttctggactg      180
caccctacg ggaacccacg accattatat gctggaatgg ttcttaccg accgctcggg      240
agctcgcccc cgcctagcct cggctgagat gcagggctct gagctccagg tcacaatgca      300
cgacaccgag gccgcagtc ccccatacca gctggactcc caggggagcc tgggtgctggc      360
tgaggccag gtgggcgagc agcgagacta cgtgtgcgtg gtgagggcag gggcggcagg      420
cactgctgag gccactgcgc ggctcaacgt gtttgcaaag ccagaggcca ctgaggctctc      480
ccccacaaca gggacactgt ctgtgatgga ggactctgcc caggagatcg ccacctgcaa      540
cagccggaac gggaaaccgg cccccaagat cactgtgtat cgcaacgggc agcgccctgga      600
ggtgcccgtg gagatgaacc cagagggcta catgaccagc cgcaacgggc agcgccctgga      660
gggcctgctc tccctacca gacacctcta cctgcggctc cgcaaggatg accgagacgc      720
cagcttccac tgcgcgccc actacagcct gcccaggggc cgccacggcc gcctggacag      780
ccccaccttc cactcacc tgcactatcc caccgagcac gtgcagttct ggggtgggcag      840
cccgctccacc ccagcaggct gggtagcgga gggtagact gtccagctgc tctgcccggg      900
ggacggcagc cccagcccg agtatacgt tttccgcctt caggatgagc aggaggaagt      960
gctgaatgtg aatctcgagg ggaacttgac cctggaggga gtgacccggg gccagagcgg      1020
gacctatggc tgcagagtgg aggattacga cgcggcagat gacgtgcagc tctccaagac      1080
gctggcagtg agcgtggcct atctggacc cctggagctc agcgagggga aggtgctttc      1140
cttacctcta aacagcagtg cagtcgtgaa ctgctccgtg caccggcctgc ccacctctgc      1200
cctacgctgg accaaggact cactccctt gggcgatggc cccatgctgt cgctcagttc      1260
tatcaccttc gattccaatg gcacctacgt atgtgaggcc tccctgccc cagtcccgtt      1320
cctcagccgc acccagaact tcacgctgct ggtccaaggc tcgccagagc taaagacagc      1380
ggaaatagag cccaaggcag atggcagctg gaggggaagga gacgaagtca cactcatctg      1440
ctctgcccgc ggccatccag accccaaact cagctggagc caattggggg gcagccccgc      1500
agagccaatc cccggacggc aggggttgggt gagcagctct ctgaccctga aagtgaccag      1560
cgccctgagc cgcatggca tctcctgtga agcctccaac cccacgggga acaagcgcca      1620
tgtcttccac ttcggcgccg tgagccccc gacctcccag gctggagtgg ccgtcatggc      1680
cgtggcgtc agcgtggccc tctgtcctt cgtcgttgct gtcttctact gcgtgagacg      1740
caaagggggc cctgctgcc gccagcggcg ggagaagggg gctccgccc caggggagcc      1800
agggtgagc cactcggggt cggagcaacc agagcagacc ggccttctca tgggagggtg      1860
ctccggagga gccaggggtg gcagcggggg cttcggagac gactgctgag ccaagaacct      1920
cctagaggct gtccctggac ctggagctgc aggcacaga gaaccagccc tgctcacgcc      1980
atgcccgcgc cgccttccc tcttccctct tccctctccc tgcccagccc tcccttccct      2040
cctctgcccg caaggcaggg acccacagt gctgcctgcc tccgggaggg aaggagaggg      2100
agggtgggtg ggtgggaggg ggccttccct cagggaatgt gactctccca ggccccagaa      2160
tagctccttg acccaagccc aaggcccagc ctgggacaag gctccgaggg tcggctggcc      2220
ggagctatct ttacctccc cctcccctgc tgggtccccc acctgacgtc ttgctgcaga      2280
gtctgacact ggattcccc cctcacccc gccctgggtc cactcctgc cccgccta      2340
cctccgcccc accccatcat ctgtggacac tggagtctgg aataaatgct gtttgtcaca      2400
tc

```

<210> 70

<211> 628
 <212> PRT
 <213> Homo sapiens

<400> 70

Met	Glu	Pro	Pro	Asp	Ala	Pro	Ala	Gln	Ala	Arg	Gly	Ala	Pro	Arg	Leu
1				5					10					15	
Leu	Leu	Leu	Ala	Val	Leu	Leu	Ala	Ala	His	Pro	Asp	Ala	Gln	Ala	Glu
			20					25					30		
Val	Arg	Leu	Ser	Val	Pro	Pro	Leu	Val	Glu	Val	Met	Arg	Gly	Lys	Ser
		35					40					45			
Val	Ile	Leu	Asp	Cys	Thr	Pro	Thr	Gly	Thr	His	Asp	His	Tyr	Met	Leu
	50				55					60					
Glu	Trp	Phe	Leu	Thr	Asp	Arg	Ser	Gly	Ala	Arg	Pro	Arg	Leu	Ala	Ser
65					70				75					80	
Ala	Glu	Met	Gln	Gly	Ser	Glu	Leu	Gln	Val	Thr	Met	His	Asp	Thr	Arg
			85					90						95	
Gly	Arg	Ser	Pro	Pro	Tyr	Gln	Leu	Asp	Ser	Gln	Gly	Arg	Leu	Val	Leu
			100					105					110		
Ala	Glu	Ala	Gln	Val	Gly	Asp	Glu	Arg	Asp	Tyr	Val	Cys	Val	Val	Arg
		115					120					125			
Ala	Gly	Ala	Ala	Gly	Thr	Ala	Glu	Ala	Thr	Ala	Arg	Leu	Asn	Val	Phe
	130					135					140				
Ala	Lys	Pro	Glu	Ala	Thr	Glu	Val	Ser	Pro	Asn	Lys	Gly	Thr	Leu	Ser
145					150					155					160
Val	Met	Glu	Asp	Ser	Ala	Gln	Glu	Ile	Ala	Thr	Cys	Asn	Ser	Arg	Asn
			165					170						175	
Gly	Asn	Pro	Ala	Pro	Lys	Ile	Thr	Trp	Tyr	Arg	Asn	Gly	Gln	Arg	Leu
		180						185					190		
Glu	Val	Pro	Val	Glu	Met	Asn	Pro	Glu	Gly	Tyr	Met	Thr	Ser	Arg	Thr
		195				200						205			
Val	Arg	Glu	Ala	Ser	Gly	Leu	Leu	Ser	Leu	Thr	Ser	Thr	Leu	Tyr	Leu
	210					215					220				
Arg	Leu	Arg	Lys	Asp	Asp	Arg	Asp	Ala	Ser	Phe	His	Cys	Ala	Ala	His
225					230					235					240
Tyr	Ser	Leu	Pro	Glu	Gly	Arg	His	Gly	Arg	Leu	Asp	Ser	Pro	Thr	Phe
			245					250						255	
His	Leu	Thr	Leu	His	Tyr	Pro	Thr	Glu	His	Val	Gln	Phe	Trp	Val	Gly
		260						265					270		
Ser	Pro	Ser	Thr	Pro	Ala	Gly	Trp	Val	Arg	Glu	Gly	Asp	Thr	Val	Gln
		275					280					285			
Leu	Leu	Cys	Arg	Gly	Asp	Gly	Ser	Pro	Ser	Pro	Glu	Tyr	Thr	Leu	Phe
	290					295					300				
Arg	Leu	Gln	Asp	Glu	Gln	Glu	Glu	Val	Leu	Asn	Val	Asn	Leu	Glu	Gly
305					310					315					320
Asn	Leu	Thr	Leu	Glu	Gly	Val	Thr	Arg	Gly	Gln	Ser	Gly	Thr	Tyr	Gly
			325					330						335	
Cys	Arg	Val	Glu	Asp	Tyr	Asp	Ala	Ala	Asp	Asp	Val	Gln	Leu	Ser	Lys
			340					345					350		
Thr	Leu	Glu	Leu	Arg	Val	Ala	Tyr	Leu	Asp	Pro	Leu	Glu	Leu	Ser	Glu
		355					360					365			
Gly	Lys	Val	Leu	Ser	Leu	Pro	Leu	Asn	Ser	Ser	Ala	Val	Val	Asn	Cys
	370					375					380				
Ser	Val	His	Gly	Leu	Pro	Thr	Pro	Ala	Leu	Arg	Trp	Thr	Lys	Asp	Ser
385					390					395					400
Thr	Pro	Leu	Gly	Asp	Gly	Pro	Met	Leu	Ser	Leu	Ser	Ser	Ile	Thr	Phe
			405					410						415	
Asp	Ser	Asn	Gly	Thr	Tyr	Val	Cys	Glu	Ala	Ser	Leu	Pro	Thr	Val	Pro
			420					425					430		

Val Leu Ser Arg Thr Gln Asn Phe Thr Leu Leu Val Gln Gly Ser Pro
 435 440 445
 Glu Leu Lys Thr Ala Glu Ile Glu Pro Lys Ala Asp Gly Ser Trp Arg
 450 455 460
 Glu Gly Asp Glu Val Thr Leu Ile Cys Ser Ala Arg Gly His Pro Asp
 465 470 475 480
 Pro Lys Leu Ser Trp Ser Gln Leu Gly Gly Ser Pro Ala Glu Pro Ile
 485 490 495
 Pro Gly Arg Gln Gly Trp Val Ser Ser Ser Leu Thr Leu Lys Val Thr
 500 505 510
 Ser Ala Leu Ser Arg Asp Gly Ile Ser Cys Glu Ala Ser Asn Pro His
 515 520 525
 Gly Asn Lys Arg His Val Phe His Phe Gly Ala Val Ser Pro Gln Thr
 530 535 540
 Ser Gln Ala Gly Val Ala Val Met Ala Val Ala Val Ser Val Gly Leu
 545 550 555 560
 Leu Leu Leu Val Val Ala Val Phe Tyr Cys Val Arg Arg Lys Gly Gly
 565 570 575
 Pro Cys Cys Arg Gln Arg Arg Glu Lys Gly Ala Pro Pro Pro Gly Glu
 580 585 590
 Pro Gly Leu Ser His Ser Gly Ser Glu Gln Pro Glu Gln Thr Gly Leu
 595 600 605
 Leu Met Gly Gly Ala Ser Gly Gly Ala Arg Gly Gly Ser Gly Gly Phe
 610 615 620
 Gly Asp Glu Cys
 625

<210> 71

<211> 5460

<212> DNA

<213> Homo sapiens

<400> 71

cgggcccggt	gctgaagggc	aggggaacaac	ttgatgggtgc	tacttttgaac	tgctttttctt	60
ttctcctttt	tgcacaaaga	gtctcatgtc	tgatatttag	acatgatgag	ctttgtgcaa	120
aaggggagct	ggctacttct	cgtctgtgct	catcccacta	ttattttggc	acaacaggaa	180
gctgttgaag	gaggatgttc	ccatcttggt	cagtcctatg	cggatagaga	tgtctggaag	240
ccagaaccat	gccaaatatg	tgtctgtgac	tcaggatccg	ttctctgcga	tgacataata	300
tgtgacgatc	aagaattaga	ctgccccaac	ccagaaattc	catttggaga	atgttgtgca	360
gtttgcccac	agcctccaac	tgtctctact	cgccctccta	atggtcaagg	acctcaaggc	420
cccaaggagg	atccaggccc	tcctgggtatt	cctggggagaa	atggtgaccc	tggtattcca	480
ggacaaccag	ggtcccctgg	ttctcctggc	ccccctggaa	tctgtgaatc	atgccctact	540
ggtcctcaga	actattctcc	ccagtatgat	tcatatgatg	tcaagtctgg	agtagcagta	600
ggaggactcg	caggctatcc	tggaccagct	ggccccccag	gccctcccgg	tccccctggt	660
acatctggtc	atcctgggtc	ccctggatct	ccaggatacc	aaggaccccc	tggtgaacct	720
gggcaagctg	gtccttcagg	ccctccaggga	cctcctgggtg	ctatagggtcc	atctgggtcct	780
gctggaaaag	atggagaatc	aggtagaccc	ggacgacctg	gagagcgagg	attgcctgga	840
cctccaggta	tcaaaggctc	agctgggata	ctgggatcc	ctgggatgaa	aggacacaga	900
ggcttcgatg	gacgaaatgg	agaaaagggt	gaaacagggtg	ctcctggatt	aaagggtgaa	960
aatggtcttc	caggcgaaaa	tggagctcct	ggacccatgg	gtccaagagg	ggctcctggt	1020
gagcgaggac	ggccaggact	tcctggggct	gcagggtgctc	ggggtaatga	cgggtgctcga	1080
ggcagtgatg	gtcaaccagg	ccctcctggt	cctcctggaa	ctgccggatt	ccctggatcc	1140
cctgggtgcta	aggggtgaagt	tggacctgca	gggtctcctg	gttcaaattgg	tgcccctgga	1200
caaagaggag	aacctggacc	tcaggggacac	gctgggtgctc	aaggctcctcc	tggccctcct	1260
gggattaatg	gtagtccctgg	tggtaaaggc	gaaatgggtc	ccgctggcat	tcctggagct	1320
cctggactga	tgggagcccg	gggtcctcca	ggaccagccg	gtgctaattgg	tgtccttgga	1380
ctgcgaggtg	gtgcaggtga	gcctggtaag	aatgggtgcca	aaggagagcc	cggaccacgt	1440
ggtgaacgctg	gtgaggctgg	tattccaggt	gttccaggag	ctaaaggcga	agatggcaag	1500
gatggatcac	ctggagaacc	tggtgcaaat	gggcttccag	gagctgcagg	agaaaggggt	1560
gccctgggtg	tccgaggacc	tgtctggacca	aatggcatcc	caggagaaaa	gggtcctgct	1620

ggagagcgtg	gtgctccagg	ccctgcaggg	cccagaggag	ctgctggaga	acctggcaga	1680
gatggcgtcc	ctggaggtcc	aggaatgagg	ggcatgcccc	gaagtccagg	aggaccagga	1740
agtgatggga	aaccagggcc	tcccggaggt	caaggagaaa	gtggtcgacc	aggtcctcct	1800
gggccatctg	gtccccgagg	tcagcctggt	gtcatgggct	tccccgggtcc	taaaggaaat	1860
gatggtgctc	ctggtaagaa	tggagaacga	ggtggccctg	gaggacctgg	ccctcagggg	1920
cctcctggaa	agaatggtga	aactggacct	caaggacccc	cagggcctac	tgggcctggt	1980
ggtgacaaag	gagacacagg	accccctggt	ccacaaggat	tacaaggctt	gcctggtaca	2040
ggtggtcctc	caggagaaaa	tggaaaacct	ggggaaccag	gtccaaaggg	tgatgccggg	2100
gcacctggag	ctccaggagg	caagggtgat	gctggtgccc	ctggtgaacg	tggacctcct	2160
ggattggcag	gggccccagg	acttagaggt	ggagctgggt	cccctgggtcc	cgaaggagga	2220
aagggtgctg	ctggtcctcc	tgggccacct	ggtgctgctg	gtactcctgg	tctgcaagga	2280
atgcctggag	aaagaggagg	tcttggaggt	cctggtccaa	agggtgacaa	gggtgaacca	2340
ggcggccacg	gtgctgatgg	tgtcccaggg	aaagatggcc	caagggtgct	tactggtcct	2400
attggtcctc	ctggcccagg	tggccagcct	ggagataagg	gtgaagggtg	tgcccccgga	2460
cttccaggta	tagctggacc	tcgtggtagc	cctggtgaga	gaggtgaaac	tggccctcca	2520
ggacctgctg	gtttccctgg	tgtccttgga	cagaatggtg	aacctggtgg	taaaggagaa	2580
agaggggctc	cgggtgagaa	aggtgaagga	ggcctcctg	gagttgcagg	accccctgga	2640
ggttctggac	ctgctgggtc	tcttgggtcc	caaggtgtca	aaggtgaacg	tggcagtcct	2700
ggtggagcctg	gtgctgctgg	cttccctggg	gctcgtgggt	ttcctggtcc	tcctggtagt	2760
aatggtaacc	caggaccccc	aggtcccagg	ggttctccag	gcaaggatgg	gccccagggt	2820
cctgcggtga	acactgggtg	tcttggcagg	cctggaggtg	ctggaccaaa	aggtgatgct	2880
ggccaaccag	gagagaaggg	atgcctgggt	gcccagggcc	caccaggagg	tccaggccca	2940
cttgggattg	ctgggatcac	tggagcacgg	ggtccttgag	gaccaccagg	catgccagggt	3000
cctaggggaa	gccctggccc	tcagggtgtc	aagggtgaaa	gtgggaaaacc	aggagctaac	3060
ggtctcagtg	gagaacgtgg	tccccctgga	ccccaggggt	ttcctggtct	ggctggtaca	3120
gctggtgaac	ctggaagaga	tggaaaacct	ggatcagatg	gtcttccagg	ccgagatgga	3180
tctcctgggt	gcaagggtga	tcgtggtgaa	aatggctctc	ctggtgcccc	tggcgctcct	3240
ggtcatccag	gcccacctgg	tctgtcgtg	ccagctggaa	agagtgggtg	agaggagaaa	3300
agtggccctg	ctggccctgc	tgggtgctccc	ggtcctgctg	gttcccaggg	tgtcctgggt	3360
cctcaaggcc	cacgtgggtg	caaagggtgaa	acagggtgaac	gtggagctgc	tggcatcaaa	3420
ggacatcgag	gattccctgg	taatccagggt	gccccagggt	ctccaggccc	tgtctggtcag	3480
cagggtgcaa	tcggcagtc	aggacctgca	ggccccagag	gacctgttgg	accagtgga	3540
cctcctggca	aagatggaac	cagtggacat	ccagggtccca	ttggaccacc	agggcctcga	3600
ggtaacagag	gtgaaagagg	atctgagggc	tccccagggc	acccagggca	accaggccct	3660
cctggacctc	ctggtgcccc	tggtccttgc	tgtggtgggt	ttggagccgc	tgccattgct	3720
gggattggag	gtcaaaaagc	tggcggtttt	gccccgtatt	atggagatga	accaatggat	3780
ttcaaaatca	acaccgatga	gattatgact	tcactcaagt	ctgttaatgg	acaaatagaa	3840
agcctcatta	gtcctgatgg	ttctcgtaaa	aaaccccgta	gaaactgcag	agacctgaaa	3900
ttctgccatc	ctgaactcaa	gagtggagaa	tactgggttg	accctaacca	aggatgcaaa	3960
ttggatgcta	tcaagggtatt	ctgtaatatg	gaaactgggg	aaacatgcat	aagtgccaat	4020
cctttgaatg	ttccacggaa	acactggtgg	acagattcta	gtgctgagaa	gaaacacgtt	4080
tggtttgagg	agtccatgga	tgggtggttt	cagtttagct	acggcaatcc	tgaacttcct	4140
gaagatgtoc	ttgatgtgca	gctggcattc	cttcgacttc	tctccagccg	agcttcccag	4200
aacatcacat	atcactgcaa	aaatagcatt	gcatacatgg	atcaggccag	tggaaaatgta	4260
agaaggccc	tgaagctgat	ggggtcaaat	gaagggtgaat	tcaaggctga	aggaaaatagc	4320
aaattcacct	acacagttct	ggaggatggt	tgcacgaaac	acactgggga	atggagcaaa	4380
acagtccttg	aatatcgaa	acgcaagggt	gtgagactac	ctattgtaga	tattgcaccc	4440
tatgacattg	gtggtcctga	tcaagaattt	ggtgtggacg	ttggccctgt	ttgcttttta	4500
taaaccacaa	tctatctgaa	atcccaacaa	aaaaaattta	actccatatg	tgttcctcct	4560
gttctaattc	tgtcaaccag	tgcaagtga	cgacaaaatt	ccagttattt	atttccaaaa	4620
tgtttggaaa	cagtataatt	tgacaaagaa	aaatgatact	tctctttttt	tgtctgtcca	4680
ccaaatacaa	ttcaaatgct	ttttgtttta	tttttttacc	aattccaatt	tcaaaatgtc	4740
tcaatggtgc	tataataaat	aaacttcaac	actctttatg	ataacaacac	tgtgttatat	4800
tctttgaatc	ctagcccatc	tgcagagcaa	tgactgtgct	caccagtaaa	agataacctt	4860
tctttctgaa	atagtcacaa	acgaaattag	aaaagccctc	cctattttta	ctacctcaac	4920
tggtcagaaa	acagatttgt	attctatgag	tcccagaaga	tgaaaaaaat	tttatagctt	4980
gataaaactt	ataaatttca	ttgattaatc	tccctggaaga	ttggtttaaa	aagaaaaagt	5040
taatgcaaga	atttaaagaa	atatttttaa	agccacaatt	attttaatat	tggatatcaa	5100
ctgcttgtaa	aggtgctcct	cttttttctt	gtcattgctg	gtcaagatta	ctaataattg	5160
ggaaggcttt	aaagacgcat	gttatggtgc	taatgtactt	tcacttttaa	actctagatc	5220

```

agaattgttg acttgcattc agaacataaa tgcacaaaat ctgtacatgt ctcccatcag      5280
aaagattcat tggcatgcca cagggattct cctccttcat cctgtaaagg tcaacaataa      5340
aaaccaaatt atggggctgc ttttgtcaca ctagcataga gaatgtgttg aaatttaact      5400
ttgtaagctt gtatgtgggtt gttgatcttt tttttcctta cagacacca taataaaata      5460

```

<210> 72

<211> 1466

<212> PRT

<213> Homo sapiens

<400> 72

```

Met Met Ser Phe Val Gln Lys Gly Ser Trp Leu Leu Leu Ala Leu Leu
 1          5          10          15
His Pro Thr Ile Leu Ala Gln Gln Glu Ala Val Glu Gly Gly Cys
 20          25          30
Ser His Leu Gly Gln Ser Tyr Ala Asp Arg Asp Val Trp Lys Pro Glu
 35          40          45
Pro Cys Gln Ile Cys Val Cys Asp Ser Gly Ser Val Leu Cys Asp Asp
 50          55          60
Ile Ile Cys Asp Asp Gln Glu Leu Asp Cys Pro Asn Pro Glu Ile Pro
 65          70          75          80
Phe Gly Glu Cys Cys Ala Val Cys Pro Gln Pro Pro Thr Ala Pro Thr
 85          90          95
Arg Pro Pro Asn Gly Gln Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly
100          105          110
Pro Pro Gly Ile Pro Gly Arg Asn Gly Asp Pro Gly Ile Pro Gly Gln
115          120          125
Pro Gly Ser Pro Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys
130          135          140
Pro Thr Gly Pro Gln Asn Tyr Ser Pro Gln Tyr Asp Ser Tyr Asp Val
145          150          155          160
Lys Ser Gly Val Ala Val Gly Gly Leu Ala Gly Tyr Pro Gly Pro Ala
165          170          175
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Thr Ser Gly His Pro Gly
180          185          190
Ser Pro Gly Ser Pro Gly Tyr Gln Gly Pro Pro Gly Glu Pro Gly Gln
195          200          205
Ala Gly Pro Ser Gly Pro Pro Gly Pro Pro Gly Ala Ile Gly Pro Ser
210          215          220
Gly Pro Ala Gly Lys Asp Gly Glu Ser Gly Arg Pro Gly Arg Pro Gly
225          230          235          240
Glu Arg Gly Leu Pro Gly Pro Pro Gly Ile Lys Gly Pro Ala Gly Ile
245          250          255
Pro Gly Phe Pro Gly Met Lys Gly His Arg Gly Phe Asp Gly Arg Asn
260          265          270
Gly Glu Lys Gly Glu Thr Gly Ala Pro Gly Leu Lys Gly Glu Asn Gly
275          280          285
Leu Pro Gly Glu Asn Gly Ala Pro Gly Pro Met Gly Pro Arg Gly Ala
290          295          300
Pro Gly Glu Arg Gly Arg Pro Gly Leu Pro Gly Ala Ala Gly Ala Arg
305          310          315          320
Gly Asn Asp Gly Ala Arg Gly Ser Asp Gly Gln Pro Gly Pro Pro Gly
325          330          335
Pro Pro Gly Thr Ala Gly Phe Pro Gly Ser Pro Gly Ala Lys Gly Glu
340          345          350
Val Gly Pro Ala Gly Ser Pro Gly Ser Asn Gly Ala Pro Gly Gln Arg
355          360          365

```


Gly Glu Pro Gly Pro Gln Gly His Ala Gly Ala Gln Gly Pro Pro Gly
 370 375 380
 Pro Pro Gly Ile Asn Gly Ser Pro Gly Gly Lys Gly Glu Met Gly Pro
 385 390 395 400
 Ala Gly Ile Pro Gly Ala Pro Gly Leu Met Gly Ala Arg Gly Pro Pro
 405 410 415
 Gly Pro Ala Gly Ala Asn Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly
 420 425 430
 Glu Pro Gly Lys Asn Gly Ala Lys Gly Glu Pro Gly Pro Arg Gly Glu
 435 440 445
 Arg Gly Glu Ala Gly Ile Pro Gly Val Pro Gly Ala Lys Gly Glu Asp
 450 455 460
 Gly Lys Asp Gly Ser Pro Gly Glu Pro Gly Ala Asn Gly Leu Pro Gly
 465 470 475 480
 Ala Ala Gly Glu Arg Gly Ala Pro Gly Phe Arg Gly Pro Ala Gly Pro
 485 490 495
 Asn Gly Ile Pro Gly Glu Lys Gly Pro Ala Gly Glu Arg Gly Ala Pro
 500 505 510
 Gly Pro Ala Gly Pro Arg Gly Ala Ala Gly Glu Pro Gly Arg Asp Gly
 515 520 525
 Val Pro Gly Gly Pro Gly Met Arg Gly Met Pro Gly Ser Pro Gly Gly
 530 535 540
 Pro Gly Ser Asp Gly Lys Pro Gly Pro Pro Gly Ser Gln Gly Glu Ser
 545 550 555 560
 Gly Arg Pro Gly Pro Gly Pro Ser Gly Pro Arg Gly Gln Pro Gly
 565 570 575
 Val Met Gly Phe Pro Gly Pro Lys Gly Asn Asp Gly Ala Pro Gly Lys
 580 585 590
 Asn Gly Glu Arg Gly Gly Pro Gly Gly Pro Gly Pro Gln Gly Pro Pro
 595 600 605
 Gly Lys Asn Gly Glu Thr Gly Pro Gln Gly Pro Pro Gly Pro Thr Gly
 610 615 620
 Pro Gly Gly Asp Lys Gly Asp Thr Gly Pro Pro Gly Pro Gln Gly Leu
 625 630 635 640
 Gln Gly Leu Pro Gly Thr Gly Gly Pro Pro Gly Glu Asn Gly Lys Pro
 645 650 655
 Gly Glu Pro Gly Pro Lys Gly Asp Ala Gly Ala Pro Gly Ala Pro Gly
 660 665 670
 Gly Lys Gly Asp Ala Gly Ala Pro Gly Glu Arg Gly Pro Pro Gly Leu
 675 680 685
 Ala Gly Ala Pro Gly Leu Arg Gly Gly Ala Gly Pro Pro Gly Pro Glu
 690 695 700
 Gly Gly Lys Gly Ala Ala Gly Pro Pro Gly Pro Pro Gly Ala Ala Gly
 705 710 715 720
 Thr Pro Gly Leu Gln Gly Met Pro Gly Glu Arg Gly Gly Leu Gly Ser
 725 730 735
 Pro Gly Pro Lys Gly Asp Lys Gly Glu Pro Gly Gly Pro Gly Ala Asp
 740 745 750
 Gly Val Pro Gly Lys Asp Gly Pro Arg Gly Pro Thr Gly Pro Ile Gly
 755 760 765
 Pro Pro Gly Pro Ala Gly Gln Pro Gly Asp Lys Gly Glu Gly Gly Ala
 770 775 780
 Pro Gly Leu Pro Gly Ile Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg
 785 790 795 800
 Gly Glu Thr Gly Pro Gly Pro Ala Gly Phe Pro Gly Ala Pro Gly
 805 810 815
 Gln Asn Gly Glu Pro Gly Gly Lys Gly Glu Arg Gly Ala Pro Gly Glu
 820 825 830
 Lys Gly Glu Gly Gly Pro Pro Gly Val Ala Gly Pro Pro Gly Gly Ser
 835 840 845

66

Gly Glu Ser Met Asp Gly Gly Phe Gln Phe Ser Tyr Gly Asn Pro Glu
 1330 1335 1340
 Leu Pro Glu Asp Val Leu Asp Val Gln Leu Ala Phe Leu Arg Leu Leu
 1345 1350 1355 1360
 Ser Ser Arg Ala Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile
 1365 1370 1375
 Ala Tyr Met Asp Gln Ala Ser Gly Asn Val Lys Lys Ala Leu Lys Leu
 1380 1385 1390
 Met Gly Ser Asn Glu Gly Glu Phe Lys Ala Glu Gly Asn Ser Lys Phe
 1395 1400 1405
 Thr Tyr Thr Val Leu Glu Asp Gly Cys Thr Lys His Thr Gly Glu Trp
 1410 1415 1420
 Ser Lys Thr Val Phe Glu Tyr Arg Thr Arg Lys Ala Val Arg Leu Pro
 1425 1430 1435 1440
 Ile Val Asp Ile Ala Pro Tyr Asp Ile Gly Gly Pro Asp Gln Glu Phe
 1445 1450 1455
 Gly Val Asp Val Gly Pro Val Cys Phe Leu
 1460 1465

<210> 73
 <211> 1051
 <212> DNA
 <213> Homo sapiens

<400> 73
 cgccggagtct gaggcgcgct cgtcccgtcc caaggccgac gccagcacgc cgtcatggcc 60
 cccgcagcgg cgacgggggg cagcaccctg cccagtggct tctcgggtctt caccaccttg 120
 cccgacttgc tcttcatctt tgagtttatc ttccgggggcc tgggtgggat cctgggtggcc 180
 tcttccctgg tgccctggcc cctgggtccag ggctgggtga tgttcgtgtc tgtgttctgc 240
 ttctgggcca ccaccacctt gatcatcctg tacataattg gagcccacgg tggagagact 300
 tcttgggtca ccttggacgc agcctaccac tgcaccgctg ccctctttta cctcagcgcc 360
 tcagtccctgg aggccctggc caccatcacg atgcaagacg gcttcaccta caggcactac 420
 catgaaaaca ttgctgccgt ggtgttctcc tacatagcca ctctgctcta cgtgggtccat 480
 gcgggtgttct ctttaatacag atggaagtct tcataaaagcc gcagtagaac ttgagctgaa 540
 aaccagatg gtgttaactg gccgccccac tttccggcat aacttttttag aaaaacagaaa 600
 tgcccttgat ggtggaaaaa agaaaacaac cccccccca ctgccccaaa aaaaaagccc 660
 tgccctgttg ctgctgggtg ctgtgtttac tctcccgctt gccttcgcgt ccgggttggg 720
 agcttgctgt gtctaacctc caactgctgt gctgtctgct agggtcacct cctgtttgtg 780
 aaaggggacc ttcttgttcg ggggtgggaa gtggcgaccg tgacctgaga aggaaagaaa 840
 gatcctctgc tgacccttg agcagctctc gagaactacc tgttggtatt gtccacaagc 900
 tctcccgagc gcccacatt gtgccatgtt ttaagtcttc atggatgttc tgcattgcat 960
 ggggactaaa actcaccaa cagatctttc cagaggtcca tgggtggaaga cgataaccct 1020
 gtgaaatact ttataaaatg tcttaatggt c 1051

<210> 74
 <211> 153
 <212> PRT
 <213> Homo sapiens

<400> 74
 Met Ala Pro Ala Ala Ala Thr Gly Gly Ser Thr Leu Pro Ser Gly Phe
 1 5 10 15
 Ser Val Phe Thr Thr Leu Pro Asp Leu Leu Phe Ile Phe Glu Phe Ile
 20 25 30
 Phe Gly Gly Leu Val Trp Ile Leu Val Ala Ser Ser Leu Val Pro Trp
 35 40 45
 Pro Leu Val Gln Gly Trp Val Met Phe Val Ser Val Phe Cys Phe Val
 50 55 60
 Ala Thr Thr Thr Leu Ile Ile Leu Tyr Ile Ile Gly Ala His Gly Gly
 65 70 75 80

Glu	Thr	Ser	Trp	Val 85	Thr	Leu	Asp	Ala	Ala 90	Tyr	His	Cys	Thr	Ala 95	Ala
Leu	Phe	Tyr	Leu	Ser 100	Ala	Ser	Val	Leu 105	Glu	Ala	Leu	Ala	Thr 110	Ile	Thr
Met	Gln	Asp	Gly	Phe 115	Thr	Tyr	Arg 120	His	Tyr	His	Glu	Asn 125	Ile	Ala	Ala
Val	Val 130	Phe	Ser	Tyr	Ile	Ala 135	Thr	Leu	Leu	Tyr	Val 140	Val	His	Ala	Val
Phe 145	Ser	Leu	Ile	Arg	Trp 150	Lys	Ser	Ser							

<210> 75

<211> 5416

<212> DNA

<213> Homo sapiens

<400> 75

gtgtcccata	gtgtttccaa	acttggaaaag	ggcgggggag	ggcggggagga	tgcgaggggc	100
ggaggtatgc	agacaacgag	tcagagtttc	cccttgaaag	cctcaaaagt	gtccacgtcc	120
tcaaaaagaa	tggaaccaat	ttaagaagcc	agccccgtgg	ccacgtccct	tccccattc	180
gggcccctct	ctgcccctcc	gcaggtctct	cccagctgtg	gctgcccggg	ccccagccc	240
cagcccctcc	attggtggag	gcccttttgg	aggcaccccta	ggggccaggga	aactttttgcc	300
gtataaatag	ggcagatccg	ggattttgta	tttttagcacc	acggcagcag	gaggttttcgg	360
ctaagttgga	ggtagctggc	acgactgcat	gcccgcgccc	gccatgtgat	acctccgccc	420
gtgaccagg	gctctgcgac	acaaggagtc	gcatgtctaa	gtgctagaca	tgctcagctt	480
tgtggatacg	ggcactttgt	tgctgcttgc	agtaacctta	tgccctagcaa	catgccaatc	540
tttacaagag	gaaactgtaa	gaaagggccc	agccggagat	agaggaccac	gtggagaaaag	600
gggtccacca	ggccccccag	gcagagatgg	tgaagatggt	cccacaggcc	ctcctggtcc	660
acctgggtcct	cctggccccc	ctgggtctcgg	tgggaacttt	gctgctcagt	atgatggaaa	720
aggagttgga	cttggccctg	gaccaatggg	cttaatggga	cctagaggcc	cacctggtgc	780
agctggagcc	ccaggccctc	aaggtttcca	aggacctgct	ggtgagccctg	gtgaacctgg	840
tcaaactgggt	cctgcaggtg	ctcgtggtcc	agctggccct	cctggcaagg	ctggtgaaga	900
tggtcaccct	ggaaaaccgc	gacgactctg	tgagagagga	gttgttggac	cacagggtgc	960
tcgtggtttc	cctggaactc	ctggacttcc	tggcttcaaa	ggcattaggg	gacacaatgg	1020
tctggatgga	ttgaaggggac	agccccgtgc	tccctggtgtg	aagggtgaac	ctggtgcccc	1080
tggtgaaaat	ggaaactccag	gtcaaacagg	agcccgtggt	cttcctggtg	agagaggacg	1140
tgttgggtgcc	cctgggtccag	ctgggtgccc	tggaagtgat	ggaagtgtgg	gtcccgtagg	1200
tcctgctggt	cctaattgggt	ctgctggccc	tccaggttcc	ccaggtgccc	ctggtcccaa	1260
gggtgaaatt	ggagctgttg	gtaacgctgg	tcctactgga	cccgcgggtc	cccgtggtga	1320
agtgggtcct	ccaggccctg	ccggccccgt	tggacctcct	ggtaatccctg	gagcaaacgg	1380
ccttactgggt	gccaagcctt	ctgctggcct	tcccggcgtt	gctggggctc	ccggcctccc	1440
tggacccgc	ggatttcctg	gccctcctgg	tgctgcgggt	actactgggtg	ccagaggact	1500
tgttgggtgag	cctgggtccag	ctgggtccaa	aggagagagc	ggtaacaagg	gtgagcccg	1560
ctccgctggt	ccccaaagtc	ctcctggtcc	cagtggtgaa	gaaggaaaga	gaggccctaa	1620
tggggaagct	ggatctgccg	gccctccagg	acctcctggg	ctgagaggta	gtcctggttc	1680
tcgtgggtcct	cctggagctg	atggcagagc	tggcgtcatg	ggccctcctg	gtagtcgtgg	1740
tgcaagtggc	cctgctggag	tccgaggacc	taatggagat	gctgggtcgcc	ctggggagcc	1800
tggtctcatg	ggaccagag	gtcttcctgg	ttccccctgga	aatatcgccg	ccgctggaaa	1860
agaaggtcct	gtcgccctcc	ctggcatcga	cggcaggcct	ggcccaattc	gccccgttgg	1920
agcaagagga	gagcctggca	acattggatt	ccctggacc	aaaggcccca	ctggtgacc	1980
tggcaaaaac	ggtgataaag	gtcatgtctg	tcttgcctggt	gctcgggggtg	ctccaggtcc	2040
tgatggaaaac	aatgggtgctc	agggacctcc	tggaccacag	gggtgttcaag	gtggaaaagg	2100
tgaacagggt	cccgtggtgc	ctccaggctt	ccagggtctg	cctggccccc	caggtcccg	2160
tggtgaagt	ggcaaaccag	gagaaagggg	tctccatggt	gagtttgggtc	tccctggtcc	2220
tgctgggtcca	agaggggaac	gcggtcccc	aggtgagagt	ggtgctgccc	gtcctaactg	2280
tcctattgga	agccgaggtc	cttctggacc	cccagggcct	gatggaaaca	agggtgaacc	2340
tggtgtgggt	ggtgctgtgg	gcactgctgg	tccatctggt	cctagtgga	tcccaggaga	2400
gaggggtgct	gctggcctac	ctggaggcaa	gggagaaaag	ggtgaacctg	gtctcagagg	2460
tgaatttggt	aacctggca	gagatggtgc	tcgtggtgct	catggtgctg	taggtgcccc	2520
tggtcctgct	ggagccacag	gtgaccgggg	cgaagctggg	gctgctggtc	ctgctggtcc	2580

tgctggtcct	cggggaagcc	ctggtgaacg	tggcgaggtc	ggctctgctg	gccccaacgg	2640
atttgctggt	ccggctggtg	ctgctggtca	accgggtgct	aaaggagaaa	gaggaggcaa	2700
agggcctaag	ggtgaaaacg	gtgttggttg	tcccacaggc	cccgttgagg	ctgctggccc	2760
agctggtcca	aatggtcccc	ccggtcctgc	tggaagtcgt	ggtgatggag	gccccctgg	2820
tatgactggt	ttccctggtg	ctgctggacg	gactgggtccc	ccaggaccct	ctggtatttc	2880
tggccctcct	ggtccccctg	gtcctgctgg	gaaagaaggg	cttcgtggtc	ctcgtggtga	2940
ccaaggcca	gttggccgaa	ctggagaagt	agggtgcagt	gggtccccctg	gcttcgctgg	3000
tgagaagggg	ccctctggag	aggctggtac	tgctggacct	cctggcactc	caggtcctca	3060
gggtcttctt	ggtgctcctg	gtattctggg	tctccctggc	tcgagagggtg	aacgtggtct	3120
acctggtggt	gctggtgctg	tgggtgaacc	tgggtcctctt	ggcattgccg	gccctcctgg	3180
ggcccgtggt	cctcctggtg	ctgtgggtag	tcctggagtc	aacggtgctc	ctggtgaagc	3240
tggctcgtgat	ggcaaccctg	ggaacgatgg	tccccaggt	cgcgatggtc	aaccgggaca	3300
caagggagag	cgcggttacc	ctggcaatat	tgggtcccgtt	ggtgctgcag	gtgcacctgg	3360
tctcatggc	cccggtgggtc	ctgctggcaa	acatggaaac	cgtggtgaaa	ctggtccttc	3420
tggctcctggt	ggtcctgctg	gtgctgttgg	cccaagaggt	cctagtggcc	cacaaggcat	3480
tcgtggcgat	aaggagagac	ccggtgaaaa	ggggcccaga	ggtcttcctg	gcttcaaggg	3540
acacaattgga	ttgcaaggtc	tgcctgggtat	cgctggtcac	catggtgatc	aaggtgctcc	3600
tggctccgtg	ggtcctgctg	gtcctagggg	ccctgctggt	ccttctggcc	ctgctggaaa	3660
agatggtcgc	actggacatc	ctggtacggg	tggacctgct	ggcattcgag	gccctcaggg	3720
tcaccaaggc	cctgctggcc	cccctgggtc	ccctggccct	cctggacctc	caggtgtaag	3780
cggtggtggt	tatgactttg	gttacgatgg	agacttctac	agggctgacc	agcctcgctc	3840
agcaccttct	ctcagaccga	aggactatga	agttgatgct	actctgaagt	ctctcaacaa	3900
ccagattgag	acccttctta	ctcctgaagg	ctctagaaag	aaccagctc	gcacatgccg	3960
tgacttgaga	ctcagccacc	cagagtggag	cagcgggttac	tactggattg	accccaacca	4020
aggatgcact	atggaagcca	tcaaagtata	ctgtgatttc	cctaccggcg	aaacctgtat	4080
ccgggcccga	cctgaaaaca	tcccagccaa	gaactggtat	aggagctcca	aggacaagaa	4140
acacgtctgg	ctaggagaaa	ctatcaatgc	tggcagccag	tttgaatata	atggtgaagg	4200
agtgaacttc	aaggaaatgg	ctacccaact	tgccttcatg	cgctgctgg	ccaactatgc	4260
ctctcagaac	atcacctacc	actgcaagaa	cagcattgca	tacatggatg	aggagactgg	4320
caacctgaaa	aaggctgtca	ttctacaggg	ctctaattgat	gttgaacttg	ttgctgaggg	4380
caacagcagg	ttcacttaca	ctgttcttgt	agatggctgc	tctaaaaaga	caaataaatg	4440
gggaaagaca	atcattgaat	acaaaacaaa	taagccatca	cgctgccct	tccttgatat	4500
tgcacctttg	gacatcggtg	gtgctgacca	tgaattcttt	gtggacattg	gccagtcctg	4560
tttcaaataa	atgaactcaa	tctaaattaa	aaaagaaaga	aatttgaaaa	aactttctct	4620
ttgccatttc	ttcttcttct	tttttaactg	aaagctgaat	ccttccattt	cttctgcaca	4680
tctacttgct	taaattgtgg	gcaaaagaga	aaaagaagga	ttgatcagag	cattgtgcaa	4740
tacagtttca	ttaactcctt	ccccgctcc	cccaaaaatt	tgaatttttt	tttcaacact	4800
cttacacctg	ttatggaaaa	tgtcaacctt	tgtgaaaaa	ccaaaataaa	aattgaaaaa	4860
taaaaacccat	aaacatttgc	accacttgtg	gcttttgaat	atcttcaca	gagggaagtt	4920
taaaacccaa	acttccaaag	gtttaaacta	cctcaaaaca	ctttcccatg	agtgtgatcc	4980
acattgttag	gtgctgacct	agacagagat	gaactgaggt	ccttgttttg	ttttgttcat	5040
aatacaaaagg	tgctaattaa	tagtatttca	gatacttgaa	gaatgttgat	ggtgctagaa	5100
gaatttgaga	agaaatactc	ctgtattgag	ttgtatcgtg	tgggtgattt	tttaaaaaat	5160
ttgatttagc	attcatattt	tccatcttat	tcccaattaa	aagtatgcag	attatttgcc	5220
caaagttgct	ctcttcttca	gattcagcat	ttgttctttg	ccagtcctcat	tttcatcttc	5280
ttccatgggt	ccacagaagc	tttgtttctt	gggcaagcag	aaaaattaaa	ttgtacctat	5340
tttgatatg	tgagatgttt	aaataaattg	tgaaaaaaat	gaaataaagc	atgtttgggtt	5400
ttccaaaaga	acatat					5416

<210> 76

<211> 1366

<212> PRT

<213> Homo sapiens

<400> 76

Met Leu Ser Phe Val Asp Thr Arg Thr Leu Leu Leu Leu Ala Val Thr

1

5

10

15

Leu	Cys	Leu	Ala	Thr	Cys	Gln	Ser	Leu	Gln	Glu	Glu	Thr	Val	Arg	Lys
			20					25					30		
Gly	Pro	Ala	Gly	Asp	Arg	Gly	Pro	Arg	Gly	Glu	Arg	Gly	Pro	Pro	Gly
		35					40					45			
Pro	Pro	Gly	Arg	Asp	Gly	Glu	Asp	Gly	Pro	Thr	Gly	Pro	Pro	Gly	Pro
		50				55					60				
Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Leu	Gly	Gly	Asn	Phe	Ala	Ala	Gln
65				70					75						80
Tyr	Asp	Gly	Lys	Gly	Val	Gly	Leu	Gly	Pro	Gly	Pro	Met	Gly	Leu	Met
			85					90					95		
Gly	Pro	Arg	Gly	Pro	Pro	Gly	Ala	Ala	Gly	Ala	Pro	Gly	Pro	Gln	Gly
		100					105					110			
Phe	Gln	Gly	Pro	Ala	Gly	Glu	Pro	Gly	Glu	Pro	Gly	Gln	Thr	Gly	Pro
		115					120					125			
Ala	Gly	Ala	Arg	Gly	Pro	Ala	Gly	Pro	Pro	Gly	Lys	Ala	Gly	Glu	Asp
		130				135					140				
Gly	His	Pro	Gly	Lys	Pro	Gly	Arg	Pro	Gly	Glu	Arg	Gly	Val	Val	Gly
145				150					155						160
Pro	Gln	Gly	Ala	Arg	Gly	Phe	Pro	Gly	Thr	Pro	Gly	Leu	Pro	Gly	Phe
			165					170						175	
Lys	Gly	Ile	Arg	Gly	His	Asn	Gly	Leu	Asp	Gly	Leu	Lys	Gly	Gln	Pro
		180					185					190			
Gly	Ala	Pro	Gly	Val	Lys	Gly	Glu	Pro	Gly	Ala	Pro	Gly	Glu	Asn	Gly
		195					200					205			
Thr	Pro	Gly	Gln	Thr	Gly	Ala	Arg	Gly	Leu	Pro	Gly	Glu	Arg	Gly	Arg
		210			215						220				
Val	Gly	Ala	Pro	Gly	Pro	Ala	Gly	Ala	Arg	Gly	Ser	Asp	Gly	Ser	Val
225				230					235						240
Gly	Pro	Val	Gly	Pro	Ala	Gly	Pro	Asn	Gly	Ser	Ala	Gly	Pro	Pro	Gly
			245					250						255	
Phe	Pro	Gly	Ala	Pro	Gly	Pro	Lys	Gly	Glu	Ile	Gly	Ala	Val	Gly	Asn
		260					265						270		
Ala	Gly	Pro	Thr	Gly	Pro	Ala	Gly	Pro	Arg	Gly	Glu	Val	Gly	Leu	Pro
		275					280					285			
Gly	Leu	Ser	Gly	Pro	Val	Gly	Pro	Pro	Gly	Asn	Pro	Gly	Ala	Asn	Gly
		290				295					300				
Leu	Thr	Gly	Ala	Lys	Gly	Ala	Ala	Gly	Leu	Pro	Gly	Val	Ala	Gly	Ala
305				310					315						320
Pro	Gly	Leu	Pro	Gly	Pro	Arg	Gly	Ile	Pro	Gly	Pro	Pro	Gly	Ala	Ala
			325					330						335	
Gly	Thr	Thr	Gly	Ala	Arg	Gly	Leu	Val	Gly	Glu	Pro	Gly	Pro	Ala	Gly
		340					345					350			
Ser	Lys	Gly	Glu	Ser	Gly	Asn	Lys	Gly	Glu	Pro	Gly	Ser	Ala	Gly	Pro
		355				360						365			
Gln	Gly	Pro	Pro	Gly	Pro	Ser	Gly	Glu	Glu	Gly	Lys	Arg	Gly	Pro	Asn
		370				375					380				
Gly	Glu	Ala	Gly	Ser	Ala	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Leu	Arg	Gly
385				390					395						400
Ser	Pro	Gly	Ser	Arg	Gly	Leu	Pro	Gly	Ala	Asp	Gly	Arg	Ala	Gly	Val
			405					410						415	
Met	Gly	Pro	Pro	Gly	Ser	Arg	Gly	Ala	Ser	Gly	Pro	Ala	Gly	Val	Arg
		420					425					430			
Gly	Pro	Asn	Gly	Asp	Ala	Gly	Arg	Pro	Gly	Glu	Pro	Gly	Leu	Met	Gly
		435					440					445			
Pro	Arg	Gly	Leu	Pro	Gly	Ser	Pro	Gly	Asn	Ile	Gly	Pro	Ala	Gly	Lys
		450				455					460				
Glu	Gly	Pro	Val	Gly	Leu	Pro	Gly	Ile	Asp	Gly	Arg	Pro	Gly	Pro	Ile
465				470					475						480
Gly	Pro	Val	Gly	Ala	Arg	Gly	Glu	Pro	Gly	Asn	Ile	Gly	Phe	Pro	Gly
			485					490						495	

Pro Lys Gly Pro Thr Gly Asp Pro Gly Lys Asn Gly Asp Lys Gly His
 500 505 510
 Ala Gly Leu Ala Gly Ala Arg Gly Ala Pro Gly Pro Asp Gly Asn Asn
 515 520 525
 Gly Ala Gln Gly Pro Pro Gly Pro Gln Gly Val Gln Gly Gly Lys Gly
 530 535 540
 Glu Gln Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Phe Gln Gly Leu Pro Gly Pro
 545 550 555 560
 Ser Gly Pro Ala Gly Glu Val Gly Lys Pro Gly Glu Arg Gly Leu His
 565 570 575
 Gly Glu Phe Gly Leu Pro Gly Pro Ala Gly Pro Arg Gly Glu Arg Gly
 580 585 590
 Pro Pro Gly Glu Ser Gly Ala Ala Gly Pro Thr Gly Pro Ile Gly Ser
 595 600 605
 Arg Gly Pro Ser Gly Pro Pro Gly Pro Asp Gly Asn Lys Gly Glu Pro
 610 615 620
 Gly Val Val Gly Ala Val Gly Thr Ala Gly Pro Ser Gly Pro Ser Gly
 625 630 635 640
 Leu Pro Gly Glu Arg Gly Ala Ala Gly Ile Pro Gly Gly Lys Gly Glu
 645 650 655
 Lys Gly Glu Pro Gly Leu Arg Gly Glu Ile Gly Asn Pro Gly Arg Asp
 660 665 670
 Gly Ala Arg Gly Ala His Gly Ala Val Gly Ala Pro Gly Pro Ala Gly
 675 680 685
 Ala Thr Gly Asp Arg Gly Glu Ala Gly Ala Ala Gly Pro Ala Gly Pro
 690 695 700
 Ala Gly Pro Arg Gly Ser Pro Gly Glu Arg Gly Glu Val Gly Pro Ala
 705 710 715 720
 Gly Pro Asn Gly Phe Ala Gly Pro Ala Gly Ala Ala Gly Gln Pro Gly
 725 730 735
 Ala Lys Gly Glu Arg Gly Gly Lys Gly Pro Lys Gly Glu Asn Gly Val
 740 745 750
 Val Gly Pro Thr Gly Pro Val Gly Ala Ala Gly Pro Ala Gly Pro Asn
 755 760 765
 Gly Pro Pro Gly Pro Ala Gly Ser Arg Gly Asp Gly Gly Pro Pro Gly
 770 775 780
 Met Thr Gly Phe Pro Gly Ala Ala Gly Arg Thr Gly Pro Pro Gly Pro
 785 790 795 800
 Ser Gly Ile Ser Gly Pro Pro Gly Pro Pro Gly Pro Ala Gly Lys Glu
 805 810 815
 Gly Leu Arg Gly Pro Arg Gly Asp Gln Gly Pro Val Gly Arg Thr Gly
 820 825 830
 Glu Val Gly Ala Val Gly Pro Pro Gly Phe Ala Gly Glu Lys Gly Pro
 835 840 845
 Ser Gly Glu Ala Gly Thr Ala Gly Pro Pro Gly Thr Pro Gly Pro Gln
 850 855 860
 Gly Leu Leu Gly Ala Pro Gly Ile Leu Gly Leu Pro Gly Ser Arg Gly
 865 870 875 880
 Glu Arg Gly Leu Pro Gly Val Ala Gly Ala Val Gly Glu Pro Gly Pro
 885 890 895
 Leu Gly Ile Ala Gly Pro Pro Gly Ala Arg Gly Pro Pro Gly Ala Val
 900 905 910
 Gly Ser Pro Gly Val Asn Gly Ala Pro Gly Glu Ala Gly Arg Asp Gly
 915 920 925
 Asn Pro Gly Asn Asp Gly Pro Pro Gly Arg Asp Gly Gln Pro Gly His
 930 935 940
 Lys Gly Glu Arg Gly Tyr Pro Gly Asn Ile Gly Pro Val Gly Ala Ala
 945 950 955 960
 Gly Ala Pro Gly Pro His Gly Pro Val Gly Pro Ala Gly Lys His Gly
 965 970 975

Asn Arg Gly Glu Thr Gly Pro Ser Gly Pro Val Gly Pro Ala Gly Ala
 980 985 990
 Val Gly Pro Arg Gly Pro Ser Gly Pro Gln Gly Ile Arg Gly Asp Lys
 995 1000 1005
 Gly Glu Pro Gly Glu Lys Gly Pro Arg Gly Leu Pro Gly Phe Lys Gly
 1010 1015 1020
 His Asn Gly Leu Gln Gly Leu Pro Gly Ile Ala Gly His His Gly Asp
 1025 1030 1035 1040
 Gln Gly Ala Pro Gly Ser Val Gly Pro Ala Gly Pro Arg Gly Pro Ala
 1045 1050 1055
 Gly Pro Ser Gly Pro Ala Gly Lys Asp Gly Arg Thr Gly His Pro Gly
 1060 1065 1070
 Thr Val Gly Pro Ala Gly Ile Arg Gly Pro Gln Gly His Gln Gly Pro
 1075 1080 1085
 Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Val Ser
 1090 1095 1100
 Gly Gly Gly Tyr Asp Phe Gly Tyr Asp Gly Asp Phe Tyr Arg Ala Asp
 1105 1110 1115 1120
 Gln Pro Arg Ser Ala Pro Ser Leu Arg Pro Lys Asp Tyr Glu Val Asp
 1125 1130 1135
 Ala Thr Leu Lys Ser Leu Asn Asn Gln Ile Glu Thr Leu Leu Thr Pro
 1140 1145 1150
 Glu Gly Ser Arg Lys Asn Pro Ala Arg Thr Cys Arg Asp Leu Arg Leu
 1155 1160 1165
 Ser His Pro Glu Trp Ser Ser Gly Tyr Tyr Trp Ile Asp Pro Asn Gln
 1170 1175 1180
 Gly Cys Thr Met Glu Ala Ile Lys Val Tyr Cys Asp Phe Pro Thr Gly
 1185 1190 1195 1200
 Glu Thr Cys Ile Arg Ala Gln Pro Glu Asn Ile Pro Ala Lys Asn Trp
 1205 1210 1215
 Tyr Arg Ser Ser Lys Asp Lys Lys His Val Trp Leu Gly Glu Thr Ile
 1220 1225 1230
 Asn Ala Gly Ser Gln Phe Glu Tyr Asn Val Glu Gly Val Thr Ser Lys
 1235 1240 1245
 Glu Met Ala Thr Gln Leu Ala Phe Met Arg Leu Leu Ala Asn Tyr Ala
 1250 1255 1260
 Ser Gln Asn Ile Thr Tyr His Cys Lys Asn Ser Ile Ala Tyr Met Asp
 1265 1270 1275 1280
 Glu Glu Thr Gly Asn Leu Lys Lys Ala Val Ile Leu Gln Gly Ser Asn
 1285 1290 1295
 Asp Val Glu Leu Val Ala Glu Gly Asn Ser Arg Phe Thr Tyr Thr Val
 1300 1305 1310
 Leu Val Asp Gly Cys Ser Lys Lys Thr Asn Glu Trp Gly Lys Thr Ile
 1315 1320 1325
 Ile Glu Tyr Lys Thr Asn Lys Pro Ser Arg Leu Pro Phe Leu Asp Ile
 1330 1335 1340
 Ala Pro Leu Asp Ile Gly Gly Ala Asp His Glu Phe Phe Val Asp Ile
 1345 1350 1355 1360
 Gly Pro Val Cys Phe Lys
 1365

<210> 77

<211> 1082

<212> DNA

<213> Homo sapiens

<400> 77

agctcccttt agcgagtcct tcttttcttg actgcagctc ttttcatttt gccatccttt 60
 tccagcacca tgatggttct gcaggtttct gcggtcccc ggacagtggc tctgacggcg 120
 ttactgatgg tgctgtcac atctgtggc cagggcaggg ccactccaga gaattacctt 180


```

ttccagggac ggcaggaatg ctacgcgttt aatgggacac agcgcttcct ggagagatac 240
atctacaacc gggaggagtt cgcgcgcttc gacagcgacg tgggggagtt ccgggcggtg 300
acggagctgg ggcggcctgc tgcggagtac tggaacagcc agaaggacat cctggaggag 360
aagcggggcag tgccggacag gatgtgcaga cacaactacg agctgggcgg gcccatgacc 420
ctgcagcgcc gagtccagcc tagggtgaat gtttccccct ccaagaaggg gcccttgcat 480
caccacaacc tgcttgtctg ccacgtgacg gatttctacc caggcagcat tcaagtccga 540
tggttcctga atggacagga ggaacacagc ggggtcgtgt ccaccaacct gatccgtaat 600
ggagactgga ccttccagat cctgggtgat ctggaaatga cccccagca gggagatgtc 660
tacacctgcc aagtggagca caccagcctg gatagtcctg tcaccgtgga gtggaaggca 720
cagtctgatt ctgcccggag taagacattg acgggagctg ggggcttcgt gctggggctc 780
atcatctgtg gagtgggcat cttcatgcac aggaggagca agaaagttca acgaggatct 840
gcataaacag ggttcctgag ctactgaaa agactattgt gccttaggaa aagcatttgc 900
tgtgtttcgt tagcatctgg ctccaggaca gaccttcaac ttccaaattg atactgctgc 960
caagaagttg ctctgaagtc agtttctatc attctgctct ttgattcaaa gcaactgttc 1020
tctcactggg cctccaacca tgttcccttc ttcttagcac cacaataat caaaacccaa 1080
ca 1082

```

<210> 78

<211> 258

<212> PRT

<213> Homo sapiens

<400> 78

```

Met Met Val Leu Gln Val Ser Ala Ala Pro Arg Thr Val Ala Leu Thr
1          5          10          15
Ala Leu Leu Met Val Leu Leu Thr Ser Val Val Gln Gly Arg Ala Thr
20          25          30
Pro Glu Asn Tyr Leu Phe Gln Gly Arg Gln Glu Cys Tyr Ala Phe Asn
35          40          45
Gly Thr Gln Arg Phe Leu Glu Arg Tyr Ile Tyr Asn Arg Glu Glu Phe
50          55          60
Ala Arg Phe Asp Ser Asp Val Gly Glu Phe Arg Ala Val Thr Glu Leu
65          70          75          80
Gly Arg Pro Ala Ala Glu Tyr Trp Asn Ser Gln Lys Asp Ile Leu Glu
85          90          95
Glu Lys Arg Ala Val Pro Asp Arg Met Cys Arg His Asn Tyr Glu Leu
100         105         110
Gly Gly Pro Met Thr Leu Gln Arg Arg Val Gln Pro Arg Val Asn Val
115         120         125
Ser Pro Ser Lys Lys Gly Pro Leu Gln His His Asn Leu Leu Val Cys
130         135         140
His Val Thr Asp Phe Tyr Pro Gly Ser Ile Gln Val Arg Trp Phe Leu
145         150         155         160
Asn Gly Gln Glu Glu Thr Ala Gly Val Val Ser Thr Asn Leu Ile Arg
165         170         175
Asn Gly Asp Trp Thr Phe Gln Ile Leu Val Met Leu Glu Met Thr Pro
180         185         190
Gln Gln Gly Asp Val Tyr Thr Cys Gln Val Glu His Thr Ser Leu Asp
195         200         205
Ser Pro Val Thr Val Glu Trp Lys Ala Gln Ser Asp Ser Ala Arg Ser
210         215         220
Lys Thr Leu Thr Gly Ala Gly Gly Phe Val Leu Gly Leu Ile Ile Cys
225         230         235         240
Gly Val Gly Ile Phe Met His Arg Arg Ser Lys Lys Val Gln Arg Gly
245         250         255
Ser Ala

```

<210> 79

<211> 996

<212> DNA

<213> Homo sapiens

<400> 79

```

gtggaattca tggcatctac ttcgtatgac tattgcagag tgcccatgga agacggggat      60
aagcgctgta agcttctgct ggggatagga attctgggtgc tcctgatcat cgtgattctg      120
ggggtgccct tgattatctt caccatcaag gccaacagcg aggctgccg ggacggcctt      180
cgggcagtga tggagtgtcg caatgtcacc catctcctgc aacaagagct gaccgaggcc      240
cagaagggtt ttcaggatgt ggaggcccag gccgccacct gcaaccacac tgtgatggcc      300
ctaattggctt ccctggatgc agagaaggcc caaggacaaa agaaagtgga ggagcttgag      360
ggagagatca ctacattaaa ccataagctt caggacgcgt ctgcagaggt ggagcgactg      420
agaagagaaa accaggtctt aagcgtgaga atcgcggaaca agaagtacta ccccagctcc      480
caggactcca gctccgctgc ggcgccccag ctgctgattg tgctgctggg cctcagcgct      540
ctgctgcagt gagatcccag gaagctggca catcttgaa ggtccgtcct gctcggcttt      600
tcgcttgaac attcccttga tctcatcagt tctgagcggg tcatggggca acacgggttag      660
cggggagagc acggggtagc cggagaaggg cctctggagc aggtctggag gggccatggg      720
gcagtcttgg gtgtggggac acagtcgggt tgaccaggg ctgtctccct ccagagcctc      780
cctccggaca atgagtcctc cctcttgtct cccaccctga gattgggcat ggggtgcggt      840
gtggggggca tgtgtgcctt gttgttatgg gtttttttgg cggggggggg tgcttttttc      900
tggggtcttt gagctccaaa aaataaacac ttcttttgag ggagagcaaa aaaaaaaaaa      960
aaaaaaaaaa aaaaaaaaaa aaagaattcc accaca                                996

```

<210> 80

<211> 180

<212> PRT

<213> Homo sapiens

<400> 80

```

Met Ala Ser Thr Ser Tyr Asp Tyr Cys Arg Val Pro Met Glu Asp Gly
 1              5              10              15
Asp Lys Arg Cys Lys Leu Leu Leu Gly Ile Gly Ile Leu Val Leu Leu
      20              25              30
Ile Ile Val Ile Leu Gly Val Pro Leu Ile Ile Phe Thr Ile Lys Ala
      35              40              45
Asn Ser Glu Ala Cys Arg Asp Gly Leu Arg Ala Val Met Glu Cys Arg
      50              55              60
Asn Val Thr His Leu Leu Gln Gln Glu Leu Thr Thr Glu Ala Gln Lys Gly
      65              70              75              80
Phe Gln Asp Val Glu Ala Gln Ala Ala Thr Cys Asn His Thr Val Met
      85              90              95
Ala Leu Met Ala Ser Leu Asp Ala Glu Lys Ala Gln Gly Gln Lys Lys
      100             105             110
Val Glu Glu Leu Glu Gly Glu Ile Thr Thr Leu Asn His Lys Leu Gln
      115             120             125
Asp Ala Ser Ala Glu Val Glu Arg Leu Arg Arg Glu Asn Gln Val Leu
      130             135             140
Ser Val Arg Ile Ala Asp Lys Lys Tyr Tyr Pro Ser Ser Gln Asp Ser
      145             150             155             160
Ser Ser Ala Ala Ala Pro Gln Leu Leu Ile Val Leu Leu Gly Leu Ser
      165             170             175
Ala Leu Leu Gln
      180

```

<210> 81

<211> 4316

<212> DNA

<213> Homo sapiens

<400> 81

```

ctgcagctaa taaaaaaaaa aaaagaaaga aagaaaactgg tctctgtcct atttcatatg

```

60

ctcaggtaca	acttttccag	agaagaagag	gagggggg	gggaggagca	ggaggaggag	120
gaaagaagga	ggagaaggag	aaggagaaga	agaggagaag	gaagagggaag	aagaagaaga	180
agaagaagag	gaagaggaag	aggaagaaga	agaagaagaa	gaagaagaag	aagaagaaga	240
agaagaagaa	gaagaagaag	aagaagaaga	ggaagaagag	gaagaagaag	aaactgtctc	300
tagaccttca	ttctcaggac	aagttcattg	tctggcacca	agctccttgg	ggtgaatttt	360
cttccaaaag	agtccgggga	gtccagggtat	ggaatgggag	gcagaaagt	caatcaaggg	420
actgggattt	cggaatgaat	aatgaaggga	gatggactgg	gtccatgccg	aaggtttctc	480
cctggtttct	cagcccccg	gcgaagactc	agggagacat	tgagacacac	cctgcacagg	540
agggggagg	ggagggggag	ggcaaagtcc	cagggcccca	ggagtggctc	tcaagggctc	600
aggccccgag	gcggtgtctg	gggttgggaag	gctcagtatt	gagaattccc	catctcccca	660
gagtttctct	ttctctccca	acccgtgtca	ggtccttcat	cctggatact	cataacgcgg	720
ccccatttct	cactcccatt	gggcgtcgcg	tttctagaga	agccaatcag	tgctcgccga	780
gttcccagg	tctaaagtcc	cacgcacccc	gcgggactca	tatttttccc	agacgcggag	840
gttgggggtca	tggcgccccg	aagcctcctc	ctgctgctct	caggggccc	ggccctgacc	900
gatacttggg	cgggtgagt	cgggggtccag	agagaaacgg	cctctgtggg	gaggagtgg	960
gggcccgc	ggtggggg	caggactcag	ggagccgcgc	ccggaggagg	gtctggcg	1020
tctcaccccc	tcctcgcccc	caggctccca	ctccttgagg	tatttcagca	ccgctgtgtc	1080
gcggccggc	cgcggggagc	cccgtacat	cgccgtggag	tacgtagacg	acacgcaatt	1140
cctgcggttc	gacagcgacg	ccgcgattcc	gaggatggag	ccgcgggagc	cgtgggtgga	1200
gcaagagggg	ccgcagtatt	gggagtggac	cacagggtac	gccaaggcca	acgcacagac	1260
tgaccgagtg	gccctgagga	acctgctccg	ccgctacaac	cagagcgagg	ctgggtgagt	1320
aaccgcggc	ggggcgcagg	tcacgaccac	ccccatccg	ccacggaccg	cccggtccc	1380
cccgagtctc	cggatccgaa	atctacccc	aggcagcgga	cccgcaccga	ccctccaccc	1440
gggagagtcc	caggcgcctt	taccgaggtt	cattttcagt	ttaggccaaa	atccccgcgg	1500
gttgggcggg	gagggggcgg	ggctagctgg	gcggggctga	ctgcggggac	cggctagggt	1560
ctcacaccct	ccaggaatg	aatggctg	acatggggcc	cgacggacgc	ctcctcgcg	1620
ggtatcacca	gcacgcgtac	gacggcaagg	attacatctc	cctgaacgag	gacctgcgct	1680
cctggaccgc	ggcggaacac	gtggctcaga	tcaccagcg	cttctatgag	gcagaggaat	1740
atgcagagga	gttcaggacc	tacctggagg	gcgagtgcct	ggagtgtgtc	cgcagatact	1800
tgagaaatgg	gaaggagacg	ctacagcgcg	caggtaccag	gggccatggg	cgcttccct	1860
atctcctgta	gatctcttgg	gatggcctcg	cacaaggttg	ggaggaaagt	gggccaatg	1920
ctaggatata	gccctccctc	tagtcctgag	taggaagaat	cttcctggct	ttcgagatcc	1980
ggtaccagag	agtgaactgt	agagtccg	ctgctctctg	ggacaattaa	gggatgaaat	2040
ctctgagggg	atggagggaa	gacagtccct	ggaataccga	tccgcgggtc	cctttgagcc	2100
ctccaacagc	cttgggcccc	gtgacttttc	tctcaagttt	tgttctctgc	ctcacactca	2160
atgtgtttgg	ggctctgatt	ccagtccctc	ggcctccact	taggtcaggg	ccagaagtcc	2220
ctgtccccca	ctcagagact	cgaactttcc	aaggaaatag	agattttccc	aggtgtctgt	2280
gtccaggctg	gtgtctgggt	tctgtgtctc	cttccccacc	ccaggtgtcc	tgtccattct	2340
caggttggtc	acatgggtgc	tgctgggggt	tcccatgagg	agtgcaaagt	gcctgaattt	2400
tctgactctt	ctcagatcct	ccaaaggcac	acgttgccca	ccaccccatc	tctgaccatg	2460
aggccaccct	gaggtgctgg	gccctgggct	tctaccctgc	ggagatcacg	ctgacctggc	2520
agcgggatgg	ggaggaacag	acccaggaca	cagagcttgt	ggagaccagg	cctgcagggg	2580
atggaaccct	ccagaagtgg	gccgtgtgtg	tggtgccttc	tggagaggaa	cagagataca	2640
catgccatgt	gcagcacgag	gggctgcccc	agccctcat	cctgagatgg	ggtaaggagg	2700
gagatgggta	aagaggggaa	cgaggggtca	tgtcttttct	cagggaaagc	aggagccctt	2760
ctggagctct	tcagcagggt	cagggctgag	gcctggagat	cagggccctc	caccttccct	2820
tcctttccca	gagcagctct	cccagcccat	catccccatc	gtgggcatcg	ttgctggcct	2880
tgttgcctt	ggagctgtgg	tcactggagc	tgtgtgtgct	gctgtgatgt	ggaggaagaa	2940
gagctcaggt	aggaaggggt	gaggagtggg	gtctgagttt	tcttgtccca	ctgggggttg	3000
caagccccaa	gtagaagtgt	gccctgcctc	attactggga	agcaccatcc	acactcatgg	3060
gtctaccag	cctgggccc	gtgtgccagc	acctactcat	ttgtaaagct	cctgtgaaaa	3120
tgaaggacag	attcttcact	tcgatgatta	tggtgggtgat	gggacctgat	cccagcagtc	3180
acaaatcaca	ggggaaggte	cctgctgatg	acagacctca	ggagggcagt	tggtccagga	3240
cccacatctg	ctttcttcat	atttcttgat	cctgcccctg	atctacagtt	acacttttct	3300
ggaaacttct	ctgggatcaa	agactagggg	tttctcttag	gaccttatgg	ccctgcctcc	3360
tttctggcct	ctcacaggac	atttcttccc	catagataga	aacagaggga	gctactctca	3420
ggctgcaggt	aagatgaagg	aggctgatcc	ctgagattgt	tgggatattg	tggtcaggag	3480
cctatgaggg	agctcaccca	ccccacagtt	cctctagcca	catctgtggg	ctctgaccag	3540
gtcctgttct	tgttctaccc	caatcactga	cagtgcccg	ggctctgggg	tgtctctcac	3600
agctaataaa	ggtgacactc	cagggcaggg	gccctgatgt	gagtggggtg	ttggggggga	3660

acagagggga	ctcagctgtg	ctattgggtt	tctttgactt	ggatgtcttg	agcatgaaat	3720
gggctattta	gagtgttacc	tctcactgtg	actgatacga	atttgttcat	gaatattttc	3780
tctatagtgt	gagacagctt	ccttggtgtg	gactgagaag	caagatatca	atgtagcaga	3840
attgcacttg	tgccctcacga	acatacataa	attttaaaaa	taaagaataa	aaatataatct	3900
ttttatagat	acaggtagat	atgtttttat	agcatgcacg	taaatgtgtg	tgtgtgtgtg	3960
tgtgtgtgaa	gagaaagagt	gaatagagag	attaagattc	ttttaatggg	gaaaagatat	4020
acatatattt	ggaattagcc	agcttgactc	agtttaggtg	atcccaattt	tggtggcaac	4080
aaccaaagca	tcgtagtcag	gagccagtcg	aacatatgcc	ttcctctctc	catcagactg	4140
aatcagagtg	ttgacttttg	ccacatcaat	gtcacaaact	tcttcacagc	ctgtttgatc	4200
tggtgcttgt	tggttttaac	atccacagtg	aacacaagta	ggctgttggt	ttctatcttc	4260
ttcacagcct	actcagtggg	cagcggaaac	ttgatgataa	catggtggtc	aagctt	4316

<210> 82

<211> 362

<212> PRT

<213> Homo sapiens

<400> 82

Met	Ala	Pro	Arg	Ser	Leu	Leu	Leu	Leu	Leu	Ser	Gly	Ala	Leu	Ala	Leu
1				5					10					15	
Thr	Asp	Thr	Trp	Ala	Gly	Ser	His	Ser	Leu	Arg	Tyr	Phe	Ser	Thr	Ala
			20					25					30		
Val	Ser	Arg	Pro	Gly	Arg	Gly	Glu	Pro	Arg	Tyr	Ile	Ala	Val	Glu	Tyr
	35						40					45			
Val	Asp	Asp	Thr	Gln	Phe	Leu	Arg	Phe	Asp	Ser	Asp	Ala	Ala	Ile	Pro
	50					55				60					
Arg	Met	Glu	Pro	Arg	Glu	Pro	Trp	Val	Glu	Gln	Glu	Gly	Pro	Gln	Tyr
65					70				75					80	
Trp	Glu	Trp	Thr	Thr	Gly	Tyr	Ala	Lys	Ala	Asn	Ala	Gln	Thr	Asp	Arg
			85					90					95		
Val	Ala	Leu	Arg	Asn	Leu	Leu	Arg	Arg	Tyr	Asn	Gln	Ser	Glu	Ala	Gly
			100					105					110		
Ser	His	Thr	Leu	Gln	Gly	Met	Asn	Gly	Cys	Asp	Met	Gly	Pro	Asp	Gly
	115						120					125			
Arg	Leu	Leu	Arg	Gly	Tyr	His	Gln	His	Ala	Tyr	Asp	Gly	Lys	Asp	Tyr
	130					135					140				
Ile	Ser	Leu	Asn	Glu	Asp	Leu	Arg	Ser	Trp	Thr	Ala	Ala	Asp	Thr	Val
145					150					155				160	
Ala	Gln	Ile	Thr	Gln	Arg	Phe	Tyr	Glu	Ala	Glu	Glu	Tyr	Ala	Glu	Glu
			165					170						175	
Phe	Arg	Thr	Tyr	Leu	Glu	Gly	Glu	Cys	Leu	Glu	Leu	Leu	Arg	Arg	Tyr
		180						185					190		
Leu	Glu	Asn	Gly	Lys	Glu	Thr	Leu	Gln	Arg	Ala	Asp	Pro	Pro	Lys	Ala
	195						200					205			
His	Val	Ala	His	His	Pro	Ile	Ser	Asp	His	Glu	Ala	Thr	Leu	Arg	Cys
	210					215					220				
Trp	Ala	Leu	Gly	Phe	Tyr	Pro	Ala	Glu	Ile	Thr	Leu	Thr	Trp	Gln	Arg
225					230					235				240	
Asp	Gly	Glu	Glu	Gln	Thr	Gln	Asp	Thr	Glu	Leu	Val	Glu	Thr	Arg	Pro
			245						250					255	
Ala	Gly	Asp	Gly	Thr	Phe	Gln	Lys	Trp	Ala	Ala	Val	Val	Val	Pro	Ser
			260					265						270	
Gly	Glu	Glu	Gln	Arg	Tyr	Thr	Cys	His	Val	Gln	His	Glu	Gly	Leu	Pro
	275						280					285			
Gln	Pro	Leu	Ile	Leu	Arg	Trp	Glu	Gln	Ser	Pro	Gln	Pro	Thr	Ile	Pro
	290					295					300				
Ile	Val	Gly	Ile	Val	Ala	Gly	Leu	Val	Val	Leu	Gly	Ala	Val	Val	Thr
305					310					315				320	
Gly	Ala	Val	Val	Ala	Ala	Val	Met	Trp	Arg	Lys	Lys	Ser	Ser	Asp	Arg
			325						330					335	

Asn Arg Gly Ser Tyr Ser Gln Ala Ala Val Thr Asp Ser Ala Gln Gly
 340 345 350
 Ser Gly Val Ser Leu Thr Ala Asn Lys Val
 355 360

<210> 83
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 83
 tcagacgcag 10

<210> 84
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 84
 ttatgggatc 10

<210> 85
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 85
 cccgcccccg 10

<210> 86
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 86
 gaggaagaag 10

<210> 87
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 87
 gaagctttgc 10

<210> 88
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 88
 taccagtgtat 10

<210> 89
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 89
 tcttctccct 10

<210> 90
<211> 10
<212> DNA
<213> Homo sapiens

<400> 90
ttggcttttc 10

<210> 91
<211> 10
<212> DNA
<213> Homo sapiens

<400> 91
ggaagggagg 10

<210> 92
<211> 10
<212> DNA
<213> Homo sapiens

<400> 92
aagccagccc 10

<210> 93
<211> 10
<212> DNA
<213> Homo sapiens

<400> 93
tttcagattg 10

<210> 94
<211> 10
<212> DNA
<213> Homo sapiens

<400> 94
gcataggctg 10

<210> 95
<211> 10
<212> DNA
<213> Homo sapiens

<400> 95
tttgtaatt 10

<210> 96
<211> 10
<212> DNA
<213> Homo sapiens

<400> 96
gagactcctg 10

<210> 97
<211> 10
<212> DNA
<213> Homo sapiens

<400> 97
cctgtaattc 10

<210> 98
<211> 10
<212> DNA
<213> Homo sapiens

<400> 98
gtggtgcgtg 10

<210> 99
<211> 10
<212> DNA
<213> Homo sapiens

<400> 99
ttggacctgg 10

<210> 100
<211> 10
<212> DNA
<213> Homo sapiens

<400> 100
cttaaggatt 10

<210> 101
<211> 10
<212> DNA
<213> Homo sapiens

<400> 101
gtctgtgaga 10

<210> 102
<211> 10
<212> DNA
<213> Homo sapiens

<400> 102
gaaactgaac 10

<210> 103
<211> 10
<212> DNA
<213> Homo sapiens

<400> 103
gggcatctct 10

<210> 104
<211> 10
<212> DNA
<213> Homo sapiens

<400> 104
tttgggccta 10

<210> 105

<211> 10
<212> DNA
<213> Homo sapiens

<400> 105
atcgtggcgg 10

<210> 106
<211> 10
<212> DNA
<213> Homo sapiens

<400> 106
tattatggta 10

<210> 107
<211> 10
<212> DNA
<213> Homo sapiens

<400> 107
gcctacccga 10

<210> 108
<211> 10
<212> DNA
<213> Homo sapiens

<400> 108
ctcgcgctgg 10

<210> 109
<211> 10
<212> DNA
<213> Homo sapiens

<400> 109
ttgcttgcca 10

<210> 110
<211> 10
<212> DNA
<213> Homo sapiens

<400> 110
cctgcttgctc 10

<210> 111
<211> 10
<212> DNA
<213> Homo sapiens

<400> 111
agggaggggc 10

<210> 112
<211> 10
<212> DNA
<213> Homo sapiens

<400> 112 tgtgggaaat	10
<210> 113 <211> 10 <212> DNA <213> Homo sapiens	
<400> 113 cctgatctgc	10
<210> 114 <211> 10 <212> DNA <213> Homo sapiens	
<400> 114 accattggat	10
<210> 115 <211> 10 <212> DNA <213> Homo sapiens	
<400> 115 agtttgtag	10
<210> 116 <211> 10 <212> DNA <213> Homo sapiens	
<400> 116 cctgggaagt	10
<210> 117 <211> 10 <212> DNA <213> Homo sapiens	
<400> 117 caactaattc	10
<210> 118 <211> 10 <212> DNA <213> Homo sapiens	
<400> 118 gcctgcagtc	10
<210> 119 <211> 10 <212> DNA <213> Homo sapiens	
<400> 119 cgacccacg	10
<210> 120	

<211> 10
<212> DNA
<213> Homo sapiens

<400> 120
ttctgtgctg 10

<210> 121
<211> 10
<212> DNA
<213> Homo sapiens

<400> 121
cgccgacgat 10

<210> 122
<211> 10
<212> DNA
<213> Homo sapiens

<400> 122
cccgcccccg 10

<210> 123
<211> 10
<212> DNA
<213> Homo sapiens

<400> 123
gatcaggcca 10

<210> 124
<211> 10
<212> DNA
<213> Homo sapiens

<400> 124
gtggaagacg 10

<210> 125
<211> 10
<212> DNA
<213> Homo sapiens

<400> 125
gatgaggaga 10

<210> 126
<211> 10
<212> DNA
<213> Homo sapiens

<400> 126
ttcccttctt 10

<210> 127
<211> 10
<212> DNA
<213> Homo sapiens

<400> 127
ccccctgcag 10

<210> 128
<211> 10
<212> DNA
<213> Homo sapiens

<400> 128
tgctgcctgt 10

<210> 129
<211> 10
<212> DNA
<213> Homo sapiens

<400> 129
tgcagcacga 10

<210> 130
<211> 10
<212> DNA
<213> Homo sapiens

<400> 130
ggttatcttg 10

<210> 131
<211> 10
<212> DNA
<213> Homo sapiens

<400> 131
tgtcatcaca 10

<210> 132
<211> 10
<212> DNA
<213> Homo sapiens

<400> 132
aaaataaaca 10

<210> 133
<211> 10
<212> DNA
<213> Homo sapiens

<400> 133
taaaaatggt 10

<210> 134
<211> 10
<212> DNA
<213> Homo sapiens

<400> 134
gagcttttga 10

<210> 135

<211> 10
 <212> DNA
 <213> Homo sapiens

<400> 135
 ggctgatgtg

10

<210> 136
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 136
 cgacgaggag

10

<210> 137
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 137
 gcccccaata

10

<210> 138
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 138
 gcaacttgga

10

<210> 139
 <211> 408
 <212> PRT
 <213> Homo sapiens

<400> 139

Met	Pro	Gly	His	Leu	Gln	Glu	Gly	Phe	Gly	Cys	Val	Val	Thr	Asn	Arg
1				5					10					15	
Phe	Asp	Gln	Leu	Phe	Asp	Asp	Glu	Ser	Asp	Pro	Phe	Glu	Val	Leu	Lys
			20					25					30		
Ala	Ala	Glu	Asn	Lys	Lys	Lys	Glu	Ala	Gly	Gly	Gly	Gly	Val	Gly	Gly
			35				40						45		
Pro	Gly	Ala	Lys	Ser	Ala	Ala	Gln	Ala	Ala	Ala	Gln	Thr	Asn	Ser	Asn
	50					55					60				
Ala	Ala	Gly	Lys	Gln	Leu	Arg	Lys	Glu	Ser	Gln	Lys	Asp	Arg	Lys	Asn
65					70					75					80
Pro	Leu	Pro	Pro	Ser	Val	Gly	Val	Val	Asp	Lys	Lys	Glu	Glu	Thr	Gln
				85					90					95	
Pro	Pro	Val	Ala	Leu	Lys	Lys	Glu	Gly	Ile	Arg	Arg	Val	Gly	Arg	Arg
			100					105					110		
Pro	Asp	Gln	Gln	Leu	Gln	Gly	Glu	Gly	Lys	Ile	Ile	Asp	Arg	Arg	Pro
			115				120						125		
Glu	Arg	Arg	Pro	Pro	Arg	Glu	Arg	Arg	Phe	Glu	Lys	Pro	Leu	Glu	Glu
			130			135					140				
Lys	Gly	Glu	Gly	Gly	Glu	Phe	Ser	Val	Asp	Arg	Pro	Ile	Ile	Asp	Arg
145					150					155					160
Pro	Ile	Arg	Gly	Arg	Gly	Gly	Leu	Gly	Arg	Gly	Arg	Gly	Gly	Arg	Gly
				165					170						175

Arg Gly Met Gly Arg Gly Asp Gly Phe Asp Ser Arg Gly Lys Arg Glu
 180 185 190
 Phe Asp Arg His Ser Gly Ser Asp Arg Ser Ser Phe Ser His Tyr Ser
 195 200 205
 Gly Leu Lys His Glu Asp Lys Arg Gly Gly Ser Gly Ser His Asn Trp
 210 215 220
 Gly Thr Val Lys Asp Glu Leu Thr Glu Ser Pro Lys Tyr Ile Gln Lys
 225 230 235 240
 Gln Ile Ser Tyr Asn Tyr Ser Asp Leu Asp Gln Ser Asn Val Thr Glu
 245 250 255
 Glu Thr Pro Glu Gly Glu Glu His His Pro Val Ala Asp Thr Glu Asn
 260 265 270
 Lys Glu Asn Glu Val Glu Glu Val Lys Glu Glu Gly Pro Lys Glu Met
 275 280 285
 Thr Leu Asp Glu Trp Lys Ala Ile Gln Asn Lys Asp Arg Ala Lys Val
 290 295 300
 Glu Phe Asn Ile Arg Lys Pro Asn Glu Gly Ala Asp Gly Gln Trp Lys
 305 310 315 320
 Lys Gly Phe Val Leu His Lys Ser Lys Ser Glu Glu Ala His Ala Glu
 325 330 335
 Asp Ser Val Met Asp His His Phe Arg Lys Pro Ala Asn Asp Ile Thr
 340 345 350
 Ser Gln Leu Glu Ile Asn Phe Gly Asp Leu Gly Arg Pro Gly Arg Gly
 355 360 365
 Gly Arg Gly Gly Arg Gly Gly Arg Gly Arg Gly Gly Arg Pro Asn Arg
 370 375 380
 Gly Ser Arg Thr Asp Lys Ser Ser Ala Ser Ala Pro Asp Val Asp Asp
 385 390 395 400
 Pro Glu Ala Phe Pro Ala Leu Ala
 405

<210> 140
 <211> 10
 <212> DNA
 <213> Homo sapiens

<400> 140
 atgataatgg

10

<210> 141
 <211> 1024
 <212> DNA
 <213> Homo sapiens

<400> 141
 cccacccga aacacactca gcccttgcac tgacctgcct tctgattgga ggctgggtgc 60
 ttccgataat gacctccagg accccactgt tggttacagc ctgtttgtat tattcttact 120
 gcaactcaag acacctgcag cagggcgtga gaaaaagtaa aagaccagta ttttcacatt 180
 gccaggatcc agaaacacag aagactgaca cccgccactt aagtggggcc agggctgggtg 240
 tctgcccatt ttgccatcct gatgggctgc ttgccacaat gagggatctt cttcaataca 300
 tcgcttgctt ctttgccctt ttctctgctg gggttttgat tgtggccacc tggactgact 360
 gttggatggg gaatgctgat gactctctgg aggtgagcac aaaatgccga ggccctctggg 420
 gggaatgcgt cacaaatgct tttgatggga ttccgcacctg tgatgagtac gattccatac 480
 ttgcggagca tcccttgaag ctgggtggtaa ctcgagcgtt gatgattact gcagatatc 540
 tagctggggt tggatttctc accctgctcc ttggtcttga ctgcgtgaaa ttcctccctg 600
 atgacccgta cattaaagtc cgcactctgt ttgttgctgg agccacgta ctaatagcag 660
 gtacccagg aatcattggc tctgtgtggg atgtgttga tgtgtatgtg gaacgttcta 720
 ctttggtttt gcacaatata tttcttggtg tccaatataa atttggttgg tccgtgtggc 780
 tcggaatggc tgggtctctg ggttgctttt tggctggagc tggtctcacc tgcgtcttat 840
 atctttttta agatgtggga cctgagaaaa ctagccttat cccttgagga aagcctattc 900

agccgcgagg tgtttccatg gccaaagtcac actcagcccc tcgcacagag acggccaaaa 960
 tgtatgctgt agacacaagg gtgtaaaatg cacgtttcag ggtgtgtttg catatgattt 1020
 aatc 1024

<210> 142

<211> 294

<212> PRT

<213> Homo sapiens

<400> 142

Pro Pro Glu Thr His Ser Ala Leu Ala Leu Thr Cys Leu Leu Ile Gly
 1 5 10 15
 Gly Trp Leu Leu Arg Ile Met Thr Ser Arg Thr Pro Leu Leu Val Thr
 20 25 30
 Ala Cys Leu Tyr Tyr Ser Tyr Cys Asn Ser Arg His Leu Gln Gln Gly
 35 40 45
 Val Arg Lys Ser Lys Arg Pro Val Phe Ser His Cys Gln Val Pro Glu
 50 55 60
 Thr Gln Lys Thr Asp Thr Arg His Leu Ser Gly Ala Arg Ala Gly Val
 65 70 75 80
 Cys Pro Cys Cys His Pro Asp Gly Leu Leu Ala Thr Met Arg Asp Leu
 85 90 95
 Leu Gln Tyr Ile Ala Cys Phe Phe Ala Phe Phe Ser Ala Gly Phe Leu
 100 105 110
 Ile Val Ala Thr Trp Thr Asp Cys Trp Met Val Asn Ala Asp Asp Ser
 115 120 125
 Leu Glu Val Ser Thr Lys Cys Arg Gly Leu Trp Trp Glu Cys Val Thr
 130 135 140
 Asn Ala Phe Asp Gly Ile Arg Thr Cys Asp Glu Tyr Asp Ser Ile Leu
 145 150 155 160
 Ala Glu His Pro Leu Lys Leu Val Val Thr Arg Ala Leu Met Ile Thr
 165 170 175
 Ala Asp Ile Leu Ala Gly Phe Gly Phe Leu Thr Leu Leu Leu Gly Leu
 180 185 190
 Asp Cys Val Lys Phe Leu Pro Asp Glu Pro Tyr Ile Lys Val Arg Ile
 195 200 205
 Cys Phe Val Ala Gly Ala Thr Leu Leu Ile Ala Gly Thr Pro Gly Ile
 210 215 220
 Ile Gly Ser Val Trp Tyr Ala Val Asp Val Tyr Val Glu Arg Ser Thr
 225 230 235 240
 Leu Val Leu His Asn Ile Phe Leu Gly Ile Gln Tyr Lys Phe Gly Trp
 245 250 255
 Ser Cys Trp Leu Gly Met Ala Gly Ser Leu Gly Cys Phe Leu Ala Gly
 260 265 270
 Ala Val Leu Thr Cys Cys Leu Tyr Leu Phe Lys Asp Val Gly Pro Glu
 275 280 285
 Lys Thr Ser Leu Ile Pro
 290

<210> 143

<211> 10

<212> DNA

<213> Homo sapiens

<400> 143

gtgggcacag

<210> 144

<211> 1851

<212> DNA

<213> Homo sapiens

<400> 144

ggatatcgctc	gacccagcgt	ccggaccggg	acagctcgcg	gccccccgag	agctctagcc	60
gtcaggagagc	tgcctgggga	cgtttccctg	ggccccagcc	tggccccgggt	caccctggca	120
tgaggagatg	ggcctgttgc	tcttggtccc	gttgctcctg	ctgcccgggt	cctacggact	180
gcccttctac	aacggcttct	actactccaa	cagcgccaac	gaccagaacc	taggcaacgg	240
tcatggcaaa	gacctcctta	atggagtga	gctggtggtg	gagacacccg	aggagaccct	300
gttcacctac	caaggggcca	gtgtgatcct	gccctgcgta	ccgctacgag	ccggccctgg	360
tctccccgcg	gcgtgtgctg	gtcaaattgt	ggaagctgtc	ggagaacggg	gccccagaga	420
aggacgtgct	ggtggccatc	gggctgaggc	accgtccctt	tgggactacc	aaggcccgct	480
gcactgcggc	aggacaaaga	gcatgagctc	tcgctggaga	tccagatctc	gctggaggac	540
tatggggctt	accgctgtga	ggtcattgac	gggctggagg	atgaaagcgg	tctggtggag	600
ctggagctgc	ggggtgtggt	ctttccttac	cagtcoccaa	cgggcgctac	cagttcaact	660
tccacgaggg	ccagcaggtc	tgtgcagagc	aggctgcggg	ggtggcctcc	tttgagcagc	720
tcttccgggc	ctgggaggag	ggcctggact	ggtgcaacgc	gggctggctg	caggatgcca	780
cggtgcagta	ccccatcatg	ttgccccggc	agccctgcgg	tggccccggg	ctggcacctg	840
gcgtgcgaag	ctacggcccc	cgccaccgcc	gacctgcacc	ctatgatgta	ttctcgttcg	900
ctactgccct	caaggggagg	gtgtactacc	tggagcacc	tgagaacgtg	acgtgacag	960
aggcaaggga	ggcctgccag	gaagatgatg	ccacgattgc	caaggtggac	agctctttgc	1020
cgcttgaag	ttccatggcc	tggaccgctg	cgacgctggc	tggctggcag	atggcagcgt	1080
ccgtaccct	gtggttcacc	cgcatectaa	ctgtggggcc	ccagagcctg	gggtccgaag	1140
ctttggcttc	cccgaaccgc	agagccgctt	gtacggtgtt	tactgtaccg	ccagcactag	1200
gacctggggc	cctccccctg	cgcattccct	cactggctgt	gtattttattg	agtggttcgt	1260
tttcccttgt	gggttggagc	catttttaact	gtttttatac	ttctcaattt	aaattttctt	1320
taaacatttt	tttactattt	tttgtaaagc	aaacagaacc	caatgcctcc	ctttgctcct	1380
ggatgcccc	ctccaggaat	catgcttgc	ccccgggctt	ctggagggtt	ccccgccatc	1440
caggctgggtc	tccctccctt	aaggagggtg	gtgccagag	tgggcgggtg	cctgtctaga	1500
atgccgccgg	gagtcggggc	atggtgggca	cagttctccc	tgccccctag	cctgggggaa	1560
gaagagggcc	tggggggctc	cggagctggg	ctttgggcct	ctcctgcca	cctctacttc	1620
tctgtgaagc	cgctgacccc	agtctgcccc	ctgaggggct	agggctggaa	gccagttcta	1680
ggcttccagg	cgaagctga	gggaaggaag	aaactccctc	cccgttcccc	ttcccccttc	1740
ggttccaaag	aatctgtttg	ttgtcatttg	tttctcctgt	ttccctgtgt	ggggaggggc	1800
cctcaggtgt	gtgtactttg	gacaataaat	ggtgctatga	ctgccttccg	c	1851

<210> 145

<211> 10

<212> DNA

<213> Homo sapiens

<400> 145

cctgccccgc

10

<210> 146

<211> 4111

<212> DNA

<213> Homo sapiens

<400> 146

ctcacagccc	agcacctgcg	gagggagcgc	tgaccatggc	tccctggcct	gaattgggag	60
atgccagacc	caaccccgat	aagtacctcg	aaggggcccgc	aggtcagcag	cccactgccc	120
ctgataaaag	caaagagacc	aacaaaaata	acactgaggc	acctgtaacc	aagattgaac	180
ttctgccgtc	ctactccacg	gctacactga	tagatgagcc	cactgagggt	gatgaccctt	240
ggaacctacc	cactcttcag	gactcgggga	tcaagtgggt	agagagagac	accaaaggga	300
agattctctg	tttcttccaa	gggattggga	gattgatttt	acttctcgga	tttctctact	360
ttttcgtgtg	ctccctggat	attcttagta	gctgctttca	gctgggttga	ggaaaaatgg	420
caggacagtt	cttcagcaac	agctctatta	tgtccaaccc	tttgttgggg	ctggtgatcg	480
gggtgctggg	gaccgtcttg	gtgcagagct	ccagcacctc	aacgtccatc	gttgtcagca	540
tgggtgcctc	ttcattgctc	actgttcggg	ctgccatccc	cattatcatg	ggggccaaca	600
ttggaacgtc	aatcaccaac	actattgttg	cgctcatgca	ggtgggagat	cggagttagt	660

tcaagaagagc	ttttgcagga	gccactgtcc	atgacttctt	caactggctg	tccttgttgg	720
tgctcttgcc	cgtggagggtg	gccacccatt	acctcgagat	cataaaccag	cttatagtgg	780
agagcttcca	cttcaagaat	ggagaagatg	ccccagatct	tctgaaagtc	atcactaagc	840
ccttcacaaa	gctcattgtc	cagctggata	aaaaagttat	cagccaaatt	gcaatgaacg	900
atgaaaaagc	gaaaaacaag	agtcttgtca	agatttgggtg	caaaactttt	accaacaaga	960
cccagattaa	cgtcactgtt	ccctcgactg	ctaactgcac	ctccccttcc	ctctgttggg	1020
cggatggcat	ccaaaactgg	accatgaaga	atgtgacctg	caaggagaac	atcgccaaat	1080
gccagcatat	ctttgtgaat	ttccacctcc	cggatcttgc	tgtgggcacc	atcttgetca	1140
tactctccct	gctggctctc	tgtggttgcc	tgatcatgat	tgtcaagatc	ctgggctctg	1200
tgctcaaggg	gcaggctgcc	actgtcatca	agaagaccat	caacactgat	ttccccttcc	1260
cctttgcatg	gttgactggc	tacctggcca	tcctcgctgg	ggcaggcatg	accttcatcg	1320
tacagagcag	ctctgtgttc	acgtcggcct	tgacccccct	gattggaatc	ggcgtgataa	1380
ccattgagag	ggcttatcca	ctcacgctgg	gctccaacat	cggcaccacc	accaccgcca	1440
tcctggccgc	cttagccagc	cctggcaatg	cattgaggag	ttcactccag	atcgccctgt	1500
gccacttttt	cttcaacatc	tcgggcatct	tgtgtgtgta	cccgatcccc	ttcactcgcc	1560
tgcccatccg	catggccaag	gggctgggca	acatctctgc	caagtatcgc	tggttcgccg	1620
tcttctacct	gatcatcttc	ttcttctctg	tcoccgctgac	ggtgtttggc	ctctcgctgg	1680
ccggctggcg	ggtgtcgggt	ggtgtcgggg	ttcccgctcgt	cttcatcacc	atcttggtac	1740
tgtgctcccg	actcctgcag	tctcgtgcc	cacgcgtcct	gccgaagaâa	ctccagaact	1800
ggaacttctc	gccgctgtgg	atgcgctcgc	tgaagccctg	ggatgccgtc	gtctccaagt	1860
tcaccggctg	cttccagatg	cgtgtgtgct	gctgtgtccg	cgtgtgtgtc	cgcgctgtgt	1920
gcttgtgtgt	tggctgcccc	aagtgtgtgc	gctgcagcaa	gtgtgtcgag	gacttggagg	1980
aggcgcagga	ggggcaggat	gtccctgtca	aggctcctga	gacctttgat	aacataacca	2040
ttagcagaga	ggctcagggt	gaggtccctg	cctcggactc	aaagaccgaa	tgcacggcct	2100
tgtaggggac	gccccagatt	gtcaggggatg	gggggatggg	ccttgagttt	tgcattgctct	2160
cctccctccc	acttctgcac	cctttcacca	cctcaggagg	atttgcctcc	cattagcgaa	2220
tgaatttgat	gcagtcctac	ctaactcgat	tccttttggc	ttgggtgggta	ggcctgcagg	2280
gcacttttat	tccaaccctc	ggtcactcag	taatctttta	ctccaggaag	gcacaggatg	2340
gtacctaaag	agaattagag	aatgaacctg	gcgggacgga	tgtctaatac	tgcacctagc	2400
tgggttgggtc	agtagaacct	attttcagac	tcaaaaacca	tcttcagaaa	gaaaaggccc	2460
aggggaaggaa	tgtatgagag	gctctcccag	atgaggaagt	gtactctcta	tgactatcaa	2520
gctcaggcct	ctcccttttt	ttaaaccaaa	gtctggcaac	caagagcagc	agctccatgg	2580
cctccttgcc	ccagatcagc	ctgggtcagg	ggacatagtg	tcattgtttg	gaaactgcag	2640
accacaaggt	gtgggtctat	cccacttctc	agtgtctccc	acattcccca	tcagggcttc	2700
ctcacgtgga	caggtgtgct	agtccaggca	gttcaacttg	agtttctctg	tcctcatgct	2760
tcggggatgg	gagccacgcc	tgaactagag	ttcaggctgg	atacatgtgc	tcacctgtg	2820
ctcttgtctt	ccaaagagac	agagagtggg	gcagatggag	gagaagaaag	tgaggaatga	2880
gtagcatagc	attctgccaa	aagggcccca	gattcttaat	ttagcaaaact	aagaagccca	2940
attcaaaagc	attgtggcta	aagtctaacg	ctcctctctt	ggtcagataa	caaaagccct	3000
ccctgttggg	tcttttgaaa	taaaacgtgc	aagttatcca	ggctcgtagc	ctgcatgctg	3060
ccaccttgaa	tcccaggagg	tatctgcacc	tgggaatagct	ctccacccct	ctctgcctcc	3120
ttactttctg	tgcaagatga	tttcttgggt	taacttctct	ctttccatcc	accacccac	3180
tggaaatctct	ttccaaacat	ttttccatct	tcccacagat	gggctttgat	tagctgtcct	3240
ctctccatgc	ctgcaaagct	ccagattttt	ggggaaagct	gtacccaact	ggactgcccc	3300
gtgaactggg	atcattgagt	acagtcgagc	acacgtgtgt	gcatgggtca	aaggggtgtg	3360
ttccttctca	tcttagatgc	cttctctgtg	ccttccacag	cctcctgcct	gattacacca	3420
ctgcccccg	cccacctca	gccatcccaa	tcttctctgg	ccagtgcgct	ccagccttat	3480
ctaggaaagg	aggagtgggt	gtagcctgtc	agcaagattg	gggcctcccc	catcccagct	3540
tctccaccat	cccagcaagt	caggatatca	gacagtcctc	ccctgaccct	cccccttgta	3600
gatatcaatt	cccaaacaga	gccaaatact	ctatatctat	agtcacagcc	ctgtacagca	3660
tttttcataa	gttatatagt	aaatgggtctg	catgatttgt	gcttctagtg	ctctcatttg	3720
gaaatgaggc	aggcttcttc	tatgaaatgt	aaagaaagaa	accactttgt	atattttgtg	3780
ataccacctc	tgtggccatg	cctgccccgc	ccactctgta	tatatgtaag	ttaaaccggg	3840
gcaggggctg	tggccgtctt	tgtactctgg	tgatttttaa	aaattgaatc	tttgtacttg	3900
cattgattgt	ataataattt	tgagaccagg	tctcgtctgt	ttgctcaggg	tggctctcaa	3960
ctcctgagat	caagcaatcc	gcccacctca	gcctcccaaa	gtgctgagat	cacaggcgtg	4020
agccaccacc	aggcctgatt	gtaatttttt	tttttttttt	tactgggttat	gggaaggagg	4080
aaataaaatc	atcaaaccct	aaaaaaaaaa	a			4111

<211> 689

<212> PRT

<213> Homo sapiens

<400> 147

```

Met Ala Pro Trp Pro Glu Leu Gly Asp Ala Gln Pro Asn Pro Asp Lys
 1          5          10          15
Tyr Leu Glu Gly Ala Ala Gly Gln Gln Pro Thr Ala Pro Asp Lys Ser
          20          25          30
Lys Glu Thr Asn Lys Asn Asn Thr Glu Ala Pro Val Thr Lys Ile Glu
          35          40          45
Leu Leu Pro Ser Tyr Ser Thr Ala Thr Leu Ile Asp Glu Pro Thr Glu
          50          55          60
Val Asp Asp Pro Trp Asn Leu Pro Thr Leu Gln Asp Ser Gly Ile Lys
65          70          75          80
Trp Ser Glu Arg Asp Thr Lys Gly Lys Ile Leu Cys Phe Phe Gln Gly
          85          90          95
Ile Gly Arg Leu Ile Leu Leu Leu Gly Phe Leu Tyr Phe Phe Val Cys
          100          105          110
Ser Leu Asp Ile Leu Ser Ser Ala Phe Gln Leu Val Gly Gly Lys Met
          115          120          125
Ala Gly Gln Phe Phe Ser Asn Ser Ser Ile Met Ser Asn Pro Leu Leu
          130          135          140
Gly Leu Val Ile Gly Val Leu Val Thr Val Leu Val Gln Ser Ser Ser
145          150          155          160
Thr Ser Thr Ser Ile Val Val Ser Met Val Ser Ser Ser Leu Leu Thr
          165          170          175
Val Arg Ala Ala Ile Pro Ile Ile Met Gly Ala Asn Ile Gly Thr Ser
          180          185          190
Ile Thr Asn Thr Ile Val Ala Leu Met Gln Val Gly Asp Arg Ser Glu
          195          200          205
Phe Arg Arg Ala Phe Ala Gly Ala Thr Val His Asp Phe Phe Asn Trp
210          215          220
Leu Ser Leu Leu Val Leu Leu Pro Val Glu Val Ala Thr His Tyr Leu
225          230          235          240
Glu Ile Ile Thr Gln Leu Ile Val Glu Ser Phe His Phe Lys Asn Gly
          245          250          255
Glu Asp Ala Pro Asp Leu Leu Lys Val Ile Thr Lys Pro Phe Thr Lys
          260          265          270
Leu Ile Val Gln Leu Asp Lys Lys Val Ile Ser Gln Ile Ala Met Asn
          275          280          285
Asp Glu Lys Ala Lys Asn Lys Ser Leu Val Lys Ile Trp Cys Lys Thr
290          295          300
Phe Thr Asn Lys Thr Gln Ile Asn Val Thr Val Pro Ser Thr Ala Asn
305          310          315          320
Cys Thr Ser Pro Ser Leu Cys Trp Thr Asp Gly Ile Gln Asn Trp Thr
          325          330          335
Met Lys Asn Val Thr Tyr Lys Glu Asn Ile Ala Lys Cys Gln His Ile
          340          345          350
Phe Val Asn Phe His Leu Pro Asp Leu Ala Val Gly Thr Ile Leu Leu
          355          360          365
Ile Leu Ser Leu Leu Val Leu Cys Gly Cys Leu Ile Met Ile Val Lys
370          375          380
Ile Leu Gly Ser Val Leu Lys Gly Gln Val Ala Thr Val Ile Lys Lys
385          390          395          400
Thr Ile Asn Thr Asp Phe Pro Phe Pro Phe Ala Trp Leu Thr Gly Tyr
          405          410          415
Leu Ala Ile Leu Val Gly Ala Gly Met Thr Phe Ile Val Gln Ser Ser
          420          425          430

```

Ser Val Phe Thr Ser Ala Leu Thr Pro Leu Ile Gly Ile Gly Val Ile
 435 440 445
 Thr Ile Glu Arg Ala Tyr Pro Leu Thr Leu Gly Ser Asn Ile Gly Thr
 450 455 460
 Thr Thr Thr Ala Ile Leu Ala Ala Leu Ala Ser Pro Gly Asn Ala Leu
 465 470 475 480
 Arg Ser Ser Leu Gln Ile Ala Leu Cys His Phe Phe Phe Asn Ile Ser
 485 490 495
 Gly Ile Leu Leu Trp Tyr Pro Ile Pro Phe Thr Arg Leu Pro Ile Arg
 500 505 510
 Met Ala Lys Gly Leu Gly Asn Ile Ser Ala Lys Tyr Arg Trp Phe Ala
 515 520 525
 Val Phe Tyr Leu Ile Ile Phe Phe Leu Ile Pro Leu Thr Val Phe
 530 535 540
 Gly Leu Ser Leu Ala Gly Trp Arg Val Leu Val Gly Val Gly Val Pro
 545 550 555 560
 Val Val Phe Ile Ile Ile Leu Val Leu Cys Leu Arg Leu Leu Gln Ser
 565 570 575
 Arg Cys Pro Arg Val Leu Pro Lys Lys Leu Gln Asn Trp Asn Phe Leu
 580 585 590
 Pro Leu Trp Met Arg Ser Leu Lys Pro Trp Asp Ala Val Val Ser Lys
 595 600 605
 Phe Thr Gly Cys Phe Gln Met Arg Cys Cys Cys Cys Arg Val Cys
 610 615 620
 Cys Arg Ala Cys Cys Leu Leu Cys Gly Cys Pro Lys Cys Cys Arg Cys
 625 630 635 640
 Ser Lys Cys Cys Glu Asp Leu Glu Glu Ala Gln Glu Gly Gln Asp Val
 645 650 655
 Pro Val Lys Ala Pro Glu Thr Phe Asp Asn Ile Thr Ile Ser Arg Glu
 660 665 670
 Ala Gln Gly Glu Val Pro Ala Ser Asp Ser Lys Thr Glu Cys Thr Ala
 675 680 685
 Leu

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 October 2001 (11.10.2001)

PCT

(10) International Publication Number
WO 01/075177 A3

(51) International Patent Classification⁷: C12Q 1/68

Lane, Columbia, MD 21045 (US). HOUGH, Colleen, D. [US/US]; 169 E. Wasatch Point Lane, #30103, Draper, UT 84020 (US).

(21) International Application Number: PCT/US01/10947

(22) International Filing Date: 3 April 2001 (03.04.2001)

(74) Agents: MILLER, Mary, L. et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Suite 1200, Atlanta, GA 30303-1811 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/194,336 3 April 2000 (03.04.2000) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/194,336 (CIP)
Filed on 3 April 2000 (03.04.2000)

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; c/o National Institutes of Health, Office of Technology Transfer, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804 (US).

Published:
— with international search report

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): MORIN, Patrice, J. [CA/US]; 8131 Greenspring Valley Road, Owings Mills, MD 21117 (US). SHERMAN-BAUST, Cheryl, A. [US/US]; 8811 Baker Avenue, Baltimore, MD 21234 (US). PIZER, Ellen, S. [US/US]; 5962 Camelback

(88) Date of publication of the international search report:
22 May 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TUMOR MARKERS IN OVARIAN CANCER

(57) Abstract: The present invention features methods of diagnosing and prognosticating ovarian tumors by detecting increased expression of an ovarian tumor marker gene in a subject or in a sample from a subject. Also featured are kits for the aforementioned diagnostic and prognostic methods. In addition, the invention features methods of treating and preventing ovarian tumors, and methods of inhibiting the growth or metastasis of ovarian tumors, by modulating the production or activity of an ovarian tumor marker polypeptide. Further featured are methods of inhibiting the growth or metastasis of an ovarian tumor by contacting an ovarian tumor cell with an antibody that specifically binds an ovarian tumor marker polypeptide.

WO 01/075177 A3

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10947

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 53040 A (SCHMITT ARMIN ;SPECHT THOMAS (DE); DAHL EDGAR (DE); HINZMANN BERND) 21 October 1999 (1999-10-21) Tabelle I, SEQ ID NO:72 --- -/--	1-22,28, 29,32

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

1 October 2002

Date of mailing of the international search report

10. 01. 2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata-Vicente, M

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>HOUGH COLLEEN D ET AL: "Comparison of sage-generated expression profiles between ovarian cancer and human ovarian surface epithelium."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03), pages 310-311, XP008008525</p> <p>91st Annual Meeting of the American Association for Cancer Research.; San Francisco, California, USA; April 01-05, 2000, March, 2000</p> <p>ISSN: 0197-016X</p> <p>the whole document</p> <p>---</p>	
A	<p>HOUGH C D ET AL: "Use of SAGE to study gene expression in ovarian cancer."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03), page 34</p> <p>XP008008524</p> <p>90th Annual Meeting of the American Association for Cancer Research; Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999</p> <p>ISSN: 0197-016X</p> <p>the whole document</p> <p>---</p>	
A	<p>DEPASQUALE S E ET AL: "Differential expression of the pRb2 tumor suppressor gene in human epithelial ovarian carcinoma compared to ovarian tumors of low malignant potential and normal ovaries."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 38, 1997, page 109 XP008008526</p> <p>Eighty-eighth Annual Meeting of the American Association for Cancer Research; San Diego, California, USA; April 12-16, 1997, 1997</p> <p>ISSN: 0197-016X</p> <p>the whole document</p> <p>---</p>	
A	<p>MOK SAMUEL C ET AL: "Molecular Cloning of Differentially Expressed Genes in Human Epithelial Ovarian Cancer."</p> <p>GYNECOLOGIC ONCOLOGY, vol. 52, no. 2, 1994, pages 247-252, XP002128355</p> <p>ISSN: 0090-8258</p> <p>page 247, right-hand column, paragraph 1</p> <p>page 248, right-hand column, last paragraph</p> <p>page 251, right-hand column</p> <p>---</p> <p style="text-align: center;">-/--</p>	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/10947

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>HOUGH COLLEEN D ET AL: "Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer." CANCER RESEARCH, vol. 60, no. 22, 15 November 2000 (2000-11-15), pages 6281-6287, XP002215320 ISSN: 0008-5472 the whole document -----</p>	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 01/10947

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 30
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims (1-22, 28, 29 and 32) - partially; claim 30 - completely

Remark n Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claim 6 and, as far as an "in vivo" method is concerned, claims 1-3, 7-13 and 19-21 and partially 22, 28 and 29 are directed to a diagnostic method practised on the human/animal body and the search has been carried out and based on the alleged effects of the compound/composition.

Claims 14-18 and partially claims 22, 28 and 29 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 30

Claim 30 refers to an antibody without giving a true technical characterization. Moreover, no such compounds are defined in the application. In consequence, the scope of said claim is ambiguous and vague, and its subject-matter is not sufficiently disclosed and supported (Art. 5 and 6 PCT). No search can be carried out for purely speculative claims whose wording is, in fact, a mere recitation of the results to be achieved.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: Claims (1-22, 28, 29 and 32) - partially; claim 30 - completely

Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the alpha prothymosin gene (SEQ ID NO:1). Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby (SEQ ID NO:2). Kit comprising the polynucleotide of the invention.

Inventions 2-19: Claims (1-22, 25, 28, 29, 31, 32 and 35) - partially

Invention 2: Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the beta polypeptide 2-like G protein subunit 1 gene (SEQ ID NO:3) or its tag SEQ ID NO:84. Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby (SEQ ID NO:4). Kits comprising the polynucleotides of the invention.

Ibidem for inventions 3-19, but restricted to each one of the other markers mentioned in claims 22 and 32: Invention 3 refers to Lutheran blood group (B-CAM) (SEQ ID NOs:5, 6 and 85) ... invention 19 refers to eIF-2-associated p67 (SEQ ID NOs:38, 39 and 102).

Inventions 20-40: Claims (1-21, 23, 26, 28, 29, 31, 33 and 36) - partially

Invention 20: Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the HLA-DR alpha chain gene (SEQ ID NO:40) or its tag SEQ ID NO:103. Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby (SEQ ID NO:41). Kits comprising the polynucleotides of the invention.

Ibidem for inventions 21-40, but restricted to each one of the other markers mentioned in claims 23 and 33: Invention 21 refers to cysteine-rich protein 1 (SEQ ID NOs:42, 43 and 104) ... invention 40 refers to HLA-Cw (SEQ ID NOs:81, 82 and 129).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Inventions 41-43: Claims (1-21, 24, 27-29, 31, 34 and 37) - partially

Invention 41: Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the HOST-3 (Claudin-16) gene (SEQ ID NO:141). Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby (SEQ ID NO:142). Kit comprising the polynucleotide of the invention.

Ibidem for inventions 42 and 43, but restricted to each one of the other markers mentioned in claims 24 and 34: Invention 42 refers to HOST-4 (SEQ ID NO:144) and invention 43 refers to HOST-5 (SEQ ID NOs:146 and 147).

Inventions 44-49: Claims (1-21, 26, 28, 29, 31 and 36) - partially

Invention 44: Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the gene tag SEQ ID NO:106. Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby. Kit comprising the polynucleotide of the invention.


Ibidem for inventions 45-49, but restricted to each one of the other tags mentioned in claims 26 and 36: Invention 45 refers to tag SEQ ID NO:107 ... invention 36 refers to tag SEQ ID NO:122.

Inventions 50-51: Claims (1-21, 27-29, 31 and 37) - partially

Invention 50: Methods for detecting/diagnosing ovarian cancer or the predisposal to develop it, as well as a method to determine the effectiveness of a treatment against ovarian cancer, all comprising measuring the expression of the gene tag SEQ ID NO:143. Method of treating or preventing ovarian cancer comprising modulating production or activity of the polypeptide encoded thereby. Kit comprising the polynucleotide of the invention.

Ibidem for invention 51, but restricted to the other tag mentioned in claims 27 and 37 (tag SEQ ID NO:145).

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/10947

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9953040	A	21-10-1999	DE 19817557 A1	21-10-1999
			WO 9953040 A2	21-10-1999
			EP 1073727 A2	07-02-2001
			JP 2002511252 T	16-04-2002
